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General introduction
Whooping cough or pertussis is a highly contagious, acute respiratory disease of humans, 
predominantly caused by the gram-negative bacterium Bordetella pertussis. Pertussis is 
typically associated with leukocytosis and paroxysmal coughing, often followed by post-tussive 
vomiting. However, pertussis can also follow a much milder or subclinical course, especially in 
partially immune individuals (1, 2). Before the introduction of vaccination in the 1940-1950s, 
pertussis was attributable for up to 13% of all-cause child mortality during some epidemics 
(3). Although extensive immunization campaigns have significantly reduced pertussis-caused 
infant mortality worldwide, pertussis has resurged since the 1990s (4, 5) and is now estimated 
to (re-)infect 40M people each year (5-7), resulting in approximately 195,000 deaths worldwide, 
mainly in unvaccinated children (8). Pertussis typically has an epidemic cycle of 2-4 years due 
to the gradual loss of immunity after natural infection, which enables pertussis to spread in the 
population and cause epidemics (9-11). Indeed, in 2010 and 2012, particularly large outbreaks 
of whooping cough were observed in the Netherlands, the USA, Australia, the UK, and several 
other countries (Figure 1; (4, 12-14)). 
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Figure 1: Reported cases of pertussis from 1991 to 2012. Figure adapted from (15). The year in 
which the acellular pertussis vaccine (aP) was introduced is indicated by an arrow.
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1This increase in pertussis incidence is seen mainly in (vaccinated) adolescents and adults, 
providing a reservoir for transmission of pertussis to unvaccinated or partially vaccinated 
newborns, who are at greatest risk of developing severe pertussis (16-18). The apparent re-
emergence of pertussis can partly be explained by increased awareness, active surveillance, 
and improved diagnostic testing, but is predominantly caused by the limited duration of 
protection conferred by pertussis vaccines and pathogen adaptation (19, 20).
Pertussis vaccination & waning immunity
Whole cell pertussis vaccines (wPs) have been developed in the 1940s to 1960s and consist 
of a suspension of formalin- or heat-inactivated B. pertussis grown in vitro under conditions 
known to express virulence factors, with aluminum salts as adjuvant. wPs were used for 
pertussis vaccination until the 1990s, but were replaced by acellular vaccines (aPs) in most 
Western countries due to their reactivity and associated reduced vaccine acceptance. In 
contrast to wPs, aPs contain only 1-5 purified pertussis antigens, admixed with aluminum 
salts. aPs are usually administered in combination with other vaccines against e.g. diphtheria, 
polio, tetanus, Haemophilus influenzae type B and Hepatitis B virus. All of the aPs contain 
inactivated pertussis toxin (Ptx), either alone or in combination with other pertussis antigens 
such as pertactin (Prn), filamentous hemagglutinin (FHA) or fimbriae type 2 and/or 3 (Fim2/3). 
These proteins were initially selected as they showed vaccine-induced protection against lung 
infection in mice. In time it became clear that immunity induced by pertussis vaccines does 
not last long enough and that waning immunity is a major cause for the pertussis problem. 
While infection-acquired immunity against pertussis disease has been suggested to last 4-20 
years, protective immunity after wP vaccination wanes after 4-12 years (21, 22). Importantly, 
several recent studies have provided evidence that immunity induced by aPs is less persistent 
compared to wPs, and only confer protection for 5-8 years (14, 23, 24). This is likely caused by 
the fact that the aP component pertussis toxin is chemically detoxified using formalin, thereby 
lowering its immunogenicity (25-27), or break-down of the very large aP antigen FHA, which 
results in the loss of important epitopes. Another potential explanation is that aPs typically 
induce a T helper type 2 (Th2) response whereas wPs, containing lipo-oligosaccharide (LOS), 
typically induce a more potent Th1-biased response (28). Another important drawback of current 
vaccine formulations is their inability to reduce bacterial colonization of the upper respiratory 
tract, resulting in high circulation of B. pertussis despite widespread aP vaccination (5, 29). 
Clearly, novel strategies to improve the efficacy of pertussis vaccination are urgently required.
Pathogen adaptation
Genomic comparison of the classical bordetellae showed that B. pertussis has evolved from 
a Bordetella bronchiseptica-like ancestor, and that this evolution coincided with high levels 
of gene loss and gene inactivation, as well as a considerable increase in the number of 
insertion sequence (IS) elements (30, 31). More recently, it has become evident that more 
subtle changes in B. pertussis populations have occurred after the introduction of vaccination. 
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These adaptations involved the acquisition of small genetic changes, mainly single nucleotide 
polymorphisms (SNPs) (20). Studies on allelic variation have focused predominantly on 
currently used aP protein antigens. Thus far, 18, 8, 13, 2, and 4 different alleles have been 
identified for the pertussis toxin promoter (ptxP), the pertussis toxin A subunit (ptxA), prn, fim2, 
and fim3, respectively (20, 32). Shifts in B. pertussis populations have resulted in antigenic 
divergence between vaccine strains and circulating strains, potentially affecting the efficacy of 
pertussis vaccines (33-35). 
In the Netherlands, the pertussis resurgence has coincided with the emergence of 
strains that carry the ptxP3 allele of the ptx operon promoter (36). Phylogenetic analyses 
showed that ptxP3 strains evolved from ptxP1 strains, possibly in the 1970s (37-39), and within 
a timeframe of 10 years, ptxP3 strains have nearly completely replaced the ptxP1 strains. 
Significantly, ptxP3 strains have spread globally, as they have emerged in several countries in 
Europe (36, 40-43), North America (44), South America (45), and Australia (46). Comparative 
genomic analysis of two newly emerged ptxP3 strains, two contemporary ptxP1 strains, and 
two pre-vaccination strains identified single nucleotide polymorphisms (SNPs) in a number of 
pathogenicity-associated genes, as well as differences in gene inactivation and reactivation 
(47). Furthermore, ptxP3 strains have been associated with higher levels of Ptx production and 
enhanced respiratory colonization (36, 48), 
Finally, the most recent adaptation identified in B. pertussis is the emergence of strains 
lacking expression of the important aP antigen pertactin (Prn-deficient strains) (49-53). 
Alarmingly, in France, Japan, and the USA, Prn-deficient strains have reached frequencies of 
13%, 32%, and 73% in recent years, respectively (50-53). The observation that B. pertussis has 
eliminated pertactin expression using several mutational events indicates strong selection for 
loss of pertactin (52, 53), and one study suggests that the expansion of (Prn-deficient) clones 
is, at least partially, driven by aP vaccination (54). With Prn-deficient strain frequencies on the 
rise, the key question is whether these strains benefit from the lack of Prn expression. There 
is as yet no evidence that Prn-deficiency affect virulence, as a pertussis infection caused by 
a Prn-deficient strain is clinically undistinguishable from an infection caused by a Prn positive 
strain (55). However, there appears to be some benefit for Prn-deficient strains in vaccinated 
populations, as experiments in mice showed that, compared to Prn-producing strains, Prn-
deficient isolates are capable of sustaining longer infection in an aP-vaccinated background 
(56). Furthermore, early studies already showed that in humans there is a strong correlation 
between the presence of Prn-specific antibodies and clinical protection (57-59). As such, it is 
not surprising that a recent study showed that individuals having received at least one pertussis 
vaccine dose are more likely to become infected with a Prn-deficient strain compared to a Prn 
positive strain (54). 
The compound effect of antigenic divergence and the emergence of more virulent ptxP3 
strains and vaccine-escape mutant strains might have aggravated the effect of waning immunity 
(60), and needs to be taken into account in the development of future pertussis vaccines.
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With the number of pertussis cases on the rise in the context of waning immunity and pathogen 
adaptation, there is a clear need for insight into the molecular mechanisms underlying the 
success of the emerging ptxP3 lineage. Knowledge on how these emerging strains adapt to 
pathogenically relevant in vitro and in vivo conditions may allow new and improved pertussis 
prevention strategies to be designed. Furthermore, the emergence of vaccine antigen-deficient 
strains also highlights the importance of identifying alternative pertussis antigens for inclusion 
into future vaccines. The aim of this thesis is to study global gene expression in recently 
emerged B. pertussis strains using comparative transcriptomic and proteomic approaches, with 
special emphasis on the identification of virulence-, biofilm-, and in vivo-expressed proteins, as 
these represent potential pertussis vaccine-candidates.
In Chapter 1.2 we summarize our current knowledge about aspects important for B. pertussis 
pathogenesis and immunity. In Chapter 2 we focused on the two-component Bvg system, 
which plays a central role in B. pertussis pathogenesis by controlling the expression of almost 
all virulence factors required to infect, persist, and cause disease in the host. More specifically, 
we investigated how strains of the ptxP1 and ptxP3 lineage adapt to in vitro sulfate-induced 
modulation of the Bvg system using a transcriptomic approach and identified several phenotypic 
differences between the two lineages. In Chapter 3 we used the same model and strains to 
modulate the Bvg-system in vitro, and applied a proteomic approach with the aim to discover 
novel vaccine candidates. Since both ptxP1 and ptxP3 strains circulate in the population, we 
believe that novel antigens should target both lineages. Therefore, in this study we focused on 
proteins that were virulence-activated and surface-exposed in both lineages, which yielded a 
number of potential candidates. In order to test their potential, identified candidates were used 
for vaccination-challenge experiments in mice. As mice mimic several features of pertussis 
disease and immunity, it represents a suitable model to screen the protective potential 
of multiple candidates. Using this approach, we were able to identify two highly protective 
antigens. In Chapter 4 we explored the vaccine potential of B. pertussis biofilms, which 
represents a respiratory tract lifestyle of B. pertussis that is important for successful infection. 
We hypothesized that a strategy by which multiple steps in infection are targeted, including 
biofilm formation, may represent an attractive approach to improve pertussis vaccines. To 
provide proof of principle that B. pertussis biofilms contain protective antigens, we vaccinated 
mice with membrane protein fractions derived from a ptxP3 strain grown in vitro under biofilm 
and planktonic conditions. Next, proteomics was used to identify highly expressed biofilm-
specific proteins, and single-antigen vaccination-challenge experiments in mice identified one 
promising biofilm vaccine candidate. In Chapter 5 we aimed to unravel how B. pertussis adapts 
to local conditions on the host respiratory mucosa, as insight into these mechanisms may 
explain why current aPs are unable to protect against B. pertussis colonization. To study this 
aspect, we measured the transcriptional response of B. pertussis during respiratory infection 
in mice and found significant differences compared to in vitro growth conditions, as well as 
differences between the upper and lower respiratory tract. Finally, in Chapter 6, the results 
12 | Chapter 1
and findings of the preceding chapters are summarized and discussed and future perspectives 
are presented.
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Abstract
Pertussis, or whooping cough, is a highly contagious, acute respiratory disease of humans 
that is caused by the Gram-negative bacterial pathogen Bordetella pertussis. In the face of 
extensive global vaccination, this extremely monomorphic pathogen has persisted and re-
emerged, causing approximately 300 000 deaths each year. In this review, we discuss the 
interaction of B. pertussis with the host mucosal epithelium and immune system. Using a large 
number of virulence factors, B. pertussis is able to create a niche for colonization in the human
respiratory tract. The successful persistence of this pathogen is mainly due to its ability to 
interfere with almost every aspect of the immune system, from the inhibition of complement- 
and phagocyte-mediated killing to the suppression of T- and B-cell responses. Based on these 
insights, we delineate ideas for the rational design of improved vaccines that can target the 
‘weak spots’ in the pathogenesis of this highly successful pathogen.
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Whooping cough or pertussis is a highly contagious, acute, respiratory disease of humans 
caused by several Gram-negative bacterial species of the genus Bordetella. Four Bordetella 
species have been mainly associated with respiratory disease in humans, i.e. Bordetella 
pertussis, Bordetella parapertussis, Bordetella bronchiseptica, and Bordetella holmesii 
(1). The first three species are closely related and are often referred to as the classical 
Bordetellae, while B. holmesii forms a distinct genetic lineage (2, 3). B. bronchiseptica infects 
a large range of mammalian hosts in which it generally causes mild and chronic disease (4). 
Infrequently, B. bronchiseptica is also isolated from the respiratory tract of humans, mostly 
from immunocompromised individuals (5). Two B. parapertussis lineages with distinct host 
specificities for humans and sheep have been identified, designated B. parapertussisHU and B. 
parapertussisOV respectively (6, 7). Although B. bronchiseptica is also commonly found in other 
mammalian species, B. pertussis, B. parapertussisHU, and B. holmesii have only been isolated 
from humans. Phylogenetic analysis has indicated that both B. pertussis and B. parapertussisHU 
evolved from B. bronchiseptica separately, implying that adaptation to humans occurred as 
two independent events (2, 8, 9). Interestingly, this switch to humans was accompanied by a 
change from chronic disease to acute. Although there will undoubtedly be many parallels that 
can be drawn to other Bordetella species that cause human respiratory disease, this review 
will focus on B. pertussis as it causes the greatest morbidity and mortality in humans. 
The hallmark symptoms of pertussis are paroxysmal coughing with whooping and 
posttussive vomiting. Persistent coughing may last for weeks to months with a gradual decrease 
in frequency and severity. However, it should be noted that B. pertussis infections, particularly 
in hosts with partial immunity to the bacterium, may also follow a much milder or subclinical 
course (10, 11). Complications that are frequently associated with classical pertussis include 
pneumonia, otitis media, seizures, encephalopathy and (brain) hemorrhages. Indeed, prior to 
the introduction of widespread vaccination in the 1950s, pertussis was a leading cause of infant 
death throughout the world. For instance, a London study that was carried out in the 1930s 
indicated that whooping cough was responsible for 1.8% of mortality in all age categories, 
while pertussis mortality in children below 10 years of age was as high as 13% (12). Although 
extensive immunization campaigns have significantly reduced pertussis-caused child mortality 
worldwide, infections with B. pertussis still pose a significant health burden. Even in highly 
vaccinated populations, annual infection rates can reach 1-7% in the general population (13, 
14). Thus, pertussis remains one of the least well-controlled vaccine-preventable diseases in 
the world, with as many as 195,000 deaths each year, worldwide. The majority of these deaths 
occur in non- or insufficiently vaccinated children (15). Interestingly, pertussis has not only 
persisted in vaccinated populations, but has even resurged in recent years (16, 17). Although 
pertussis is traditionally considered a childhood disease, the observed increase in pertussis 
incidence is seen in mainly adolescents and adults (16-18). This shift of pertussis infections 
towards older age categories poses significant health concerns, as these individuals provide a 
reservoir of B. pertussis for transmission to infants which are at the highest risk of developing 
severe pertussis (19-22). 
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The persistence and resurgence of pertussis in countries with highly vaccinated 
populations has been attributed to various factors including increased awareness, improved 
diagnostics, suboptimal vaccines, waning immunity, and pathogen adaptation (16, 17, 23). 
Of significant concern is that most currently used acellular pertussis vaccines (ACV) only 
protect against infections for a period of six to eight years, while protection against subclinical 
infections declines even faster (24-26). 
Several recent reviews have focused on the resurgence of pertussis and the evolution 
of Bordetellae (16, 17, 23, 27). Knowledge about the molecular mechanisms by which B. 
pertussis infects the host and evades clearance by the immune system will provide insight 
into its survival strategies and may facilitate the rational design of novel therapeutic and/or 
preventive strategies that target the ‘weak’ spots of this versatile pathogen. Thus, in this review, 
we focus on the molecular interplay between host and pathogen and provide an overview of 
how this bacterium is able persist and resurge in the face of intensive vaccination.
Regulation of virulence genes
Infection of the host by B. pertussis is initiated through contact with respiratory secretions from 
an infected individual. Following the inhalation of these particles, bacteria enter the upper 
respiratory tract and adhere to (ciliated) epithelial cells in the nasopharynx and trachea. Once 
attached to the mucosal surface, B. pertussis produces a myriad of virulence factors, including 
adhesins, immune-modulating factors, and toxins. The concerted expression of these factors 
prevents rapid clearance of the bacteria and enables replication and dissemination to the lower 
areas of the respiratory tract, causing pneumonia. Since the recognition of B. pertussis as the 
causative agent of whooping cough in humans (10), research has focused on understanding 
its pathogenic lifestyle. In particular the identification of bacterial factors that contribute to the 
development of disease has been comprehensively investigated. One of the initial, intriguing 
observations was that B. pertussis displayed variation in the expression of surface antigens 
(designated antigenic modulation at that time) in response to environmental signals (28, 
29). We now know that these phenomena can be explained by the existence of a master 
regulator that controls transcription of nearly all known virulence genes: the Bordetella master 
virulence regulatory system (bvgASR) locus, as well as a second, more recently identified two-
component regulatory system (TCS) called the RisAS system. Although there are a number of 
other sensory transduction system genes present in the Bordetella genome (8), the BvgASR 
and RisAS systems have been the most extensively studied and will be discussed here. 
The bvgASR virulence regulon  
The transcription of many of the B. pertussis genes known to be involved in virulence is controlled 
by the activity of BvgS and BvgA, originally designated the vir locus by Weiss & Falkow (30, 
31). These two proteins form a typical TCS that allows dynamic variation of gene expression 
in response to changes in extracellular signals from the surrounding environment. BvgA is a 
23-kDa DNA-binding response regulator (32) and BvgS is a 135-kDa transmembrane sensor 
kinase. BvgS contains a periplasmic domain, a linker region, a transmitter, a receiver, and a 
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histidine phosphotransfer domain (33). BvgAS is responsive to several known environmental 
signals that can modulate its expression, at least under laboratory conditions. For instance, 
growing B. pertussis at 37oC induces the expression of BvgAS, while the presence of millimolar 
amounts of sulfate or nicotinic acid, or growth at or below 25oC suppresses BvgAS production 
(34, 35). B. pertussis strains cultured under so-called “nonmodulating”, virulent conditions 
are referred to as Bvg+ phase bacteria. Of all currently known inducers of BvgAS activity, 
temperature seems to be most relevant for sensing changes in the in vivo environment. 
Currently, the in vivo contributions of sulfate and nicotinic acid remain unclear. 
During the virulent Bvg+ phase, the periplasmic domain of BvgS relays environmental 
signals through the membrane to the transmitter domain, which then autophosphorylates. 
Phosphorylated BvgS subsequently transfers its phosphate group to BvgA (BvgA-P), which 
then becomes activated and binds to specific cis-acting promoter sequences, thus inducing 
the transcription of Bvg+ phase-specific genes, commonly designated vags (for “vir-activated 
genes”) (36-38). Simultaneously, the transcription of vrgs (for “vir-repressed genes”) is 
repressed by a third protein that is expressed from the bvgASR locus, the 32 kDa cytoplasmic 
repressor protein BvgR (39, 40). Based on in vitro growth experiments, vags have been 
classified into three different temporal classes: early, intermediate, and late genes (41-43). 
Early genes, encoding the adhesins filamentous hemagglutinin (FHA) and fimbriae (Fim) 
respond rapidly to activation and require a lower concentration of BvgA-P for induction (42). 
Late genes, which include those encoding adenylate cyclase toxin (ACT) and pertussis toxin 
(Ptx), show relatively slow induction kinetics and require higher concentrations of BvgA-P for 
expression (42). The gene encoding pertactin (Prn) has been suggested to belong to the class 
of intermediate genes (44). The BvgASR locus is autogenously regulated and belongs to the 
early genes, providing an additional level of regulation for Bvg-induced class-switching (45). 
This phenomenon of differential gene expression has been attributed to architectural promoter 
differences, with the promoters of the late genes requiring higher levels of BvgA-P compared to 
the early promoter sequences (46). A similar expression pattern has been observed in vivo (43), 
which presumably enables the bacterium to adapt its virulence factor expression to different 
stages of infection or to niches containing different signals (e.g. temperature changes). The 
molecular mechanisms by which these virulence factors interact with the host will be discussed 
later in this review. 
When B. pertussis is grown under “modulating conditions” the BvgAS phosphorelay is 
inactivated (35). Under these conditions, BvgAS is unable to activate transcription of vags, 
whereas in turn, vrgs are expressed due to the absence of the repressor BvgR, resulting 
in an avirulent phenotype referred to as Bvg- phase. It is currently unknown whether this 
avirulent phase is still relevant and functional in B. pertussis. In contrast to the host-restricted 
B. pertussis, B. bronchiseptica has the capacity to survive for weeks in water suggesting the 
ex vivo environment may play a role in its transmission cycle (47). In B. bronchiseptica, motility 
(flagella) and urease-encoding genes are expressed specifically in the Bvg- phase, and it has 
been shown that this phase is essential for survival under nutrient-limiting conditions (48, 49). 
In comparison to B. bronchiseptica, B. pertussis has undergone significant loss of genes during 
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its host-adaptation, presumably because of the lack of a need for the environmental phase to 
enhance transmission rates (8). It is therefore not-unlikely that the Bvg- phase in B. pertussis 
represents an evolutionary remnant. 
In addition to the Bvg- and Bvg+ phenotypes that were originally observed in vitro, a third 
phase has since been identified, designated the intermediate or Bvgi phase. This phase can 
be induced under semi-modulating conditions, or by substituting one basepair in the bvgS 
gene (49). The Bvgi phase is typically characterized by the absence of vrg expression, the 
expression of some vags (e.g. FHA) but not others (e.g. Ptx, ACT) (50), and a third class of 
genes (class III genes) that is expressed exclusively in this phase (41). The main representative 
of the Bvgi phase is the Bvg-intermediate phase A (BipA) protein, which has been suggested 
to be important for early colonization of the airways (51, 52). A potential explanation for the 
existence of this phase is that it may play a role in the transmission and early respiratory 
tract colonization of B. pertussis (51). Mouse respiratory tract infection experiments with Bvgi-
locked and BipA deletion mutants have strengthened this hypothesis. The Bvgi-locked mutant 
was found to colonize the upper respiratory tract efficiently during early phases of infection, 
but was unable to persist during later stages of infection (53). Interestingly, using a Bvgi-locked 
BipA deletion mutant, this successful early colonization of the Bvgi-locked mutant was shown 
to be dependent on BipA (53). 
Although the Bvg-, Bvgi, and Bvg+ phases are highly distinctive in that each phase shows 
specific expression of certain genes, it is important to note that these findings apply to B. 
pertussis cultured under relatively static in vitro conditions. In contrast, the human respiratory 
tract is a highly variable environment, and under these conditions it is unlikely that the BvgAS 
system functions as an ‘on-off’ switch, but rather that it facilitates a spectrum of expression 
levels transitioning between the Bvg+, Bvgi, and Bvg- phases in response to local changes in 
environmental conditions (41). Due to its flexibility, the BvgASR system is nowadays considered 
a ‘rheostat’ (54).
The RisAS system
In addition to the BvgASR system, B. pertussis contains a second TCS called the regulator 
of intracellular response (Ris) system. This system is encoded by the risAS locus, originally 
identified in B. bronchiseptica. The ris locus encodes a response regulator (RisA) and a sensor 
kinase (RisS) (55). In B. bronchiseptica, this system functions independently of BvgAS, and 
contributes to persistence in the host by regulating the expression of multiple factors involved 
in intracellular survival (55, 56). The ability and mechanisms by which B. pertussis may survive 
in host cells will be discussed later in this review. In B. pertussis, the risS gene contains a 
conserved frameshift, and consequently encodes a truncated non-functional form of the RisS 
sensor (57). In contrast, RisA is still expressed and functional in B. pertussis. Indeed, the 
observation that deletion of risA results in a strong reduction of transcription of vrgs suggests 
that RisA plays an antagonistic role to BvgR in the regulation of vrg gene expression (57, 
58). Possibly, BvgR inhibits vrg gene expression by preventing binding of RisA to the vrg 
promoters, either by direct competition for promoter sequences, or indirectly by binding to 
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RisA. Alternatively, BvgR may act as a regulator of RisA expression analogous to its repression 
of vrg gene expression in the Bvg+ phase. However, a direct link between BvgR and RisA 
expression could not be established as no changes in risA transcription were observed when 
the bvgR gene was deleted (58). Another unresolved issue is the question whether or not RisA, 
similar to BvgA, requires phosphorylation in order to be active and if so, which factor mediates 
this reaction. Further research is needed to elucidate the exact interactions between RisA and 
BvgR and to characterize the contribution of RisA to the in vivo survival of B. pertussis. 
Interaction with the mucosal epithelium
The human respiratory tract poses a significant challenge to airway pathogens, like B. 
pertussis. The ciliated epithelium that lines the respiratory tracts ensures that mucus secretions 
containing particles (e.g. pathogenic microorganisms or pollen) are mechanically cleared 
from the nasal cavities, trachea and bronchial tubes. Colonizing B. pertussis also faces direct 
competition with the resident flora for nutrients and space, and is exposed to a range of host 
defense mechanisms that have evolved to limit or prevent microbial colonization, such as iron 
sequestration and the innate immune system. Successful infection of the host by B. pertussis 
is therefore critically dependent on its ability to resist these antimicrobial defense mechanisms. 
To this end, B. pertussis produces a number of adhesins and toxins that can alter the local 
environment to promote adhesion, invasion and biofilm formation on the host respiratory 
mucosa.
 
Iron acquisition 
B. pertussis, like all other bacteria, requires iron for a number of essential cellular processes. 
However, the free iron concentration in the human host is tightly regulated, with free [Fe3+] in 
the order of 10-24M on mucosal surfaces, while bacterial growth is only supported above 10-
7M (59). The human glycoprotein lactoferrin, as well as other iron-binding proteins, plays an 
important role in sequestering extracellular iron (60). To enable infection of the host, B. pertussis 
has evolved multiple iron acquisition pathways (reviewed in (61)). Additionally, B. pertussis 
is also able to use iron bound by exogenous siderophores. So far, four endogenous high-
affinity transport systems have been genetically characterized in B. pertussis. These include 
the alcaligin (62), the enterobactin (63), the heme utilization systems (64), and the fbpABC 
system which utilizes multiple distinct siderophores (65). Under iron-replete conditions, global 
expression of these systems is inhibited by the iron-dependent transcriptional repressor Fur 
(66). Conversely, under iron-limiting conditions, Fur-regulated genes become derepressed and 
transcription of these genes occurs. Importantly, the expression of each of these systems can 
be regulated independently by specific transcriptional activators that are responsive to their 
cognate iron source (67). Upon early colonization of the host mucosal surface, lactoferrin, which 
is abundantly present in the mucin-rich airway surface fluid, is most likely the predominant iron 
source taken up by the alcaligin siderophore system (68). This is supported by the observation 
that a B. pertussis strain with an inactive alcaligin transport system is outcompeted by its 
isogenic counterpart during early phases of infection (68). During the progression of infection, 
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both the host inflammatory response to B. pertussis and the pathogenic effects of secreted 
toxins compromise the integrity of the host epithelial barrier. Ultimately, when significant host 
cell lysis occurs, additional intracellular iron sources such as transferrin and heme proteins 
become available that can also be utilized by B. pertussis. The importance of these iron 
sources during the later stages of infection has also been recognized in vivo, as inactivation of 
the heme system rendered B. pertussis less infectious (69). 
Although the B. pertussis iron transport systems have been well studied, little is known 
about the role of other important trace metals such as magnesium, manganese, copper, cobalt, 
lithium, and zinc etc, which have been shown to play essential roles in other pathogenic bacteria 
(70, 71). Analysis of the B. pertussis genome has indicated the existence of genes coding for 
predicted trace metal transporters such as a putative permease protein for cobalt transport, a 
CorC protein for magnesium and cobalt efflux, and two homologs of GufA, a member of the 
ZIP zinc transporter family (8, 72). 
In conclusion, the existence of at least four distinct iron uptake mechanisms in the 
genome of B. pertussis clearly emphasizes the importance of iron during infection of the host. 
By using multiple iron acquisition pathways, B. pertussis is able to adapt rapidly to changes in 
available iron sources during infection. It is likely that other, less-studied trace metals may be 
of similar importance and further research into the utilization mechanisms for these metals is 
warranted to elucidate their exact contribution to colonization of the host.
Adherence and cytotoxicity
Many bacterial pathogens that occupy the mucosal surfaces of the human host produce 
adhesins and toxins that facilitate adhesion and transmission. The main B. pertussis virulence 
factors that have been associated with direct adhesion to host airways are FHA, fimbriae 
and Prn. Furthermore, three major protein toxins have been identified thus far, Ptx, ACT, and 
BteA, an effector of the type III secretion system (T3SS). Additionally, tracheal cytotoxin (TCT) 
is released from the cell wall of colonizing B. pertussis. These factors jointly facilitate the 
adhesion of B. pertussis to the human respiratory tract (see Figure 1 and Table 1). Before 
discussing the molecular mechanisms in detail, the modular structure of the adhesins and 
toxins will be briefly reviewed. 
Figure 1. Interaction of B. pertussis with the mucosal epithelium. In order to create a niche 
for colonization, B. pertussis engages multiple strategies. From left to the right: Several virulence 
factors mediate adhesion to respiratory cells. Tracheal cytotoxin (TCT) and lipo-oligosaccharide 
(LOS) synergistically evoke ciliary damage to the respiratory epithelium by initiating the release 
of destructive reactive oxygen species (ROS) such as nitric oxide (NO) via interleukin 1 (IL-1) 
induced type II nitric oxide synthases (inducible NOS, or iNOS) activation in mucus-secreting goblet 
cells (purple). B. pertussis invades epithelial cells and is able to form biofilms on the respiratory 
mucosa. Adenylate cyclase toxin (ACT) and the type III secretion system (T3SS) with its effector 
protein BteA subvert intraepithelial signaling pathways leading to cytotoxicity. Cytotoxicity leads 
to the availability of alternative iron-sources (Fe3+) and the exposure of cryptic binding sites. 
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Table 1. Virulence factors associated with colonization of the respiratory mucosa1
Bacterial 
factor(s)
Adhesion and 
invasion
Cytotoxicity Other function(s) Comment(s)
FHA Adhesion and cell 
invasion 
HBD and MCD mediate binding to 
host sugar-containing lipids; the 
RGD motif is involved in invasion; 
binding requires lipid raft in the host 
cell membrane
Fim Adhesion Probably bind to sugar-containing 
lipids; VLA-5 ligand implicated in 
epithelial invasion
Prn Adhesion and cell 
invasion
RGD implicated in adhesion and 
invasion
ACT Facilitates FHA-
mediated adhesion
Penetrates and 
intoxicates epithelial cells 
through cAMP production
BteA (T3SS) Implicated in 
facilitating adhesion
Induces a rapid, non-
apoptotic death in 
epithelial cells 
Associates with the cytoplasmic 
face of host lipid rafts
TCT and LOS Induces ROS production 
leading to ciliary 
epithelial cell damage 
Alcaligin 
system
Iron acquisition via 
lactoferrin
Enterobactin 
system
Iron acquisition 
via the 
xenosiderophore 
enterobactin
Heme system Iron acquisition via 
heme
Bps 
polysaccharide
Adhesion Biofilm formation
1 See text for references. Abbreviations: HBD, heparin-binding domain; MCD, mature C-terminal domain; 
ROS, reactive oxygen species; VLA-5, very late antigen 5. 
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The major adhesion factors 
FHA is a 232 kDa protein, present both in secreted and surface-associated form (73). The 
translocation and secretion of FHA is mediated by a two-partner secretion system. An 
important step in the FHA secretion pathway is the proteolytic removal of roughly one-third 
of the C-terminus of FHA by SphB1, a specific protease of the subtilisin superfamily (74, 75). 
Following cleavage, mature FHA remains noncovalently bound to the cell surface, probably 
via interactions between its N-terminal domain and a translocation-mediating protein called 
FhaC (76). Since adhesins typically remain associated with the bacterial surface to promote 
maximal attachment, the observation that FHA is weakly surface-associated and even released 
in copious amounts seems counterintuitive (74). However, colonizing bacteria can also benefit 
from a weaker interaction between bacterial adhesins and their host cell-ligands, as this may 
facilitate bacterial dissemination to other regions of the respiratory tract. The significance of 
this phenomenon has been demonstrated with an SphB1-deletion mutant that produces FHA 
exclusively in an immature, strongly membrane-associated form. Despite the enhanced ability 
of the mutant to bind pulmonary epithelial cells in vitro, it is significantly attenuated in the 
lungs of mice (77). Binding of FHA to cell-surface receptors on respiratory epithelial cells is 
mediated by the action of multiple binding domains including an Arg-Gly-Asp (RGD) domain, 
a carbohydrate recognition domain (CRD), a binding domain for heparin and other sulfated 
carbohydrates (HBD) present on host cell surfaces, a potential integrin binding domain, and its 
mature C-terminal domain (MCD), located distally from the cell surface (76).
Fimbriae are long, thin adhesive structures that extend from the outer bacterial membrane. 
B. pertussis fimbriae consist of one of the major fimbrial subunits (Fim2 or Fim3), and a minor 
subunit called FimD (78-82). FimD and two additional fimbrial chaperone proteins, designated 
FimB and FimC, mediate correct formation of the fimbrial structure and outer membrane 
translocation (82, 83). The Fim2, and most likely also the Fim3 subunit contain two regions 
with heparin binding activity (84), which may be involved in binding to the extracellular matrix 
of respiratory epithelial cells. 
Prn is a member of the autotransporter family and is characterized by its ability to direct 
its own secretion across the outer membrane using the Sec machinery (85, 86). Mature Prn 
(also known as p.69) is produced from a precursor protein of 93 kDa (p.93), following the 
removal of the 34 aa N-terminal signal peptide and a 30 kDa C-terminal part (p.30) (87, 88). 
Prn contains two proline-rich regions consisting of tandem repeats and an RGD-motif that has 
been implicated in adhesion (89). 
Toxins
Ptx is a secreted protein toxin and a key virulence factor produced exclusively by B. pertussis 
(reviewed in (90, 91)). Ptx is a hexameric AB5 protein toxin with a total mass of 117 kDa, 
consisting of five dissimilar subunits (PtxA-E, or S1-S5 respectively). It is transported across 
the bacterial outer membrane by the Ptl type IV secretion system, which is co-transcribed 
with the Ptx genes (92, 93). The A part consists of the PtxA subunit that contains the catalytic 
(ADP-ribosylating) domain. The B5 oligomer contains the PtxB-PtxE subunits (with two copies 
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of PtxD) that are involved in receptor binding. The N-terminus of the PtxB and PtxC subunits 
contain lectin-like CRDs that have been implicated in binding to cell-surface receptors (93-95). 
For Ptx activity, binding of NAD is critical as it donates its ADP-moiety during the ADP-ribose 
transfer reaction.
Another secreted toxin with a key role in B. pertussis pathogenesis is ACT (reviewed in 
(90)), which is a 200 kDa polypeptide that is secreted by a type I secretion system. It contains 
two major domains: a catalytic domain that includes the active site as well as a calmodulin-
binding site, and a hemolytic binding domain that is composed of a hydrophobic channel domain 
and calcium binding RTX repeats (96). The functional activity of ACT is critically dependent 
on the toxin having undergone post-translational palmitoylation of the K983 residue, which 
is catalyzed by CyaC during protein maturation (97). Additionally, post-translational acylation 
is important for the apoptotic and cytotoxic effects of ACT (98). Although the majority of ACT 
remains associated with the bacterium in an inactive form, a small amount of active toxin is 
secreted into the environment (99, 100). 
The T3SS represents a specialized secretory apparatus used by a wide variety of gram-
negative bacteria to interfere with host cell functioning. These systems enable translocation 
of effector proteins directly into the host cell cytosol. The majority of effector proteins are 
enzymes that modify cytoplasmic targets involved in important cellular events, including 
actin cytoskeleton remodeling, intracellular signaling and apoptosis (101). T3SS have been 
implicated as important mediators of virulence in a range of bacterial pathogens including 
Escherichia coli, Salmonella spp. and Yersinia spp. (102, 103). A BvgASR regulated T3SS and 
its effector proteins, such as BteA, have also been identified in Bordetella species, initially in B. 
bronchiseptica (103, 104) but later also in B. pertussis (105). BteA is a 69 kDa T3SS effector 
protein with an N-terminal lipid raft targeting domain and a C-terminal domain implicated in 
cytotoxicity (106, 107). 
Another toxin contributing to respiratory epithelial adhesion by B. pertussis is TCT (108). 
TCT is a 921 Da disaccharide-tetrapeptide belonging to the muramyl peptide family (109). In 
contrast to the other toxins described above, TCT is not a protein toxin but is released from B. 
pertussis cell wall peptidoglycans at relatively high levels (110).
Binding to the respiratory epithelium
Direct physical binding of B. pertussis to epithelial cells of the respiratory tract has been shown 
to be mediated predominately by the two major adhesins FHA and Fim described above (111-
113). A number of in vitro adhesion studies have shown that deletion of FHA from B. pertussis 
almost completely abrogates adherence to a wide variety of ciliated and non-ciliated epithelial 
cells, emphasizing the importance of FHA in this process. Tuomanen and coworkers first 
established a crucial role for FHA in a human tracheal epithelial cell model (114), followed by the 
identification of its host-ligand, i.e. galactose-glucose containing glycolipids (115). Subsequent 
studies implicated the CRD and HBD domains in the binding of sulfated carbohydrates and 
glycolipids present on the surface of ciliated and non-ciliated epithelial cells, respectively (116-
118). Interestingly, using blocking antibodies that specifically bind to each of the major FHA 
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domains implicated in binding it was shown recently that besides the HBD, the MCD is also 
involved in bacterial adhesion to non-ciliated cells (119). The binding potential of FHA is to 
some extent determined by its interaction with ACT (100). Membrane-bound ACT physically 
associates with FHA, and it has been postulated that this interaction may enhance the adhesive 
capacity of FHA as it changes the orientation of its binding domains (120). Furthermore, FHA-
mediated binding of B. pertussis to respiratory epithelial cells is dependent on the presence of 
lipid rafts in the host cell membrane (121). Lipid rafts are clusters of proteins and lipids in the 
membrane bilayer that are held together by cholesterol (122). When cholesterol was depleted, 
bacteria were significantly less able to bind to host cells, suggesting that cholesterol-containing 
lipid rafts are important for binding of FHA (121). This lipid raft dependency is not exclusive to 
B. pertussis, as lipid rafts are a prominent target for attaching bacterial pathogens by providing 
a platform with clustered signaling proteins (e.g. receptors) and lipid cofactors (reviewed in 
(123)). 
In both ciliated and non-ciliated tracheal and laryngeal adhesion models, deletion of 
the major and/or minor subunit genes of fimbriae significantly reduced adherence by more 
than 50%, emphasizing the importance of this virulence factor to cell attachment (113, 124). 
Although a specific receptor for fimbriae has not been identified on host tissues yet, sulfated 
sugar-containing molecules may be involved in fimbrial binding to the respiratory epithelium 
(84, 125). 
Despite initial reports that describe the effects of Prn deletion on adherence to Chinese 
hamster ovary cells and human nonrespiratory epithelial HeLa cells (86, 126), the exact 
contribution of Prn to adherence remains enigmatic. When Prn was first described in 1991 
by Leininger and coworkers, they showed a significant reduction in adherence when the Prn 
gene was deleted. Furthermore, binding inhibition studies with synthetic Prn-derived RGD-
containing peptides suggested that the RGD domain is important for adherence (86). However, 
later studies were unable to show a role for Prn in adherence to human laryngeal and bronchial 
epithelial cells (113, 127). Moreover, as Prn host ligands have as yet not been identified, 
the question remains whether Prn primarily contributes to adhesion or to other aspects of 
pathogenesis (see below). 
Early studies suggested a role for Ptx in bacterial binding to ciliated cells. A Ptx deficient 
strain was shown to be attenuated in its ability to adhere to ciliated cells in vitro, which could 
be restored when exogenous Ptx was provided (114). In support of this observation, it was 
reported that Ptx-mediated binding occurred in a carbohydrate dependent manner, by means 
of the lectin-like binding properties of the PtxB (S2) and PtxC (S3) subunits (95, 128). Although 
purified Ptx has been shown to bind to non-ciliated human bronchial and laryngeal cells in 
a dose-dependent fashion, adherence of a Ptx deletion mutant strain to these cells was not 
attenuated (113). Based on these and other recent observations, the current hypothesis is that 
Ptx is not an adhesin, but rather facilitates adhesin-driven binding by modulating host immune 
responses (129) (discussed later in this review). 
B. pertussis adhesion to the respiratory epithelium is further supported by toxin-induced 
cytotoxicity, as this leads to the exposure of cryptic receptors on the basement membrane. 
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ACT for instance is able to penetrate the cytoplasmic membrane of host cells, which is 
followed by the cleavage and cytoplasmic release of its adenylate cyclase (AC) domain. 
Upon internalization, AC becomes activated by the binding of intracellular calmodulin, and 
concomitantly subverts cellular signaling pathways by the uncontrolled conversion of ATP to 
cyclic AMP (cAMP), which is a key secondary messenger molecule (130). Initially, ACT was 
found to target cells expressing complement receptor 3 (CR3, also known as CD11b/CD18), 
an integrin and pattern-recognition receptor (PRR) expressed on the surface of phagocytic 
leukocytes, such as macrophages, neutrophils, and dendritic cells (DCs), as well as on natural 
killer (NK) cells (130). More recently, ACT was found to intoxicate epithelial cells as well by 
targeting their basolateral membrane (131). 
Respiratory epithelial adhesion is further supported by the highly potent cytotoxic 
activities of the T3SS effector protein BteA (132) and TCT (108). BteA is translocated to the 
cytoplasmic site of lipid rafts in the host cell membrane via an N-terminal lipid raft-targeting 
domain (106). Interestingly, BteA was shown to associate with the cytoplasmic side of lipid 
rafts which are known to function as Bordetella attachment sites (106). However, BteA is 
not directly involved in adhesion, as a T3SS-inactivated mutant was found to adhere to lipid 
rafts in a similar manner as its parental wild-type strain (106). Instead, BteA acts indirectly by 
inducing a rapid, non-apoptotic death, as shown in HeLa, rat lung epithelium (L2) and human 
renal epithelial (293T) cell models (132-134). Thus far the mechanisms underlying this potent 
cytotoxicity have not been established. In contrast, the molecular mechanisms of TCT-induced 
toxicity have been the subject of study for decades and are very well understood. In vitro 
studies performed in the 1980s already showed that TCT was able to inhibit DNA synthesis in 
tracheal epithelial cells and that it caused progressive cytotoxic alterations in ciliated cells of 
primary hamster tracheal organ cultures (108). These cytotoxic effects are very similar to the 
TCT-induced effects on human-derived tissue (135). Further research showed that TCT-like 
muramyl peptides were able to stimulate the production of interleukin-1 (IL-1) by phagocytes 
(136) and hamster tracheal epithelial cells (137). In the latter study, IL-1 production was found 
to induce cellular cytotoxicity. As the induction of IL-1 in and of itself may also be associated 
with a protective response against infection with B. pertussis, the specific downstream effects 
of IL-1 induction were investigated in a follow-up study by Heiss et al. (138). They showed that 
the TCT-mediated expression of IL-1 induced type II nitric oxide synthases (inducible NOS, or 
iNOS), leading to the synthesis of nitric oxide (NO). Under normal circumstances, the synthesis 
of NO is tightly regulated, as too much free NO may lead to the production of reactive oxygen 
or nitrogen species (ROS or RNS, respectively). On the one hand, these free radicals play an 
important protective role in the immunological response, as they are released by phagocytic 
cells in a respiratory burst, thus contributing to the control of invading microbial pathogens. On 
the other hand, the TCT-mediated induction of IL-1 may also lead to the uncontrolled formation 
of high levels of free radicals, which may subsequently inhibit vital cellular processes. It is 
currently believed that the high levels of NO are responsible for the observed respiratory 
cytotoxicity of TCT (138). A later study showed that the production of NO is not induced by 
TCT alone, but requires the synergistic action of TCT and lipo-oligosaccharide (LOS), the 
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endotoxin produced by B. pertussis (139). Although NO primarily affects ciliated epithelial cells, 
the source of NO is in fact not the ciliated epithelium itself, but adjacent non-ciliated mucus-
producing goblet cells. These goblet cells themselves remain undamaged during this process 
(140), and NO may be released through diffusion, thus contributing to remote cytopathologic 
effects on the ciliated epithelium. 
In conclusion, current evidence indicated that FHA and Fim are the major adhesins used 
by B. pertussis to bind receptors on the host cell epithelium, while Ptx, ACT, BteA and TCT 
(in synergy with LOS), indirectly contribute to bacterial attachment at different levels. First, 
cytotoxic activity establishes a niche devoid of ciliary epithelium, thus preventing mechanical 
clearance of attaching bacteria. Secondly, induced cellular damage results in the exposure 
of cryptic receptors on the basement membrane, thus allowing the pathogen to attach more 
efficiently. The inability of the host to remove mucus from the respiratory tract due to lack 
of ciliary action has been linked to the persistent coughing observed in individuals suffering 
from pertussis. As coughing is likely to contribute to spread of B. pertussis throughout the 
population, these virulence factors may play a pivotal role in the ecology of B. pertussis not 
only by enabling adherence, but also by contributing to transmission.
 
Importance of adhesins and toxins for colonization in animal models 
The contribution of FHA, fimbriae, and Prn to infection in the host has also been studied 
in various animal models. The fhaB and fim genes belong to the early genes, while prn is 
optimally expressed in the intermediate phase (see above). This may suggest that FHA and 
Fim are important at an earlier phase of infection compared to Prn. In 1991, Roberts and 
coworkers tested a Prn deletion mutant in a mouse pulmonary infection model and found 
no significant colonization defect in either trachea or lungs (127). This would suggest that 
Prn is not essential for successful colonization of the lower respiratory tract, at least in mice. 
In contrast, we have recently found that deletion of the Prn gene does affect colonization 
in the mouse (141). Furthermore, studies with B. bronchiseptica have shown that although 
inactivation of the Prn gene did not affect adherence to epithelial and macrophage-like cells or 
respiratory infection in rats (142), the mutant was cleared much faster than wild-type bacteria in 
a mouse model. This was predominantly caused by the effect of Prn on inhibition of neutrophil-
mediated clearance. It was also shown that the RGD motif, in contrast to previous reports, 
did not contribute to Prn function in the mouse model (142). B. bronchiseptica was also used 
to study the role of FHA and Prn in its natural host, the swine (143). Colonization by the FHA 
mutant was strongly reduced compared to the wild-type. In comparison, while the Prn mutant 
caused similar disease severity as the wild-type, it was significantly attenuated in colonization 
during early and late infection. These results emphasize the multi-factorial contribution of Prn 
to infection, and suggest that the primary role of Prn may not be adhesion but that it rather has 
toxin-like activities. 
Using a mouse model of infection, FHA and Fim were both shown to be important 
for bacterial persistence in the trachea, whereas only FHA contributed to nasopharyngeal 
colonization (144). In this study, neither FHA nor Fim mutants were attenuated in the lungs 
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(144). This study also used fimbrial mutants lacking the major fimbrial subunit genes. It was 
later found that such mutants still expressed the minor fimbrial subunit FimD on their surface 
(79), confounding the interpretation of previous findings. A comparison of an FHA mutant to 
a strain lacking both major and minor fimbrial subunits showed that the Fim mutant had the 
greatest defect, as it was significantly less able to colonize the nasopharynx, trachea, and 
lungs (79). Interestingly, a later study showed that the complete Fim mutant induced a more 
severe lung inflammation compared to an FHA mutant and the wild-type strain, suggesting 
that Fim may also act as an immunosuppressant (145). Kimura et al. found that FHA was only 
important for initial colonization of the mouse trachea, but not for colonization of the lungs 
(146). In summary, these animal studies suggest an especially important role for fimbriae in 
colonization, but also imply FHA and Prn in this process. 
Similar to the adhesins, the roles of the toxins have also been studied in various animal 
models. Using mixed infection experiments in mice, Carbonetti and coworkers established 
markedly distinct roles for Ptx and ACT in respiratory tract colonization. A Ptx deficient strain 
was shown to be severely attenuated in colonization. This became apparent within 1-2 days 
post infection, but showed the strongest defect seven days post infection. Co-administration of 
soluble Ptx with the Ptx deficient strain restored colonization to wild-type levels (129). Although 
an ACT deletion mutant was also attenuated in colonization, the phenotype was significantly 
different from the Ptx mutant. The ACT mutant was able to colonize as efficiently as the wild-
type parental strain during the early phase of infection, but was unable to persist beyond the 
first four days post-infection. In contrast to Ptx, providing soluble ACT together with the deletion 
mutant did not have any significant effect (147). However, since ACT is an integral membrane 
protein that is only functional upon direct contact with its target cell (148), it cannot be excluded 
that the protein production and purification procedure may have rendered ACT inactive. Thus, 
while Ptx already contributes during the initial phases of infection, the effects of ACT do 
not become apparent until later during infection. This suggests that these two toxins serve 
complementary functions in the pathogenesis of infection, On the one hand by contributing to 
the initial establishment of infection, and secondly to persistence in the respiratory tract. 
The in vivo contribution of the T3SS in B. pertussis has been studied by Fennelly and 
coworkers. Similar to studies with Salmonella and Yersinia (149, 150), they deleted the BscN 
gene in B. pertussis, which resulted in an abolished secretion of T3SS effector proteins (105). 
The BscN deletion mutant colonized the lungs significantly less efficiently during the complete 
course of infection, and it was cleared earlier than the wild-type strain (105). 
In addition to the virulence factors discussed above, B. pertussis produces several other 
factors that are important for colonization. One of these factors is a 34 kDa protein designated 
tracheal colonization factor (TcfA) (151, 152). Finn and coworkers showed that a TcfA-deficient 
mutant strain colonized the trachea of mice at 10-fold lower levels, but found similar colonization 
rates in the lungs (152). In spite of this interesting observation, the mechanisms through which 
TcfA contributes to B. pertussis pathogenesis have not yet been elucidated. 
The effects observed in these animal studies are not easily associated with a single 
aspect of disease, as the majority of virulence factors are implicated in multiple virulence-
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related processes. For instance, FHA is an important adhesin, but it has also been linked to 
the apoptotic induction of host epithelial and phagocytic cells (153). Furthermore, Ptx and 
ACT both facilitate adhesin-mediated adherence to host cells, but are primarily involved in 
modulating the host immune response (discussed later in this review). Nonetheless, the 
virulence factors discussed above are all important for the ability of B. pertussis to colonize the 
human respiratory epithelium.
Epithelial cell invasion and survival
Many pathogens invade host cells to hide from the immune system, to intoxicate effector cells, 
or to gain access to scarce (metabolic) resources (101, 154). A number of studies have provided 
evidence that B. pertussis may also be capable of cell invasion, using both primary cell cultures 
as well as cell lines. Thus far, several virulence factors that are involved in this process have 
been identified. However, it should be noted that these studies often presented conflicting roles 
for particular virulence factors. For example, a B. pertussis Hela cell invasion model identified 
both FHA and Ptx as positive mediators of invasion (155). In contrast, two other studies were 
unable to reproduce these findings, although a similar positive trend was observed for FHA 
and Ptx (156, 157). A more convincing role for FHA in cellular invasion of human respiratory 
epithelial cells has subsequently been established using three other cell invasion models of 
both human cell lines and primary cultures (156, 158). Ishibashi and coworkers investigated 
which molecular domains of FHA are involved in this process. By substituting one amino 
acid in the RGD domain of FHA, they were able to show that this domain is essential for 
bacterial entry into host epithelial cells (158). Follow-up studies implicated the intercellular 
adhesion molecule 1 (ICAM-1, or CD54) and the very late antigen 5 (VLA-5, also known as 
ITGA5 or CD49e) integrins in FHA-mediated cellular entry (158, 159). ICAM-1 expression by 
epithelial cells was found to be upregulated in response to B. pertussis in a nuclear factor κB 
(NF-κB) dependent manner, and this upregulation required participation of both FHA (with 
its RGD domain) and VLA-5 (159, 160). Although invasion by B. pertussis is associated with 
increased ICAM-1 expression through the early expressed FHA, induction of ICAM-1 has also 
been shown to be associated with increased leukocyte recruitment and clearance of bacterial 
pathogens (161). Interestingly, Ptx, which is expressed maximally later during infection, has 
been shown to inhibit the expression of ICAM-1 (159). This may point to a concerted modulation 
of the host by B. pertussis, by which the bacterium first enables adhesion and cellular entry 
through FHA-mediated ICAM-I up-regulation. Later during infection, when the ability to spread 
to other niches and hosts outweighs the need for adherence, inhibition of ICAM-1 by Ptx would 
become important. Although VLA-5 integrin has been shown to be involved in invasion, a direct 
interaction with FHA appears unlikely, as VLA-5 has been found to interact specifically with 
FimD (162). To study the contribution of fimbriae to invasion, Fim2 and Fim3 deletion mutants 
were tested for their ability to invade epithelial cells. No difference in uptake levels compared 
to wild-type was seen for either mutant, suggesting they are not required for invasion (156). 
However, given that these mutants still express FimD on their surface, a role for fimbriae in 
invasion cannot be completely ruled out yet. 
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Studies showed conflicting results with regard to involvement of Prn in invasion. Initially, it 
was suggested that Prn was not involved in bacterial uptake, as a Prn deletion mutant invaded 
Hela cells to the same extent as its parental wild-type strain (127). In contrast, the same mutant 
was found to be significantly attenuated for invasion in a human laryngeal epithelial cell model 
(156). A role for Prn in invasion was further supported by the observation that this process was 
inhibited in the presence of peptides derived from Prn with the RGD motif (163). Based on the 
last two studies, it seems plausible that Prn contributes to the ability of B. pertussis to bind and 
invade respiratory epithelial cells, but the underlying molecular mechanism has not yet been 
resolved.
Similar to FHA, Fim and Prn, the involvement of ACT in epithelial cell invasion remains 
an enigma. An identical ACT deletion mutant (164) has been used in three different studies, 
all of which employed a Hela cell invasion model. Although one study could not identify a role 
for ACT in invasion (157), the other two studies showed that inactivation of ACT enhanced 
the uptake of B. pertussis by Hela cells (155, 156). Bassinet and coworkers also showed that 
the ACT mutant was more rapidly taken up by tracheal epithelial cells, suggesting that ACT 
may be able to inhibit epithelial cell invasion (156). Given the indirect effect of ACT on FHA-
mediated binding (100), and the role of FHA in epithelial cell invasion, one may expect that ACT 
inactivation would reduce uptake. However, as experimental evidence points to the contrary, 
further research is required to unravel the specific mechanism by which ACT contributes to 
epithelial cell invasion. 
The first in vivo evidence of intracellular survival of B. pertussis in an animal host dates 
from 1969, when Cheers & Gray challenged mice intranasally with B. pertussis. Following 
infection, bacteria were detected inside alveolar macrophages (165). This intracellular 
phenotype has later been confirmed in two other animal studies that described the presence 
of viable, intracellular bacteria in the broncho-alveolar lavage 19 days after infection (145, 
166). Although these findings suggest that B. pertussis can survive inside cells, interpretation 
of these results is complex as the studies do not discriminate between bacteria that have 
only just entered cells and bacteria that have survived intracellularly for a longer time. All 
of these findings bring us to an important question: when and where during infection does 
cellular invasion contribute to the survival of B. pertussis? For instance, if invasion reflects an 
immune evasion strategy to survive in the host, one would expect B. pertussis to also be able 
to survive for an extended period of time inside these cells. However, there is strong data that 
suggests otherwise. E.g. despite the fact that B. pertussis was highly proficient in invading 
human colonic epithelial (Caco-2) cells, survival of intracellular bacteria was impaired (167). 
Similarly, B. pertussis was also unable to survive in human tracheal epithelial cells (156). 
To conclude, despite a significant amount of data in support of invasion of epithelial cells, 
its role in the life cycle of B. pertussis remains enigmatic. Importantly, the exact molecular 
mechanisms underlying this process remain currently unknown, and many of the experimental 
observations from invasion studies may in fact be more incidental as the result of tight adherence, 
rather than represent a specific invasion mechanism. It may be possible that epithelial cell 
invasion does not play a role in the ecology of B. pertussis at all, but represents an evolutionary 
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dead-end road, similar to the invasion of meninges caused by Neisseria meningitidis (168). 
Further research is clearly warranted to establish the importance of these mechanisms for 
bacterial infection and persistence in the host.
Biofilm formation 
Many pathogenic bacteria are capable of forming well-structured communities on various 
substrates or cells, commonly referred to as biofilms. Biofilm formation is an essential pro-
cess for many mucosal pathogens, as it facilitates successful colonization and persistence in 
the host (169), mainly by providing resistance to antibiotics and host immune defenses (170). 
In the last few years it has been recognized that B. pertussis forms biofilms in vitro and in 
vivo (171-174). Here we will discuss the role and consequences of this phenotype during B. 
pertussis infection. 
The development of a biofilm is a very complex process, in which bacteria transit through 
distinct stages of multicellular organization in response to various environmental stimuli (175). 
Initially, planktonic bacteria irreversibly attach to a surface, for instance the respiratory tract 
mucosa. This is followed by the formation of discrete cell clusters called microcolonies. This 
can either be due to clonal expansion of attached bacteria or via the recruitment of additional 
planktonic cells. These microcolonies then grow in size and coalesce to form mature 
macrocolonies, in which cells are embedded in amorphous slimy material, primarily consisting 
of exopolysaccharides, proteins, and DNA (176). Finally, macrocolonies can dissolve, leading to 
the release and dissemination of bacteria to other surface areas. Several models are available 
for studying biofilm formation in vitro, ranging from simple methodologies such as growth on 
agar plates and plastic microtiter dishes to more advanced flow cell methods (reviewed in 
(177)). It seems likely that these methods mimic biofilm formation in the host only to varying 
degrees. 
Biofilm formation by pathogenic bacteria is generally considered to be a highly regulated 
process, tightly coupled to the regulation of virulence (178). Studies from the last 20 years 
revealed that bis-(3´-5´)-cyclic dimeric guanosine monophosphate (c-di-GMP) is a conserved 
key regulatory molecule controlling the transition between motile planktonic and sedentary 
biofilm-associated lifestyles of many bacterial species. It does this by regulating genes involved 
in motility, cell-cell communication (or quorum sensing), and the biosynthesis of adhesins and 
exopolysaccharide matrix substances (for recent reviews see (178-180)). Thus far, the role 
of c-di-GMP in the regulation of B. pertussis biofilm formation remains largely speculative, as 
most of our assumptions are based on in silico analysis that have not been confirmed in the 
laboratory yet. Analysis of the B. pertussis genome identified the presence of five putative 
diguanylate cyclase (DGC) encoding genes (181). These enzymes are characterized by the 
presence of a GGDEF domain and are capable of catalyzing the formation of c-di-GMP (182). 
Wan and coworkers showed that a mutant strain deficient in one of the DGCs (BpeGReg, B. 
pertussis globin-coupled regulator) has a reduced ability to form biofilms on plastic, suggesting 
a role for c-di-GMP signaling in biofilm formation by B. pertussis (181). Additionally, the B. 
pertussis genome contains four genes encoding putative phosphodiesterases (PDEs). PDEs 
Introduction | 35
1
contain an EAL domain, associated with cyclic di-GMP phosphodiesterase activity, and are 
able to hydrolyze c-di-GMP (182). Interestingly, one of the B. pertussis proteins that contain an 
EAL domain is BvgR (183). It has been postulated that the increased expression of BvgR in the 
virulent phase may result in a reduction of the amount of cellular c-di-GMP, thereby inhibiting 
biofilm formation. However, whether BvgR actually displays PDE activity has not yet been 
confirmed. Furthermore, in vitro experiments with wild-type B. pertussis and a Bvg- phase-
locked derivative showed that biofilm formation occurred exclusively under Bvg+ conditions, 
suggesting that BvgR many not play a crucial role in this process (173, 184). Conversely, in 
B. bronchiseptica, the Bvg- phase has recently been shown to be important for the early initial 
stages of biofilm formation (185) while earlier work showed maximal biofilm formation under 
Bvgi phase conditions (186). Further research is warranted to elucidate the role of c-di-GMP 
signaling and the BvgASR system in B. pertussis biofilm formation. 
For a better understanding of the significance of biofilm formation in pertussis 
pathogenesis, identification of the molecular factors involved in this process is of utmost 
importance. The observation that Bvg- phase-locked B. pertussis are unable to form biofilms 
(173) may suggest that vags are important for biofilm formation. As biofilm formation is initiated 
by the attachment of planktonic cells (175), adhesins are hypothesized to play an essential 
role in this process. In vitro experiments with B. bronchiseptica suggested that this is indeed 
the case, as FHA and Fim deletion mutants were shown to be highly attenuated in their ability 
to form biofilms on plastic (186). More recently it was found that FHA-mediated adhesion 
is critical for in vitro as well as in vivo B. pertussis biofilm formation (187). The observed 
attenuation of B. bronchiseptica was Bvg-phase dependent, as the Fim deletion mutant was 
affected in biofilm formation under Bvg+ conditions, whereas the FHA deletion mutant showed 
a defect under Bvgi conditions (186). Furthermore, this study also showed that deletion of 
ACT resulted in increased biofilm formation (186), which suggests that ACT may directly or 
indirectly inhibit biofilm formation in B. bronchiseptica. Given that ACT is expressed maximally 
in the Bvg+ phase whilst FHA is expressed under both Bvgi and Bvg+ conditions (49), it has 
been speculated that the weaker biofilm phenotype of Bvg+-phase B. bronchiseptica is at least 
partially mediated by the interaction of ACT with FHA (100). Interestingly, B. pertussis shows a 
similar phase-dependent expression pattern of FHA and ACT (41); further research is required 
to elucidate the molecular mechanisms by which these factors contribute to biofilm formation. 
For the formation of a mature biofilm, or macrocolony, bacteria present in microcolonies 
need to produce and secrete matrix components such as proteins, lipids, DNA, and most 
importantly, polysaccharides (188). Parise and coworkers identified a locus required for the 
production of cell surface-associated poly-ß-1,6-N-acetyl-D-glucosamine (poly-ß-1,6-GlcNAc, 
also called Bps polysaccharide), which was designated the Bordetella BpsABCD locus (174). 
This study showed that biofilm formation was inhibited both in the presence of dispersin 
B, a Bps polysaccharide-degrading enzyme, or in a BpsABCD deficient background (174). 
Furthermore, a follow-up study showed that the BpsABCD deletion mutant was unable to form 
a robust biofilm in the mouse respiratory tract, validating previous in vitro data (189). Moreover, 
a recent study showed that the role of the Bps polysaccharide is limited to early colonization 
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and biofilm formation in the nose and trachea but not in the lungs (172). Interestingly, the Bps 
polysaccharide was found to function as an adhesin, as it specifically promoted adhesion to 
human nasal epithelial cells and not to human lung epithelial cells (172). This suggests that the 
cryptic receptor for Bps is specifically expressed in the upper respiratory tract, and that biofilm 
formation may be especially important for colonization, and possibly also for transmission. 
In order to gain a deeper insight in the macromolecular composition of B. pertussis 
biofilms, Serra and coworkers used a combined approach of proteomics and Fourier transform 
infrared spectroscopy to identify molecules involved in biofilm formation (190). Their analysis 
showed that in vitro biofilm formation has a distinctive and specific impact on the bacterial 
physiology compared to planktonic growth. The proteome profile revealed that about 8-10% 
of the proteins are differentially regulated in biofilms, including an increased expression of 
Prn and BipA (190). Significantly, the most outstanding and distinctive physiological feature of 
B. pertussis biofilms was linked to carbohydrate metabolism. B. pertussis biofilms displayed 
an increase in carbohydrate production which coincided with the de novo expression and 
over-expression of three proteins involved in polysaccharide biosynthesis, modification, and 
transport (190). Further characterization showed that B. pertussis specifically produces an 
acidic-type polysaccharide. However, they did not identify the Bps polysaccharide discussed 
earlier (174), suggesting that the polysaccharide composition of B. pertussis biofilms is rather 
complex.
In summary, biofilm formation by B. pertussis is a novel and largely unexplored field 
of research, with potentially significant implications for the design of therapeutics. Further 
experiments using specific gene-deficient strains are required for the clarification of the 
factors involved in the complex process of biofilm formation by B. pertussis. Importantly, 
the mechanisms by which the BvgASR system controls biofilm formation, and under which 
conditions and in which niche biofilm formation occurs in the host, should be further elucidated.
 
Modulation of the host immune response 
Infection with B. pertussis leads to the induction of an innate response and the subsequent 
development of specific immunity (191). The respiratory epithelium, together with resident 
antigen presenting cells (APCs) such as alveolar macrophages and DCs are the primary 
host innate immune cells that sense and shape initial local immune responses towards B. 
pertussis. As the infection progresses B. pertussis is challenged by an additional host defense 
mechanism: the adaptive immune system. The main effectors of this system are the T and 
B lymphocytes, which eventually mediate clearance through the development of protective 
immunity against the pathogen. However, B. pertussis has evolved a number of strategies to 
prevent or modulate specific aspects of this response, thus delaying clearance and improving 
survival chances and transmission to the next host (see Figure 2 and Table 2). In this section 
we will discuss how B. pertussis interacts with specific components of the immune system to 
modulate the host immune response to facilitate survival and replication in the respiratory tract. 
Introduction | 37
1
DNon-apoptotic
cell death Apoptosis
LOS
Classical pathway
LOS
Immune cell
recruitment
Blood circulation
Chemokine
production
Complement
inhibition
IL-8
CXCL5
Ptx
FHA
ACT
BrkA
C1INH
SP-A
B. pertussis
TLR4
CR3
CR3
N
CR3
CR3
ACT
DC
AMAM
AM
Ptx
Ab 
response
C4BP
Mucosa
Lumen
Chemotaxis
Respiratory burst
Phagocytic killing
BopN
IL-10
IL-12
Ptx
FHA
TLR4
T3SS
Immune 
suppression
B
E
A
C
G
F
H
Figure 2. B. pertussis virulence factors modulating the host immune response. The most 
relevant aspects of host immune manipulation by B. pertussis in the respiratory tract are schematically 
illustrated. (A) The lipo-oligosaccharide (LOS) molecule of B. pertussis is not recognized and bound by 
host surfactant protein A (SP-A) due to its atypical structure, and thereby protects the pathogen from 
SP-A-mediated clearance. (B) B. pertussis inhibits complement-mediated killing (classical pathway) 
through the action of Bordetella resistance to killing A (BrkA), and by the recruitment of host C1 esterase 
inhibitor (C1INH) and C4b-binding protein (C4BP). (C) Pertussis toxin (Ptx) is able to intoxicate alveolar 
macrophages (AMs) by ADP-ribosylation of its G-proteins. (D) Ptx inhibits the recruitment of immune 
cells including AMs, neutrophils (N), and T cells (not shown) by inducing the release of chemokines (IL-
8 and CXCL5) from epithelial cells. (E) Adenylate cyclase toxin (ACT) and filamentous hemagglutinin 
(FHA) inhibit macrophage effector functioning by inducing apoptosis in a complement receptor 3 (CR3) 
dependent manner. (F) Cellular immunity is suppressed by the concomitant action of LOS and Ptx on 
Toll-like receptor 4 (TLR4), FHA and ACT on CR3, and the type III secretion system (T3SS) secreted 
protein BopN, on dendritic cells (DCs), which mediate the suppression of IL-12 and the induction of 
IL-10. (G) ACT is able to subvert cyclic AMP (cAMP) signaling in phagocytes and thereby affects their 
bactericidal activity by inhibiting chemotaxis, the production of superoxides (and hence the respiratory 
burst), and killing. (H) Ptx is able to enter the circulation and suppress antibody responses to B. pertussis 
antigens. 
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Table 2. Virulence factors that modulate the host immune system1
Bacterial 
factor(s)
Innate immune system Adaptive immune system Comment(s)
FHA Drives phagocytes into apoptosis, 
Stimulates IL-10 expression in DCs; 
Implicated in C4BP binding and recruitment
Skews T cell differentiation 
towards Th17 subtype 
Induces CR3 up-regulation 
in PMN; suppresses IL-12 
and induces IL-10 and IL-6 in 
macrophages
Ptx Inhibits immune cell recruitment; 
Intoxicates AMs through ADP-ribosylation 
of their G-proteins; Suppresses phagocytic 
activity of monocytes
Suppresses antibody 
responses; Skews T cell 
differentiation towards Th17 
subtype
PAMP for TLR2/4, Induces CR3 
up-regulation in PMN
ACT Suppresses the bactericidal activity 
of monocytes and neutrophils; Drives 
phagocytes into apoptosis; Synergizes 
LOS induced IL-10 production
Skews T cell differentiation 
towards Th17 subtype
BopN 
(T3SS)
Penetrates DCs and induces IL-10 
expression 
TCT Inhibits immune cell recruitment PAMP for murine Nod1
LOS PAMP for TLR4, not recognized 
by SP-A
BrkA Inhibits the deposition of soluble 
complement factors on the bacterial 
membrane
1 See text for references. Abbreviations; AMs, alveolar macrophages; C4BP, C4-binding protein; CR3, 
complement receptor 3; DCs; dendritic cells; IL, interleukin; Nod1, nucleotide-binding oligomerization 
domain-like receptor 1; PAMP, pathogen-associated molecular patterns; PMN, polymorphonuclear 
neutrophils; SP-A. surfactant protein A; TLR, Toll-like receptor. 
Innate recognition 
The initial recognition by resident immune cells and respiratory epithelial cells represents an 
important step in the successful induction of specific immunity. DCs and macrophages are 
specialized inflammatory cells that are strategically localized throughout the body near potential 
pathogen entry portals, including the respiratory tract. These cells act as sentinels for the 
immune system by sensing the presence of potential pathogens through PRRs. Their main aim 
is to recognize and process antigens and present these to the adaptive immune system. PRRs 
recognize distinct evolutionary conserved microbial components called pathogen-associated 
molecular patterns (PAMPs) such as lipids, lipoproteins, proteins, and nucleic acids, derived 
from a wide range of bacteria, viruses, parasites, and fungi (reviewed by (192, 193)). There 
are many different classes of PRRs, including surface-expressed Toll-like receptors (TLRs), 
cytosolic nucleotide-binding oligomerization domain (NOD)-like receptors, C-type lectin 
receptors, and retinoic acid-inducible gene-I-like receptors. Prevention of an effective immune 
response, either through directly preventing recognition or by modulating the downstream 
pathways, is an effective survival mechanism for bacteria. The biological mechanisms by 
which B. pertussis achieves this will be discussed here.
Most efforts aimed at elucidating the interaction between B. pertussis and innate immune 
cells have looked at human monocyte-derived DCs (MDDCs), as these cells are relatively 
easy to culture in vitro. Immature MDDCs express a repertoire of PRRs, such as TLR2, TLR4, 
TLR5, but not TLR9, as well as a range of intracellular PRRs, that are able to recognize several 
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bacterial PAMPs.
TLR4 is involved in the recognition of LPS (192, 194). Typically, LPS structures are 
comprised of three distinct structural domains, the lipid A, the core oligosaccharide, and 
O-antigenic repeats. LPS is bound by the LPS-binding protein, which forms a complex with 
CD14, followed by the transfer of LPS to the surface-exposed TLR4-MD-2 complex. Following 
recruitment of MyD88 and TRIF to the cytoplasmic domain of TLR4, NF-κB and interferon 
regulatory factor 3 (IRF3) signaling pathways are induced, leading to the production of pro-
inflammatory cytokines including type I interferons and IL-6 (193). 
In contrast to most Gram-negative bacteria, B. pertussis produces a LOS that has a 
branched core structure with a non-repetitive trisaccharide, rather than a long repeating O-side 
chain (195). The lipid A moiety of B. pertussis LOS also activates TLR4 signaling pathways in 
MDDCs, albeit significantly less efficient compared to the typical lipid A domain present on the 
LPS structure of enteric Gram-negative pathogens (196, 197). 
Activation of TLR4 signaling pathways by LOS is dependent on recognition of the 
relatively conserved lipid A structure moiety (193). In recent years, it has become apparent that 
variation in bacterial LPS is not restricted to the O-antigen repeats but also occurs in the lipid 
A region, leading to differential inflammatory responses (198). Initially, Preston et al. showed 
that the lipid A moiety of B. bronchiseptica LPS is modified through the palmitoyl transferase 
activity of the Bvg+ phase-specific PagP enzyme (199). By expressing B. bronchiseptica PagP 
and its antagonist PagL in B. pertussis, Geurtsen et al. revealed that these enzymes can 
modify B. pertussis LOS in a similar fashion. Importantly, they showed that the PagP-mediated 
palmitoylation is crucial for the endotoxic activity of LOS (200). However, it should be mentioned 
that although the genome of B. pertussis contains both genes, they are both pseudogenes and 
therefore cannot explain the high degree of LPS variation that was observed by the authors 
(200). This implies that other enzymes with similar activity may be expressed in B. pertussis, 
such as the outer membrane phospholipase A. 
It is tempting to speculate that B. pertussis is able to modulate its LOS in response to 
changing conditions within the host, as for example has been observed in B. bronchiseptica 
in which LPS biosynthesis is Bvg-regulated (201). In fact, B. pertussis has been found to 
substitute the lipid A phosphate groups of its LOS with glucosamine (GlcN), which also 
occurs in a BvgAS-dependent manner under Bvg+ conditions (202, 203). Importantly, GlcN 
substituents have been shown to be more potent inducers of the release of proinflammatory 
cytokines by macrophages (204). Although the in vivo significance of this observation has not 
yet been determined, it could be hypothesized that GlcN-modifications of LOS are important 
for skewing the host immune response, as they induce a different cytokine response. The 
mucosal surfaces of the upper respiratory tract are colonized with a plethora of other species 
and consequentially, the innate immune system is stimulated with a complex mixture of PAMPs, 
including B. pertussis LOS. In contrast, B. pertussis LOS may be able to interact in a more 
direct manner with the innate immune system in the lungs, which are normally sterile. It would 
be interesting to investigate if GlcN-modification of LOS is dependent on the location and 
differs between the upper and lower respiratory tract. One interesting alternative hypothesis for 
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the biological effect of the modified LOS is that it may also play a role in altering the outcome 
of bacterial competition by directing the innate immune response to competing flora. There is 
precedent for this, as Lysenko et al. have shown that species-specific stimulation of the innate 
immune response can be an effective strategy to outcompete nasal flora (205). 
The lipid A and the oligosaccharide core domain of LPS can also be recognized by the 
surfactant proteins A and D (SP-A and SP-D, respectively), hydrophilic lipid-binding lectins 
that are ubiquitously expressed in the lower respiratory tract of humans (reviewed in (206)). 
Binding of SP-A to LPS induces agglutination, destabilizes the bacterial membrane, and 
facilitates phagocytosis (reviewed in (207)). Further, SP-A-mediated recognition of LPS can 
also modify LBP-CD14 complexes, thus contributing to an altered recognition of LPS by TLR4 
(208). Interestingly, wild-type B. pertussis LOS is not recognized and bound by SP-A or SP-D 
(209, 210). However, after removal of one or more sugars from the terminal trisaccharide, LOS 
is recognized by SP-A and SP-D, leading to effective bacterial opsonization and phagocytosis 
(209). Thus, it appears that the terminal trisaccharide of B. pertussis LOS prevents access 
of SP-A and SP-D to the lipid A domain through steric hindrance, and thereby protects the 
bacteria from surfactant-mediated clearance. 
Because LPS is such a characteristic and dominant feature of Gram-negative bacteria, 
the host has evolved multiple recognition receptors to sense the presence of this molecule, 
e.g. through surfactants. By expressing LOS, B. pertussis is able to effectively prevent 
surfactant-mediated recognition and clearance. Furthermore, by changing the composition of 
the lipid A moiety, it is able to modulate the LOS-mediated immune response. It remains to be 
investigated whether or not the stronger inflammatory response initiated by the Bvg+-phase-
specific modification favors within-host survival.
Besides LPS, TLR4 has also been shown to recognize other factors expressed by 
pathogens, e.g. the pneumolysin that is released by Streptococcus pneumoniae or the fusion 
(F) protein on the surface of respiratory syncytial virus (211, 212). B. pertussis, Ptx also 
activates TLR4 signaling pathways in MDDCs (213). In addition to TLR4, stimulation of MDDCs 
with intact B. pertussis also induces TLR2 signaling, and Ptx has recently been established to 
be the agonist triggering these TLR2 signaling pathways by utilizing TLR2/TLR4 engagement 
(214, 215). 
The intracellular cytosolic sensor Nod1, which recognizes peptidoglycans (216), has 
been shown to be activated by TCT, which essentially is a diaminopimelic (DAP)-containing 
tetrapeptide muramylpeptide (M-TetraDAP) (217). Surprisingly, this recognition was found 
to be mouse-specific. Whilst murine Nod1–mediated detection of TCT led to an efficient 
cytokine response and the production of NO (the mediators of cytotoxicity), human Nod1 
was unresponsive to TCT (217). Differential recognition of TCT was shown to be dependent 
on a distinct preference of murine Nod1 for M-TetraDAP, whereas human Nod1 preferentially 
recognized DAP-containing tripeptide muramylpeptides (M-TriDAP). Importantly, this observation 
implies that the initially observed TCT-induced cytotoxicity in tracheal epithelial cells may not 
be due to the effect of TCT itself, but may predominately be caused by M-TriDAP, or alternatively 
by an unknown TCT-receptor. 
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To conclude, host innate immune cells sense the presence of B. pertussis predominantly 
by TLR4-mediated recognition of LOS and to a minor extent by TLR2-mediated recognition of 
Ptx. 
Recruitment of immune cells 
Colonization of the mucosal surfaces of the respiratory tract by B. pertussis initiates a local 
chemokine response, resulting in the recruitment of immune cells to the site of infection. 
Usually, neutrophils are the first immune cells to arrive, followed by a second wave of NK-cells, 
macrophages, DCs, and lymphocytes (145, 218-221). 
It has been well established that the toxins Ptx and TCT are able to inhibit immune 
cell trafficking to the respiratory tract. Meade and coworkers already showed that systemic 
administration of Ptx resulted in reduced recruitment of macrophages to the site of infection 
(222). Additionally, in vitro experiments have shown that Ptx is able to inhibit chemotaxis of 
lymphocytes and neutrophils (223). This effect on neutrophil trafficking has also been observed 
in vivo (224, 225), and the underlying molecular mechanisms are well understood. Ptx has 
been shown to affect chemotaxis indirectly by suppressing the release of chemokines from 
resident airway cells. Using a mouse model of infection, it was shown that a mutant B. pertussis 
strain lacking Ptx induced significantly higher levels of keratinocyte-derived chemokine and 
macrophage inflammatory protein 2, i.e. the murine functional equivalents of human IL-8, 
compared to the wild-type strain. Further, LPS-induced CXC chemokine, the murine homolog 
to human CXCL5/ENA-78, was also inhibited by Ptx (226). It is likely that the Ptx-mediated 
decrease in chemokine release also contributed to the reduced early infiltration of leukocytes 
observed in earlier studies (222, 223). Ptx also interferes with with DC-mediated imprinting 
of lung-associated trafficking receptors on T lymphocytes, thereby delaying T cell responses 
(227). In addition to Ptx, TCT has also been shown to inhibit neutrophil chemotaxis, at least in 
vitro (228), which may also partially contribute to this effect. 
In conclusion, by producing Ptx and TCT, B. pertussis is able to delay phagocytic 
clearance by inhibiting the recruitment of phagocytes. 
Phagocytosis
The efficiency of bacterial phagocytosis differs between phagocytic cell types, and distinct 
innate immune cells may process internalized bacteria differently. An important question is 
which are the bacterial and host factors that are predominantly involved in the interaction of B. 
pertussis with these phagocytic cells? The current model is that phagocytosis of B. pertussis 
occurs either via direct recognition of surface-exposed molecules on the bacterial membrane, 
or via antibody-mediated recognition of surface-bound opsonins (antibodies and complement 
system components). Both mechanisms will be discussed here, as well as the strategies used 
by B. pertussis to interfere with phagocytosis and subsequent cellular killing mechanisms.
 
The role of antibodies in phagocytosis
The importance of antibody opsonization in the phagocytosis of B. pertussis has been studied 
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extensively. Based on in vitro experiments with FITC-labeled B. pertussis, it was initially 
suggested that opsonization enhances the uptake of the pathogen by human monocytes 
and neutrophils (229, 230). However, the FITC labeling procedure was later shown to have 
intrinsic effects on protein function, including ACT, thereby confounding previous results (231). 
Subsequent experiments using a genetically modified B. pertussis strain stably expressing 
green fluorescent protein actually showed an opposite effect, whereby B. pertussis failed to 
be internalized efficiently (231). A subsequent study suggested that incubating bacteria with 
heat-inactivated serum containing antibodies to B. pertussis LOS as well as to several other 
surface-localized protein virulence factors (232), inhibited both attachment and uptake by 
human neutrophils (233). In these experiments, the majority of surface-exposed bacterial 
antigens were bound by antibodies, and hence shielded from phagocyte binding. Based 
on these studies it was suggested that phagocytosis of B. pertussis occurs independent of 
opsonization, but requires a specific, direct interaction with factors present on the bacterial 
membrane. 
Although antibody-independent phagocytosis plays an important role (discussed below), 
there is also substantial clinical and epidemiological evidence, including passive immunization 
trials, that antibodies are essential for protection against B. pertussis. In 1943, Miller and 
colleagues already observed that individuals with high antibody titers were significantly less 
susceptible to infection with B. pertussis (234). Since then, multiple studies established a 
strong correlation between clinical protection and the presence of specific IgG antibodies 
against fimbriae, Ptx, and most importantly Prn (235-238). It is therefore not surprising that 
recent studies established a role for antibody-mediated phagocytosis in the clearance of B. 
pertussis from the host. 
IgA and IgG antibodies against B. pertussis were both found to mediate binding, 
phagocytosis, and subsequent killing of the pathogen by polymorphonuclear neutrophils (PMN) 
in vitro (239, 240). IgA-dependent uptake by PMN was shown to be mediated by the human 
myeloid IgA receptor FcαRI (CD89), whereas the IgG-dependent uptake was shown to be 
mediated by the synergistic action of the IgG receptors FcγRIIa (CD32) and FcγRIIIb (CD16) 
(240, 241). Although CR3 (discussed below) and Fc receptors both play an important role in 
phagocytosis, the contribution of each pathway to bacterial clearance remained unknown. 
Therefore, the CR3- versus FcR-mediated uptake of B. pertussis was compared in an in 
vivo model. Importantly, only FcγR-mediated uptake was shown to facilitate clearance of B. 
pertussis from the lungs (239). These findings support a model whereby internalization of 
bacteria through the CR3-dependent pathway is advantageous to B. pertussis, whereas FcR-
mediated uptake is associated with protection against infection. Further proof of the crucial 
role of antibodies in protection comes from a study from Andreasen & Carbonetti, where they 
showed that neutrophil depletion prior to inoculation of naïve mice did not have any effect on 
bacterial colonization. In contrast, immunized neutropenic mice showed a significant reduction 
in clearance compared to immunized wild-type mice (242). 
Taken together, the presence of B. pertussis antibodies facilitates Fc-receptor mediated 
phagocytosis by phagocytic cells, eventually leading to clearance of the pathogen. 
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Antibody-independent phagocytosis
The construction of B. pertussis deletion mutants has made it possible to study the involve-
ment of specific bacterial molecules and host receptors in the recognition of B. pertussis by 
phagocytes. In particular, the interaction of B. pertussis with monocytes and monocyte-de-
rived macrophages has been well characterized. Although there are a number of dissimi-
larities between these two cell types, they also share many surface receptors and signaling 
pathways. In vitro adhesion assays using FHA, FimD, or Prn deletion mutants suggested 
that they are all involved in the recognition and binding of B. pertussis by monocytes (229). 
Although the involvement of FHA and FimD in this process is undisputed, the extent to which 
Prn contributes to this process is currently not well understood. Relman and coworkers ini-
tially found that the RGD domain of FHA binds to the CR3 integrin on macrophages (243), a 
receptor known to be involved in the phagocytosis of C3-mediated complement-opsonized 
bacteria. Later work showed that FHA, in addition to the RGD domain, contains three regions 
with sequence and functional similarity to the binding loops of factor X of the coagulation 
cascade, a factor known to bind CR3 with high affinity (244). Thus, both the RGD domain 
and the factor X-like domains may facilitate FHA-mediated binding of B. pertussis to CR3. 
However, CR3 has been shown to recognize multiple other ligands with varying affinity, in-
cluding LPS, iC3b, ICAM-1, and fibrinogen, and binding of CR3 may activate different sig-
naling pathways, related to extravasation, chemotaxis, and activation of phagocytic cells 
(reviewed by (245)). It is currently not well-understood which signaling pathways are induced 
by the binding of FHA to CR3. Another study showed that FHA-mediated binding to mono-
cytes can be inhibited by a monoclonal antibody specific for the fibronectin receptor VLA-5 
(246). Based on these data, the authors suggested that the recognition of FHA by CR3 is 
dependent on VLA-5. Subsequent efforts to identify the precise mechanisms by which these 
factors facilitate bacterial uptake showed that the bacterial ligand for VLA-5 is FimD. Further, 
binding of FimD to VLA-5 facilitated the subsequent interaction between FHA and CR3 in a 
phosphorylation-dependent manner (162, 247). This model complies with previous work that 
showed that binding and activation of VLA-5 allowed the CR3 receptor to mediate phagocy-
tosis (248). 
Monocytes and macrophages both express CR3 and VLA-5, suggesting that monocytes 
may be able to phagocytose B. pertussis in a similar FHA-dependent manner. However, 
Schaeffer & Weiss could not reproduce previous findings with FHA in the context of monocytes 
(249). A possible explanation for this observation could be that monocytes are significantly less 
able to internalize bacteria compared to more differentiated macrophages, potentially caused 
by differences in signaling pathways. Furthermore, the mechanism by which CR3 facilitates 
bacterial uptake may be dependent on other, unknown factors. For instance, CR3 is known 
to interact with the surface-expressed low affinity Ig receptor CD16, and this interaction is lost 
during the differentiation to DCs (250). It is conceivable that differentiation-stage dependent 
factors, such as CD16, may also contribute to the CR3-mediated uptake of B. pertussis. 
The ability of neutrophils to internalize and kill B. pertussis has also been studied. Work 
by Hazenbos and coworkers initially showed that human neutrophils were unable to bind 
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B. pertussis (246). At that time, the authors suggested that this may be due to the 10-fold 
lower expression level of VLA-5 on the cell surface of neutrophils, compared to monocytes 
or macrophages (246). In contrast, a later study suggested that murine neutrophils were able 
to recognize and bind B. pertussis efficiently (233). These differences might be explained by 
the host-specific recognition of B. pertussis by VLA-5, similar to the observed differences in 
the recognition of TCT by Nod1 described above. Furthermore, Weingard & Weiss showed 
that differences in experimental design between the studies could also have contributed to 
these differences (233). To determine the effect of FHA binding to CR3, human neutrophil 
adhesion assays were performed with either an FHA-deletion mutant or in the presence of a 
CR3-specific blocking antibody. Results from these experiments indicated that the interaction 
between B. pertussis and human neutrophils, similar to previous findings with macrophages, 
was in fact also mediated by CR3 and FHA (233, 251). The importance of this interaction 
is further supported by the observation that an SphB1-deletion mutant, with immature FHA 
strongly bound to the bacterial cell surface, was more efficiently bound and phagocytosed by 
neutrophils (251). It was mentioned before that lipid rafts containing cholesterol are crucial for 
the ability of B. pertussis to bind to epithelial cells in an FHA-mediated manner (121). A similar 
mechanism might apply to the recognition of B. pertussis by neutrophils, as cholesterol depletion 
of neutrophils dramatically diminished their ability to bind and internalize non-opsonized B. 
pertussis (252). The findings that lipid rafts contribute to this complex process may also explain 
the observation that monocytes were unable to bind FHA, as receptor clustering within these 
rafts plays an important role in determining the molecular interaction between receptor and 
ligand (253). 
In conclusion, in the absence of opsonizing antibodies, B. pertussis can be bound and 
phagocytosed by monocytes, macrophages, and neutrophils, promoting bacterial survival. 
This process is dependent on the interactions between FHA-CR3 and FimD-VLA-5. The 
specific interactions between these factors and the effects on activation of signaling pathways 
remain largely unknown, although it is known that CR3- and FcγR-dependent phagocytosis is 
mediated through different signal transduction pathways (254). Interestingly, CR3-mediated 
phagocytosis seems to occur in the absence of an oxidative burst (255), providing further 
evidence that CR3 is exploited by B. pertussis for intracellular survival. Both FHA and Ptx were 
found to induce CR3 expression by PMNs (251). In addition, in vivo respiratory colonization 
experiments in mice revealed that Ptx is able to suppress serum antibody responses to various 
B. pertussis antigens (256, 257). Together, these effects may shift the balance towards the 
non-killing CR3-mediated phagocytic route, allowing the pathogen to escape from clearance 
by the more efficient Fc receptor-mediated pathway. 
Foiling phagocytosis 
Phagocytic uptake of bacteria is generally followed by fusion of the phagosome with the 
lysosome, generating a new compartment called the phagolysosome (258). Bacteria present 
in this compartment are then exposed to an acidified environment as well as a number of 
antibacterial molecules, including ROS and proteolytic enzymes that break down the bacterium. 
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It is thought that once B. pertussis is taken up into the phagolysosome of phagocytes, it is 
killed rapidly because the acidic environment of this compartment is detrimental for the growth 
and survival rate of B. pertussis (259). For instance, phagocytic killing assays by adherent 
monocytes and neutrophils showed virtually no bacterial survival after only two hours (249, 260). 
In contrast, other studies suggest that internalization by macrophages does not automatically 
lead to killing of the pathogen. This was already observed by Friedman and coworkers in 
the early 1990s, who showed that B. pertussis was able to survive for at least three days 
following internalization (261). Recently, Lamberti and coworkers established that the route 
of intracellular trafficking determines the fate of internalized B. pertussis. They observed that 
while the majority of bacteria taken up by macrophages end up in an acidic compartment and 
are killed rapidly, the residual bacteria were able to survive and replicate inside a nonacidic 
early endosome-like compartment (262). The mechanisms that underlie this non-killing route 
of intracellular trafficking have not yet been established. 
Besides survival through entering the endosomal compartment, B. pertussis employs 
several other strategies to suppress phagocytic activity, which will be discussed here. 
Within minutes to hours of infection, B. pertussis encounters alveolar macrophages (AM). 
The importance of these cells in the host defense against B. pertussis has been elegantly 
demonstrated by Carbonetti and coworkers. They showed that depletion of AMs from the lungs 
of mice prior to inoculation with wild-type B. pertussis resulted in enhanced respiratory infection 
(263). Interestingly, a similar phenotype was observed after challenge with a Ptx-deficient 
strain, suggesting that Ptx is able to suppress AMs. Indeed, Ptx was shown to intoxicate 
AMs by ADP-ribosylation of its G-proteins, thereby contributing to the initial establishment 
of infection (263). The specific effects of Ptx on G-coupled proteins have been well-studied 
and have been reviewed elsewhere (90). As infection progresses, other phagocytic cell types 
such as monocytes and neutrophils migrate to the site of infection. Importantly, Ptx is able to 
suppress the phagocytic activity of monocytes (249), although the effect of Ptx on neutrophils 
has not been studied yet. 
B. pertussis also evades phagocytosis by suppressing the bactericidal activity 
of   phagocytes (264). As mentioned before, ACT rapidly induces cellular cAMP levels in 
CR3+ phagocytes, including PMNs (130). The rapid elevation of cAMP signals causes a 
transient and selective inactivation of RhoA, a member of the Rho family GTPases which 
are key regulators of actin cytoskeletal dynamics (265). This inactivation of RhoA results 
in the dephosphorylation of the actin filament-severing protein cofilin, and causes massive 
actin cytoskeletal rearrangements that coincide with phagocytic ruffling and the loss of 
macropinocytic fluid-phase uptake (265). The cAMP-induced pathways were shown to affect 
the in vitro bactericidal activity of monocytes and neutrophils by inhibiting chemotaxis and the 
production of superoxides, thereby hampering their ability to elicit a respiratory (or oxidative) 
burst of ROS (266, 267). 
B. pertussis also evades phagocytic killing by driving phagocytes into apoptosis. Both 
in vitro (268) and in vivo (269) experiments have shown that ACT is the major virulence factor 
involved in host cell apoptosis. In contrast to the anti-phagocytic effects of ACT reviewed 
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above, the induction of apoptosis occurs independently of its enzymatic activity and the 
concurrent supraphysiological rise in cAMP levels (98). For ACT to induce apoptosis, it must be 
posttranslationally acylated (98), internalized by means of CR3-mediated vesicular transport 
(270), and conformationally changed (271). The importance of correct delivery of ACT into cells 
is reflected by the observation that ACT-mediated apoptotic effects are significantly reduced 
upon inhibition of macropinocytosis, depletion of cholesterol, or disruption of the Golgi network 
(270). Once ACT has entered the cell via the vesicular transport pathway, apoptotic signals 
reduce mitochondrial functioning. For instance, when monocytes were treated with purified ACT, 
their mitochondrial membrane potential was found to be disrupted (272). Furthermore, ACT 
induces the activity of the effector caspases 3 and 7 in macrophages, which are the key factors 
triggering apoptosis (271). Programmed cell death is further promoted by the ability of ACT to 
form cation-selective pores in the host cell membranes (273), which has been attributed to its 
tendency to form multimers (274). Another B. pertussis virulence factor that affects apoptosis is 
FHA. Abramson and coworkers showed that purified FHA induced dose-dependent apoptosis 
in human phagocytic and epithelial cells (153). Using a FHA deletion mutant, they showed that 
strains lacking FHA induced significantly less apoptosis compared to wild-type strains (153). 
However, since an earlier study did not identify FHA as an inducer of apoptosis (275), the 
specific role of FHA in the induction of apoptosis requires further investigation. 
To summarize, by producing Ptx, ACT, and FHA, B. pertussis delays the efficient removal 
by phagocytes by (i) entering the phagocytic endosomal compartment (ii) intoxicating resident 
AMs, (iii) suppressing the bactericidal activity of monocytes and macrophages, and (iv) inducing 
apoptosis. Thus, the concerted action of these three virulence factors allows the bacterium to 
persist longer in the respiratory tract. 
The complement system
The complement system plays an important role in host defense and can be activated via 
three different pathways, i.e. the classical, antibody-dependent pathway, the lectin pathway, 
and the alternative pathway. Activation of these pathways can initiate a number of antibacterial 
mechanisms, such as agglutination, opsonization and phagocytosis, the recruitment of 
inflammatory cells through chemotaxis, and finally direct killing of bacteria through the formation 
of the membrane attack complex (MAC). As the complement system can have damaging 
effects on the host itself if kept unchecked, regulation of complement activation occurs through 
complement-inhibitory proteins. In the past few years it has become clear that many bacterial 
pathogens have evolved mechanisms to evade complement activation, either by recruitment 
of these inhibitory proteins or by direct inhibition of complement factors (for recent reviews see 
(276-278)). Similarly, B. pertussis employs a number of strategies to overcome complement-
mediated removal from the respiratory tract, which will be reviewed here.
B. pertussis inhibits complement-induced phagocytosis through Bordetella resistance 
to killing A (BrkA), a virulence factor that interferes specifically with the classical pathway of 
complement activation (279). In this pathway, opsonizing antibody complexes on the surface 
of a bacterium provide a docking site for the C1 complex. Binding of C1 to the bacterial surface 
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initiates an enzymatic cascade of proteolytic cleavages, resulting in the deposition of other 
complement components including C4b, C2a, C3b, and C5b. Membrane-bound C3b functions 
as an opsonin for phagocytosis and is recognized by the CR1 and CR3 receptors expressed on 
phagocytes (280). Work by Barnes and Weiss showed that BrkA interferes with the deposition 
of C4b, C2a, C3b, and C5b onto the C1-complex, thereby preventing subsequent phagocytosis 
and killing by neutrophils (281). It is currently unknown whether BrkA exerts its effect via direct 
inhibition of complement function, or alternatively through the recruitment of a complement-
inhibitory protein. 
More recently, three BrkA-independent mechanisms of complement resistance have 
been identified. B. pertussis has been found to bind and recruit the C4b-binding protein 
(C4BP) as well as the human C1 esterase inhibitor (C1INH), both major inhibitors of the 
classical complement pathway (282, 283). C4BP inhibits killing of host cells by binding C4b, 
which renders C4b more susceptible to degradation by factor I (C3b inactivator) (284, 285). 
Conversely, C1INH interferes with the formation of the C1 complex by inhibiting the action of 
the C1s and C1r proteases (286). Importantly, both mechanisms of complement resistance 
were shown to be regulated by the BvgASR system, emphasizing their importance during 
colonization of the host. FHA and the autotranporter protein Vag8 have been implicated in the 
binding and recruitment of C4BP and C1INH by B. pertussis, respectively (282, 287). Besides 
recruiting host complement inhibitors, the Bps polysaccharide of B. pertussis also provides 
complement resistance by directly inhibiting the deposition of complement proteins and the 
formation of MAC (288). The observation that the absence of FHA does not render B. pertussis 
completely susceptible to complement killing (289), suggests that the other complement 
resistance mechanisms provide sufficient protection in the absence of C4BP recruitment. 
In summary, the recruitment and binding of host C1INH and C4BP act in concert with 
the expression of BrkA and Bps to ensure inhibition of complement activation at a very early 
stage. Experiments with antibody-depleted serum suggested that the lectin and alternative 
pathways may be less relevant for B. pertussis compared to the classical pathway (281). 
This is supported by the identification of four distinct mechanisms to prevent activation of the 
classical pathway, which further highlights the important role of antibodies in the protection 
against B. pertussis. 
Cellular immunity
During infection with B. pertussis, multiple PRRs engage bacterial molecules, leading to the 
induction of innate signaling pathways. Consequently, immune cells are recruited through the 
release of chemokines, and an adaptive response is initiated through cytokine production 
and the upregulation of co-stimulatory molecules. APCs, such as DCs and macrophages are 
pivotal to this process. In response to PRR activation, these cells initiate the presentation of 
B. pertussis-derived antigens to cells of the adaptive immune system, with the aim to induce 
specific immunity. Insight into the development of T cell immunity during infection with B. 
pertussis is of critical importance for the rational design of novel vaccines. In this section, we 
will focus on how infection with B. pertussis affects the differentiation of naïve lymphocytes to 
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specific T cell subtypes with antibacterial effector functions. Furthermore, B. pertussis virulence 
factors that are known to modulate this process, in particular regarding the production of 
cytokines, will also be discussed. 
T cell responses to B. pertussis 
Cellular immunity against B. pertussis is predominantly mediated by CD4+ T lymphocytes, 
whereas CD8+ T lymphocytes are mostly dispensable (191, 290). Traditionally, CD4+ cells have 
been subdivided as T helper type 1 (Th1) or Th2 cells, based on their cytokine expression 
profile (291, 292). Th1 cells typically express interferon-γ (IFN-γ) and IL-2, and these cells 
play an important role in cell-mediated inflammatory responses (293). Conversely, Th2 cells 
are more important for the development of antibody responses and are characterized by the 
secretion of high levels of IL-4, IL-5, and IL-13 (293). More recently, a distinct subset of T 
helper cells has been discovered, designated Th17 cells (294). Th17 cells typically express IL-
17, IL-21, and IL-22, and have been implicated in host inflammatory responses against various 
bacterial pathogens (295). 
The fate of T cell differentiation is to a large extent determined by the local cytokine 
environment during priming, together with the antigen dose, antigen affinity, major 
histocompatibility complex haplotypes, and the co-stimulatory molecules present on DCs 
(reviewed in (291)). 
High levels of IFN-γ and IL-12 typically promote expansion of Th1 cells, while 
simultaneously inhibiting Th2 cell proliferation. Conversely, high levels of IL-4 induce Th2 cell 
proliferation and suppress Th1 subtype expansion (296, 297). IL-1β, IL-6, and IL-23 have been 
implicated as mediators for the expansion of the Th17 subtype (298-300). Another important 
cytokine in this respect is the anti-inflammatory cytokine IL-10. The induction of this cytokine 
has been shown to suppress the host immune response to certain pathogens, such as S. 
pneumonia and other species (301). 
Thus far, several studies have demonstrated a dominant role for antigen-specific IFN-γ 
secreting Th1 cells in the protection against B. pertussis (302-304), which are predominantly 
induced after infection or immunization with whole cell pertussis vaccines (305). Additionally, 
the generation of antigen-specific Th17 cells also correlates with protection, further supported 
by the finding that IL-17-deficient mice showed increased susceptibility to B. pertussis infections 
(306, 307). Taken together, these findings suggest that the induction of a combined Th1 and 
Th17 response is essential to induce protective immunity against pertussis (308). Furthermore, 
although antibodies have also been shown to correlate with protection, Th2 responses are 
dispensible for immunity (305) and it is currently unknown how Th2 cells contribute to the 
induction of these antibodies.
Suppression of T cell responses 
Several bacterial factors have been shown to induce cytokine production in APCs that are 
known to induce Th17 T cells. For instance, exposing MDDCs to Ptx has been shown to 
induce the production of the Th17 expansion-mediator cytokines IL-1β, IL-6, and IL-23 in a 
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TLR2/4-dependent manner (215). Other bacterial factors that drive Th17 induction are FHA 
and ACT (309, 310), both of which have been shown to suppress a key inhibitor of Th17 
expansion, IL-12 (311). FHA inhibits the secretion of IL-12 by LPS (and LOS)-stimulated 
macrophages through the up-regulation of IL-6 and IL-10 (312). Furthermore, FHA may also 
inhibit IL-12 production by APCs through its cognate interaction with CR3, as it was shown 
that monoclonal antibody-mediated activation of CR3 also reduced IL-12 secretion (313). The 
mechanism by which ACT affects IL-12 production has also been characterized. Dependent 
on the adenylate cyclase activity, ACT inhibits the induction of IRF-1, IRF-8, and IFN-β, which 
are master regulators of IL-12.p35, one of the two subunits of IL-12. (310, 314). In addition, 
ACT potently induces the inflammasome of DCs (306), a multiprotein complex involved in the 
initiation of the inflammatory response. Activation of the inflammasome results in the secretion 
of proinflammatory cytokines, including IL-1β (315). Similarly, the pore-forming capacity of ACT 
induces a decrease in intracellular K+ levels, and this has been shown to activate caspase-1 
and NALP3, resulting in an increased release of IL-1β and a Th17 response (306). 
Because the induction of a Th17 response has also been shown to be associated with 
protection, the bacterium employs another strategy to enable survival on the respiratory 
mucosal surface. Importantly, clinical studies have shown that high levels of IL-10 are clinically 
associated with an increased susceptibility to infections with B. pertussis, which is due to the 
IL-10-mediated suppression of IFN-γ (316). Through the action of multiple virulence factors, B. 
pertussis is able to induce an IL-10 phenotype.
As discussed before, activation of TLR4 by LOS is essential for efficient recognition 
by DCs. As such, LOS represents one of the most important immunostimulating factors of 
B. pertussis (196, 197). In vitro stimulation of MDDCs with purified LOS resulted in a low 
expression of Th1 cytokines IFN-γ and IL-12, together with high amounts of the Th2 cytokines 
IL-5 and IL-10 and the Th17 cytokines IL-1β, IL-6, and IL-23 (196, 197). This suggests that 
LOS, through its aberrant structure and lipid A modifications, may skew the cytokine production 
of DCs to a Th2/Th17 phenotype. Furthermore, ACT has been found to act synergistically with 
LOS in the induction of IL-6 and IL-10 (317). Importantly, FHA is also able to stimulate IL-10 
expression by DCs, resulting in the induction of local IL-10-producing T cells (309). 
In addition to these well-known virulence factors, the T3SS has also been implicated in 
suppression of both cell-mediated and humoral immune responses. Infection of mice with a 
mutant B. pertussis strain lacking a functional T3SS resulted in an increased pro-inflammatory 
cytokine response, as well as an increased IL-17, IFN-γ, and IgG response (105). BopN has 
recently been characterized as the T3SS secreted molecule that is responsible for these 
effects. In a MDDCs infection model it was shown that BopN induces the expression of IL-10 
through the inhibition of both extracellular signal-regulated kinase and NF-κB pathways (318).
Thus, recognition of B. pertussis by APCs results in the induction of Th1/Th17-associated 
cytokines, which are protective. However, through the modulating effect of several virulence 
factors, IL-10 is produced as well, reducing the effectiveness of the T cell response. Considering 
the importance of co-stimulatory molecules in the presentation of antigens to T and B cells, it 
will be interesting to investigate the effects of the above-mentioned virulence factors on co-
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stimulatory molecule expression. 
Conclusions and future perspectives 
Despite the fact that pertussis morbidity and mortality have decreased dramatically after 
vaccine introduction, pertussis remains one of the least well-controlled vaccine-preventable 
childhood diseases in the world. B. pertussis is a highly monomorphic pathogen, suggesting 
that its gene repertoire is well adapted to its present niche and that only fine tuning is required 
for its persistence (17). With this review, we aimed to clarify the mechanisms by which B. 
pertussis is able to persist in the face of vaccination. In particular we discussed the interaction 
of B. pertussis with the host mucosal epithelium and immune system (Figures 1 and 2), and 
how this knowledge may be used to improve pertussis vaccines. 
Recently vaccinated children are well-protected, indicating that B. pertussis cannot cope 
with an activated adaptive immune response. We propose that B. pertussis has evolved to 
delay the adaptive immune response, in particular the induction of antibodies, until transmission 
occurs. The implication is that immunity against B. pertussis can be maintained if sufficiently 
high levels of antibodies are present in a large part of the population. There is evidence of 
pertussis immunity in the absence of (high levels of) antibodies (319, 320). This suggests 
that if memory is still robust, antibody induction can outpace immune suppression. Choice of 
antigens and ways to prevent decay of memory are crucial to the solution of the B. pertussis 
problem.
Adaptations may reveal weak spots in the bacterial defense and B. pertussis has used 
different strategies to adapt to vaccinated populations, including antigenic divergence with 
vaccine strains and upregulation of Ptx production (16, 17). Antigenic divergence has been 
observed in particular with respect to Prn and Ptx, and pertussis vaccines may be improved 
by including protein variants found in current B. pertussis populations. This may improve both 
the effectivity of antibodies and memory. Increased Ptx production confers an advantage in 
populations where transmission of B. pertussis is mainly dependent on primed (vaccinated) 
hosts (321) and this adaptation can be neutralized by “adapting” vaccines so that they induce 
Ptx neutralizing antibodies that persist longer. One way this can be accomplished is by replacing 
chemically detoxified Ptx with the genetically detoxified variant which has been shown to be 
more immunogenic (322, 323). Higher initial titers of Ptx antibodies may increase the period 
in which protective antibody levels are maintained. Additional reasons to replace chemically 
detoxified Ptx are that formaldehyde treatment of Ptx has been shown to constrain antigen 
presentation to T cells, and that chemical detoxification has a significant effect on protein 
structure and may destroy protective epitopes (324). Both may affect immunological memory.
 Significantly, Ptx is the only known B. pertussis virulence factor showing polymorphisms 
in both structure and regulation, underlining the importance of this protein in the ecology of 
B. pertussis. Ptx induced leukocytosis has been associated with mortality (325, 326) and it 
is difficult to envisage a pertussis vaccine without this toxin. As more genome sequences 
become available, comparative genomics can be exploited to identify genetic changes that 
are associated with the introduction of vaccination. This might reveal novel genes that are 
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important for the suppression of host immune responses, and the associated gene products 
may represent potential vaccine candidates.
A number of toxins shown to be crucial for infection are promising vaccine candidates. 
Antibodies against these toxins may target the pathogen directly, through effector functions, and 
indirectly, through toxin neutralization. Promising toxin vaccine candidates include ACT, LOS, 
TCT, and T3SS toxins. ACT functions as an adjuvant, enhancing both Th1 and Th2 responses 
as well as protective antibody responses (327). LOS also possesses powerful adjuvant activity, 
but requires detoxification before being used as a vaccine component (328). TCT could be 
made immunogenic by conjugation. The T3SS and its effector proteins have been tested in 
animal models as vaccines (reviewed in (329)). It is doubtful whether antibodies against effector 
molecules will be very effective, as these toxins are directly injected into host cells. However, 
structural components of the T3SS have been shown to induce protective immunity against 
Pseudomonas aeruginosa in a mouse infection model (330). Indeed, Medhekar et al. showed 
that the B. bronchiseptica T3SS protein, Bsp22, which forms a filamentous T3SS tip complex 
on the cell surface, is highly immunogenic in mice. Furthermore, Bsp22 antibodies were found 
to be protective against B. bronchiseptica infection (331). Unfortunately, a recent study showed 
that Bsp22 does not induce protective immunity against B. pertussis infection in mice (332). 
Antibodies against antigens expressed early in infection may be particularly effective, 
especially if they prevent manipulation of the (subsequent) host immune response. Such 
proteins can be identified by applying currently available genome-wide approaches such as 
transcriptional profiling, proteomics or elegant in vivo technologies (43). These techniques 
can also be used to identify proteins important for biofilm formation. Although this field of 
research is largely unexplored for B. pertussis, the approach of targeting specific bacterial 
biofilm factors with vaccines has already found proof of principle for other human pathogens 
including staphylococci, Escherichia coli and the fungus Cryptococcus neoformans (170, 333-
335). The effectiveness of such vaccines may rely on their ability to suppress the activity of 
biofilm-stimulating factors and thereby prevent this process at the early stages of infection. 
B. pertussis also forms biofilms in the nose, trachea and lungs (172) and it is known that 
biofilms are inherently more resistant towards host immune defenses (reviewed in (170)). This 
suggests that the inclusion of biofilm antigens in novel vaccines, likely in combination with 
vaccine antigens that target essential processes of the pathogenesis of B. pertussis, may 
provide an additional level of protection compared to currently used vaccines.
Finally, a promising approach to induce protective immunity in infants is to mimic natural 
infection, by using a live attenuated B. pertussis strain. Vaccination with an attenuated strain 
was shown to provide superior protection compared to an ACV in a mouse model (336). 
Interestingly, the nasal route of vaccination was also shown to protect against B. parapertussis, 
which is another highly desired feature of pertussis vaccines (336). 
There clearly are plenty of scientifically valid rationals to improve current pertussis 
vaccines. However, the major hurdle to this is not a scientific one, but an economic one. Most 
commercial vaccine producers have little incentive to improve pertussis vaccines, as they have 
made significant investments in the new generation of ACVs. It can therefore be expected 
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that vaccine producers promote the strategy of repetitive boostering. The development and 
testing of the next generation pertussis vaccines may require incentives from both commercial 
vaccine producers and governments.
Acknowledgement 
D.d.G. is supported by Grant 125020001 from the Netherlands Organization of Scientific 
Research (ZonMw). We thank Ms K. Short and Dr. G. Ferwerda for critically reading the 
manuscript.
References
1. Mooi, F. R., Q. He, and N. Guiso. 2007. Phylogeny, Evolution and Epidemiology of Bordetellae, p. 17-45. 
In C. Locht (ed.), Bordetella Molecular Microbiology, vol. First. Horizon Bioscience, Norfolk UK.
2. Diavatopoulos, D. A., C. A. Cummings, L. M. Schouls, M. M. Brinig, D. A. Relman, and F. R. Mooi. 
2005. Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-
associated lineage of B. bronchiseptica. PLoS pathogens 1:e45.
3. Diavatopoulos, D. A., C. A. Cummings, H. G. van der Heide, M. van Gent, S. Liew, D. A. Relman, 
and F. R. Mooi. 2006. Characterization of a highly conserved island in the otherwise divergent Bordetella 
holmesii and Bordetella pertussis genomes. Journal of bacteriology 188:8385-8394.
4. Goodnow, R. A. 1980. Biology of Bordetella bronchiseptica. Microbiological reviews 44:722-738.
5. Woolfrey, B. F., and J. A. Moody. 1991. Human infections associated with Bordetella bronchiseptica. 
Clinical microbiology reviews 4:243-255.
6. Porter, J. F., K. Connor, and W. Donachie. 1996. Differentiation between human and ovine isolates of 
Bordetella parapertussis using pulsed-field gel electrophoresis. FEMS Microbiol Lett 135:131-135.
7. van der Zee, A., H. Groenendijk, M. Peeters, and F. R. Mooi. 1996. The differentiation of Bordetella 
parapertussis and Bordetella bronchiseptica from humans and animals as determined by DNA 
polymorphism mediated by two different insertion sequence elements suggests their phylogenetic 
relationship. International journal of systematic bacteriology 46:640-647.
8. Parkhill, J., M. Sebaihia, A. Preston, L. D. Murphy, N. Thomson, D. E. Harris, M. T. Holden, C. M. 
Churcher, S. D. Bentley, K. L. Mungall, A. M. Cerdeno-Tarraga, L. Temple, K. James, B. Harris, M. 
A. Quail, M. Achtman, R. Atkin, S. Baker, D. Basham, N. Bason, I. Cherevach, T. Chillingworth, M. 
Collins, A. Cronin, P. Davis, J. Doggett, T. Feltwell, A. Goble, N. Hamlin, H. Hauser, S. Holroyd, K. 
Jagels, S. Leather, S. Moule, H. Norberczak, S. O’Neil, D. Ormond, C. Price, E. Rabbinowitsch, S. 
Rutter, M. Sanders, D. Saunders, K. Seeger, S. Sharp, M. Simmonds, J. Skelton, R. Squares, S. 
Squares, K. Stevens, L. Unwin, S. Whitehead, B. G. Barrell, and D. J. Maskell. 2003. Comparative 
analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella 
bronchiseptica. Nature genetics 35:32-40.
9. van der Zee, A., F. Mooi, J. Van Embden, and J. Musser. 1997. Molecular evolution and host adaptation 
of Bordetella spp.: phylogenetic analysis using multilocus enzyme electrophoresis and typing with three 
insertion sequences. Journal of bacteriology 179:6609-6617.
10. Bordet, J., and U. Gengou. 1906. Le microbe de la coqueluche. Ann Inst Pasteur 20:731-741.
11. Cherry, J. D., and U. Heininger. 2004. Pertussis and other Bordetella infections, p. 1588-1608. In R. D. 
Feigin, J. D. Cherry, G. J. Demmler, and S. Kaplan (ed.), Textbook of pediatric infectious diseases, vol. 5th. 
The W. B. Saunders Co, Philadelphia, Pa.
12. Stocks, P., and M. N. Kam. 1932. On the Epidemiology of Pertussis Cough in London. J Hygiene 32:582-
619.
13. de Melker, H. E., F. G. Versteegh, J. F. Schellekens, P. F. Teunis, and M. Kretzschmar. 2006. The 
incidence of Bordetella pertussis infections estimated in the population from a combination of serological 
surveys. The Journal of infection 53:106-113.
14. Ward, J. I., J. D. Cherry, S. J. Chang, S. Partridge, W. Keitel, K. Edwards, M. Lee, J. Treanor, D. P. 
Greenberg, S. Barenkamp, D. I. Bernstein, R. Edelman, and A. S. Group. 2006. Bordetella pertussis 
infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective 
randomized Acellular Pertussis Vaccine Trial (APERT). Clinical infectious diseases : an official publication 
of the Infectious Diseases Society of America 43:151-157.
15. Black, R. E., S. Cousens, H. L. Johnson, J. E. Lawn, I. Rudan, D. G. Bassani, P. Jha, H. Campbell, C. 
F. Walker, R. Cibulskis, T. Eisele, L. Liu, C. Mathers, W. H. O. Child Health Epidemiology Reference 
Group of, and Unicef. 2010. Global, regional, and national causes of child mortality in 2008: a systematic 
Introduction | 53
1
analysis. Lancet 375:1969-1987.
16. He, Q., and J. Mertsola. 2008. Factors contributing to pertussis resurgence. Future microbiology 3:329-
339.
17. Mooi, F. R. 2010. Bordetella pertussis and vaccination: the persistence of a genetically monomorphic 
pathogen. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics 
in infectious diseases 10:36-49.
18. von Konig, C. H., S. Halperin, M. Riffelmann, and N. Guiso. 2002. Pertussis of adults and infants. The 
Lancet infectious diseases 2:744-750.
19. Bisgard, K. M., F. B. Pascual, K. R. Ehresmann, C. A. Miller, C. Cianfrini, C. E. Jennings, C. A. 
Rebmann, J. Gabel, S. L. Schauer, and S. M. Lett. 2004. Infant pertussis: who was the source? The 
Pediatric infectious disease journal 23:985-989.
20. de Greeff, S. C., F. R. Mooi, A. Westerhof, J. M. Verbakel, M. F. Peeters, C. J. Heuvelman, D. W. 
Notermans, L. H. Elvers, J. F. Schellekens, and H. E. de Melker. 2010. Pertussis disease burden in 
the household: how to protect young infants. Clinical infectious diseases : an official publication of the 
Infectious Diseases Society of America 50:1339-1345.
21. Elliott, E., P. McIntyre, G. Ridley, A. Morris, J. Massie, J. McEniery, and G. Knight. 2004. National 
study of infants hospitalized with pertussis in the acellular vaccine era. The Pediatric infectious disease 
journal 23:246-252.
22. Kowalzik, F., A. P. Barbosa, V. R. Fernandes, P. R. Carvalho, M. L. Avila-Aguero, D. Y. Goh, A. Goh, 
J. G. de Miguel, F. Moraga, J. Roca, M. Campins, M. Huang, J. Quian, N. Riley, D. Beck, and T. 
Verstraeten. 2007. Prospective multinational study of pertussis infection in hospitalized infants and their 
household contacts. The Pediatric infectious disease journal 26:238-242.
23. Berbers, G. A., S. C. de Greeff, and F. R. Mooi. 2009. Improving pertussis vaccination. Human vaccines 
5:497-503.
24. De Serres, G., and B. Duval. 2005. Pertussis vaccination beyond childhood. Lancet 365:1015-1016.
25. Gustafsson, L., L. Hessel, J. Storsaeter, and P. Olin. 2006. Long-term follow-up of Swedish children 
vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster 
dose at 5 to 7 years of age. Pediatrics 118:978-984.
26. Hallander, H. O., L. Gustafsson, M. Ljungman, and J. Storsaeter. 2005. Pertussis antitoxin decay after 
vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. 
Vaccine 23:5359-5364.
27. Elomaa, A., Q. He, N. N. Minh, and J. Mertsola. 2009. Pertussis before and after the introduction of 
acellular pertussis vaccines in Finland. Vaccine 27:5443-5449.
28. Lacey, B. W. 1960. Antigenic modulation of Bordetella pertussis. The Journal of hygiene 58:57-93.
29. Leslie, P. H., and A. D. Gardner. 1931. The Phases of Haemophilus pertussis. The Journal of hygiene 
31:423-434.
30. Stibitz, S. 2007. The bvg regulon, p. 47-68. In C. Locht (ed.), Bordetella Molecular Microbiology, vol. First. 
Horizon Bioscience, Norfolk UK.
31. Weiss, A. A., and S. Falkow. 1984. Genetic analysis of phase change in Bordetella pertussis. Infection 
and immunity 43:263-269.
32. Boucher, P. E., and S. Stibitz. 1995. Synergistic binding of RNA polymerase and BvgA phosphate to the 
pertussis toxin promoter of Bordetella pertussis. Journal of bacteriology 177:6486-6491.
33. Stibitz, S., and M. S. Yang. 1991. Subcellular localization and immunological detection of proteins 
encoded by the vir locus of Bordetella pertussis. Journal of bacteriology 173:4288-4296.
34. Melton, A. R., and A. A. Weiss. 1989. Environmental regulation of expression of virulence determinants 
in Bordetella pertussis. Journal of bacteriology 171:6206-6212.
35. Melton, A. R., and A. A. Weiss. 1993. Characterization of environmental regulators of Bordetella pertussis. 
Infection and immunity 61:807-815.
36. Uhl, M. A., and J. F. Miller. 1994. Autophosphorylation and phosphotransfer in the Bordetella pertussis 
BvgAS signal transduction cascade. Proceedings of the National Academy of Sciences of the United 
States of America 91:1163-1167.
37. Uhl, M. A., and J. F. Miller. 1996. Integration of multiple domains in a two-component sensor protein: the 
Bordetella pertussis BvgAS phosphorelay. The EMBO journal 15:1028-1036.
38. Uhl, M. A., and J. F. Miller. 1996. Central role of the BvgS receiver as a phosphorylated intermediate in a 
complex two-component phosphorelay. The Journal of biological chemistry 271:33176-33180.
39. Akerley, B. J., D. M. Monack, S. Falkow, and J. F. Miller. 1992. The bvgAS locus negatively controls 
motility and synthesis of flagella in Bordetella bronchiseptica. Journal of bacteriology 174:980-990.
40. Merkel, T. J., and S. Stibitz. 1995. Identification of a locus required for the regulation of bvg-repressed 
genes in Bordetella pertussis. Journal of bacteriology 177:2727-2736.
41. Cummings, C. A., H. J. Bootsma, D. A. Relman, and J. F. Miller. 2006. Species- and strain-specific 
control of a complex, flexible regulon by Bordetella BvgAS. Journal of bacteriology 188:1775-1785.
42. Scarlato, V., B. Arico, A. Prugnola, and R. Rappuoli. 1991. Sequential activation and environmental 
regulation of virulence genes in Bordetella pertussis. The EMBO journal 10:3971-3975.
54 | Chapter 1
43. Veal-Carr, W. L., and S. Stibitz. 2005. Demonstration of differential virulence gene promoter activation in 
vivo in Bordetella pertussis using RIVET. Molecular microbiology 55:788-798.
44. Kinnear, S. M., P. E. Boucher, S. Stibitz, and N. H. Carbonetti. 1999. Analysis of BvgA activation of the 
pertactin gene promoter in Bordetella pertussis. Journal of bacteriology 181:5234-5241.
45. Roy, C. R., J. F. Miller, and S. Falkow. 1990. Autogenous regulation of the Bordetella pertussis bvgABC 
operon. Proceedings of the National Academy of Sciences of the United States of America 87:3763-3767.
46. Zu, T., R. Manetti, R. Rappuoli, and V. Scarlato. 1996. Differential binding of BvgA to two classes 
of virulence genes of Bordetella pertussis directs promoter selectivity by RNA polymerase. Molecular 
microbiology 21:557-565.
47. Porter, J. F., R. Parton, and A. C. Wardlaw. 1991. Growth and survival of Bordetella bronchiseptica in 
natural waters and in buffered saline without added nutrients. Applied and environmental microbiology 
57:1202-1206.
48. Cotter, P. A., and J. F. Miller. 1994. BvgAS-mediated signal transduction: analysis of phase-locked 
regulatory mutants of Bordetella bronchiseptica in a rabbit model. Infection and immunity 62:3381-3390.
49. Cotter, P. A., and J. F. Miller. 1997. A mutation in the Bordetella bronchiseptica bvgS gene results in 
reduced virulence and increased resistance to starvation, and identifies a new class of Bvg-regulated 
antigens. Molecular microbiology 24:671-685.
50. Deora, R., H. J. Bootsma, J. F. Miller, and P. A. Cotter. 2001. Diversity in the Bordetella virulence 
regulon: transcriptional control of a Bvg-intermediate phase gene. Molecular microbiology 40:669-683.
51. Stockbauer, K. E., B. Fuchslocher, J. F. Miller, and P. A. Cotter. 2001. Identification and characterization 
of BipA, a Bordetella Bvg-intermediate phase protein. Molecular microbiology 39:65-78.
52. Sukumar, N., M. Mishra, G. P. Sloan, T. Ogi, and R. Deora. 2007. Differential Bvg phase-dependent 
regulation and combinatorial role in pathogenesis of two Bordetella paralogs, BipA and BcfA. Journal of 
bacteriology 189:3695-3704.
53. Vergara-Irigaray, N., A. Chavarri-Martinez, J. Rodriguez-Cuesta, J. F. Miller, P. A. Cotter, and G. 
Martinez de Tejada. 2005. Evaluation of the role of the Bvg intermediate phase in Bordetella pertussis 
during experimental respiratory infection. Infection and immunity 73:748-760.
54. Cotter, P. A., and A. M. Jones. 2003. Phosphorelay control of virulence gene expression in Bordetella. 
Trends in microbiology 11:367-373.
55. Jungnitz, H., N. P. West, M. J. Walker, G. S. Chhatwal, and C. A. Guzman. 1998. A second two-
component regulatory system of Bordetella bronchiseptica required for bacterial resistance to oxidative 
stress, production of acid phosphatase, and in vivo persistence. Infection and immunity 66:4640-4650.
56. Zimna, K., E. Medina, H. Jungnitz, and C. A. Guzman. 2001. Role played by the response regulator Ris 
in Bordetella bronchiseptica resistance to macrophage killing. FEMS Microbiol Lett 201:177-180.
57. Stenson, T. H., A. G. Allen, J. A. Al-Meer, D. Maskell, and M. S. Peppler. 2005. Bordetella pertussis risA, 
but not risS, is required for maximal expression of Bvg-repressed genes. Infection and immunity 73:5995-
6004.
58. Croinin, T. O., V. K. Grippe, and T. J. Merkel. 2005. Activation of the vrg6 promoter of Bordetella pertussis 
by RisA. Journal of bacteriology 187:1648-1658.
59. Ratledge, C., and L. G. Dover. 2000. Iron metabolism in pathogenic bacteria. Annual review of microbiology 
54:881-941.
60. Aisen, P., and I. Listowsky. 1980. Iron transport and storage proteins. Annual review of biochemistry 
49:357-393.
61. Brickman, T. J., and S. K. Armstrong. 2009. Temporal signaling and differential expression of Bordetella 
iron transport systems: the role of ferrimones and positive regulators. Biometals 22:33-41.
62. Moore, C. H., L. A. Foster, D. G. Gerbig, Jr., D. W. Dyer, and B. W. Gibson. 1995. Identification of 
alcaligin as the siderophore produced by Bordetella pertussis and B. bronchiseptica. Journal of bacteriology 
177:1116-1118.
63. Beall, B., and G. N. Sanden. 1995. A Bordetella pertussis fepA homologue required for utilization of 
exogenous ferric enterobactin. Microbiology 141 ( Pt 12):3193-3205.
64. Vanderpool, C. K., and S. K. Armstrong. 2001. The Bordetella bhu locus is required for heme iron 
utilization. Journal of bacteriology 183:4278-4287.
65. Brickman, T. J., C. A. Cummings, S. Y. Liew, D. A. Relman, and S. K. Armstrong. 2011. Transcriptional 
profiling of the iron starvation response in Bordetella pertussis provides new insights into siderophore 
utilization and virulence gene expression. Journal of bacteriology 193:4798-4812.
66. Beall, B. W., and G. N. Sanden. 1995. Cloning and initial characterization of the Bordetella pertussis fur 
gene. Current microbiology 30:223-226.
67. Brickman, T. J., T. Hanawa, M. T. Anderson, R. J. Suhadolc, and S. K. Armstrong. 2008. Differential 
expression of Bordetella pertussis iron transport system genes during infection. Molecular microbiology 
70:3-14.
68. Brickman, T. J., and S. K. Armstrong. 2007. Impact of alcaligin siderophore utilization on in vivo growth 
of Bordetella pertussis. Infection and immunity 75:5305-5312.
69. Brickman, T. J., C. K. Vanderpool, and S. K. Armstrong. 2006. Heme transport contributes to in vivo 
Introduction | 55
1
fitness of Bordetella pertussis during primary infection in mice. Infection and immunity 74:1741-1744.
70. Agranoff, D., and S. Krishna. 2004. Metal ion transport and regulation in Mycobacterium tuberculosis. 
Frontiers in bioscience : a journal and virtual library 9:2996-3006.
71. Papp-Wallace, K. M., and M. E. Maguire. 2006. Manganese transport and the role of manganese in 
virulence. Annual review of microbiology 60:187-209.
72. Armstrong, S. K., and R. Gross. 2007. Primary Metabolism and Physiology of Bordetella Species, p. 
165-190. In C. Locht (ed.), Bordetella Molecular Microbiology, vol. First. Horizon Bioscience, Norfolk UK.
73. Renauld-Mongenie, G., J. Cornette, N. Mielcarek, F. D. Menozzi, and C. Locht. 1996. Distinct roles of 
the N-terminal and C-terminal precursor domains in the biogenesis of the Bordetella pertussis filamentous 
hemagglutinin. Journal of bacteriology 178:1053-1060.
74. Coutte, L., R. Antoine, H. Drobecq, C. Locht, and F. Jacob-Dubuisson. 2001. Subtilisin-like 
autotransporter serves as maturation protease in a bacterial secretion pathway. The EMBO journal 
20:5040-5048.
75. Siezen, R. J., and J. A. Leunissen. 1997. Subtilases: the superfamily of subtilisin-like serine proteases. 
Protein science : a publication of the Protein Society 6:501-523.
76. Mazar, J., and P. A. Cotter. 2006. Topology and maturation of filamentous haemagglutinin suggest a new 
model for two-partner secretion. Molecular microbiology 62:641-654.
77. Coutte, L., S. Alonso, N. Reveneau, E. Willery, B. Quatannens, C. Locht, and F. Jacob-Dubuisson. 
2003. Role of adhesin release for mucosal colonization by a bacterial pathogen. The Journal of experimental 
medicine 197:735-742.
78. Blom, J., G. A. Hansen, and F. M. Poulsen. 1983. Morphology of cells and hemagglutinogens of Bordetella 
species: resolution of substructural units in fimbriae of Bordetella pertussis. Infection and immunity 42:308-
317.
79. Geuijen, C. A., R. J. Willems, M. Bongaerts, J. Top, H. Gielen, and F. R. Mooi. 1997. Role of the 
Bordetella pertussis minor fimbrial subunit, FimD, in colonization of the mouse respiratory tract. Infection 
and immunity 65:4222-4228.
80. Locht, C., M. C. Geoffroy, and G. Renauld. 1992. Common accessory genes for the Bordetella pertussis 
filamentous hemagglutinin and fimbriae share sequence similarities with the papC and papD gene families. 
The EMBO journal 11:3175-3183.
81. Willems, R. J., C. Geuijen, H. G. van der Heide, M. Matheson, A. Robinson, L. F. Versluis, R. Ebberink, 
J. Theelen, and F. R. Mooi. 1993. Isolation of a putative fimbrial adhesin from Bordetella pertussis and the 
identification of its gene. Molecular microbiology 9:623-634.
82. Willems, R. J., H. G. van der Heide, and F. R. Mooi. 1992. Characterization of a Bordetella pertussis 
fimbrial gene cluster which is located directly downstream of the filamentous haemagglutinin gene. 
Molecular microbiology 6:2661-2671.
83. Willems, R. J., C. Geuijen, H. G. van der Heide, G. Renauld, P. Bertin, W. M. van den Akker, C. Locht, 
and F. R. Mooi. 1994. Mutational analysis of the Bordetella pertussis fim/fha gene cluster: identification 
of a gene with sequence similarities to haemolysin accessory genes involved in export of FHA. Molecular 
microbiology 11:337-347.
84. Geuijen, C. A., R. J. Willems, P. Hoogerhout, W. C. Puijk, R. H. Meloen, and F. R. Mooi. 1998. 
Identification and characterization of heparin binding regions of the Fim2 subunit of Bordetella pertussis. 
Infection and immunity 66:2256-2263.
85. Henderson, I. R., and J. P. Nataro. 2001. Virulence functions of autotransporter proteins. Infection and 
immunity 69:1231-1243.
86. Leininger, E., M. Roberts, J. G. Kenimer, I. G. Charles, N. Fairweather, P. Novotny, and M. J. Brennan. 
1991. Pertactin, an Arg-Gly-Asp-containing Bordetella pertussis surface protein that promotes adherence 
of mammalian cells. Proceedings of the National Academy of Sciences of the United States of America 
88:345-349.
87. Charles, I. G., G. Dougan, D. Pickard, S. Charfield, M. Smith, P. Novotny, and N. Fairweather. 1988. 
Molecular cloning and analysis of P. 69, a vir-controlled protein from Bordetella pertussis. The Tokai journal 
of experimental and clinical medicine 13 Suppl:227-234.
88. Makoff, A. J., M. D. Oxer, S. P. Ballantine, N. F. Fairweather, and I. G. Charles. 1990. Protective surface 
antigen P69 of Bordetella pertussis: its characterization and very high level expression in Escherichia coli. 
Bio/technology 8:1030-1033.
89. Emsley, P., I. G. Charles, N. F. Fairweather, and N. W. Isaacs. 1996. Structure of Bordetella pertussis 
virulence factor P.69 pertactin. Nature 381:90-92.
90. Carbonetti, N. H. 2010. Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella 
pertussis and cell biology tools. Future microbiology 5:455-469.
91. Locht, C., L. Coutte, and N. Mielcarek. 2011. The ins and outs of pertussis toxin. The FEBS journal 
278:4668-4682.
92. Verma, A., and D. L. Burns. 2007. Requirements for assembly of PtlH with the pertussis toxin transporter 
apparatus of Bordetella pertussis. Infection and immunity 75:2297-2306.
93. Verma, A., A. M. Cheung, and D. L. Burns. 2008. Stabilization of the pertussis toxin secretion apparatus 
56 | Chapter 1
by the C terminus of PtlD. Journal of bacteriology 190:7285-7290.
94. Heerze, L. D., P. C. Chong, and G. D. Armstrong. 1992. Investigation of the lectin-like binding domains 
in pertussis toxin using synthetic peptide sequences. Identification of a sialic acid binding site in the S2 
subunit of the toxin. The Journal of biological chemistry 267:25810-25815.
95. Saukkonen, K., W. N. Burnette, V. L. Mar, H. R. Masure, and E. I. Tuomanen. 1992. Pertussis toxin has 
eukaryotic-like carbohydrate recognition domains. Proceedings of the National Academy of Sciences of 
the United States of America 89:118-122.
96. Vojtova, J., J. Kamanova, and P. Sebo. 2006. Bordetella adenylate cyclase toxin: a swift saboteur of host 
defense. Current opinion in microbiology 9:69-75.
97. Hackett, M., C. B. Walker, L. Guo, M. C. Gray, S. Van Cuyk, A. Ullmann, J. Shabanowitz, D. F. Hunt, 
E. L. Hewlett, and P. Sebo. 1995. Hemolytic, but not cell-invasive activity, of adenylate cyclase toxin is 
selectively affected by differential fatty-acylation in Escherichia coli. The Journal of biological chemistry 
270:20250-20253.
98. Boyd, A. P., P. J. Ross, H. Conroy, N. Mahon, E. C. Lavelle, and K. H. Mills. 2005. Bordetella pertussis 
adenylate cyclase toxin modulates innate and adaptive immune responses: distinct roles for acylation and 
enzymatic activity in immunomodulation and cell death. Journal of immunology 175:730-738.
99. Gray, M. C., G. M. Donato, F. R. Jones, T. Kim, and E. L. Hewlett. 2004. Newly secreted adenylate 
cyclase toxin is responsible for intoxication of target cells by Bordetella pertussis. Molecular microbiology 
53:1709-1719.
100. Zaretzky, F. R., M. C. Gray, and E. L. Hewlett. 2002. Mechanism of association of adenylate cyclase toxin 
with the surface of Bordetella pertussis: a role for toxin-filamentous haemagglutinin interaction. Molecular 
microbiology 45:1589-1598.
101. Cossart, P., and P. J. Sansonetti. 2004. Bacterial invasion: the paradigms of enteroinvasive pathogens. 
Science 304:242-248.
102. Hueck, C. J. 1998. Type III protein secretion systems in bacterial pathogens of animals and plants. 
Microbiology and molecular biology reviews : MMBR 62:379-433.
103. Yuk, M. H., E. T. Harvill, P. A. Cotter, and J. F. Miller. 2000. Modulation of host immune responses, 
induction of apoptosis and inhibition of NF-kappaB activation by the Bordetella type III secretion system. 
Molecular microbiology 35:991-1004.
104. Yuk, M. H., E. T. Harvill, and J. F. Miller. 1998. The BvgAS virulence control system regulates type III 
secretion in Bordetella bronchiseptica. Molecular microbiology 28:945-959.
105. Fennelly, N. K., F. Sisti, S. C. Higgins, P. J. Ross, H. van der Heide, F. R. Mooi, A. Boyd, and K. H. 
Mills. 2008. Bordetella pertussis expresses a functional type III secretion system that subverts protective 
innate and adaptive immune responses. Infection and immunity 76:1257-1266.
106. French, C. T., E. M. Panina, S. H. Yeh, N. Griffith, D. G. Arambula, and J. F. Miller. 2009. The Bordetella 
type III secretion system effector BteA contains a conserved N-terminal motif that guides bacterial virulence 
factors to lipid rafts. Cellular microbiology 11:1735-1749.
107. Kuwae, A., T. Matsuzawa, N. Ishikawa, H. Abe, T. Nonaka, H. Fukuda, S. Imajoh-Ohmi, and A. Abe. 
2006. BopC is a novel type III effector secreted by Bordetella bronchiseptica and has a critical role in type 
III-dependent necrotic cell death. The Journal of biological chemistry 281:6589-6600.
108. Goldman, W. E., D. G. Klapper, and J. B. Baseman. 1982. Detection, isolation, and analysis of a released 
Bordetella pertussis product toxic to cultured tracheal cells. Infection and immunity 36:782-794.
109. Goldman, W. E., and L. A. Herwaldt. 1985. Bordetella pertussis tracheal cytotoxin. Developments in 
biological standardization 61:103-111.
110. Rosenthal, R. S., W. Nogami, B. T. Cookson, W. E. Goldman, and W. J. Folkening. 1987. Major 
fragment of soluble peptidoglycan released from growing Bordetella pertussis is tracheal cytotoxin. 
Infection and immunity 55:2117-2120.
111. Relman, D. A., M. Domenighini, E. Tuomanen, R. Rappuoli, and S. Falkow. 1989. Filamentous 
hemagglutinin of Bordetella pertussis: nucleotide sequence and crucial role in adherence. Proceedings of 
the National Academy of Sciences of the United States of America 86:2637-2641.
112. Rodriguez, M. E., S. M. Hellwig, M. L. Perez Vidakovics, G. A. Berbers, and J. G. van de Winkel. 
2006. Bordetella pertussis attachment to respiratory epithelial cells can be impaired by fimbriae-specific 
antibodies. FEMS immunology and medical microbiology 46:39-47.
113. van den Berg, B. M., H. Beekhuizen, R. J. Willems, F. R. Mooi, and R. van Furth. 1999. Role of Bordetella 
pertussis virulence factors in adherence to epithelial cell lines derived from the human respiratory tract. 
Infection and immunity 67:1056-1062.
114. Tuomanen, E., A. Weiss, R. Rich, F. Zak, and O. Zak. 1985. Filamentous hemagglutinin and pertussis 
toxin promote adherence of Bordetella pertussis to cilia. Developments in biological standardization 
61:197-204.
115. Tuomanen, E., H. Towbin, G. Rosenfelder, D. Braun, G. Larson, G. C. Hansson, and R. Hill. 1988. 
Receptor analogs and monoclonal antibodies that inhibit adherence of Bordetella pertussis to human 
ciliated respiratory epithelial cells. The Journal of experimental medicine 168:267-277.
116. Hannah, J. H., F. D. Menozzi, G. Renauld, C. Locht, and M. J. Brennan. 1994. Sulfated glycoconjugate 
Introduction | 57
1
receptors for the Bordetella pertussis adhesin filamentous hemagglutinin (FHA) and mapping of the 
heparin-binding domain on FHA. Infection and immunity 62:5010-5019.
117. Menozzi, F. D., R. Mutombo, G. Renauld, C. Gantiez, J. H. Hannah, E. Leininger, M. J. Brennan, and 
C. Locht. 1994. Heparin-inhibitable lectin activity of the filamentous hemagglutinin adhesin of Bordetella 
pertussis. Infection and immunity 62:769-778.
118. Prasad, S. M., Y. Yin, E. Rodzinski, E. I. Tuomanen, and H. R. Masure. 1993. Identification of a 
carbohydrate recognition domain in filamentous hemagglutinin from Bordetella pertussis. Infection and 
immunity 61:2780-2785.
119. Julio, S. M., C. S. Inatsuka, J. Mazar, C. Dieterich, D. A. Relman, and P. A. Cotter. 2009. Natural-
host animal models indicate functional interchangeability between the filamentous haemagglutinins of 
Bordetella pertussis and Bordetella bronchiseptica and reveal a role for the mature C-terminal domain, but 
not the RGD motif, during infection. Molecular microbiology 71:1574-1590.
120. Perez Vidakovics, M. L., Y. Lamberti, W. L. van der Pol, O. Yantorno, and M. E. Rodriguez. 2006. 
Adenylate cyclase influences filamentous haemagglutinin-mediated attachment of Bordetella pertussis to 
epithelial alveolar cells. FEMS immunology and medical microbiology 48:140-147.
121. Lamberti, Y., J. Alvarez Hayes, M. L. Perez Vidakovics, and M. E. Rodriguez. 2009. Cholesterol-
dependent attachment of human respiratory cells by Bordetella pertussis. FEMS immunology and medical 
microbiology 56:143-150.
122. Simons, K., and R. Ehehalt. 2002. Cholesterol, lipid rafts, and disease. The Journal of clinical investigation 
110:597-603.
123. Lafont, F., L. Abrami, and F. G. van der Goot. 2004. Bacterial subversion of lipid rafts. Current opinion in 
microbiology 7:4-10.
124. Funnell, S. G., and A. Robinson. 1993. A novel adherence assay for Bordetella pertussis using tracheal 
organ cultures. FEMS Microbiol Lett 110:197-203.
125. Geuijen, C. A., R. J. Willems, and F. R. Mooi. 1996. The major fimbrial subunit of Bordetella pertussis 
binds to sulfated sugars. Infection and immunity 64:2657-2665.
126. Everest, P., J. Li, G. Douce, I. Charles, J. De Azavedo, S. Chatfield, G. Dougan, and M. Roberts. 1996. 
Role of the Bordetella pertussis P.69/pertactin protein and the P.69/pertactin RGD motif in the adherence 
to and invasion of mammalian cells. Microbiology 142 ( Pt 11):3261-3268.
127. Roberts, M., N. F. Fairweather, E. Leininger, D. Pickard, E. L. Hewlett, A. Robinson, C. Hayward, 
G. Dougan, and I. G. Charles. 1991. Construction and characterization of Bordetella pertussis mutants 
lacking the vir-regulated P.69 outer membrane protein. Molecular microbiology 5:1393-1404.
128. Saukkonen, K., C. Cabellos, M. Burroughs, S. Prasad, and E. Tuomanen. 1991. Integrin-mediated 
localization of Bordetella pertussis within macrophages: role in pulmonary colonization. The Journal of 
experimental medicine 173:1143-1149.
129. Carbonetti, N. H., G. V. Artamonova, R. M. Mays, and Z. E. Worthington. 2003. Pertussis toxin plays an 
early role in respiratory tract colonization by Bordetella pertussis. Infection and immunity 71:6358-6366.
130. Guermonprez, P., N. Khelef, E. Blouin, P. Rieu, P. Ricciardi-Castagnoli, N. Guiso, D. Ladant, and C. 
Leclerc. 2001. The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha(M)
beta(2) integrin (CD11b/CD18). The Journal of experimental medicine 193:1035-1044.
131. Eby, J. C., W. P. Ciesla, W. Hamman, G. M. Donato, R. J. Pickles, E. L. Hewlett, and W. I. Lencer. 
2010. Selective translocation of the Bordetella pertussis adenylate cyclase toxin across the basolateral 
membranes of polarized epithelial cells. The Journal of biological chemistry 285:10662-10670.
132. Panina, E. M., S. Mattoo, N. Griffith, N. A. Kozak, M. H. Yuk, and J. F. Miller. 2005. A genome-wide 
screen identifies a Bordetella type III secretion effector and candidate effectors in other species. Molecular 
microbiology 58:267-279.
133. Shrivastava, R., and J. F. Miller. 2009. Virulence factor secretion and translocation by Bordetella species. 
Current opinion in microbiology 12:88-93.
134. Stockbauer, K. E., A. K. Foreman-Wykert, and J. F. Miller. 2003. Bordetella type III secretion induces 
caspase 1-independent necrosis. Cellular microbiology 5:123-132.
135. Wilson, R., R. Read, M. Thomas, A. Rutman, K. Harrison, V. Lund, B. Cookson, W. Goldman, H. 
Lambert, and P. Cole. 1991. Effects of Bordetella pertussis infection on human respiratory epithelium in 
vivo and in vitro. Infection and immunity 59:337-345.
136. Dinarello, C. A., and J. M. Krueger. 1986. Induction of interleukin 1 by synthetic and naturally occurring 
muramyl peptides. Federation proceedings 45:2545-2548.
137. Heiss, L. N., S. A. Moser, E. R. Unanue, and W. E. Goldman. 1993. Interleukin-1 is linked to the 
respiratory epithelial cytopathology of pertussis. Infection and immunity 61:3123-3128.
138. Heiss, L. N., J. R. Lancaster, Jr., J. A. Corbett, and W. E. Goldman. 1994. Epithelial autotoxicity of nitric 
oxide: role in the respiratory cytopathology of pertussis. Proceedings of the National Academy of Sciences 
of the United States of America 91:267-270.
139. Flak, T. A., L. N. Heiss, J. T. Engle, and W. E. Goldman. 2000. Synergistic epithelial responses to 
endotoxin and a naturally occurring muramyl peptide. Infection and immunity 68:1235-1242.
140. Flak, T. A., and W. E. Goldman. 1999. Signalling and cellular specificity of airway nitric oxide production 
58 | Chapter 1
in pertussis. Cellular microbiology 1:51-60.
141. van Gent, M., I. H. van Loo, K. J. Heuvelman, A. J. de Neeling, P. Teunis, and F. R. Mooi. 2011. Studies 
on Prn variation in the mouse model and comparison with epidemiological data. PloS one 6:e18014.
142. Inatsuka, C. S., Q. Xu, I. Vujkovic-Cvijin, S. Wong, S. Stibitz, J. F. Miller, and P. A. Cotter. 2010. 
Pertactin is required for Bordetella species to resist neutrophil-mediated clearance. Infection and immunity 
78:2901-2909.
143. Nicholson, T. L., S. L. Brockmeier, and C. L. Loving. 2009. Contribution of Bordetella bronchiseptica 
filamentous hemagglutinin and pertactin to respiratory disease in swine. Infection and immunity 77:2136-
2146.
144. Mooi, F. R., W. H. Jansen, H. Brunings, H. Gielen, H. G. van der Heide, H. C. Walvoort, and P. A. 
Guinee. 1992. Construction and analysis of Bordetella pertussis mutants defective in the production of 
fimbriae. Microbial pathogenesis 12:127-135.
145. Vandebriel, R. J., S. M. Hellwig, J. P. Vermeulen, J. H. Hoekman, J. A. Dormans, P. J. Roholl, and F. 
R. Mooi. 2003. Association of Bordetella pertussis with host immune cells in the mouse lung. Microbial 
pathogenesis 35:19-29.
146. Kimura, A., K. T. Mountzouros, D. A. Relman, S. Falkow, and J. L. Cowell. 1990. Bordetella pertussis 
filamentous hemagglutinin: evaluation as a protective antigen and colonization factor in a mouse respiratory 
infection model. Infection and immunity 58:7-16.
147. Carbonetti, N. H., G. V. Artamonova, C. Andreasen, and N. Bushar. 2005. Pertussis toxin and adenylate 
cyclase toxin provide a one-two punch for establishment of Bordetella pertussis infection of the respiratory 
tract. Infection and immunity 73:2698-2703.
148. Basler, M., O. Knapp, J. Masin, R. Fiser, E. Maier, R. Benz, P. Sebo, and R. Osicka. 2007. Segments 
crucial for membrane translocation and pore-forming activity of Bordetella adenylate cyclase toxin. The 
Journal of biological chemistry 282:12419-12429.
149. Eichelberg, K., C. C. Ginocchio, and J. E. Galan. 1994. Molecular and functional characterization of the 
Salmonella typhimurium invasion genes invB and invC: homology of InvC to the F0F1 ATPase family of 
proteins. Journal of bacteriology 176:4501-4510.
150. Woestyn, S., A. Allaoui, P. Wattiau, and G. R. Cornelis. 1994. YscN, the putative energizer of the 
Yersinia Yop secretion machinery. Journal of bacteriology 176:1561-1569.
151. Finn, T. M., R. Shahin, and J. J. Mekalanos. 1991. Characterization of vir-activated TnphoA gene fusions 
in Bordetella pertussis. Infection and immunity 59:3273-3279.
152. Finn, T. M., and L. A. Stevens. 1995. Tracheal colonization factor: a Bordetella pertussis secreted 
virulence determinant. Molecular microbiology 16:625-634.
153. Abramson, T., H. Kedem, and D. A. Relman. 2001. Proinflammatory and proapoptotic activities associated 
with Bordetella pertussis filamentous hemagglutinin. Infection and immunity 69:2650-2658.
154. Knodler, L. A., J. Celli, and B. B. Finlay. 2001. Pathogenic trickery: deception of host cell processes. 
Nature reviews. Molecular cell biology 2:578-588.
155. Ewanowich, C. A., A. R. Melton, A. A. Weiss, R. K. Sherburne, and M. S. Peppler. 1989. Invasion of 
HeLa 229 cells by virulent Bordetella pertussis. Infection and immunity 57:2698-2704.
156. Bassinet, L., P. Gueirard, B. Maitre, B. Housset, P. Gounon, and N. Guiso. 2000. Role of adhesins 
and toxins in invasion of human tracheal epithelial cells by Bordetella pertussis. Infection and immunity 
68:1934-1941.
157. Lee, C. K., A. L. Roberts, T. M. Finn, S. Knapp, and J. J. Mekalanos. 1990. A new assay for invasion of 
HeLa 229 cells by Bordetella pertussis: effects of inhibitors, phenotypic modulation, and genetic alterations. 
Infection and immunity 58:2516-2522.
158. Ishibashi, Y., D. A. Relman, and A. Nishikawa. 2001. Invasion of human respiratory epithelial cells by 
Bordetella pertussis: possible role for a filamentous hemagglutinin Arg-Gly-Asp sequence and alpha5beta1 
integrin. Microbial pathogenesis 30:279-288.
159. Ishibashi, Y., and A. Nishikawa. 2002. Bordetella pertussis infection of human respiratory epithelial cells 
up-regulates intercellular adhesion molecule-1 expression: role of filamentous hemagglutinin and pertussis 
toxin. Microbial pathogenesis 33:115-125.
160. Ishibashi, Y., and A. Nishikawa. 2003. Role of nuclear factor-kappa B in the regulation of intercellular 
adhesion molecule 1 after infection of human bronchial epithelial cells by Bordetella pertussis. Microbial 
pathogenesis 35:169-177.
161. O’Brien, A. D., T. J. Standiford, K. A. Bucknell, S. E. Wilcoxen, and R. Paine, 3rd. 1999. Role of 
alveolar epithelial cell intercellular adhesion molecule-1 in host defense against Klebsiella pneumoniae. 
The American journal of physiology 276:L961-970.
162. Hazenbos, W. L., B. M. van den Berg, C. W. Geuijen, F. R. Mooi, and R. van Furth. 1995. Binding of 
FimD on Bordetella pertussis to very late antigen-5 on monocytes activates complement receptor type 3 
via protein tyrosine kinases. Journal of immunology 155:3972-3978.
163. Leininger, E., C. A. Ewanowich, A. Bhargava, M. S. Peppler, J. G. Kenimer, and M. J. Brennan. 1992. 
Comparative roles of the Arg-Gly-Asp sequence present in the Bordetella pertussis adhesins pertactin and 
filamentous hemagglutinin. Infection and immunity 60:2380-2385.
Introduction | 59
1
164. Weiss, A. A., E. L. Hewlett, G. A. Myers, and S. Falkow. 1983. Tn5-induced mutations affecting virulence 
factors of Bordetella pertussis. Infection and immunity 42:33-41.
165. Cheers, C., and D. F. Gray. 1969. Macrophage behaviour during the complaisant phase of murine 
pertussis. Immunology 17:875-887.
166. Hellwig, S. M., W. L. Hazenbos, J. G. van de Winkel, and F. R. Mooi. 1999. Evidence for an intracellular 
niche for Bordetella pertussis in broncho-alveolar lavage cells of mice. FEMS immunology and medical 
microbiology 26:203-207.
167. Schipper, H., G. F. Krohne, and R. Gross. 1994. Epithelial cell invasion and survival of Bordetella 
bronchiseptica. Infection and immunity 62:3008-3011.
168. Join-Lambert, O., P. C. Morand, E. Carbonnelle, M. Coureuil, E. Bille, S. Bourdoulous, and X. Nassif. 
2010. Mechanisms of meningeal invasion by a bacterial extracellular pathogen, the example of Neisseria 
meningitidis. Progress in neurobiology 91:130-139.
169. Costerton, J. W., P. S. Stewart, and E. P. Greenberg. 1999. Bacterial biofilms: a common cause of 
persistent infections. Science 284:1318-1322.
170. Lewis, K. 2001. Riddle of biofilm resistance. Antimicrobial agents and chemotherapy 45:999-1007.
171. Conover, M. S., C. J. Redfern, T. Ganguly, N. Sukumar, G. Sloan, M. Mishra, and R. Deora. 2012. BpsR 
modulates Bordetella biofilm formation by negatively regulating the expression of the Bps polysaccharide. 
Journal of bacteriology 194:233-242.
172. Conover, M. S., G. P. Sloan, C. F. Love, N. Sukumar, and R. Deora. 2010. The Bps polysaccharide of 
Bordetella pertussis promotes colonization and biofilm formation in the nose by functioning as an adhesin. 
Molecular microbiology 77:1439-1455.
173. Mishra, M., G. Parise, K. D. Jackson, D. J. Wozniak, and R. Deora. 2005. The BvgAS signal transduction 
system regulates biofilm development in Bordetella. Journal of bacteriology 187:1474-1484.
174. Parise, G., M. Mishra, Y. Itoh, T. Romeo, and R. Deora. 2007. Role of a putative polysaccharide locus in 
Bordetella biofilm development. Journal of bacteriology 189:750-760.
175. Monds, R. D., and G. A. O’Toole. 2009. The developmental model of microbial biofilms: ten years of a 
paradigm up for review. Trends in microbiology 17:73-87.
176. Karatan, E., and P. Watnick. 2009. Signals, regulatory networks, and materials that build and break 
bacterial biofilms. Microbiology and molecular biology reviews : MMBR 73:310-347.
177. Branda, S. S., S. Vik, L. Friedman, and R. Kolter. 2005. Biofilms: the matrix revisited. Trends in 
microbiology 13:20-26.
178. Cotter, P. A., and S. Stibitz. 2007. c-di-GMP-mediated regulation of virulence and biofilm formation. 
Current opinion in microbiology 10:17-23.
179. Hengge, R. 2009. Principles of c-di-GMP signalling in bacteria. Nature reviews. Microbiology 7:263-273.
180. Schirmer, T., and U. Jenal. 2009. Structural and mechanistic determinants of c-di-GMP signalling. Nature 
reviews. Microbiology 7:724-735.
181. Wan, X., J. R. Tuckerman, J. A. Saito, T. A. Freitas, J. S. Newhouse, J. R. Denery, M. Y. Galperin, G. 
Gonzalez, M. A. Gilles-Gonzalez, and M. Alam. 2009. Globins synthesize the second messenger bis-(3’-
5’)-cyclic diguanosine monophosphate in bacteria. Journal of molecular biology 388:262-270.
182. Galperin, M. Y., A. N. Nikolskaya, and E. V. Koonin. 2001. Novel domains of the prokaryotic two-
component signal transduction systems. FEMS Microbiol Lett 203:11-21.
183. Merkel, T. J., C. Barros, and S. Stibitz. 1998. Characterization of the bvgR locus of Bordetella pertussis. 
Journal of bacteriology 180:1682-1690.
184. Serra, D., A. Bosch, D. M. Russo, M. E. Rodriguez, A. Zorreguieta, J. Schmitt, D. Naumann, and 
O. Yantorno. 2007. Continuous nondestructive monitoring of Bordetella pertussis biofilms by Fourier 
transform infrared spectroscopy and other corroborative techniques. Analytical and bioanalytical chemistry 
387:1759-1767.
185. Nicholson, T. L., M. S. Conover, and R. Deora. 2012. Transcriptome profiling reveals stage-specific 
production and requirement of flagella during biofilm development in Bordetella bronchiseptica. PloS one 
7:e49166.
186. Irie, Y., S. Mattoo, and M. H. Yuk. 2004. The Bvg virulence control system regulates biofilm formation in 
Bordetella bronchiseptica. Journal of bacteriology 186:5692-5698.
187. Serra, D. O., M. S. Conover, L. Arnal, G. P. Sloan, M. E. Rodriguez, O. M. Yantorno, and R. Deora. 
2011. FHA-mediated cell-substrate and cell-cell adhesions are critical for Bordetella pertussis biofilm 
formation on abiotic surfaces and in the mouse nose and the trachea. PloS one 6:e28811.
188. Vu, B., M. Chen, R. J. Crawford, and E. P. Ivanova. 2009. Bacterial extracellular polysaccharides involved 
in biofilm formation. Molecules 14:2535-2554.
189. Sloan, G. P., C. F. Love, N. Sukumar, M. Mishra, and R. Deora. 2007. The Bordetella Bps polysaccharide 
is critical for biofilm development in the mouse respiratory tract. Journal of bacteriology 189:8270-8276.
190. Serra, D. O., G. Lucking, F. Weiland, S. Schulz, A. Gorg, O. M. Yantorno, and M. Ehling-Schulz. 
2008. Proteome approaches combined with Fourier transform infrared spectroscopy revealed a distinctive 
biofilm physiology in Bordetella pertussis. Proteomics 8:4995-5010.
191. Mills, K. H. 2001. Immunity to Bordetella pertussis. Microbes and infection / Institut Pasteur 3:655-677.
60 | Chapter 1
192. Kawai, T., and S. Akira. 2009. The roles of TLRs, RLRs and NLRs in pathogen recognition. International 
immunology 21:317-337.
193. Kawai, T., and S. Akira. 2010. The role of pattern-recognition receptors in innate immunity: update on 
Toll-like receptors. Nature immunology 11:373-384.
194. Poltorak, A., X. He, I. Smirnova, M. Y. Liu, C. Van Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. 
Galanos, M. Freudenberg, P. Ricciardi-Castagnoli, B. Layton, and B. Beutler. 1998. Defective LPS 
signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085-2088.
195. Caroff, M., J. Brisson, A. Martin, and D. Karibian. 2000. Structure of the Bordetella pertussis 1414 
endotoxin. FEBS letters 477:8-14.
196. Fedele, G., I. Celestino, F. Spensieri, L. Frasca, M. Nasso, M. Watanabe, M. E. Remoli, E. M. Coccia, 
F. Altieri, and C. M. Ausiello. 2007. Lipooligosaccharide from Bordetella pertussis induces mature human 
monocyte-derived dendritic cells and drives a Th2 biased response. Microbes and infection / Institut 
Pasteur 9:855-863.
197. Fedele, G., M. Nasso, F. Spensieri, R. Palazzo, L. Frasca, M. Watanabe, and C. M. Ausiello. 2008. 
Lipopolysaccharides from Bordetella pertussis and Bordetella parapertussis differently modulate human 
dendritic cell functions resulting in divergent prevalence of Th17-polarized responses. Journal of 
immunology 181:208-216.
198. Dixon, D. R., and R. P. Darveau. 2005. Lipopolysaccharide heterogeneity: innate host responses to 
bacterial modification of lipid a structure. Journal of dental research 84:584-595.
199. Preston, A., E. Maxim, E. Toland, E. J. Pishko, E. T. Harvill, M. Caroff, and D. J. Maskell. 2003. 
Bordetella bronchiseptica PagP is a Bvg-regulated lipid A palmitoyl transferase that is required for 
persistent colonization of the mouse respiratory tract. Molecular microbiology 48:725-736.
200. Geurtsen, J., L. Steeghs, H. J. Hamstra, J. Ten Hove, A. de Haan, B. Kuipers, J. Tommassen, and P. 
van der Ley. 2006. Expression of the lipopolysaccharide-modifying enzymes PagP and PagL modulates 
the endotoxic activity of Bordetella pertussis. Infection and immunity 74:5574-5585.
201. van den Akker, W. M. 1998. Lipopolysaccharide expression within the genus Bordetella: influence of 
temperature and phase variation. Microbiology 144 ( Pt 6):1527-1535.
202. Geurtsen, J., M. Dzieciatkowska, L. Steeghs, H. J. Hamstra, J. Boleij, K. Broen, G. Akkerman, H. 
El Hassan, J. Li, J. C. Richards, J. Tommassen, and P. van der Ley. 2009. Identification of a novel 
lipopolysaccharide core biosynthesis gene cluster in Bordetella pertussis, and influence of core structure 
and lipid A glucosamine substitution on endotoxic activity. Infection and immunity 77:2602-2611.
203. Marr, N., A. Tirsoaga, D. Blanot, R. Fernandez, and M. Caroff. 2008. Glucosamine found as a substituent 
of both phosphate groups in Bordetella lipid A backbones: role of a BvgAS-activated ArnT ortholog. Journal 
of bacteriology 190:4281-4290.
204. Marr, N., A. M. Hajjar, N. R. Shah, A. Novikov, C. S. Yam, M. Caroff, and R. C. Fernandez. 2010. 
Substitution of the Bordetella pertussis lipid A phosphate groups with glucosamine is required for robust 
NF-kappaB activation and release of proinflammatory cytokines in cells expressing human but not murine 
Toll-like receptor 4-MD-2-CD14. Infection and immunity 78:2060-2069.
205. Lysenko, E. S., A. J. Ratner, A. L. Nelson, and J. N. Weiser. 2005. The role of innate immune responses 
in the outcome of interspecies competition for colonization of mucosal surfaces. PLoS pathogens 1:e1.
206. Chaby, R., I. Garcia-Verdugo, Q. Espinassous, and L. A. Augusto. 2005. Interactions between LPS and 
lung surfactant proteins. Journal of endotoxin research 11:181-185.
207. McCormack, F. X., and J. A. Whitsett. 2002. The pulmonary collectins, SP-A and SP-D, orchestrate 
innate immunity in the lung. The Journal of clinical investigation 109:707-712.
208. Stamme, C., M. Muller, L. Hamann, T. Gutsmann, and U. Seydel. 2002. Surfactant protein a inhibits 
lipopolysaccharide-induced immune cell activation by preventing the interaction of lipopolysaccharide with 
lipopolysaccharide-binding protein. American journal of respiratory cell and molecular biology 27:353-360.
209. Schaeffer, L. M., F. X. McCormack, H. Wu, and A. A. Weiss. 2004. Bordetella pertussis lipopolysaccharide 
resists the bactericidal effects of pulmonary surfactant protein A. Journal of immunology 173:1959-1965.
210. Schaeffer, L. M., F. X. McCormack, H. Wu, and A. A. Weiss. 2004. Interactions of pulmonary collectins 
with Bordetella bronchiseptica and Bordetella pertussis lipopolysaccharide elucidate the structural basis of 
their antimicrobial activities. Infection and immunity 72:7124-7130.
211. Kurt-Jones, E. A., L. Popova, L. Kwinn, L. M. Haynes, L. P. Jones, R. A. Tripp, E. E. Walsh, M. W. 
Freeman, D. T. Golenbock, L. J. Anderson, and R. W. Finberg. 2000. Pattern recognition receptors 
TLR4 and CD14 mediate response to respiratory syncytial virus. Nature immunology 1:398-401.
212. Malley, R., P. Henneke, S. C. Morse, M. J. Cieslewicz, M. Lipsitch, C. M. Thompson, E. Kurt-Jones, 
J. C. Paton, M. R. Wessels, and D. T. Golenbock. 2003. Recognition of pneumolysin by Toll-like receptor 
4 confers resistance to pneumococcal infection. Proceedings of the National Academy of Sciences of the 
United States of America 100:1966-1971.
213. Wang, Z. Y., D. Yang, Q. Chen, C. A. Leifer, D. M. Segal, S. B. Su, R. R. Caspi, Z. O. Howard, and J. J. 
Oppenheim. 2006. Induction of dendritic cell maturation by pertussis toxin and its B subunit differentially 
initiate Toll-like receptor 4-dependent signal transduction pathways. Experimental hematology 34:1115-
1124.
Introduction | 61
1
214. Fedele, G., F. Spensieri, R. Palazzo, M. Nasso, G. Y. Cheung, J. G. Coote, and C. M. Ausiello. 2010. 
Bordetella pertussis commits human dendritic cells to promote a Th1/Th17 response through the activity 
of adenylate cyclase toxin and MAPK-pathways. PloS one 5:e8734.
215. Nasso, M., G. Fedele, F. Spensieri, R. Palazzo, P. Costantino, R. Rappuoli, and C. M. Ausiello. 2009. 
Genetically detoxified pertussis toxin induces Th1/Th17 immune response through MAPKs and IL-10-
dependent mechanisms. Journal of immunology 183:1892-1899.
216. Girardin, S. E., I. G. Boneca, L. A. Carneiro, A. Antignac, M. Jehanno, J. Viala, K. Tedin, M. K. 
Taha, A. Labigne, U. Zahringer, A. J. Coyle, P. S. DiStefano, J. Bertin, P. J. Sansonetti, and D. J. 
Philpott. 2003. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 
300:1584-1587.
217. Magalhaes, J. G., D. J. Philpott, M. A. Nahori, M. Jehanno, J. Fritz, L. Le Bourhis, J. Viala, J. P. Hugot, 
M. Giovannini, J. Bertin, M. Lepoivre, D. Mengin-Lecreulx, P. J. Sansonetti, and S. E. Girardin. 2005. 
Murine Nod1 but not its human orthologue mediates innate immune detection of tracheal cytotoxin. EMBO 
reports 6:1201-1207.
218. Byrne, P., P. McGuirk, S. Todryk, and K. H. Mills. 2004. Depletion of NK cells results in disseminating lethal 
infection with Bordetella pertussis associated with a reduction of antigen-specific Th1 and enhancement of 
Th2, but not Tr1 cells. European journal of immunology 34:2579-2588.
219. Khelef, N., C. M. Bachelet, B. B. Vargaftig, and N. Guiso. 1994. Characterization of murine lung 
inflammation after infection with parental Bordetella pertussis and mutants deficient in adhesins or toxins. 
Infection and immunity 62:2893-2900.
220. McGuirk, P., B. P. Mahon, F. Griffin, and K. H. Mills. 1998. Compartmentalization of T cell responses 
following respiratory infection with Bordetella pertussis: hyporesponsiveness of lung T cells is associated 
with modulated expression of the co-stimulatory molecule CD28. European journal of immunology 28:153-
163.
221. McWilliam, A. S., S. Napoli, A. M. Marsh, F. L. Pemper, D. J. Nelson, C. L. Pimm, P. A. Stumbles, T. N. 
Wells, and P. G. Holt. 1996. Dendritic cells are recruited into the airway epithelium during the inflammatory 
response to a broad spectrum of stimuli. The Journal of experimental medicine 184:2429-2432.
222. Meade, B. D., P. D. Kind, and C. R. Manclark. 1985. Altered mononuclear phagocyte function in mice 
treated with the lymphocytosis promoting factor of Bordetella pertussis. Developments in biological 
standardization 61:63-74.
223. Spangrude, G. J., F. Sacchi, H. R. Hill, D. E. Van Epps, and R. A. Daynes. 1985. Inhibition of lymphocyte 
and neutrophil chemotaxis by pertussis toxin. Journal of immunology 135:4135-4143.
224. Kirimanjeswara, G. S., L. M. Agosto, M. J. Kennett, O. N. Bjornstad, and E. T. Harvill. 2005. Pertussis 
toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis. The 
Journal of clinical investigation 115:3594-3601.
225. Thomazzi, S. M., M. H. Souza, A. A. Melo-Filho, E. L. Hewlett, A. A. Lima, and R. A. Ribeiro. 1995. 
Pertussis toxin from Bordetella pertussis blocks neutrophil migration and neutrophil-dependent edema 
in response to inflammation. Brazilian journal of medical and biological research = Revista brasileira de 
pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et al.] 28:120-124.
226. Andreasen, C., and N. H. Carbonetti. 2008. Pertussis toxin inhibits early chemokine production to delay 
neutrophil recruitment in response to Bordetella pertussis respiratory tract infection in mice. Infection and 
immunity 76:5139-5148.
227. Nguyen, T. M., D. Ravindra, B. Kwong, S. Waheed, R. Ferguson, N. Tarlton, V. Wu, C. S. Sequeira, M. 
Bremer, and T. Abramson. 2012. Differential expression of alpha 4 integrins on effector memory T helper 
cells during Bordetella infections. Delayed responses in Bordetella pertussis. PloS one 7:e52903.
228. Cundell, D. R., K. Kanthakumar, G. W. Taylor, W. E. Goldman, T. Flak, P. J. Cole, and R. Wilson. 1994. 
Effect of tracheal cytotoxin from Bordetella pertussis on human neutrophil function in vitro. Infection and 
immunity 62:639-643.
229. Hazenbos, W. L., B. M. van den Berg, J. W. van’t Wout, F. R. Mooi, and R. van Furth. 1994. Virulence 
factors determine attachment and ingestion of nonopsonized and opsonized Bordetella pertussis by 
human monocytes. Infection and immunity 62:4818-4824.
230. Steed, L. L., M. Setareh, and R. L. Friedman. 1991. Intracellular survival of virulent Bordetella pertussis 
in human polymorphonuclear leukocytes. Journal of leukocyte biology 50:321-330.
231. Weingart, C. L., G. Broitman-Maduro, G. Dean, S. Newman, M. Peppler, and A. A. Weiss. 1999. 
Fluorescent labels influence phagocytosis of Bordetella pertussis by human neutrophils. Infection and 
immunity 67:4264-4267.
232. Weiss, A. A., P. S. Mobberley, R. C. Fernandez, and C. M. Mink. 1999. Characterization of human 
bactericidal antibodies to Bordetella pertussis. Infection and immunity 67:1424-1431.
233. Weingart, C. L., and A. A. Weiss. 2000. Bordetella pertussis virulence factors affect phagocytosis by 
human neutrophils. Infection and immunity 68:1735-1739.
234. Miller, J. J., R. J. Silverberg, T. M. Saito, and J. B. Humber. 1943. An agglutinative reaction for hemophilus 
pertussis: II. Its relation to clinical immunity. The Journal of pediatrics 22:644-651.
235. Cherry, J. D., J. Gornbein, U. Heininger, and K. Stehr. 1998. A search for serologic correlates of immunity 
62 | Chapter 1
to Bordetella pertussis cough illnesses. Vaccine 16:1901-1906.
236. Hellwig, S. M., M. E. Rodriguez, G. A. Berbers, J. G. van de Winkel, and F. R. Mooi. 2003. Crucial role 
of antibodies to pertactin in Bordetella pertussis immunity. The Journal of infectious diseases 188:738-742.
237. Storsaeter, J., H. O. Hallander, L. Gustafsson, and P. Olin. 1998. Levels of anti-pertussis antibodies 
related to protection after household exposure to Bordetella pertussis. Vaccine 16:1907-1916.
238. Storsaeter, J., H. O. Hallander, L. Gustafsson, and P. Olin. 2003. Low levels of antipertussis antibodies 
plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella 
pertussis. Vaccine 21:3542-3549.
239. Hellwig, S. M., H. F. van Oirschot, W. L. Hazenbos, A. B. van Spriel, F. R. Mooi, and J. G. van 
De Winkel. 2001. Targeting to Fcgamma receptors, but not CR3 (CD11b/CD18), increases clearance of 
Bordetella pertussis. The Journal of infectious diseases 183:871-879.
240. Hellwig, S. M., A. B. van Spriel, J. F. Schellekens, F. R. Mooi, and J. G. van de Winkel. 2001. 
Immunoglobulin A-mediated protection against Bordetella pertussis infection. Infection and immunity 
69:4846-4850.
241. Rodriguez, M. E., S. M. Hellwig, D. F. Hozbor, J. Leusen, W. L. van der Pol, and J. G. van de Winkel. 
2001. Fc receptor-mediated immunity against Bordetella pertussis. Journal of immunology 167:6545-
6551.
242. Andreasen, C., and N. H. Carbonetti. 2009. Role of neutrophils in response to Bordetella pertussis 
infection in mice. Infection and immunity 77:1182-1188.
243. Relman, D., E. Tuomanen, S. Falkow, D. T. Golenbock, K. Saukkonen, and S. D. Wright. 1990. 
Recognition of a bacterial adhesion by an integrin: macrophage CR3 (alpha M beta 2, CD11b/CD18) binds 
filamentous hemagglutinin of Bordetella pertussis. Cell 61:1375-1382.
244. Rozdzinski, E., J. Sandros, M. van der Flier, A. Young, B. Spellerberg, C. Bhattacharyya, J. Straub, 
G. Musso, S. Putney, R. Starzyk, and et al. 1995. Inhibition of leukocyte-endothelial cell interactions and 
inflammation by peptides from a bacterial adhesin which mimic coagulation factor X. The Journal of clinical 
investigation 95:1078-1085.
245. Agramonte-Hevia, J., A. Gonzalez-Arenas, D. Barrera, and M. Velasco-Velazquez. 2002. Gram-
negative bacteria and phagocytic cell interaction mediated by complement receptor 3. FEMS immunology 
and medical microbiology 34:255-266.
246. Hazenbos, W. L., B. M. van den Berg, and R. van Furth. 1993. Very late antigen-5 and complement 
receptor type 3 cooperatively mediate the interaction between Bordetella pertussis and human monocytes. 
Journal of immunology 151:6274-6282.
247. Hazenbos, W. L., C. A. Geuijen, B. M. van den Berg, F. R. Mooi, and R. van Furth. 1995. Bordetella 
pertussis fimbriae bind to human monocytes via the minor fimbrial subunit FimD. The Journal of infectious 
diseases 171:924-929.
248. Pommier, C. G., S. Inada, L. F. Fries, T. Takahashi, M. M. Frank, and E. J. Brown. 1983. Plasma 
fibronectin enhances phagocytosis of opsonized particles by human peripheral blood monocytes. The 
Journal of experimental medicine 157:1844-1854.
249. Schaeffer, L. M., and A. A. Weiss. 2001. Pertussis toxin and lipopolysaccharide influence phagocytosis 
of Bordetella pertussis by human monocytes. Infection and immunity 69:7635-7641.
250. Preynat-Seauve, O., C. L. Villiers, G. Jourdan, M. J. Richard, J. Plumas, A. Favier, P. N. Marche, 
and M. C. Favrot. 2004. An interaction between CD16 and CR3 enhances iC3b binding to CR3 but is lost 
during differentiation of monocytes into dendritic cells. European journal of immunology 34:147-155.
251. Mobberley-Schuman, P. S., and A. A. Weiss. 2005. Influence of CR3 (CD11b/CD18) expression on 
phagocytosis of Bordetella pertussis by human neutrophils. Infection and immunity 73:7317-7323.
252. Lamberti, Y., M. L. Perez Vidakovics, L. W. van der Pol, and M. E. Rodriguez. 2008. Cholesterol-
rich domains are involved in Bordetella pertussis phagocytosis and intracellular survival in neutrophils. 
Microbial pathogenesis 44:501-511.
253. van Zanten, T. S., A. Cambi, M. Koopman, B. Joosten, C. G. Figdor, and M. F. Garcia-Parajo. 2009. 
Hotspots of GPI-anchored proteins and integrin nanoclusters function as nucleation sites for cell adhesion. 
Proceedings of the National Academy of Sciences of the United States of America 106:18557-18562.
254. Caron, E., and A. Hall. 1998. Identification of two distinct mechanisms of phagocytosis controlled by 
different Rho GTPases. Science 282:1717-1721.
255. Berton, G., C. Laudanna, C. Sorio, and F. Rossi. 1992. Generation of signals activating neutrophil 
functions by leukocyte integrins: LFA-1 and gp150/95, but not CR3, are able to stimulate the respiratory 
burst of human neutrophils. The Journal of cell biology 116:1007-1017.
256. Carbonetti, N. H., G. V. Artamonova, C. Andreasen, E. Dudley, R. M. Mays, and Z. E. Worthington. 
2004. Suppression of serum antibody responses by pertussis toxin after respiratory tract colonization by 
Bordetella pertussis and identification of an immunodominant lipoprotein. Infection and immunity 72:3350-
3358.
257. Mielcarek, N., G. Riveau, F. Remoue, R. Antoine, A. Capron, and C. Locht. 1998. Homologous and 
heterologous protection after single intranasal administration of live attenuated recombinant Bordetella 
pertussis. Nature biotechnology 16:454-457.
Introduction | 63
1
258. Cohn, Z. A., and M. E. Fedorko. 1969. The formation and fate of lysosomes, p. 1-47. In J. T. Dingle and 
H. B. Fell (ed.), Lysosomes in Biology and Pathology. North Holland Publishing Co., London.
259. Schneider, B., R. Gross, and A. Haas. 2000. Phagosome acidification has opposite effects on intracellular 
survival of Bordetella pertussis and B. bronchiseptica. Infection and immunity 68:7039-7048.
260. Lenz, D. H., C. L. Weingart, and A. A. Weiss. 2000. Phagocytosed Bordetella pertussis fails to survive in 
human neutrophils. Infection and immunity 68:956-959.
261. Friedman, R. L., K. Nordensson, L. Wilson, E. T. Akporiaye, and D. E. Yocum. 1992. Uptake and 
intracellular survival of Bordetella pertussis in human macrophages. Infection and immunity 60:4578-4585.
262. Lamberti, Y. A., J. A. Hayes, M. L. Perez Vidakovics, E. T. Harvill, and M. E. Rodriguez. 2010. 
Intracellular trafficking of Bordetella pertussis in human macrophages. Infection and immunity 78:907-913.
263. Carbonetti, N. H., G. V. Artamonova, N. Van Rooijen, and V. I. Ayala. 2007. Pertussis toxin targets 
airway macrophages to promote Bordetella pertussis infection of the respiratory tract. Infection and 
immunity 75:1713-1720.
264. Weingart, C. L., P. S. Mobberley-Schuman, E. L. Hewlett, M. C. Gray, and A. A. Weiss. 2000. 
Neutralizing antibodies to adenylate cyclase toxin promote phagocytosis of Bordetella pertussis by human 
neutrophils. Infection and immunity 68:7152-7155.
265. Kamanova, J., O. Kofronova, J. Masin, H. Genth, J. Vojtova, I. Linhartova, O. Benada, I. Just, and 
P. Sebo. 2008. Adenylate cyclase toxin subverts phagocyte function by RhoA inhibition and unproductive 
ruffling. Journal of immunology 181:5587-5597.
266. Friedman, R. L., R. L. Fiederlein, L. Glasser, and J. N. Galgiani. 1987. Bordetella pertussis adenylate 
cyclase: effects of affinity-purified adenylate cyclase on human polymorphonuclear leukocyte functions. 
Infection and immunity 55:135-140.
267. Pearson, R. D., P. Symes, M. Conboy, A. A. Weiss, and E. L. Hewlett. 1987. Inhibition of monocyte 
oxidative responses by Bordetella pertussis adenylate cyclase toxin. Journal of immunology 139:2749-
2754.
268. Khelef, N., A. Zychlinsky, and N. Guiso. 1993. Bordetella pertussis induces apoptosis in macrophages: 
role of adenylate cyclase-hemolysin. Infection and immunity 61:4064-4071.
269. Gueirard, P., A. Druilhe, M. Pretolani, and N. Guiso. 1998. Role of adenylate cyclase-hemolysin in 
alveolar macrophage apoptosis during Bordetella pertussis infection in vivo. Infection and immunity 
66:1718-1725.
270. Khelef, N., P. Gounon, and N. Guiso. 2001. Internalization of Bordetella pertussis adenylate cyclase-
haemolysin into endocytic vesicles contributes to macrophage cytotoxicity. Cellular microbiology 3:721-
730.
271. Cheung, G. Y., S. M. Kelly, T. J. Jess, S. Prior, N. C. Price, R. Parton, and J. G. Coote. 2009. Functional 
and structural studies on different forms of the adenylate cyclase toxin of Bordetella pertussis. Microbial 
pathogenesis 46:36-42.
272. Bachelet, M., M. J. Richard, D. Francois, and B. S. Polla. 2002. Mitochondrial alterations precede 
Bordetella pertussis-induced apoptosis. FEMS immunology and medical microbiology 32:125-131.
273. Benz, R., E. Maier, D. Ladant, A. Ullmann, and P. Sebo. 1994. Adenylate cyclase toxin (CyaA) of 
Bordetella pertussis. Evidence for the formation of small ion-permeable channels and comparison with 
HlyA of Escherichia coli. The Journal of biological chemistry 269:27231-27239.
274. Szabo, G., M. C. Gray, and E. L. Hewlett. 1994. Adenylate cyclase toxin from Bordetella pertussis 
produces ion conductance across artificial lipid bilayers in a calcium- and polarity-dependent manner. The 
Journal of biological chemistry 269:22496-22499.
275. Khelef, N., and N. Guiso. 1995. Induction of macrophage apoptosis by Bordetella pertussis adenylate 
cyclase-hemolysin. FEMS Microbiol Lett 134:27-32.
276. Blom, A. M., T. Hallstrom, and K. Riesbeck. 2009. Complement evasion strategies of pathogens-
acquisition of inhibitors and beyond. Molecular immunology 46:2808-2817.
277. Laarman, A., F. Milder, J. van Strijp, and S. Rooijakkers. 2010. Complement inhibition by gram-positive 
pathogens: molecular mechanisms and therapeutic implications. Journal of molecular medicine 88:115-
120.
278. Lambris, J. D., D. Ricklin, and B. V. Geisbrecht. 2008. Complement evasion by human pathogens. 
Nature reviews. Microbiology 6:132-142.
279. Fernandez, R. C., and A. A. Weiss. 1994. Cloning and sequencing of a Bordetella pertussis serum 
resistance locus. Infection and immunity 62:4727-4738.
280. Newman, S. L., J. E. Devery-Pocius, G. D. Ross, and P. M. Henson. 1984. Phagocytosis by human 
monocyte-derived macrophages. Independent function of receptors for C3b (CR1) and iC3b (CR3). 
Complement 1:213-227.
281. Barnes, M. G., and A. A. Weiss. 2001. BrkA protein of Bordetella pertussis inhibits the classical pathway 
of complement after C1 deposition. Infection and immunity 69:3067-3072.
282. Berggard, K., E. Johnsson, F. R. Mooi, and G. Lindahl. 1997. Bordetella pertussis binds the human 
complement regulator C4BP: role of filamentous hemagglutinin. Infection and immunity 65:3638-3643.
283. Marr, N., R. A. Luu, and R. C. Fernandez. 2007. Bordetella pertussis binds human C1 esterase inhibitor 
64 | Chapter 1
during the virulent phase, to evade complement-mediated killing. The Journal of infectious diseases 
195:585-588.
284. Fujita, T., I. Gigli, and V. Nussenzweig. 1978. Human C4-binding protein. II. Role in proteolysis of C4b 
by C3b-inactivator. The Journal of experimental medicine 148:1044-1051.
285. Gigli, I., T. Fujita, and V. Nussenzweig. 1979. Modulation of the classical pathway C3 convertase by 
plasma proteins C4 binding protein and C3b inactivator. Proceedings of the National Academy of Sciences 
of the United States of America 76:6596-6600.
286. Caliezi, C., W. A. Wuillemin, S. Zeerleder, M. Redondo, B. Eisele, and C. E. Hack. 2000. C1-Esterase 
inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary 
angioedema. Pharmacological reviews 52:91-112.
287. Marr, N., N. R. Shah, R. Lee, E. J. Kim, and R. C. Fernandez. 2011. Bordetella pertussis autotransporter 
Vag8 binds human C1 esterase inhibitor and confers serum resistance. PloS one 6:e20585.
288. Ganguly, T., J. B. Johnson, N. D. Kock, G. D. Parks, and R. Deora. 2014. The Bordetella pertussis Bps 
polysaccharide enhances lung colonization by conferring protection from complement-mediated killing. 
Cellular microbiology.
289. Fernandez, R. C., and A. A. Weiss. 1998. Serum resistance in bvg-regulated mutants of Bordetella 
pertussis. FEMS Microbiol Lett 163:57-63.
290. Leef, M., K. L. Elkins, J. Barbic, and R. D. Shahin. 2000. Protective immunity to Bordetella pertussis 
requires both B cells and CD4(+) T cells for key functions other than specific antibody production. The 
Journal of experimental medicine 191:1841-1852.
291. Liew, F. Y. 2002. T(H)1 and T(H)2 cells: a historical perspective. Nature reviews. Immunology 2:55-60.
292. Mosmann, T. R., and R. L. Coffman. 1989. TH1 and TH2 cells: different patterns of lymphokine secretion 
lead to different functional properties. Annual review of immunology 7:145-173.
293. Mosmann, T. R., H. Cherwinski, M. W. Bond, M. A. Giedlin, and R. L. Coffman. 1986. Two types of 
murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. 
Journal of immunology 136:2348-2357.
294. Park, H., Z. Li, X. O. Yang, S. H. Chang, R. Nurieva, Y. H. Wang, Y. Wang, L. Hood, Z. Zhu, Q. Tian, and 
C. Dong. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. 
Nature immunology 6:1133-1141.
295. Ouyang, W., J. K. Kolls, and Y. Zheng. 2008. The biological functions of T helper 17 cell effector cytokines 
in inflammation. Immunity 28:454-467.
296. Fernandez-Botran, R., V. M. Sanders, T. R. Mosmann, and E. S. Vitetta. 1988. Lymphokine-mediated 
regulation of the proliferative response of clones of T helper 1 and T helper 2 cells. The Journal of 
experimental medicine 168:543-558.
297. Gajewski, T. F., and F. W. Fitch. 1988. Anti-proliferative effect of IFN-gamma in immune regulation. I. 
IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. Journal of 
immunology 140:4245-4252.
298. Acosta-Rodriguez, E. V., G. Napolitani, A. Lanzavecchia, and F. Sallusto. 2007. Interleukins 1beta and 
6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing 
human T helper cells. Nature immunology 8:942-949.
299. Veldhoen, M., R. J. Hocking, C. J. Atkins, R. M. Locksley, and B. Stockinger. 2006. TGFbeta in the 
context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. 
Immunity 24:179-189.
300. Wilson, N. J., K. Boniface, J. R. Chan, B. S. McKenzie, W. M. Blumenschein, J. D. Mattson, B. 
Basham, K. Smith, T. Chen, F. Morel, J. C. Lecron, R. A. Kastelein, D. J. Cua, T. K. McClanahan, E. P. 
Bowman, and R. de Waal Malefyt. 2007. Development, cytokine profile and function of human interleukin 
17-producing helper T cells. Nature immunology 8:950-957.
301. Saraiva, M., and A. O’Garra. 2010. The regulation of IL-10 production by immune cells. Nature reviews. 
Immunology 10:170-181.
302. Barbic, J., M. F. Leef, D. L. Burns, and R. D. Shahin. 1997. Role of gamma interferon in natural clearance 
of Bordetella pertussis infection. Infection and immunity 65:4904-4908.
303. Mahon, B. P., B. J. Sheahan, F. Griffin, G. Murphy, and K. H. Mills. 1997. Atypical disease after 
Bordetella pertussis respiratory infection of mice with targeted disruptions of interferon-gamma receptor or 
immunoglobulin mu chain genes. The Journal of experimental medicine 186:1843-1851.
304. Peppoloni, S., L. Nencioni, A. Di Tommaso, A. Tagliabue, P. Parronchi, S. Romagnani, R. Rappuoli, 
and M. T. De Magistris. 1991. Lymphokine secretion and cytotoxic activity of human CD4+ T-cell clones 
against Bordetella pertussis. Infection and immunity 59:3768-3773.
305. Ross, P. J., C. E. Sutton, S. Higgins, A. C. Allen, K. Walsh, A. Misiak, E. C. Lavelle, R. M. McLoughlin, 
and K. H. Mills. 2013. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella 
pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS pathogens 
9:e1003264.
306. Dunne, A., P. J. Ross, E. Pospisilova, J. Masin, A. Meaney, C. E. Sutton, Y. Iwakura, J. Tschopp, P. 
Sebo, and K. H. Mills. 2010. Inflammasome activation by adenylate cyclase toxin directs Th17 responses 
Introduction | 65
1
and protection against Bordetella pertussis. Journal of immunology 185:1711-1719.
307. Higgins, S. C., A. G. Jarnicki, E. C. Lavelle, and K. H. Mills. 2006. TLR4 mediates vaccine-induced 
protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. Journal of immunology 
177:7980-7989.
308. Higgs, R., S. C. Higgins, P. J. Ross, and K. H. Mills. 2012. Immunity to the respiratory pathogen 
Bordetella pertussis. Mucosal immunology 5:485-500.
309. McGuirk, P., C. McCann, and K. H. Mills. 2002. Pathogen-specific T regulatory 1 cells induced in the 
respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a 
novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. The Journal of 
experimental medicine 195:221-231.
310. Spensieri, F., G. Fedele, C. Fazio, M. Nasso, P. Stefanelli, P. Mastrantonio, and C. M. Ausiello. 2006. 
Bordetella pertussis inhibition of interleukin-12 (IL-12) p70 in human monocyte-derived dendritic cells 
blocks IL-12 p35 through adenylate cyclase toxin-dependent cyclic AMP induction. Infection and immunity 
74:2831-2838.
311. Hoeve, M. A., N. D. Savage, T. de Boer, D. M. Langenberg, R. de Waal Malefyt, T. H. Ottenhoff, and 
F. A. Verreck. 2006. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. 
European journal of immunology 36:661-670.
312. McGuirk, P., and K. H. Mills. 2000. Direct anti-inflammatory effect of a bacterial virulence factor: IL-
10-dependent suppression of IL-12 production by filamentous hemagglutinin from Bordetella pertussis. 
European journal of immunology 30:415-422.
313. Marth, T., and B. L. Kelsall. 1997. Regulation of interleukin-12 by complement receptor 3 signaling. The 
Journal of experimental medicine 185:1987-1995.
314. Hickey, F. B., C. F. Brereton, and K. H. Mills. 2008. Adenylate cyclase toxin of Bordetella pertussis 
inhibits TLR-induced IRF-1 and IRF-8 activation and IL-12 production and enhances IL-10 through MAPK 
activation in dendritic cells. Journal of leukocyte biology 84:234-243.
315. Sutterwala, F. S., Y. Ogura, M. Szczepanik, M. Lara-Tejero, G. S. Lichtenberger, E. P. Grant, J. 
Bertin, A. J. Coyle, J. E. Galan, P. W. Askenase, and R. A. Flavell. 2006. Critical role for NALP3/CIAS1/
Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24:317-327.
316. Dirix, V., V. Verscheure, T. Goetghebuer, M. Hainaut, A. S. Debrie, C. Locht, and F. Mascart. 2009. 
Monocyte-derived interleukin-10 depresses the Bordetella pertussis- specific gamma interferon response 
in vaccinated infants. Clinical and vaccine immunology : CVI 16:1816-1821.
317. Ross, P. J., E. C. Lavelle, K. H. Mills, and A. P. Boyd. 2004. Adenylate cyclase toxin from Bordetella 
pertussis synergizes with lipopolysaccharide to promote innate interleukin-10 production and enhances 
the induction of Th2 and regulatory T cells. Infection and immunity 72:1568-1579.
318. Nagamatsu, K., A. Kuwae, T. Konaka, S. Nagai, S. Yoshida, M. Eguchi, M. Watanabe, H. Mimuro, S. 
Koyasu, and A. Abe. 2009. Bordetella evades the host immune system by inducing IL-10 through a type 
III effector, BopN. The Journal of experimental medicine 206:3073-3088.
319. Cassone, A., P. Mastrantonio, and C. M. Ausiello. 2000. Are only antibody levels involved in the 
protection against pertussis in acellular pertussis vaccine recipients? The Journal of infectious diseases 
182:1575-1577.
320. Mahon, B. P., M. T. Brady, and K. H. Mills. 2000. Protection against Bordetella pertussis in mice in the 
absence of detectable circulating antibody: implications for long-term immunity in children. The Journal of 
infectious diseases 181:2087-2091.
321. Mooi, F. R., I. H. van Loo, M. van Gent, Q. He, M. J. Bart, K. J. Heuvelman, S. C. de Greeff, D. 
Diavatopoulos, P. Teunis, N. Nagelkerke, and J. Mertsola. 2009. Bordetella pertussis strains with 
increased toxin production associated with pertussis resurgence. Emerging infectious diseases 15:1206-
1213.
322. Peppoloni, S., M. Pizza, M. T. De Magistris, A. Bartoloni, and R. Rappuoli. 1995. Acellular pertussis 
vaccine composed of genetically inactivated pertussis toxin. Physiological chemistry and physics and 
medical NMR 27:355-361.
323. Robbins, J. B., R. Schneerson, B. Trollfors, H. Sato, Y. Sato, R. Rappuoli, and J. M. Keith. 2005. The 
diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically 
inactivated mutant toxins. The Journal of infectious diseases 191:81-88.
324. di Tommaso, A., M. T. de Magistris, M. Bugnoli, I. Marsili, R. Rappuoli, and S. Abrignani. 1994. 
Formaldehyde treatment of proteins can constrain presentation to T cells by limiting antigen processing. 
Infection and immunity 62:1830-1834.
325. Paddock, C. D., G. N. Sanden, J. D. Cherry, A. A. Gal, C. Langston, K. M. Tatti, K. H. Wu, C. S. 
Goldsmith, P. W. Greer, J. L. Montague, M. T. Eliason, R. C. Holman, J. Guarner, W. J. Shieh, and 
S. R. Zaki. 2008. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clinical 
infectious diseases : an official publication of the Infectious Diseases Society of America 47:328-338.
326. Pierce, C., N. Klein, and M. Peters. 2000. Is leukocytosis a predictor of mortality in severe pertussis 
infection? Intensive care medicine 26:1512-1514.
327. Cheung, G. Y., D. Xing, S. Prior, M. J. Corbel, R. Parton, and J. G. Coote. 2006. Effect of different forms 
66 | Chapter 1
of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine 
in a murine model. Infection and immunity 74:6797-6805.
328. Geurtsen, J., F. Fransen, R. J. Vandebriel, E. R. Gremmer, L. J. de la Fonteyne-Blankestijn, B. 
Kuipers, J. Tommassen, and P. van der Ley. 2008. Supplementation of whole-cell pertussis vaccines 
with lipopolysaccharide analogs: modification of vaccine-induced immune responses. Vaccine 26:899-
906.
329. Abe, A., K. Nagamatsu, and M. Watanabe. 2008. The Bordetella type III secretion system: its application 
to vaccine development. Microbiology and immunology 52:128-133.
330. Sawa, T., T. L. Yahr, M. Ohara, K. Kurahashi, M. A. Gropper, J. P. Wiener-Kronish, and D. W. Frank. 
1999. Active and passive immunization with the Pseudomonas V antigen protects against type III 
intoxication and lung injury. Nature medicine 5:392-398.
331. Medhekar, B., R. Shrivastava, S. Mattoo, M. Gingery, and J. F. Miller. 2009. Bordetella Bsp22 forms a 
filamentous type III secretion system tip complex and is immunoprotective in vitro and in vivo. Molecular 
microbiology 71:492-504.
332. Villarino Romero, R., I. Bibova, O. Cerny, B. Vecerek, T. Wald, O. Benada, J. Zavadilova, R. Osicka, 
and P. Sebo. 2013. The Bordetella pertussis type III secretion system tip complex protein Bsp22 is not 
a protective antigen and fails to elicit serum antibody responses during infection of humans and mice. 
Infection and immunity 81:2761-2767.
333. Cerca, N., T. Maira-Litran, K. K. Jefferson, M. Grout, D. A. Goldmann, and G. B. Pier. 2007. Protection 
against Escherichia coli infection by antibody to the Staphylococcus aureus poly-N-acetylglucosamine 
surface polysaccharide. Proceedings of the National Academy of Sciences of the United States of America 
104:7528-7533.
334. Martinez, L. R., and A. Casadevall. 2005. Specific antibody can prevent fungal biofilm formation and this 
effect correlates with protective efficacy. Infection and immunity 73:6350-6362.
335. Visai, L., C. R. Arciola, G. Pietrocola, S. Rindi, P. Olivero, and P. Speziale. 2007. Staphylococcus 
biofilm components as targets for vaccines and drugs. The International journal of artificial organs 30:813-
819.
336. Mielcarek, N., A. S. Debrie, D. Raze, J. Bertout, C. Rouanet, A. B. Younes, C. Creusy, J. Engle, W. 
E. Goldman, and C. Locht. 2006. Live attenuated B. pertussis as a single-dose nasal vaccine against 
whooping cough. PLoS pathogens 2:e65.
Transcriptomics of a globally emerged pathogen | 67
2
Chapter 2
Differentially expressed genes in 
Bordetella pertussis strains belonging to a 
lineage which recently spread globally
Daan de Gouw, Peter W.M. Hermans, Hester J. Bootsma, 
Aldert Zomer, Kees Heuvelman, Dimitri A. Diavatopoulos & 
Frits R. Mooi.
PLoS One. 2014, 9(1); e84523.
68 | Chapter 2
Abstract
Pertussis is a highly contagious, acute respiratory disease in humans caused by the Gram-
negative pathogen Bordetella pertussis. Pertussis has resurged in the face of intensive 
vaccination and this has coincided with the emergence of strains carrying a particular allele for 
the pertussis toxin promoter, ptxP3, which is associated with higher levels of pertussis toxin 
(Ptx) production. Within 10 to 20 years, ptxP3 strains have nearly completely replaced the 
previously dominant ptxP1 strains resulting in a worldwide selective sweep. In order to identify 
B. pertussis genes associated with the selective sweep, we compared the expression of genes 
in ptxP1 and ptxP3 strains that are under control of the Bordetella master virulence regulatory 
locus (bvgASR). The BvgAS proteins comprise a two component sensory transduction 
system which is regulated by temperature, nicotinic acid and sulfate. By increasing the sulfate 
concentration, it is possible to change the phase of B. pertussis from virulent to avirulent. Until 
recently, the only distinctive phenotype of ptxP3 strains was a higher Ptx production. Here we 
identify additional phenotypic differences between ptxP1 and ptxP3 strains which may have 
contributed to its global spread by comparing global transcriptional responses under sulfate-
modulating conditions. We show that ptxP3 strains are less sensitive to sulfate-mediated gene 
suppression, resulting in an increased production of the vaccine antigens pertactin (Prn) and 
Ptx and a number of other virulence genes, including a type III secretion toxin, Vag8, a protein 
involved in complement resistance, and lpxE involved in lipid A modification. Furthermore, 
enhanced expression of the vaccine antigens Ptx and Prn by ptxP3 strains was confirmed 
at the protein level. Identification of genes differentially expressed between ptxP1 and ptxP3 
strains may elucidate how B. pertussis has adapted to vaccination and allow the improvement 
off pertussis vaccines by identifying novel vaccine candidates. 
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Introduction
Bordetella pertussis is the major causative agent of whooping cough or pertussis, a highly 
contagious, acute respiratory disease in humans. Before the introduction of vaccination in 
the 1950s, pertussis was a leading cause of infant death throughout the world (1) Although 
extensive immunization campaigns have significantly reduced pertussis-caused infant mortality 
worldwide, infections with B. pertussis still pose an important health burden, with an annual 
infection rate of 1-9% in some highly vaccinated populations (2) and an estimated 195,000 
deaths worldwide (3). Significantly, pertussis notifications have increased during the last two 
decades, especially in adolescents and adults. This increase of pertussis infections in older age 
categories represents significant health risks, as they are a source of B. pertussis transmission 
to unvaccinated infants for whom pertussis is a severe, life threatening, disease (4-6). In 2010 
and 2012 particularly large outbreaks of pertussis were observed in several countries (7-
9). Suggested causes for the increase in pertussis include increased awareness, improved 
diagnostics, suboptimal vaccines, waning immunity, and pathogen adaptation (10,11). 
Studies performed in several countries provide evidence that B. pertussis has diverged 
antigenically from vaccine strains and has increased expression of pertussis toxin (Ptx) and the 
type III effector toxin BteA (12,13). In the Netherlands, the pertussis resurgence has coincided 
with the emergence of strains that carry a particular allele of the ptx operon promoter, ptxP3, which 
is associated with higher levels of Ptx expression (13). Within a timeframe of 10 years, ptxP3 
strains have nearly completely replaced the previously dominant ptxP1 strains. Significantly, 
ptxP3 strains have spread globally, as they have emerged in several countries in Europe 
(13-17), North America (18), South America (19), and Australia (20). Phylogenetic analyses 
showed that ptxP3 strains evolved from ptxP1 strains, possibly in the 1970s (21,22). A recent 
comparative genomic analysis of two newly emerged ptxP3 strains, two contemporary ptxP1 
strains, and two pre-vaccination strains identified single nucleotide polymorphisms (SNPs) 
in a number of pathogenicity-associated genes, as well as differences in gene inactivation 
and reactivation (23). Thus far, very little information is available on phenotypic differences 
between ptxP1 and ptxP3 strains, such as the regulation and expression of virulence genes.
B. pertussis produces multiple toxins, including pertussis toxin (Ptx), adenylate cyclase 
toxin (ACT), type III secretion system (T3SS) effectors, dermonecrotic toxin (DNT), and tracheal 
cytotoxin (TCT) that, together with other virulence factors, facilitate within-host survival by 
manipulating many aspects of the human immune system, including the complement system, 
phagocytosis, immune cell recruitment, and antibody responses (reviewed in (24,25). The 
expression of most of these virulence factors is regulated by the activity of BvgS and BvgA, 
which form a typical two-component regulatory system, and the repressor protein BvgR 
which is expressed from the same BvgASR locus (26) (reviewed in (27)). Several external 
factors have been identified that can modulate the activity of this system, which results in a 
spectrum of different Bvg-phases that affect bacterial virulence. For instance, low temperature, 
and increasing concentrations of nicotinic acid or sulfate have all been shown to facilitate the 
transition from virulent (Bvg+) through intermediate (Bvgi) to nonvirulent (Bvg-) bacteria (28,29). 
Until recently, the only distinctive phenotypes described for ptxP3 strains was a higher 
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Ptx production and enhanced respiratory colonization (13,30). Here we identify additional 
phenotypic differences between ptxP1 and ptxP3 strains by comparing global transcriptional 
responses under sulfate-modulating conditions. We show that ptxP3 strains are less sensitive 
to sulfate-mediated suppression, which is associated with an increased production of a 
number of virulence genes, including Ptx, a type III secretion toxin, Vag8, a protein involved in 
complement resistance (31), and lpxE involved in lipid A modification. Identification of genes 
differentially expressed between ptxP1 and ptxP3 strains may elucidate how B. pertussis has 
adapted to vaccination and allow the improvement of pertussis vaccines. 
Results
To gain more insight into the mechanisms underlying the emergence of B. pertussis ptxP3 
strains, we investigated differences in global gene expression between a representative 
ptxP1 and ptxP3 strain. Strains B1920 (ptxP1) and B1917 (ptxP3) were cultured in vitro in 
the presence of low (<0.02 mM), medium (5 mM) or high (50 mM) MgSO4. Our rationale for 
selecting MgSO4 is that free sulfate plays an important role in regulating the expression of a 
number of B. pertussis virulence genes through the bvg locus (28). However, as sulfate may 
also affect expression of B. pertussis genes independent of the BvgASR system, we used the 
following definition of sulfate-regulated gene categories: high sulfate repressed (HSR) genes, 
high sulfate induced (HSI) genes, medium sulfate repressed (MSR) genes, and medium sulfate 
induced (MSI) genes. HSR and HSI genes were defined as those genes which were at least 
three-fold down- or upregulated in the presence of 50 mM sulfate compared to low sulfate, 
respectively. Similarly, MSI or MSR genes were defined as genes which were significantly up- 
or down regulated respectively by at least three-fold when cells were grown in the presence of 
5 mM sulfate compared to low sulfate. The majority of the classical Bvg+, Bvg-, and Bvgi genes 
are a subset of the HSR, HSI, and MSI genes respectively. MSR genes have, to the best of our 
knowledge, not been defined before.
Validation of sulfate-induced BvgASR-modulation 
To confirm the modulating effect of sulfate on Bvg-associated genes for the two selected strains, 
qPCR was performed on kpsT, bipA, and ptxA, coding for KpsT, a protein involved in capsule 
biosynthesis, the outer membrane ligand binding protein BipA and the PtxA (or S1) subunit. 
The kpsT, bipA, and ptxA genes were chosen as they have previously been shown to be 
optimally expressed in vitro under Bvg-, Bvgi, and Bvg+ conditions, respectively (32,33). Here, 
we used them to represent HSI, MSI, and HSR genes, respectively. qPCR analysis showed a 
strong correlation between sulfate concentration and expression of ptxA, bipA and kpsT, thus 
demonstrating the classical sulfate-dependent expression phenotype in both strains (Figure 1).
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Figure 1. Sulfate-mediated modulation in B. pertussis strain B1920 (ptxP1) and B1917 (ptxP3). 
Sulfate was added to the culture medium to induce a high (50 mM), medium (5 mM), and low (<0.02 mM, 
represented as 0 mM on the x-axis) sulfate conditions. qRT-PCR data shows the relative expression 
level of kpsT, bipA, and ptxA expressed as fold changes relative to the high sulfate condition, with the 
values being the mean of four biological replicate cultures. Asterisks indicate a statistically significant 
difference between the groups as determined by Student’s t-test with Welch’s correction: * P value < 
0.05, ** P value < 0.005, *** P value < 0.0005.
Sulfate-dependent transcriptional responses in a ptxP1 and ptxP3 strain
In order to identify HSR, HSI, MSI, and MSR genes, we performed global transcriptional 
analysis on B. pertussis strains B1920 (ptxP1) and B1917 (ptxP3) in the presence of low, 
medium and high sulfate. The expression levels of all genes for both strains can be found in 
Table S7. To identify gene categories enriched for HSR, HSI, MSI, and MSR genes, genes 
were aggregated based on their function and predicted subcellular localization. 
High sulfate repressed genes
Comparative analysis identified 133 and 138 HSR genes in the ptxP3 and ptxP1 strain, 
respectively (Figure 2A-C and Table S3, see Table S4 for strain-specific HSR and HSI genes). 
Of these genes, a large number (102 genes, corresponding to 74% of all HSR genes) was 
shared between ptxP1 and ptxP3, while 31 (23%) and 36 (28%) were repressed by high sulfate 
only in the ptxP3 or the ptxP1 strain, respectively (Figure 2). Functional class categorization of 
these 31 ptxP3-specific HSR genes showed enrichment for genes encoding ABC-transporters 
known to be involved in the uptake of small molecules, including sulfate. 
Interestingly, based on the annotated Tohama I sequence and BLAST searches, 9 of the 
30 genes predicted to be involved in sulfate-uptake and metabolism were ptxP3-specific HSR 
genes (N=9, 29%, P<0.001, Table 1, Table S4). These results strongly suggested that sulfate 
uptake and metabolism are different between ptxP1 and ptxP3 strains. Besides sulfate genes, 
22 other genes were identified as ptxP3 strain-specific HSR genes (Table S4). Perhaps most 
interesting were the virulence-associated fim3 and lpxE genes, encoding the major fimbrial 
subunit of serotype 3 fimbriae and a lipid A-1 phosphatase with LPS modifying properties, 
respectively (Table S4). Although fim3 was also suppressed at the high sulfate concentration 
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in the B1920 strain, the value did not reach statistical significance. qPCR analysis supported 
the observation that the fim3 gene is a HSR gene exclusively in the ptxP3 strain (Figure S1). 
In addition to the ptxP3-specific genes, we also identified 36 HSR genes which were 
repressed by high sulfate only in the ptxP1 strain (Table S4). Although these 36 genes were 
not significantly enriched for any functional class, three virulence-associated genes were 
identified, namely the T3SS gene (bscO), an autotransporter (bapC), and a TonB-dependent 
receptor for iron transport (bfrE) (Table S4). However, it should be noted that all three genes 
showed a HSR phenotype in the ptxP3 strain but were excluded because the signal intensity 
of the microarray signal was below 500. 
Figure 2. Functional categorization of sulfate-regulated genes in B. pertussis strain B1920 
(ptxP1) and B1917 (ptxP3). Venn diagrams show overlapping and unique sulfate-regulated genes that 
are at least 3-fold downregulated relative to the low sulfate condition (A; high sulfate repressed (HSR)), 
3-fold upregulated relative to the low sulfate condition (D; high sulfate induced (HSI)), 3-fold up- or 
down-regulated under medium sulfate conditions relative to the low sulfate condition (G; medium sulfate 
induced (MSI) and repressed (MSR)). HSR, HSI, and MSR genes were grouped by functional categories 
(B, E, and H) and PSORTb-predicated subcellular localization (C, F and I). Data are expressed as 
the percentage that is sulfate-regulated among all annotated genes in each class. Asterisks indicate 
statistically significant enrichment of sulfate-regulated genes in a certain class as determined by Fisher’s 
exact test. * P value < 0.05, ** P value < 0.005, *** P value < 0.0005. 
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Table 1: Transcriptional regulation of sulfate genes in B. pertussis strain B1920 (ptxP1) and B1917 
(ptxP3).
General gene information
Predicted 
localization
HSR 
Fold change
Fold difference between 
strains (ptxP3/ptxP1)
ORF Gene Product ptxP3 ptxP1 0 mM 5 mM 50 mM
BB0537 sulfurtransferase Un † † † † †
BP0380 Sodium:sulfate symportert Cm -1.0 1.5 1.0 1.3 1.6
BP0958 cysM cysteine synthase B C -1.0 -1.1 -1.0 1.0 -1.2
BP0966 sbp sulfate-binding protein precursor P 7.3* † 9.3 3.1 †
BP0967 cysT sulfate transport system permease protein (Pseudogene) Cm 4.7
* † 4.2 † †
BP0968 cysW sulfate transport system permease protein (Pseudogene) Un † † † † †
BP0969 cysA sulfate transport ATP-binding protein Cm † † † † †
BP0970 cysH phosphoadenosine phosphosulfate reductase (Pseudogene) P † † † † †
BP0970A cysD sulfate adenylyltransferase subunit 2 C † † † † †
BP0971 cysN sulfate adenylyltransferase subunit 1 (Pseudogene) Un † † † † †
BP1055 cysG siroheme synthase C 4.7* † 3.2 † †
BP1362 amino-acid ABC transporter, ATP-binding protein Cm 3.6
* † 3.4 † †
BP1363 amino-acid ABC transporter, permease protein Cm 6.2
* † 4.4 3.2 †
BP1364
amino-acid ABC transporter, 
periplasmic amino acid-binding 
protein
P 4.2* 1.8 2.7 1.7 1.1
BP1908 cysS cysteinyl-tRNA synthetase C -1.5 -1.3 -1.5 -1.9 -1.3
BP2416 cysB LysR-family transcriptional regulator C 2.2* -1.3 2.7* 1.2 -1.1
BP2816 ABC transport protein, ATP-binding component Cm 3.5
* 1.2 3.1* 1.1 1.0
BP3432 cysI sulfite reductase C 4.5* 2.2 2.7 1.4 1.3
BP3434 exported protein Cm 3.7* † 3.8* 1.6 1.4
BP3455 taurine dioxygenase C † † † † †
BP3674 periplasmic solute-binding protein P † † † † †
BP3675 ABC transport system permease protein Cm † † † † †
BP3676 ABC transporter ATP-binding protein Cm † † † † †
BP3701 exported protein Un † -23.9* † † -4.1*
BP3702 lpxL1 GntR-family transcriptional regulator C † -14.2* † † †
BP3703 lpxL2 transport system permease protein Cm † -18.9* † † -4.0*
BP3705 ABC transporter ATP-binding protein Cm † -16.8* † † -2.9
BP3854 ABC transporter ATP-binding protein Cm † † † † †
BP3855 periplasmic protein P † † † † †
BP3856 taurine catabolism dioxygenase C † † † † †
Abbreviations; C, cytoplasmic; Cm, cytoplasmic membrane; FC, fold change; HSR, high sulfate 
repressed; ORF, open reading frame; P, periplasmic; Un, unknown. The columns with fold change 
difference show the ratio of absolute expression (ptxP3/ptxP1) under low (0 mM), intermediate (5 mM), 
and high (50 mM) sulfate conditions. Asterisks indicate a statistically significant difference. † indicates 
that the gene was excluded because signal intensity was ≤500 in both the conditions compared. 
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Table 2: Medium-sulfate regulated genes in B. pertussis strain B1920 (ptxP1) and B1917 (ptxP3).
General gene information
Predicted 
localization
MSR
Fold change
Fold difference 
between strains
(ptxP3/ptxP1)
ORF Gene Product ptxP3 ptxP1 0 mM 5 mM 50 mM
Genes upregulated by 5 mM sulfate
BP1112 bipA outer membrane ligand binding protein Om -3.3* -4.4** -3.1 1.0 †
BP2923 lipoprotein Un -3.9* -4.9* † -1.3 -1.6
BP0713 membrane protein (Pseudogene) Un -3.8* -4.1* † 1.6 1.8
BP0468 AsnC-family transcriptional regulator C -1.4 -3.7* 2.5 -1.0 -1.1
BP0903 membrane protein Cm -1.9 -3.6* † -4.1* †
BP1311 membrane protein Cm -2.4* -3.5* 1.4 -1.0 1.2
Virulence genes downregulated by 5 mM sulfate
BP3783 ptxA pertussis toxin subunit 1 precursor E 3.7* 6.3* -1.3 1.5 1.1
BP3784 ptxB pertussis toxin subunit 2 precursor E 1.6 6.2* -1.0 4.0* †
BP3785 ptxD pertussis toxin subunit 4 precursor E 1.1 4.4* 1.0 4.0* †
BP3787 ptxC pertussis toxin subunit 3 precursor E 1.0 3.2* -1.0 3.2* †
BP0499 btcA t3ss chaperone P 3.0* 4.5* 1.1 1.5 1.4
BP0500 bteA t3ss toxin E 1.8 3.3* 1.2 2.3 †
BP2234 brpL RNA polymerase sigma factor C 2.8* 7.1* -1.5 1.8 †
BP2244 bscO type III secretion protein C 1.8 3.2* -1.3 † †
BP2261 bcrD type III secretion pore protein Cm 1.6 3.0* -1.9 1.1 †
BP2265 type III secretion chaperone Cm 4.6* 3.2* 1.1 -1.4 †
BP2315 vag8 autotransporter E 1.4 3.6* 1.4 3.9* †
BP2738 bapC autotransporter (pseudogene) E 1.4 3.7* -1.2 † †
BP2674 fimX fimbrial protein E 2.0* 3.0* 1.7 2.9 †
Other genes downregulated by 5 mM sulfate
BP0398 lmgB glycosyl transferase Cm 3.2* 1.6 1.2 † †
BP0399 lmgA glycosyl transferase Cm 3.1* 1.5 -1.0 -2.0 †
BP1252 exported protein Un 3.6* 2.4* 1.1 -1.3 †
BP1286 conserved hypothetical protein Un 3.1* 1.1 7.2* 2.5 †
BP1487 smoM periplasmic solute-binding protein P 2.1* 3.4* -1.2 1.4 -1.1
BP2141 exported protein Un 3.4* 5.1* -2.0 -1.3 †
BP2147 exported protein Un 1.9 3.0* 1.3 2.1 †
BP2486 exported protein Cm 4.4* 4.0* -1.6 † †
BP2925 conserved hypothetical protein C 1.2 4.0* -1.6 1.9 †
BP2926 conserved hypothetical protein Un 1.5 3.4* -1.5 1.7 †
BP3095 modB molybdate-binding periplasmic protein precursor P -1.1 3.4
* 1.4 5.1* 1.9
BP3405 ompQ outer membrane porin protein OmpQ Om 1.3 3.6* -1.1 2.4 †
Abbreviations; C, cytoplasmic; Cm, cytoplasmic membrane; E, extracellular; FC, fold change; MSR, 
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medium sulfate repressed; Om, outer membrane; ORF, open reading frame; P, periplasmic; Un, unknown. 
The columns with fold change difference show the ratio of absolute expression (ptxP3/ptxP1) under low (0 
mM), intermediate (5 mM), and high (50 mM) sulfate conditions. * Asterisks indicate a statistically significant 
difference. ** indicate a fold-change and statistically significant difference as determined by qPCR (see Fig. 
1). † indicates that the gene was excluded because signal intensity was ≤500 in both the conditions compared.
High sulfate induced genes
Larger differences between the two strains were found when HSI genes were compared. 
Eighty and 120 high-sulfate induced genes were identified in the ptxP3 and ptxP1 strain, 
respectively (Figure 2D-F and Table S3), of which 61 (51%) were shared. Of the non-shared 
genes, 19 (24%) and 59 (49%) were unique for the ptxP3 and ptxP1 strain, respectively. Whilst 
the ptxP3 strain-specific HSI genes were not significantly enriched for any functional category 
or subcellular localization, the 59 ptxP1-specific genes were significantly enriched for ABC-
transporters involved in the transport of cyanate/nitrate, branched-chain amino acids, and 
capsular polysaccharides (N=13, 22%, P<0.001, see Table S4). These data show that the HSI 
gene repertoire is highly different between the ptxP1 and ptxP3 strain.
Medium-sulfate regulated genes
Culturing B. pertussis in the presence of medium sulfate levels allowed us to identify both 
MSI and MSR genes by comparing the transcriptional levels to low sulfate conditions. This 
analysis yielded three and five MSI genes in the ptxP3 and ptxP1 strain, respectively, of which 
two were medium-sulfate induced in both strains (Figure 2G, Table 2, and Table S5). Despite 
the relatively low number of identified MSI genes as compared to the number of HSI and HSR 
genes, the MSI genes were significantly enriched for genes encoding cell envelope proteins in 
both the ptxP3 (P=0.027) and the ptxP1 (P=0.017) strain. 
Larger differences were found when MSR genes were compared, as we identified eight 
and twenty-one MSR genes in the ptxP3 and ptxP1 strain, respectively. Of these genes, only 
four were shared between the two strains (Figure 2G, Table 2, and Table S5). In the MSR 
category, we found pronounced differences between the ptxP1 and ptxP3 strains in genes 
involved in cellular processes (a category which included most virulence factors) and genes 
encoding extracellular proteins (Figure 2H & I, Table 2). In particular, several known virulence 
genes were repressed only in the ptxP1 strain under medium sulfate conditions, including two 
autotransporters (vag8 and bapC), five T3SS genes (btcA, bteA, bscO, bcrD, and BP2265) 
and three ptx genes (ptxB, ptxC, ptxD) (Table 2 and Table S5). This strain-specific suppression 
of virulence genes under medium sulfate conditions became even more pronounced at a fold 
change cut-off of ≥2, at which five autotransporters, twelve T3SS and seven ptx genes were 
suppressed in the ptxP1 strain compared to the ptxP3 strain (Table S5). Taken together, these 
data suggest that the ptxP3 strain is less sensitive to sulfate-mediated modulation of virulence 
gene expression.
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Absolute differences in sulfate-dependent gene expression
Above, we assessed the effect of sulfate concentration on transcriptional up or down regulation 
within each strain. Whilst this approach is useful to identify strain-specific sulfate-regulated 
genes, it does not provide insight into differences between these strains in absolute terms. 
Therefore, we also compared absolute transcription levels between the ptxP1 and ptxP3 strain 
under low, medium, and high sulfate conditions. 
Under low sulfate conditions, the overall absolute gene expression levels were highly 
similar between the two strains. Only seven and nine genes were more than threefold higher 
expressed in the ptxP3 and ptxP1 strain, respectively, with no significant enrichment for genes 
of any particular functional category (Figure 3A and Table S6). In the previous section we 
showed that several genes involved in sulfate uptake and metabolism were differentially 
regulated by sulfate between the ptxP1 and ptxP3 strain. When looking at absolute expression 
levels under low sulfate conditions, seven sulfate genes were ≥3-fold higher expressed in the 
ptxP3 strain, although only two were statistically significant (Table 1). The cysB gene, encoding 
the master regulator for cys gene expression, was also expressed at significant higher levels 
in the ptxP3 strain, by 2.7 fold (Table 1). 
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Figure 3. Genes differentially regulated between B. pertussis strain B1920 (ptxP1) and B1917 
(ptxP3) strains upon sulfate-modulation. Sulfate was used to induce high (50 mM), medium (5 mM), 
and low (<0.02 mM, represented as 0 mM) sulfate conditions in a ptxP1 and ptxP3 strain. A) The number 
of genes expressed at least 3-fold higher between strains are indicated for each sulfate concentration. 
B&C) The pie charts subdivide the 44 genes expressed higher in the ptxP1 strain as compared to the 
ptxP3 strain under high sulfate conditions (B) and the 61 genes expressed higher in the ptxP3 strain as 
compared to the ptxP1 strain under medium sulfate conditions (C) into functional gene categories. The 
number of genes belonging to each category is numbered between brackets. 
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Under medium sulfate conditions, the overall absolute gene expression levels were more 
distinct between the strains (Figure 3A and Table S6). Respectively, 61 and 22 genes were ≥3-
fold higher expressed in the ptxP3 and ptxP1 strain. The higher expression of transcriptional 
regulators and virulence-associated genes by the ptxP3 strain was the most prominent, with 
eight transcriptional regulators, one autotransporter gene (vag8), six genes for Ptx and eleven 
genes for the T3SS toxin being expressed at higher levels in the ptxP3 strain (Figure 3C and 
Table S6). In contrast, the genes expressed at higher levels in the ptxP1 strain contained 
no obvious virulence-associated genes but predominantly housekeeping genes, in particular 
genes involved in leucine synthesis. 
Under high sulfate conditions, the overall absolute gene expression levels were also 
distinct between the strains, with 17 and 44 genes being ≥3-fold higher expressed in the ptxP3 
and ptxP1 strain, respectively (Figure 3A and Table S6). The 44 genes expressed higher in 
the ptxP1 strain included a number of capsule genes and genes involved in lipid metabolism 
(Figure 3B and Table S6). 
Differences in gene expression between ptxP1 and ptxP3 strains in relation to 
DNA polymorphisms
The availability of the complete genome sequences of the two B. pertussis strains used in 
this study allows the association of gene expression differences to strain-specific DNA 
polymorphisms (23). The expression levels of all genes associated with strain-specific 
polymorphisms can be found in Table S8. Of the 13 genes that are deleted in strain B1917, 
seven were expressed above the expression minima (see Text S1) in the B1920 strain, while 
7 of the 18 genes absent in strain B1920 were expressed in the B1917 strain. Strain-specific 
transcriptional regulators may have a large impact on differential gene expression between 
strains. Indeed, both strains contain a unique transcriptional regulator (BP1963 in B1920 and 
BB1150 in B1917), both of which were expressed. With the exception of the two transcriptional 
regulators and the SNP in ptxP, no other polymorphism suggested underlying causes for the 
differences in gene expression between the two strains.
Validation of sulfate-related differences in gene expression using multiple 
ptxP1 and ptxP3 strains. 
Microarray analysis suggested that ptxP3 strains are less sensitive to sulfate-mediated 
suppression of virulence gene expression, resulting in a higher expression of virulence genes 
under medium sulfate conditions. To determine whether this is a general lineage-dependent 
phenotypical difference, 16 non-epidemiologically related ptxP1 (n=9) and ptxP3 (n=7) strains 
(Table 3) were cultured in vitro in the presence of low, medium, and high sulfate and analyzed 
by qPCR for a number of genes (Figure 4A). qPCR analysis showed that not only vag8, lpxE, 
sbp, cysB, but also the three major vaccine antigens ptxA, prn and fhaB were significantly 
higher expressed in the ptxP3 strains under medium sulfate conditions (Figure 4A). Since 
transcriptional activity does not necessarily correlate with the amount of protein produced, we 
used a Luminex assay to quantify the amount of Ptx, Prn and FHA protein produced by these 
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strains. Similar to qPCR, we found that ptxP3 strains produced more Ptx and Prn than the 
ptxP1 strain, but not FHA (Figure 4B). 
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Figure 4. Validation of microarray data using multiple B. pertussis ptxP1 and ptxP3 strains. 
Sulfate was added to the culture medium to induce high (50 mM), medium (5 mM), and low (<0.02 
mM, represented as 0 mM) sulfate conditions. A) qRT-PCR data showing the relative expression level 
of vag8, lpxE, sbp, cysB, ptxA, prn, and fhaB between ptxP1 strains (represented by white symbols) 
and ptxP3 strains (represented by black symbols) grown under low (0 mM), medium (5 mM) and high 
(50 mM) sulfate conditions. The data are expressed as fold changes relative to the ptxP1 strains grown 
under low sulfate conditions, with horizontal bars representing the geometrical mean, so that any 
sulfate-dependent effects on gene expression become apparent. B) Luminex data showing Ptx, Prn, 
and FHA protein expression in ptxP1 and ptxP3 strains grown under low (0 mM), medium (5 mM) and 
high (50 mM) sulfate conditions. Protein expression is expressed in absolute amounts (nanograms) with 
horizontal bars representing the geometrical mean. The expression values of the two strains that were 
used for microarray analysis (B1920 (ptxP1) and B1917 (ptxP3)) are depicted in grey. Asterisks indicate 
a statistically significant difference between the groups as determined by an unpaired Student’s t-test: * 
P value < 0.05, ** P value < 0.005, *** P value < 0.0005.
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Table 3: Characteristics of the Dutch Bordetella pertussis strains used in this study.
Strain Year isolation Age patient(in months) Serotype
Alleles
ptxA ptxP prn fim3 fim2
B0638 1996 96 3 ptxA1 ptxP1 prn3 fim3-1 fim2-1
B0888 1991 9 3 ptxA1 ptxP1 prn3 fim3-1 fim2-1
B1878 2000 45 2 ptxA1 ptxP1 prn2 fim3-1 fim2-1
B1920 2000 9 3 ptxA1 ptxP1 prn2 fim3-1 fim2-1
B2414 2002 25 3 ptxA1 ptxP1 prn1 fim3-4 fim2-2
B2968 1987 unknown 2,3 ptxA2 ptxP1 prn1 fim3-1 fim2-1
B3124 2007 1 2 ptxA1 ptxP1 prn2 fim3-1 fim2-1
B3214 2008 160 2 ptxA1 ptxP1 prn2 fim3-1 fim2-1
B3379 2009 43 2 ptxA1 ptxP1 unknown fim3-1 fim2-1
B1917 2000 44 3 ptxA1 ptxP3 prn2 fim3-2 fim2-1
B2584 2003 2 3 ptxA1 ptxP3 prn2 fim3-1 fim2-1
B3034 2005 1 3 ptxA1 ptxP3 prn2 fim3-2 fim2-1
B3230 2008 21 3 ptxA1 ptxP3 prn2 fim3-2 fim2-1
B3448 2010 1 2 ptxA1 ptxP3 prn2 fim3-1 fim2-1
B3928 2012 13 2 unknown ptxP3 unknown fim3-1 fim2-1
B3956 2012 2 2 ptxA1 ptxP3 prn2 fim3-1 fim2-1
Discussion
The worldwide selective sweep of the ptxP3 lineage and its link to recent pertussis epidemics 
in some countries clearly emphasizes the importance of studies on the molecular mechanisms 
underlying these phenomena (13,20,22). Although the success of a particular lineage is also 
determined by host immunity factors, here we focused on the molecular characterization of 
the ptxP3 lineage. Until recently, the only distinctive phenotypes described for ptxP3 strains 
was a higher Ptx production and enhanced respiratory colonization (13,30). Here we identify 
additional phenotypic differences between ptxP1 and ptxP3 strains which may have contributed 
to its global spread. In previous comparative genomic studies we showed that ptxP1 and 
ptxP3 strains have different SNPs in a number of virulence-associated genes, differences in 
pseudogenes, as well as differences in gene content (23,34). A recent transcriptional comparison 
of ptxP1 and ptxP3 strains under non-modulating conditions indicated that multiple virulence-
associated genes are expressed at slightly higher levels in ptxP3 strains as compared to ptxP1 
strains (30). Here, we compared sulfate-dependent expression profiles between these strains, 
with the rationale that sulfate affects the expression of all major B. pertussis virulence factors 
(28). This approach identified several additional differences between the ptxP1 and ptxP3 
strains, including sulfate-dependent differences in expression levels of a number of important 
virulence genes and a different sensitivity for sulfate-mediated regulation. Conceivably, the two 
are interconnected. 
The most pronounced phenotypic difference revealed by microarray analysis was that 
ptxP1 and ptxP3 strains responds differently to sulfate mediated-regulation. Based on genome 
annotations and BLAST searches we identified 30 genes that are likely involved in sulfate 
metabolism, nine of which were differentially regulated between the ptxP3 and ptxP1 strain. 
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The sulfate genes included genes involved in uptake and metabolism of sulfate, cysteine, 
methionine and taurine. Interestingly, taurine is one of the most abundant sources of sulfate in 
the host, comprising 0.1% of the total human body weight (35). In general, the sulfate genes 
were expressed at higher levels by the ptxP3 strain under low sulfate conditions compared to 
the ptxP1 strain (Table 1). For instance, the sbp gene, which facilitates transport of external 
sulfate into the cell (36,37), showed a 9-fold higher level of gene expression in the ptxP3 
strain. Furthermore, nine other sulfate genes were expressed at two- to four-fold higher level 
in the ptxP3 strain under low sulfate conditions, although not all values reached statistical 
significance. The increased expression of sulfate genes in the ptxP3 strain may be explained by 
the observation that the positive master regulator for cys gene expression, cysB (38), was more 
highly expressed in ptxP3 strains than ptxP1 strains under low and medium sulfate conditions. 
It is tempting to speculate that the expression profile of these genes contributes to the reduced 
sensitivity of ptxP3 strains to sulfate-mediated suppression of known Bvg-regulated genes as 
shown in this work. For instance, we found that ptxP3 strains in particular, and to a lesser extent 
ptxP1 strains, expressed higher levels of Ptx in the presence of 5 mM sulfate (Fig 4), whilst 
ptx genes have been described to be suppressed under this condition (39,40). This suggests 
that the protein expression pattern of Ptx in ptxP3 strains more accurately reflects a Bvgi-
phase protein than the classical Bvg+ profile. Recently, it was described that the BvgS sensor 
molecule is active by default and is only inhibited when sulfate or other negative modulators 
bind to the Venus Flytrap (VFT) 2 region in the periplasmic domain of this sensor molecule (41). 
Whilst the concentration of free sulfate in the respiratory tract is low (0.6 mM; (42)), infection 
may increase sulfate concentration locally, e.g. through desulfation of sulfated host proteins 
(43), potentially through pertussis proteins containing a sulfatase domain (BP1635, BP1654, 
BP2327, and BP3136) of which ORF BP3136 was expressed above the expression minima 
in both strains. Interestingly, the wcbQ gene (BP1654) encoding a capsular polysaccharide 
biosynthesis protein with a sulfatase domain, was expressed exclusively and at 4.5 fold higher 
levels in the ptxP1 strain under low and medium sulfate conditions, as compared to the ptxP3 
strain (Table S7). Extracellular sulfate can diffuse freely through the outer membrane into the 
periplasmic region and bind to the VFT2 region of BvgS (44). As such, ptxP3 strains may 
benefit from the lack of wcbQ expression and the increased expression of the sbp, cysT, and 
cysW sulfate transport genes, as this might lower periplasmic sulfate levels. It is therefore 
conceivable that the concentration of free sulfate in the periplasmic space is lower in the ptxP3 
strain compared to the ptxP1 strain. Thus, at equal concentrations of extracellular sulfate, less 
suppression would occur in the ptxP3 strain. It is questionable whether this effect is transduced 
by the BvgASR system only, as only a limited number of known Bvg-regulated genes were 
affected. Here, we speculate that sulfate may regulate B. pertussis (virulence) genes via a 
second route, possibly comprised of a sensory transduction system. Indeed under medium 
sulfate conditions eight transcriptional regulators were more highly expressed in the ptxP3 
strain compared to the ptxP1 strain (Fig 3C, Table S6). This hypothetical second regulon 
includes both Bvg-regulated genes and genes which are regulated independent of the Bvg-
system. One possibility to test this hypothesis would be to examine the response of Bvg-phase 
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locked mutants to different sulfate concentrations. 
The higher expression level of cys genes in the ptxP3 strain may also suggest that these 
strains are more resistant to Reactive Oxygen Species (ROS), as several publications have 
found a link between the two (45,46). However, this remains to be investigated. 
Another interesting gene which was differentially regulated between the ptxP3 and ptxP1 
strains was lpxE, encoding a lipid A-1 phosphatase. The lpxE gene was identified as a HSR gene 
specifically in the ptxP3 strain and was also expressed at four-fold higher levels in the ptxP3 
strains under medium sulfate conditions. The lipid A-1 phosphatase encoded by this gene is 
responsible for selectively dephosphorylating the 1-position of lipid A (47). It is well established 
that the presence of phosphate groups on the lipid A moiety of the lipo-oligosaccharide (LOS) 
is essential for the endotoxic activity of LOS (47,48). Since LOS lacking the 1-phosphate group 
are recognized less efficiently by the Toll-like receptor 4 (TLR4)/myeloid differentiation factor 
(MD-2) receptor complex of the mammalian innate immune system, they induce a weaker 
proinflammatory cytokine response (49). This effect has been described for a number of 
bacterial pathogens. For instance, in Salmonella typhymurium, genomic introduction of the 
lpxE gene from Francisella tularensis led to a clear reduction of virulence in a mouse model 
(50). Furthermore, the human pathogen Helicobacter pylori uses dephosphorylation of both 
the 1- and 4-phosphate to hide itself from recognition by the innate immune system, allowing 
the pathogen to survive in the gastric mucosa (51). Whether the lpxE gene facilitates a similar 
function in B. pertussis remains unknown. For B. pertussis it is known that the 1-phosphate 
group of lipid A can be substituted by glucosamine in a BvgAS-regulated manner and that this 
modulates hosts immune defenses (52,53). However, this substitution is strain-specific, and 
has been studied exclusively in routinely used laboratory strains (54). Consequently, the lipid 
A composition of currently circulating B. pertussis strains remains unknown. Nonetheless, it 
is tempting to speculate that the differential sulfate-dependent regulation of the lpxE gene in 
ptxP1 and ptxP3 strains has an influence on the endotoxic activity and immune modulating 
capacity of these strains. 
Another difference between the ptxP1 and ptxP3 strains identified in this study was the 
limited overlap (51%) in genes being induced by high sulfate (HSI genes, Fig 2D). However, 
this in itself is not unexpected, as previous work also showed significant gene expression 
differences in Bvg- locked B. pertussis strains (55). This heterogeneity in HSI gene profiles 
may indicate a lack of purifying selection, which further supports the idea that the Bvg- phase 
of B. pertussis is an evolutionary remnant (56). In B. bronchiseptica, the evolutionary ancestor 
of B. pertussis, the Bvg- phase is assumed to be important for (ex vivo) survival under nutrient-
limiting conditions (39,57). However, B. pertussis has evolved into an obligate human pathogen 
which does not require an environmental niche (58). 
In a previous study we showed that ptxP3 strains grown on plates produce more Ptx than 
ptxP1 strains (13). We explored this difference further here using liquid cultures and observed 
that the largest difference in Ptx expression was observed at medium sulfate concentrations. 
We did not observe increased Ptx expression under non-modulating conditions as in our 
previous study. However, this might be related to the different growth media used (plates 
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versus chemically defined liquid medium) and/or the growth phase at which the bacteria were 
collected (after 3 days on plate versus during mid-log growth). A novel finding was the higher 
expression of T3SS proteins and of the autotransporters Prn and Vag8 by ptxP3 strains under 
medium sulfate conditions. Slightly increased levels (fold change 1.2-1.8) of T3SS and Vag8 
have also been reported by others under non-modulating conditions (30). The difference in 
Ptx expression may be explained by the mutation in the Ptx promoter region, as suggested 
previously (13). However, no mutations were found in the ORFs or promoter regions of the 
Prn, Vag8, and T3SS genes, suggesting that polymorphisms in other genes may (also) be 
involved in their transcriptional regulation. All ptxP3 strains analyzed to date contain a deletion 
encompassing BP1948-1966 (34) and it is possible that the deletion of these genes plays a role 
in the differential regulation of these genes. Conversely, the ptxP3 strain B1917 also contains 
genes (BB1140-BB1158) that are absent from ptxP1 strain B1920, including two transcriptional 
activators (BB1141 and BB1150), which may also contribute to the observed differences. The 
expression phenotype of these three important virulence factors in the ptxP3 strains at medium 
sulfate concentrations, is significant as all three are involved in suppression and modulation 
of the host immune response. In this sense, Ptx is the most versatile virulence factor, as it is 
able to intoxicate alveolar macrophages (AMs) (59), inhibit the mucosal recruitment of immune 
cells (such as AMs, neutrophils, and T cells) (60-62), modulates the cellular immune response 
(63), and suppresses serum antibody responses (64,65). Furthermore, T3SS represents a 
multi-component secretion machinery used by a wide variety of gram-negative bacteria to 
secrete effectors directly into the cytosol of host cells and interfere with host cell functioning. 
In B. pertussis, two proteins have been identified as T3SS effectors: BteA and BopN. BteA is 
a cytotoxin that induces a rapid non-apoptotic death in host epithelial cells (66) while BopN 
modulates cellular immune responses (67). Additionally, the autotransporter Vag8 mediates 
the binding of human C1 esterase inhibitor on the bacterial surface and thereby confers 
resistance to complement-mediated killing (31). Given the important virulence properties of 
these proteins, ptxP3 strains may benefit from their increased expression, although a direct 
link to enhanced immune suppression remains to be established. 
Taken together, comparative transcriptional profiling of a ptxP1 and a globally emerged 
ptxP3 strain of B. pertussis provided novel insights into sulfate-mediated modulation of the 
ptxP3 lineage and should stimulate research into the role of sulfate in the pathogenesis of B. 
pertussis. Although it is tempting to focus on specific genes, the overall increased expression 
of multiple virulence factors in the ptxP3 strain may be more important, as this suggests that 
this strain is in a higher state of virulence, which may allow for better transmission among 
immune hosts. Thus both antigenic divergence with vaccine strains (11) and increased immune 
suppression may have contributed to the global spread of ptxP3 strains. 
Materials and Methods
Ethics Statement
The only patient material collected were strains which are not collected by us and not specifically 
for this study. The strains were collected by Medical Microbiology Laboratories from patients 
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suspected of whooping cough and sent to the RIVM in the context of routine surveillance (as 
required by law). The strains are sent to the RIVM for confirmation of clinical diagnosis, species 
determination and subtyping. Strictly anonymized patient information is included, which is 
limited to age, sex and postal code. For this type of surveillance ethical evaluation or patient 
consent are not required. The strains have been used in previous studies (22).
Bacterial strains and growth conditions
Two recent B. pertussis strains isolated from patients in the Netherlands in 2000 were selected 
to study sulfate-modulated gene expression: B1920 (ptxP1), and B1917 (ptxP3) (13) (Table 
3). The effect of sulfate on gene expression was extended with eight and six additional non-
related ptxP1 and ptxP3 strains, respectively, isolated from patients from different geographical 
regions in the Netherlands between 1987 and 2012 (Table 3). B. pertussis strains were grown 
on Bordet-Gengou agar plates supplemented with 15% sheep blood (Tritium Microbiology, 
Eindhoven, The Netherlands) and incubated for four days at 37°C. Liquid cultures were grown 
overnight in chemically defined THIJS medium (68) supplemented with 0.2 mg/ml Heptakis-
cyclodextrin (Sigma) and then re-inoculated into pre-warmed medium at an optical density at 
620 nm (OD620) of 0.075. For modulation of the BvgASR regulatory system, magnesium sulfate 
was added to the cultures at a final concentration of 5 and 50 mM to induce medium and high 
sulfate conditions respectively. In the absence of additional sulfate, the concentration of free 
sulfate in THIJS medium was <0.02 mM as determined using the QuantiChrom sulfate assay 
kit (BioAssay Systems), thereby inducing low sulfate conditions. Cultures were grown at 37°C 
until a mid-log OD620 of 0.5 to 0.6, at which point the bacteria were harvested for RNA isolation 
and Luminex analysis as described below. 
RNA isolation and qRT-PCR
Aliquots of 5 ml mid-log culture were mixed with two volumes of RNA Protect Bacteria Reagent 
(Qiagen). Total RNA was extracted using the RNeasy Mini kit (Qiagen) and contaminating 
genomic DNA was subsequently removed by DNase treatment (DNAfree, Ambion). DNA-free 
total RNA (125 ng) was reverse transcribed using 300 ng of random hexamers (Invitrogen), 
and Superscript III reverse transcriptase (200U, Invitrogen) in 1x First-Strand buffer, 10 mM 
DTT, and 0.5 mM dNTPs. To confirm the absence of genomic DNA, control reactions were 
carried out without reverse transcriptase. Relative amounts of ptxA (BP3783), bipA (BP1112), 
kpsT (BP1624), prn (BP1054), fim3 (BP1568), fhaB (BP1879), vag8 (BP2315), lpxE (BP0835), 
sbp (BP0966), and cysB (BP2416) transcripts were determined by quantitative real-time-PCR 
(qRT-PCR) using the SYBR green technology with the primers listed in Table S1 on a 7500 Fast 
real-time PCR system (PE Applied Biosystems) according to the manufacturer’s instructions. 
The relative quantification ΔΔCt method was used to compare expression levels between the 
different strains and bvg-conditions (69). The recA (BP2546) amplicon was used as internal 
control for normalization of data. 
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Microarray expression profiling
Five µg of total RNA was labeled by a method adapted from Ouellet et al. (70), as described 
by de Vries and coworkers (71). Two μg of labeled cDNA was applied to a 12x135K custom 
design NimbleGen array. Overnight hybridization at 42°C and subsequent washing of arrays 
was performed according to the manufacturer’s instructions. The NimbleGen array contained 
1-8 probes for all coding sequences (CDS) with an average coverage of 7.5 probes per CDS 
and pseudogene, 15 bp overlapping tiling probes covering both strands of the intergenic 
regions, and 7,304 random probes with a similar length distribution and GC content as the 
experimental probes. The array design was based on the genome sequence of B. pertussis 
Tohama I (72), supplemented with additional B. bronchiseptica CDS and intergenic sequences 
that are present in the B. pertussis strains used in this study (23). Array images were acquired 
with a NimbleGen MS200 scanner, and images were processed with NimbleScan software. 
Normalized expression data was analyzed by ArrayStar (DNASTAR, Madison, WI, USA) 
using the Robust Multiarray Analysis (RMA) algorithm for background correction and quantile 
normalization (73). For the identification of sulfate-modulated genes the raw expression data 
under low, medium, and high sulfate was normalized individually for each strain. To identify 
absolute differences in gene expression between the ptxP1 and ptxP3 strain, normalization was 
performed using the raw expression data of both strains under all sulfate conditions. The latter 
normalized expression values can be found in Table S7. Log2 transformed signals were used to 
generate kernel density plots using a Gaussian model with stepwise increasing bandwidth until 
a single local minimum was found between the distributions of background signal and gene 
expression. Positions where the first derivative of the density traverses from values below to 
values above zero were considered local minima. The corresponding expression value is the 
value closest to the minimum between the peaks of expressed and non-expressed genes and 
was therefore considered as a cutoff value to determine whether a gene was expressed or not. 
Further validation of the transcriptomic dataset is described in Text S1 and Table S2.
A moderated Student t-tests using Benjamin Hochberg correction with a cutoff P-value 
of 0.05 was used to compare the mean gene expression values. Genes were excluded if 
the expression was low (signal intensity < 500) in both conditions that were compared. High 
sulfate repressed (HSR) genes and high sulfate induced (HSI) genes were defined as those 
genes which were expressed at a level at least three times higher or lower, respectively, 
in the absence of sulfate compared to growth in the presence of 50 mM sulfate. Medium 
sulfate induced (MSI) or medium sulfate repressed (MSR) genes were defined as those genes 
which were significantly up- or down regulated respectively by at least three-fold when cells 
were grown in the presence of 5 mM sulfate compared to 0 mM sulfate. Functional class 
distribution was assessed using the Institute for Genomic Sciences (IGS) classification (http://
www.igs.umaryland.edu/) and the protein localization was predicted using PSORTb v3.0 (74). 
Enrichment for functional class and localization was assessed using the Fishers exact (one-
tail) test and considered significant at a p-value < 0.05. Enrichment for specific sets of genes 
were assessed using the Database for Visualization and Integrative Discovery (DAVID) (75).
 
Transcriptomics of a globally emerged pathogen | 85
2
Microarray data
All microarray data have been deposited in NCBI’s Gene Expression Omnibus (GEO) database 
(www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO Series accession number 
GSE49385 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE49385).
Multiplex immunoassay
One ml aliquots of mid-log cultures were heat-inactivated (HI) for 30 min at 56oC and used 
in a multiplex immunoassay (MIA) for the quantification of pertussis toxin (Ptx), filamentous 
hemagglutinin (FHA), and pertactin (Prn) by a method adapted from van Gageldonk et al. 
(76). Purified monoclonal antibodies anti-Ptx (Pem 9), anti-FHA (29E7), and anti-Prn (Pem 85) 
(kindly provided by Dr. Guy A.M. Berbers) were coupled to activated carboxylated microspheres 
(Bio-Rad Laboratories) by using a two-step carbodiimide reaction (77). Bead regions were 
carefully chosen not to be directly adjacent to each other: 9 (anti-Prn), 24 (anti-FHA), 33 (anti-
Ptx). A solution of 500 µl of carboxylated microspheres (6.25 × 106 beads) was washed once 
by centrifugation (12,000 ×g for 1-2 min) with 250 μl dH2O and resuspended in 200 μl 0.1 
M Monobasic Sodium Phosphate, pH 6.2 and activated by addition of 25 µl of N-hydroxy-
sulfosuccinimide (sulfo-NHS. Pierce) 50mg/ml and 25 µl of 1-ethyl-3-(-3-dimethylaminopro-
pyl)-carbodiimide hydrochloride (EDC. Pierce) 50mg/ml. The solution was incubated for 20 
min at room temperature (RT), in the dark under constant rotation at 25 rpm. The activated 
microspheres were washed two times with 0.05 M 2[N-Morpholino] ethanesulfonic acid (MES, 
Sigma-Aldrich) pH 5.0 by centrifugation (12,000 ×g for 1-2 min) and resuspended in 1,250 μl 
0.05 M MES pH 5.0 with a monoclonal to bead ratio of 12.5 µg/6.25 × 106 activated beads for 
anti-Ptx and anti-Prn, and 62.5 µg/6.25 × 106 activated beads for anti-FHA. The beads were 
incubated for 2 h at RT in the dark under constant rotation at 25 rpm. Subsequently, the beads 
were washed three times with PBS containing 0.05% Tween 20 (PBST) and stored in 1,000 µl 
PBST at 4 °C in the dark until used. 
HI-cultures were diluted 1/50 in PBS pH 7.2 containing 0.1% (v/v) Tween-20 and 1% 
(w/v) BSA (assaybuffer) before use. Ptx obtained from Kaketsuken (Kumamoto, Japan), FHA 
obtained from SmithKline Beecham, and Prn obtained from the Pediacell vaccine of Sanofi 
Pasteur MSD were used as standards in a concentration range of 243, 81, 9, 3, and 1 ng/ml 
in assaybuffer. Each dilution of the standard and culture samples (25 µl) was mixed with an 
equal volume of the conjugated microspheres (Ptx, Fha, Prn; 4000 beads/region/well) in a 96-
well Multiscreen HTS filter plate (Millipore Corporation, Billerica, MA). Plates were incubated 
for 60 min at RT in the dark on a plate shaker at 600 rpm. Blanks were included on every plate. 
The beads were collected by filtration using a vacuum manifold and washed three times with 
100 µl assaybuffer. A volume of 50 µl of a 1/200 dilution of Human Pertussis Antiserum (WHO 
International Standard Pertussis Antiserum 06/140 NIBSC, Hertfordshire, UK) was added to 
each well and the plate was incubated in the dark for 20 min with continued shaking. The 
beads were collected and washed as described above. To each well 100 µl of a 1/200 dilution 
of R-phycoerthyryn (R-PE)-conjugated goat anti-human IgG (Fcy Fragment specific, Jackson 
ImmunoResearch Laboratories Inc, Westgrove, Pa) was added and the plate was incubated 
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for 20 min in the dark with continued shaking. The beads were collected and washed in PBS 
containing 0.05 % Tween as described above. Finally the beads were resuspended in 125 
µl PBS and shaken in the dark before analysis with a Bio-Plex 100 system in combination 
with Bio-Plex Manager software version 4.1.1 (Bio-Rad Laboratories, Hercules, CA). For each 
analyte, median fluorescent intensity (MFI) was converted to ng/ml by interpolation from a 
5-parameter logistic standard curve (log–log) for every bead region/standard. 
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Figure S1. Sulfate-mediated fim3 expression in B. pertussis strain B1920 (ptxP1) and B1917 
(ptxP3). Sulfate was added to the culture medium to induce high (50 mM), medium (5 mM), and low 
(<0.02 mM, represented as 0 mM) sulfate conditions. qRT-PCR data shows the relative expression level 
of fim3 expressed as fold changes relative to the high sulfate condition, with the values being the mean 
of four biological replicate cultures. Asterisks indicate a statistically significant difference between the 
groups as determined by Student’s t-test with Welch’s correction: * P value < 0.05, ** P value < 0.005, 
*** P value < 0.0005.
Supplemental Text S1
Validation transcriptomic datasets
At the mRNA level, 74% of the 3552 genes present in the ptxP3 strain and 79% of the 3548 
genes present in ptxP1 were found to be expressed based on cutoffs defined by kernel density 
plots. Pearson correlation analysis was used to determine the correlation in mRNA abundance 
between the sulfate conditions of the ptxP1 and ptxP3 strain. The obtained correlation coefficient 
varied between 0.00 and 1.00, in which a value of 1.00 indicates a perfect correlation and a value 
of 0.00 indicates the absolute lack of correlation. Log2 values of the mean signal intensities 
(SI) of all genes on the microarray were used in this analysis and revealed excellent correlation 
(0.96-0.98) between the two strains for each sulfate-condition (Table S2). Furthermore, as 
expected, within strains we observed a strong correlation between the low and medium sulfate 
condition (0.99) and a weaker correlation between the low and high sulfate condition (0.87-0.90).
Table S1: qRT-PCR primers used in this study.
Primer Nucleotide sequence (5’ to 3’) Target gene
BP2546_Fw CAAGCTGACGGCCACCAT recA
BP2546_Rv CGGATCTGGTTGATGAAGATGA recA
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BP3783_Fw CGCCAGCTCGTACTTCGAAT ptxA
BP3783_Rv GGATACGGCCGGCATTG ptxA
BP1112_Fw ACCTGGCTCGGGAATCG bipA
BP1112_Rv GACTCGAAATCGTGGCTCAAC bipA
BP1624_Fw CATTTCGCTGCGCAATGTC kpsT
BP1624_Rv TGCGCCTGATGCCTTTCT kpsT
BP1879_Fw GCGGAGGATTCGATAACGAA fhaB
BP1879_Rv CCTGCCATTGCTGAACTGTTC fhaB
BP1568_Fw GCGCGCTCAAGCTGTATTTC fim3
BP1568_Rv ATCGCCCGTGTCGTAGTTG fim3
BP1054_Fw TGCCGACTGGAACAACCA prn
BP1054_Rv GTCGGAGCCCTGGATATGG prn
BP2315_Fw GCGTCGGTCTTTTTGCAGAA vag8
BP2315_Rv TGGACAGAGACGCCCAATG vag8
BP0835_Fw CATGCCTCCGCCTCCAT lpxE
BP0835_Rv TGCGCAACATCAGGTAGCA lpxE
BP0966_Fw ACCTCGACCATCGTGTTCCT sbp
BP0966_Rv CGTCCCAATCGTGGATCTG sbp
BP2416_Fw GCGTCTCGAAGGCGATCAT cysB
BP2416_Rv GCCGCTCGAAGATCTTGATG cysB
Table S2: Pearson correlation analysis of the microarray datasets of the ptxP1 
and ptxP3 B. pertussis strains grown in the presence of different sulfate concen-
trations.
mRNA within and between strains        
Strain Sulfate (mM) Pearson correlation (Log2(SI) values)
ptxP1
0 vs 5 0.99
0 vs 50 0.87
5 vs 50 0.89
ptxP3
0 vs 5 0.99
0 vs 50 0.90
5 vs 50 0.91
ptxP1 0 vs ptxP3 0 0.98
ptxP1 5 vs ptxP3 5 0.96
ptxP1 50 vs ptxP3 50 0.97
ptxP1 0 vs ptxP3 5 0.97
ptxP1 5 vs ptxP3 0 0.97
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Table S3: Identification of high sulfate induced and repressed genes in ptxP1 and 
ptxP3 strains. Please refer to: http://journals.plos.org/plosone/article/asset?unique&id=in-
fo:doi/10.1371/journal.pone.0084523.s005
Table S4: Identification of ptxP1 and ptxP3 strain-specific HSI and HSR genes.
Please refer to: http://journals.plos.org/plosone/article/asset?unique&id=info:doi/10.1371/jour-
nal.pone.0084523.s006
Table S5: Identification of medium sulfate induced or repressed genes in the 
ptxP1 and ptxP3 strain. Please refer to: http://journals.plos.org/plosone/article/as-
set?unique&id=info:doi/10.1371/journal.pone.0084523.s007
Table S6: Genes that show significantly different levels of expression in ptxP1 
and ptxP3 strains in the presence of low, medium, and high sulfate. Please re-
fer to: http://journals.plos.org/plosone/article/asset?unique&id=info:doi/10.1371/journal.
pone.0084523.s008
Table S7: Absolute expression levels of genes in ptxP1 and ptxP3 strains ac-
cording to microarray analyses. Please refer to: http://journals.plos.org/plosone/article/
asset?unique&id=info:doi/10.1371/journal.pone.0084523.s009
Table S8: Sulfate-regulated expression levels of genes with strain-specific DNA 
polymorphisms in ptxP1 and ptxP3 strains. Please refer to: http://journals.plos.org/
plosone/article/asset?unique&id=info:doi/10.1371/journal.pone.0084523.s010
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Abstract 
Pertussis is a highly infectious respiratory disease of humans caused by the bacterium 
Bordetella pertussis. Despite high vaccination coverage, pertussis has re-emerged globally. 
Causes for the re-emergence of pertussis include limited duration of protection conferred by 
acellular pertussis vaccines (aP) and pathogen adaptation. Pathogen adaptations involve 
antigenic divergence with vaccine strains, the emergence of strains which show enhanced in 
vitro expression of a number of virulence-associated genes and of strains that do not express 
pertactin, an important aP component. Clearly, the identification of more effective B. pertussis 
vaccine antigens is of utmost importance. To identify novel antigens, we used proteomics to 
identify B. pertussis proteins regulated by the master virulence regulatory system BvgAS in vitro. 
Five candidates proteins were selected and it was confirmed that they were also expressed 
in the lungs of naïve mice seven days after infection. The five proteins were expressed in 
recombinant form, adjuvanted with alum and used to immunize mice as stand-alone antigens. 
Subsequent respiratory challenge showed that immunization with the autotransporters Vag8 
and SphB1 significantly reduced bacterial load in the lungs. Whilst these antigens induced 
strong opsonizing antibody responses, we found that none of the tested alum-adjuvanted 
vaccines - including a three-component aP - reduced bacterial load in the nasopharynx, 
suggesting that alternative immunological responses may be required for efficient bacterial 
clearance from the nasopharynx.
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Introduction
Pertussis (or whooping cough) is a highly contagious, acute respiratory disease of humans 
caused by the Gram-negative bacterium Bordetella pertussis. Although pertussis-related 
mortality has dropped significantly after the introduction of childhood vaccination, pertussis 
has resurged in many industrialized countries, with particularly large outbreaks occurring in 
2010 and 2012 in Australia, the USA, the UK, the Netherlands, and several other countries (1-
4). This increase in pertussis incidence is seen mainly in (vaccinated) adolescents and adults, 
providing a reservoir for transmission of pertussis to unvaccinated or partially vaccinated 
newborns, who are at greatest risk of developing severe pertussis (5-7).
Although current pertussis vaccines are effective in limiting the development of severe 
clinical symptoms, they are much less effective in preventing colonization of the upper 
respiratory tract and consequently do not adequately reduce circulation in the population (8). 
Moreover, vaccine-induced protection wanes rapidly leaving vaccinated individuals susceptible 
to develop disease after 5-7 years (9). The apparent inability of current vaccines to significantly 
reduce the circulation of B. pertussis may have facilitated pathogen adaptation. Pathogen 
adaptation has resulted in antigenic divergence between vaccine strains and circulating strains 
and the emergence of strains, designate P3 strains, which show enhanced in vitro expression 
of a number of virulence-associated genes (10, 11). Most recently, strains belonging to the P3 
lineage have emerged which do not produce pertactin (Prn), a component of most aPs. Prn-
deficient strains have reached frequencies of up to 55% in some countries (12-15). Efforts to 
improve the immunogenicity of pertussis vaccines have thus far focused on skewing immunity 
towards more effective bacterial clearance, for instance through the use of novel adjuvants 
(16, 17). However, the emergence of Prn-deficient strains also highlights a need to identify 
novel protective antigens, which may be included in improved aPs.
The expression of nearly all pertussis virulence factors, including the antigens present 
in aPs, is positively regulated by the two-component sensory transduction system BvgAS 
(reviewed in (18)). Bvg-activated proteins are generally associated with virulence and modulation 
or evasion of host immunity (19) and play an important, or even essential role, during infection. 
These proteins therefore represent potential vaccine targets. In vitro, low temperature and 
increasing concentration of nicotinic acid or sulfate are known to suppress the Bvg-system, 
resulting in the transition from virulent (Bvg+) through intermediate (Bvgi) to nonvirulent (Bvg-
) bacteria (20). In this study, we analyzed the Bvg+, Bvgi, and Bvg- phase-dependent protein 
content of two clinical isolates derived from the P1 and P3 lineages which dominated globally 
before and after the 1990s, respectively (11, 21). Conserved in vivo expressed candidates 
were then evaluated for their ability to confer protection against respiratory infection in mice. 
Results
Proteomic analysis and vaccine antigen selection
The regulation of the Bvg-system is dependent on environmental signals, including free sulfate 
(20). In this study, we compared the proteome of two currently circulating B. pertussis lineages 
under in vitro Bvg+ (low sulfate), Bvgi (medium sulfate), and Bvg- (high sulfate) conditions. 
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B. pertussis strains B1917 and B1920 were used as representatives for the P3 and P1 
lineages, respectively (21). Bacterial cultures were grown in four replicates under different Bvg 
conditions, fractionated into cytosolic and membrane protein fractions and analyzed by mass 
spectrometry. This approach identified a total of 940 proteins in B1917 and 952 proteins in 
B1920, with 91% overlap between these strains (see Supplementary Text S1 and Figure 1A), 
representing ~28% of the predicted 3449 protein-coding ORFs in the B. pertussis genome 
(22). The IDEAL-Q algorithm (23) was used to identify proteins that were ≥2.5 fold higher 
expressed under Bvg+ or Bvgi conditions compared to the Bvg- condition, which yielded 159 
and 104 Bvg-activated proteins in B1917 and B1920, respectively (Supplementary Table S1).
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Figure 1. Vaccine antigen selection and functional clustering of Bvg-activated proteins. A) 
Putative protein antigens were selected based on ≥2.5-fold Bvg-activation at both protein (this work) and 
mRNA level (10), presence in the core genome of B. pertussis (25), and PSORTb v3.0 predicted surface 
accessibility (outer membrane or extracellular) (26). This resulted in the identification of 15 putative 
vaccine candidates. † known B. pertussis protective antigens. Proteins in bold were selected for further 
examination. The proteins in bold The 855 and 51 proteins that were respectively identified and Bvg-
activated at the protein level in both strains, were grouped by functional categories (B) and PSORTb-
predicated subcellular localization (C). The relative frequency of Bvg-activated proteins compared to 
the total number of annotated proteins identified in both strains for each functional class are listed on 
the right-hand side. Asterisks indicate statistically significant enrichment of Bvg-activated proteins in a 
certain class as determined by Fisher’s exact test. *P < 0.05, ***P< 0.0005.
 
Since P3 and P1 strains both circulate in the population (24), novel antigens should 
target both lineages. We therefore first selected proteins that were Bvg-activated in both 
strains, resulting in 51 potential candidates (Figure 1A). Aggregation based on function and 
predicted subcellular localization showed that these 51 candidates were significantly enriched 
for proteins involved in cellular processes (n=6, 15%), outer membrane proteins (n=6, 20%) 
and extracellular proteins (n=10, 44%; Figure 1B and C). Subsequent selection based on Bvg-
dependent in vitro transcription levels (10), presence in the core genome of B. pertussis (25) 
and predicted surface-exposed localization (26) yielded 15 vaccine candidates (Figure 1A). 
Of these 15 proteins, eight represent known B. pertussis protective antigens (Figure 1A), thus 
validating our strategy to identify virulence factors, some of which have proven immunogenic 
properties. Of the remaining candidates, the autotransporters SphB1 and Vag8, the TonB-
dependent receptor for iron transport BfrD, the zinc protease BP2497, and the outer membrane 
porin protein Q (OmpQ), were selected for further examination (Figure 1A). Although the outer 
membrane ligand binding protein BipA and FhaC are also promising vaccine candidates based 
on these criteria, their vaccine potential was not assessed due to limited resources. 
The list of vaccine candidates was supplemented with proteins that were highly abundant 
under all Bvg conditions, as these may also represent attractive targets for the host immune 
response. Based on protein abundance estimation by emPAI (27) (Supplementary Table S2), 
the two most abundant proteins, outer membrane proteins A and P (OmpA, OmpP), were also 
selected for further analysis. 
Recombinant protein production and vaccination
To analyze the protective potential of the selected vaccine candidates, recombinant His-tagged 
fusion proteins were expressed, purified, and refolded. BfrD and OmpQ could not be produced 
due to low expression and protein degradation. The five remaining proteins were adjuvanted 
with alum (5 µg for each antigen, 1 µg for SphB1 due to low protein yield) and administered to 
BALB/c mice (six mice per group) as stand-alone antigens by subcutaneous injection at day 0 
and 14. In parallel, groups of mice were vaccinated with a 3-component aP or with PBS and/
or alum. Three weeks after the final vaccination, mice were challenged by intranasal infection 
with B. pertussis strain B1917. B1917 was chosen as the challenge strain, as it belongs to the 
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predominant P3 lineage, which has spread worldwide (11, 24). Importantly, the amino acid 
sequences of the tested antigens are highly conserved in all sequenced B. pertussis strains 
(24).
aP-vaccinated mice showed the strongest (>220-fold) reduction in bacterial load in the 
lungs at both 3 and 7 days after infection. Of the novel vaccine candidates, rOmpA did not 
confer any protection. Although vaccination with rOmpP and rBP2497 resulted in a small but 
significant reduction of bacterial numbers in the lungs at day 3 (1.7 and 1.8-fold, respectively), 
these differences were not observed at day 7, suggesting that these proteins have only limited 
vaccine potential (Figure 2A and B). In contrast, vaccination with either rSphB1 or rVag8 resulted 
in a nearly 10-fold reduction in bacterial load in the lungs day 3 and a more pronounced 26 and 
68-fold reduction at day 7, respectively (Figure 2A and B). Of note, although alum-vaccination 
induced a significant 7.3 fold reduction in bacterial load in the upper respiratory tract (URT) 
at day 7 compared to the PBS group, none of the vaccines, including aP, was able to reduce 
bacterial load in the URT (Figure 2C and D).
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Figure 2. Effect of immunization with novel vaccine candidates on infection with B. pertussis 
in the lower and upper respiratory tract. Naïve adult female BALB/c mice were subcutaneously 
immunized as described in the text and infected intranasally with 2×107 CFU of B. pertussis strain 
B1917. The bacterial load in the lungs and nose was quantified three (A and C) and seven (B and 
D) days after challenge. Each symbol represents one mouse. Horizontal lines represents the mean. 
Dashed lines indicate the lower limit of detection. *P < 0.05, **P< 0.005 relative to PBS mice; 2-tailed 
Mann-Whitney U test.
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Antibody responses to vaccine antigens 
To determine the potential role of antibodies in vaccine-mediated opsonization, ELISA was 
performed using sera from vaccinated mice. Figure 3 suggests that all vaccine candidates 
induced production of antigen-specific IgG. The absence of pre-existing antigen-specific 
antibodies was confirmed using pre-immune serum. 
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Figure 3. Detection of antigen-specific IgG in the serum of immunized mice. Post-immune 
serum (day 28) was used to determine the amount of total IgG specific for each recombinant antigens 
using ELISA as described in the text. Each symbol represents one mouse and the geometric mean is 
represented by a line. Dashed lines indicate the lower limit of detection (93 ng/ml). *P<0.05; 1-tailed 
Wilcoxon Signed Rank Test. 
To assess binding to native epitopes on the bacterial surface, flow cytometry was used to 
measure binding of antibodies in serum and nasal lavage to the challenge strain B1917 grown 
under Bvg+ and Bvg- conditions. Serum antibodies from rVag8, rSphB1, and aP-vaccinated 
mice opsonized Bvg+ bacteria at significant levels. Although opsonization levels were reduced 
for Bvg- bacteria, rVag8 and aP-vaccinated mice sera still bound significantly to Bvg- bacteria 
(Figure 4A), which is most likely due to residual expression of these proteins under Bvg- 
conditions (Supplementary Table S2). For nasal lavage samples, binding to Bvg+ bacteria was 
only detected for rVag8 and aP-treated animals (Figure 4B). 
Finally, whole-cell ELISA was performed for each antigen. Analysis of the subtype 
distribution of opsonizing IgG1, IgG2a, and IgG2b antibodies showed that IgG1 was the 
dominant subtype for each antigen (Figure 4C, D en E).
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Figure 4. Antibody-mediated opsonization of B. pertussis. The binding of serum (A) and 
nasal lavage (B) IgG antibodies to Bvg+ or Bvg- grown B. pertussis B1917 was determined using flow 
cytometry. Bars represent the geometric mean ± 95% confidence interval (CI) of 6 individual mice. 
*P<0.05, ***P<0.0005 relative to PBS group; Kruskal-Wallis test followed by a Dunns post-hoc test 
(α= 5%). To determine the distribution of IgG subtypes, whole-cell ELISA was performed with the post-
immunization serum samples to detect pertussis-specific IgG1 (C), IgG2a (D), and IgG2b (E). Each 
symbol represents one mouse and the geometric mean is represented by a line. Dashed lines indicate 
the lower limit of detection (23, 4, and 27 ng/ml for IgG1, IgG2a, and IgG2b, respectively). For IgG1, a 
1-tailed Wilcoxon Signed Rank Test was performed because IgG1 levels of the PBS mice were below 
the detection limit. IgG2a and IgG2b levels were statistically compared to the PBS mice using a 2-tailed 
Mann-Whitney U-test. *P<0.05, **P<0.005.
In vivo expression of vaccine antigens
To determine whether the selected vaccine candidates were expressed during infection, naïve 
adult BALB/c mice were infected intranasally with B1917 or B1920. Seven days after infection, 
gene expression was analyzed on bacteria isolated from the lungs for the five vaccine candidate 
genes as well as for ptxA, prn, fhaB, and fim3, which encode all currently used aP antigens 
except for Fim2. The expression of these genes was compared to the kpsT gene, which 
encodes a protein involved in capsule biosynthesis that has previously been identified as a 
Bvg- gene (28). Transcriptional analysis showed that all vaccine candidates and aP antigens 
were highly expressed in the lungs of mice in relation to kpsT (Figure 5). 
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Figure 5. In vivo expression of vaccine-candidate genes. Naïve adult female BALB/c mice 
(n=4) were infected intranasally with B. pertussis strain B1917 or B1920. After 7 days, bacteria were 
collected through broncho-alveolar lavage and used for in vivo transcriptional analysis using antigen-
specific primers as described in the text. The transcription data is expressed as 40-ΔCt value, which is 
a measure of expression relative to the recA household gene (ΔCt = Ct target – Ct recA). The number 
40 represents the number of PCR cycles. A 40-ΔCt value of 40 indicates that the gene is expressed at 
equal levels as recA, while higher values correspond to higher expression. 
Discussion 
The increase in pertussis outbreaks and the many adaptations observed in B. pertussis 
populations, including the down-regulation of Prn, indicates that more potent pertussis 
vaccines are warranted. Here, using an integrated ‘omics’ approach, we identified OmpP, 
OmpA, SphB1, Vag8, and BP2497 as in vivo expressed vaccine candidates. Stand-alone 
immunization with the autotransporters SphB1 and Vag8 induced significant protection against 
lower respiratory tract (LRT) infection, at a level which was only 10- and 3-fold lower compared 
to the reference 3-component aP vaccine (containing Ptx, Prn, and FHA), respectively. Thus 
far, four B. pertussis autotransporters have shown to confer protection in the mouse model, 
Prn (29), TcfA (30), SphB1, and Vag8, suggesting that these proteins represent an attractive 
class of protective antigens. 
Since aluminum adjuvants typically induce a strong T helper type 2 (Th2) response 
and high levels of antibodies (31), we primarily focused on the contribution of antibodies to 
protection. Although all five selected vaccine candidates induced significant levels of specific 
serum IgGs (predominantly IgG1), only rSphB1 and rVag8 conferred significant protection. A 
potential explanation for this result may be that only antibodies to rSphB1 and rVag8 opsonized 
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B. pertussis (Figure 4). The inability of antibodies specific for rOmpP, rOmpA, and rBP2497 
to successfully opsonize bacteria may be due to incorrect folding of the recombinant proteins, 
which is essential to induce bactericidal antibodies particularly to integral outer membrane 
proteins like OmpP and OmpA (32). 
At present, the exact mechanisms of protection induced by SphB1 and Vag8 remain 
unknown. Antibodies to these proteins may facilitate phagocytosis and subsequent killing, or 
result in the deposition of complement factors on the bacterial surface. Alternatively, antibodies 
may neutralize the biological activity of these antigens. For instance, antibodies against 
Vag8 may enhance the susceptibility of B. pertussis to complement-mediated killing (33). 
Interestingly, SphB1 induced similar protection levels compared as Vag8 (Figure 2), despite 
much lower opsonization levels (Figure 4). This could be a direct consequence of the lower 
absolute expression levels of sphB1 during infection compared to vag8 (Figure 5). Alternatively, 
the lower level of opsonizing antibodies may still be sufficient to effectively neutralize the 
biological activity of SphB1 on the bacterial surface. SphB1 is a serine protease which plays 
an essential role in the maturation of the adhesin and immune-modulating factor FHA (34). 
Previous studies have shown that deletion of the sphB1 gene dramatically attenuated the 
ability of B. pertussis to infect mice (35) and enhanced phagocytosis (36). Taken together 
with our observation that sphB1 is not expressed at high levels during infection, this gene 
represents a very attractive target because even low concentrations of neutralizing antibodies 
may be sufficient for protection. 
Although we found that SphB1 and Vag8 were both expressed during infection in naïve 
mice, antibodies against these (recombinant) antigens were undetectable in convalescent 
pertussis patients (data not shown). Although it is possible that these proteins have poor 
intrinsic immunogenicity in humans during natural infection, another explanation may be that 
vaccinated individuals who are subsequently infected with B. pertussis preferentially respond 
to only a limited number of immunodominant vaccine antigens, also known as original antigenic 
sin (37).
Finally, an important observation was that none of the vaccine formulations, including aP, 
was able to reduce bacterial colonization of the URT. As colonization of the URT is probably 
essential for transmission, this may explain epidemiological studies which show that high 
circulation of B. pertussis occurs despite widespread aP vaccination (38). Similarly, recent 
observations in the baboon model have shown that aP-vaccinated baboons are protected 
against disease but remain susceptible to colonization and are able to transmit the disease 
(8). These data suggest that the immunological mechanisms which are required for effective 
clearance from the lungs (e.g. antibodies (39)) are distinct from those in the URT, an observation 
which has also been made for other respiratory bacterial pathogens, including Streptococcus 
pneumonia (40-42). Cellular immunity in particular may represent an important component for 
effective clearance of the URT (43) and in order to prevent both disease and colonization, a 
combined antibody and cellular response may be required (8, 17, 44-47). 
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Materials and Methods
Ethics statement
Animal experiments were approved by the Radboudumc Committee for Animal Ethics and 
conducted in accordance with the relevant Dutch legislation. Bacterial strains were collected 
by regional Medical Microbiology Laboratories from patients suspected of whooping cough 
and sent to the National Institute for Public Health and the Environment (RIVM) in the context 
of routine surveillance (as required by law). The strains are sent to the RIVM for confirmation of 
clinical diagnosis, species determination and subtyping. Strictly anonymized patient information 
is included, which is limited to age, sex and postal code. For this type of surveillance ethical 
evaluation or patient consent are not required. The strains have been used in previous studies 
(48).
Bacterial strains and growth conditions
Culture samples of B. pertussis strains grown under Bvg+, Bvgi, and Bvg- conditions in chemically 
defined THIJS medium (49) from a previous study (10) were used for proteomic analysis (4 
replicates). For modulation of the BvgASR regulatory system, magnesium sulfate was added to 
cultures at a final concentration of 5 and 50 mM to induce Bvgi and Bvg- conditions respectively. 
In the absence of additional sulfate, the concentration of free sulfate was determined to be 
0.02 mM, thereby inducing Bvg+ conditions. Correct modulation of the Bvg system by sulfate 
was confirmed in previous work (10). Bacteria harvested at mid-log (OD620 of 0.5-0.6) were 
used for protein isolation. 
For recombinant protein expression, Escherichia coli OverExpress™ C41(DE3) (Lucigen, 
USA) was grown in Luria Bertani medium (LB) containing appropriate antibiotics (ampicillin, 
kanamycin and/or chloramphenicol at a concentration of 50 µg/ml) at 37oC. 
Proteomics analysis 
Bacterial pellets from 5 mL of mid-log culture were lysed by sonication. Cytosolic and membrane 
protein fractions were then isolated using the ReadyPrep Protein Extraction Kit Membrane I 
(Bio-Rad Laboratories, Hercules, CA, USA), according to the manufacturers protocol. The 
obtained soluble and insoluble fractions, containing the cytosolic and membrane (-associated) 
proteins respectively, were precipitated using the ReadyPrep 2-D clean-up Kit (Bio-Rad 
Laboratories). Protein pellets were then dissolved in 8M urea in 10 mM Tris-HCl pH 8.0 and 
subjected to in-solution digestion and C18 reversed phase nano flow LC-MS/MS analysis as 
described in Supplementary Text S1.
Recombinant antigen production 
The DNA sequences of the selected vaccine antigens lacking their N-terminal signal 
sequences and/or other targeting domains to allow cytosolic expression, were codon optimized 
for expression in E. coli, synthesized by GenScript (USA), and cloned into pET28-TEVsite 
vector (modified from pET28a vector, Novagen, Denmark) to generate N-terminally His6-
tagged proteins (Supplementary Table 3). E. coli OverExpress™ C41(DE3) (Lucigen, USA) 
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was cultured to an OD600 = 0.6-0.7 at 37oC, after which recombinant protein expression was 
induced through the addition of 1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) for 3 
hours. For cell lysis, bacteria were sonicated in Bacterial Protein Extraction Reagent (B-PER, 
Thermo Scientific). Recombinant proteins in inclusion bodies were dissolved in 20 mM sodium 
phosphate, 500 mM NaCl, 4 M urea and 20 mM imidazole and purified on a AKTA FPLC 
system using affinity chromatography on a HisTrap™ FF crude 1 ml column prepacked with Ni 
Sepharose™ 6 Fast Flow (GE Healthcare, Sweden) as described (50). Protein concentrations 
were determined using the 2-D Quant Kit (GE Healthcare, USA). Recombinant proteins were 
refolded by rapid 50-fold dilution in refolding buffer (for BP2315 and BP2497 according to (51) 
and for BP0840 and BP0943 according to (52)) Refolding of BP0216 was performed in 10 mM 
Benzamidine, 1 mM EDTA, 100 mM NaCL, 1 M urea, and 50 mM diethanolamine (pH9.5). 
Vaccination
Individual groups of six naïve female, 6-8 week old BALB/c mice (Charles River) were 
immunized subcutaneously on day 0 and 14 with 5 μg of recombinant protein (1µg for BP0216 
due to low protein yield) mixed 1:1 in 1.3% alum adjuvant (Alhydrogel; Sigma). As a control, 
mice were immunized with PBS and Alhydrogel, or with PBS alone. Since the PBS group 
was the most used group for statistical comparisons, 12 mice were included in this group to 
enhance the statistical power. In order to compare efficacy to current aPs, one group of mice 
was immunized with 1/50th of the human dose (equals 1.16 µg of B. pertussis protein) of the 
commercial hexavalent 3-component acellular pertussis vaccine InfanrixTM (GSK, Belgium). 
On day 35, mice were challenged by intranasal (i.n.) infection with 2×107 colony forming units 
(CFU) of B. pertussis strain B1917 in 40 µL. Bacterial load in the nasopharynx and lungs was 
determined on day 38 and 42 (3 and 7 days after challenge) as described previously (50). 
Including the 7 day time-point allowed comparison to aP vaccination, which in mice typically 
leads to clearance of the pathogen from the lungs within 7 days (17). Furthermore, the 3 day 
time point allowed us to determine whether the selected antigens are able to induce early 
protection against infection. Serum samples were collected on days 0, 28, 38, and 42.
In vivo transcriptional analysis
Groups of 4 female, naïve 6-8 week old BALB/c mice (Charles River) were infected i.n. with 
B. pertussis strain B1917 or B1920 as described above. After 7 days (at the peak of infection), 
bacteria were collected from the lungs through a bronchoalveolar lavage (BAL) with PBS and 
stabilized with RNA Protect Bacteria Reagent (Qiagen). Total RNA was extracted using the 
RNeasy Mini kit (Qiagen) and contaminating genomic DNA was removed by DNase treatment 
(DNAfree, Ambion). Bacterial RNA was enriched and amplified using the MICROBEnrich 
(Ambion) and SensationPlus™ FFPE Amplification (Affymetrix) kits, respectively. Enriched RNA 
was reverse-transcribed using the SuperScript® One-Cycle cDNA Kit (Invitrogen) and used for 
quantitative real-time PCR analysis (primer sequences available on request). To determine 
relative expression levels, ΔCt values were calculated by subtracting the Ct value of the recA 
(BP2546) household gene from the Ct value of the target gene (53). The transcription data are 
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expressed as 40-ΔCt value, with 40 representing the number of PCR cycles as detection limit. 
A 40-ΔCt value of 0 indicates that the gene is expressed at equal levels as recA, while higher 
values correspond to increased expression.
Antibody analysis
Protein ELISA
IgG titers against the recombinant antigens in mouse and human sera were determined by 
sandwich enzyme-linked immunosorbent assay (ELISA) analysis, essentially as described 
previously (50). 
Whole-cell ELISA 
The binding of IgG subtypes to whole bacteria was measured using a whole-cell ELISA method 
adapted from Abdillahi and Poolman (54). Briefly, ELISA plates were coated with Bvg+ mid-log 
culture of the challenge strain B1917, washed with PBS containing 0.05% Tween 20 (PBST), 
blocked with 1% BSA/PBS, and incubated with mouse serum. Bound IgG1, IgG2a, and IgG2b 
was detected using anti-mouse secondary antibodies (BD Pharmingin and Southern Biotech) 
and appropriate substrates. The optical density was measured on an ELISA plate reader 
(Tecan Infinite F50) and antibody subtype concentrations were determined by comparison to 
standard curves with known concentrations of each IgG subtype. 
Opsonization
1% BSA/PBS was used for all dilutions. 106 CFU of Bvg+ and Bvg- B1917 (challenge strain) 
were incubated with serum or nasal lavage (NL) samples from vaccinated mice for 30 min at 
4°C. Bacteria were fixed in 2% paraformaldehyde and surface-bound IgG was detected using 
anti-mouse IgG-Fc-FITC-conjugated antibodies (Sigma-Aldrich) on a BD LSRII flow cytometer 
(BD Biosciences). The amount of surface-bound antibodies was expressed in arbitrary units as 
a fluorescence index (FI), calculated by multiplying the geometric mean fluorescence intensity 
by the percentage of FITC-positive bacteria (55). Data were analyzed using FlowJo version 
7.6.5. 
Statistical analyses
A 2-tailed Mann-Whitney U test was used for comparison of bacterial load in NL and lung 
homogenate between PBS-vaccinated mice and recombinant antigen-vaccinated mice. A 
Kruskal-Wallis test followed by a Dunns post-hoc test (α= 5%) was used for comparison of 
antibody-mediated opsonization by serum and NL samples between PBS-vaccinated mice 
and recombinant antigen-vaccinated mice. A 1-tailed Wilcoxon Signed Rank Test was used to 
determine whether ELISA measured IgG levels were significantly above the detection limit. All 
statistical analyses were performed using the GraphPad Prism software program, version 5.0, 
where p<0.05 was considered significant.
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Supplementary information
Text S1: Supplemental Methods. 
In-solution digestion
Cytosolic and membrane protein extracts (15 µg) present in 8M urea in 10 mM Tris-HCl pH 
8.0 were subjected to disulfide reduction. For this, 1 µL 10 mM dithiothreitol (DTT) was added 
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and incubated for 30 min at RT. Then, proteins were alkylated by adding 1 µL of 50 mM of 
iodoacetamide (IAA) in 50 mM Ammonium bicarbonate (ABC) and incubating for 20 min at RT. 
After digestion with Endoproteinase LysC (1:50 w/w) (Wako Chemicals, USA) for 3 hours at 
RT, the solution was diluted to 2M urea with ABC and incubated overnight in the presence of 
sequencing grade modified trypsin (1:50 w/w) (Promega, Madison, WI) at 37 oC for complete 
digestion. Subsequently, the peptide mixture was concentrated and desalted using stop and 
go elution (STAGE) tips as described by Rappsilber and coworkers (1). Briefly, the acidified 
peptides were bound on activated C18 reversed phase material fixed in a standard pipettor 
tip, washed with 0.5% acetic acid and eluted with 80% acetonitrile 0.5% acetic acid. Finally, 
the acetonitrile buffer was removed using a SpeedVac (Savant DNA 110 SpeedVac; Global 
Medical Instruments) after which the peptides were dissolved in 0.5% acetic acid for nLC-MS/
MS analysis. 
C18 Reversed phase LC-MS/MS analysis
The C18 reversed phase nanoflow LC-MS/MS analyses were performed using a Proxeon 
nanoflow liquid chromatograph (Easy-nLC, Thermo Fisher, Bremen, Germany) coupled 
on-line to a 7T linear quadrupole ion trap Fourier transform ion cyclotron resonance mass 
spectrometer (LTQ-FT Ultra, Thermo Fisher Scientific, Bremen, Germany) as described 
(2). Briefly, chromatographic separations were performed using a 15-cm fused silica emitter 
(PicoTip emitter; tip, 8 ± 1 μm; internal diameter, 100 μm; FS360-100-8-N-5-C15; New Objective) 
packed in-house with reverse phase ReproSil-Pur C18AQ 3 μm resin (Dr. Maisch GmbH). 
Peptides were eluted from the column using a linear gradient of 8-16% acetonitrile in 75 min 
and 16-32% acetonitrile in 55 minutes at a flow rate of 300 nL/min. The LTQ-FT ultra mass 
spectrometer was programmed to acquire a survey MS scan in the ICR cell (350-1600 m/z, 
R=100.000 FWHM @ 400 m/z, 1E6 ions) with parallel MS/MS spectra acquisition of the top 
4 most abundant ions in the linear ion trap (30% normalized collision energy, 30ms activation 
time, activation Q=0.250, 3000 ions). Dynamic exclusion was enabled to prevent re-analyses 
of peptides during the analysis (exclusion duration: 180 seconds, early expiration enabled: 
10 scans with S/N=2). Only ions with charge states z=2+ and 3+ were considered for MS/MS 
spectra acquisition.
Database searching and result validation
Database searches and validation of results was performed as described (2). Briefly, the raw 
data files acquired by the nLC-MS/MS instrument were converted to mascot generic files using 
DTA supercharge (3). Peptides and proteins were identified using Mascot software (Mascot 2.2; 
Matrix Science) to search a local copy of an in-house created pan-genomic B. pertussis protein 
database (based on described sequence data (4)) supplemented with known contaminant protein 
sequences (e.g. Trypsin, LysC and human skin proteins). The following parameters were used: 
15 ppm precursor mass tolerance and a 0.5 Da fragment ion mass tolerance. Furthermore, 
one missed trypsin cleavage was tolerated and carbamidomethylation of cysteines was set 
as a fixed modification. Variable modifications included oxidation of methionine residues and 
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N-terminal protein acetylation. The Mascot search results were subjected to heuristic iterative 
protein false discovery rate validation method of Weatherly to achieve a 1% false discovery 
rate or better (5). A protein was considered identified when it was detected in at least 3 out of 4 
biological replicates of at least one Bvg-condition. Exponentially modified PAI (emPAI) scores 
were calculated (6) to determine protein abundance in the different samples. 
Label-Free Quantitative analysis 
The IDEAL-Q (ID-based Elution time Alignment by Linear regression Quantification) software 
program was used for the label-free quantitative analysis of the nLC-MS/MS data (7). The 
cytosolic and membrane protein fractions of both strains were processed independently. Semi-
quantitative information was extracted from the LC-MS data and the Mascot search results by 
extracted ion currents. Details of the IDEAL-Q method are described by Tsou and coworkers 
(7). Briefly, IDEAL-Q attempts to extract ion current information for every identified peptide 
(identified in any analysis) even in the absence of Mascot identification data for a peptide in 
some of the analyses. The following peptide ion information is used by IDEAL-Q to pinpoint 
ions across files where no identification information is available: mass to charge ratio (m/z), 
charge state (z), normalized retention time, and isotopic pattern. The combination of all of the 
above mentioned peptide ion characteristics allow IDEAL-Q to identify ions when no Mascot 
data is available for a specific analysis. Settings used by IDEAL-Q include 30 ppm mass 
tolerance, nondegenerate unique peptides only, and Dixon’s outlier test to eliminate peptide 
ratio outliers for each proteins at 95% significance level. Protein ratios were calculated as the 
weighted average of all respective peptide ratios. 
Processing semi-quantitative proteomics data
Protein abundance ratios were generated by IDEAL-Q for each biological replicate relative 
to Bvg- sample one and normalized using the median ratio of all proteins quantified. The 
normalized ratios were Log2 transformed and used for a One-Way ANOVA with the maximum 
number of permutations (=34650) to identify proteins that were significantly different (p-value 
≤0.05) between the three groups. Proteins that were found to be significantly different based 
on less than three out of four biological replicates in one of the groups that were significant 
were excluded. The p-values of all the remaining proteins (both significant and non-significant) 
were corrected for multiple testing using the FDR method of Storey and Tibshirani to obtain 
q-values (8). Proteins with a q-value ≤ 0.05 and a fold change of ≥3 or ≤-3 were considered 
as Bvg-regulated. Due to the high complexity of our (fractionated) protein samples and the 
limited capacity of the mass spectrometer to detect and quantify every peptide from every 
protein in all samples, quantitative information about the complete proteome was not available 
in our proteomic datasets. For some proteins quantitative information was lacking or highly 
variable, making it impossible to determine whether these proteins were Bvg-regulated. To 
partially overcome this limitation, we compared both the Bvg+ and Bvgi groups to the Bvg- group 
and considered proteins that were at least 3-fold up or downregulated in either the cytosolic 
fraction, the membrane fraction, or both fractions, as Bvg-regulated. Bvg-regulated proteins 
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were aggregated based on function (main role according to the TIGR B. pertussis genome and 
B. bronchiseptica database) and subcellular localization (predicted using PSORTb v3.0 (9)) 
and significant enrichment in a certain class was determined by Fisher’s exact test.
Validation proteomic datasets
Proteomics allowed us to identify a total of 940 proteins in P3 and 952 proteins in P1, representing 
28% of the total predicted ORFs in the P3 and P1 genomes. 855 proteins (91%) were identified 
in both strains. Of the 940 proteins identified in the P3 strain, 253 (27%) proteins were found 
only in the cytosolic fraction, 164 (17%) only in the membrane fraction, and 523 proteins 
(56%) were identified in both fractions. In the P1 strain, 613 of the 952 proteins (64%) were 
identified in both fractions whereas 181 (19%) and 158 (17%) proteins were found uniquely in 
the cytosolic and membrane protein fraction respectively. 
Correct fractionation of the cytosolic and membrane proteins was confirmed using the 
protein abundance emPAI values of proteins with a strongly predicted cytosolic and outer 
membrane localization (determined using PSORTb v3.0). This revealed clear enrichment 
(high emPAI scores) for cytosolic predicted proteins in the cytosol fractions and membrane-
predicted proteins in the membrane fractions of all conditions in both strains (data not shown). 
Furthermore, western blot analysis revealed that the outer membrane protein BP0840 was 
exclusively present in the membrane protein fraction of all samples (data not shown). This data 
indicates correct protein fractionation of all samples. 
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Table S1: Proteomics data of statistically significant Bvg-regulated proteins iden-
tified in the cytosolic and membrane fraction of B. pertussis strains B1917 (P3) 
and B1920 (P1). Please refer to: http://journals.plos.org/plosone/article/asset?unique&id=in-
fo:doi/10.1371/journal.pone.0105011.s001
Table S2: Protein abundance of all proteins identified in the cytosolic and 
membrane fraction of B. pertussis strains B1917 (P3) and B1920 (P1). Please 
refer to: http://journals.plos.org/plosone/article/asset?unique&id=info:doi/10.1371/journal.
pone.0105011.s002
            
Table S3: Constructing His-fusions of the selected candidate antigens.  
General gene information specifies the open reading frame (ORF) number, gene, and protein product 
from each candidate antigen.
Domains deleted specificies the amino acid locations of predicted signal peptide (based on SignalP 
3.0) and other targeting domains. These sequences were removed in the final His-fusions.
Predicted localization: Localizations were predicted using PSORTb v3.0.
His-fusion proteins: Specifies the amino acid part of the protein which are included in the His-fusion 
as well as the number of amino acids and corresponding molecular weight (in kDa) of the final His-fu-
sions.  
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Abstract 
Pertussis is an infectious respiratory disease of humans caused by the Gram-negative 
pathogen Bordetella pertussis. The use of acellular pertussis vaccines (aPs) which induce 
immunity of relative short duration and the emergence of vaccine-adapted strains are thought 
to have contributed to the recent resurgence of pertussis in industrialized countries despite high 
vaccination coverage. Current pertussis vaccines consist of antigens derived from planktonic 
bacterial cultures. However, recent studies have shown that biofilm formation represents an 
important aspect of B. pertussis infection, and antigens expressed during this stage may 
therefore be potential targets for vaccination. Here we provide evidence that vaccination of mice 
with B. pertussis biofilm-derived membrane proteins protects against infection. Subsequent 
proteomic analysis of the protein content of biofilm and planktonic cultures yielded 11 proteins 
which were ≥3-fold more abundant in biofilms, of which BipA was the most abundant, surface-
exposed protein. As proof of concept, mice were vaccinated with recombinantly produced BipA. 
Immunization significantly reduced colonization of the lungs and antibodies to BipA were found 
to efficiently opsonize bacteria. Finally, we confirmed that bipA is expressed during respiratory 
tract infection of mice, and that anti-BipA antibodies are present in the serum of convalescent 
whooping cough patients. Together, these data suggest that biofilm proteins and in particular 
BipA may be of interest for inclusion into future pertussis vaccines. 
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Introduction
The Gram-negative bacterium Bordetella pertussis is the main causative agent of whooping 
cough or pertussis. During epidemics in the pre-vaccination era, pertussis was attributable 
for up to 13% of all-cause child mortality (≤10 y) (1). Whilst this percentage has dropped 
significantly following the introduction of widespread vaccination in the 1950s, pertussis has 
resurged since the 1990s (2, 3) and is now estimated to (re-)infect 40M people each year (3-5), 
resulting in approximately 195,000 deaths worldwide, mainly in children (6). 
Although acellular pertussis vaccines (aPs) are highly effective in protecting infants 
from developing severe pertussis, immunity already wanes after 5-10 years (7, 8) and aPs 
may not effectively reduce circulation of B. pertussis in the population (9). This may have 
facilitated the evolution of antigenically divergent strains and, more recently, the emergence 
of a lineage (designated the P3 lineage) that produces higher amounts of several virulence 
factors, including pertussis toxin (Ptx) (10, 11). Alarmingly, within this P3 lineage, strains that do 
not express pertactin (Prn), a component of most aPs, have emerged in the last six years and 
are now becoming increasingly dominant (12-14). Clearly, there is a need for novel antigens 
for inclusion in pertussis vaccines to improve their effectiveness. Here we have focused on 
biofilms as a potential source of protective antigens. 
B. pertussis is able to produce biofilms in the respiratory tract and this process has been 
shown to contribute to successful infection (15-18). In general, biofilm-associated bacteria differ 
significantly from their planktonic counterparts (19) and studies with B. pertussis have shown 
that ~10% of the proteome is differentially expressed between these conditions (20). Most 
B. pertussis proteins that interact directly with the host are regulated by the two-component 
Bordetella master virulence regulatory system BvgAS which transduces environmental signals 
such as temperature, nicotinic acid and sulfate, to gene regulation (reviewed in (21)). Based 
on the activity of this system, the Bvg+, Bvgi, and Bvg- phase have been defined. In the Bvg+ 
phase, almost in which almost all virulence factors are expressed (10, 21). The Bvgi phase, 
characterized by the expression of the Bordetella intermediate protein A (BipA), has been 
suggested to be involved in transmission and biofilm formation (22-24). Bvg+ and Bvgi phase 
bacteria have been shown to be virulent in mice, whereas Bvg--locked bacteria, which cannot 
switch to the Bvg+ or Bvgi phase, are unable to establish infection (24, 25). 
Here we examined the ability of B. pertussis biofilms to protect against pertussis using a 
mouse model. Having confirmed the protective potential of biofilms, we then comprehensively 
analyzed the biofilm antigenic protein composition and compared it to in vitro planktonic grown 
bacteria. Finally, we evaluated whether immunization with a single biofilm protein, BipA, was 
able to protect mice against respiratory infection with B. pertussis and examined the expression 
of bipA during infection. 
Results
Membrane-associated proteins derived from biofilms or planktonic grown cells 
confer protection against respiratory tract infection in mice
To evaluate the potential of biofilm-grown bacteria to confer protection against respiratory tract 
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infection in mice, we cultured a B. pertussis clinical isolate (B1917, isolated in 2000) under 
biofilm-forming and planktonic conditions. This particular strain belongs to the P3 lineage 
which emerged in the 1980s and currently predominates in many vaccinated populations (33). 
For planktonic conditions, bacteria were grown to mid-log and stationary phase. Following 
growth, bacteria were harvested and cytosolic and membrane (-associated) proteins were 
extracted (34). The membrane fractions were adjuvanted with Alhydrogel and the equivalent 
of 1 µg of protein was used to vaccinate female BALB/c mice 2× by subcutaneous injection, 
with two-week intervals. In parallel, groups of mice were vaccinated with a currently licensed 
3-component aP (Infanrix) or mock-vaccinated with PBS or adjuvant only. Immunized mice 
were then challenged by intranasal infection with strain B1917, after which the lung and nose 
bacterial load was determined three and seven days later. 
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Figure 1. Immunization with membrane protein fractions derived from biofilm and mid-log and 
stationary planktonic cultures. Naïve adult female BALB/c mice were subcutaneously immunized 
with 1 µg membrane proteins. Negative controls consisted of adjuvant only (Alum) and PBS, while an 
acellular vaccine (aP) containing 0.5 µg Ptx, 0.5 µg FHA and 0.16 µg Prn was used as a positive control. 
Subsequently, mice were infected intranasally with 2×107 CFU of B. pertussis strain B1917. The bacterial 
load in the lungs and nose was quantified three (A and C) and seven (B and D) days after challenge. 
Each symbol represents one mouse. Horizontal lines represent the mean. Dashed lines indicate the 
lower limit of detection. *P<0.05, **P<0.005 relative to PBS mice; 2-tailed Mann-Whitney U test.
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Mice vaccinated with aP showed a significant reduction (>220-fold) in lung CFUs at day 3 and 
day 7 (Figures 1A and 1B). At three days following infection, significant protection was observed 
in the lungs of mice immunized with proteins derived from planktonic as well as biofilm-grown 
bacteria (Figure 1A). After seven days, protection was more pronounced, with 29-fold, 43-
fold, and 170-fold reduction in bacterial load in mice immunized with biofilm, mid-log, and 
stationary proteins, respectively (Figure 1B). The differences in protection induced by the three 
membrane fractions were not significant. Of note, we observed that none of the vaccinated 
mice, including those vaccinated with aP, were protected against infection with B. pertussis 
in the URT (Figures 1C and 1D). Taken together, these data suggest that immunization with 
biofilms can induce protection against infection.
Proteomic analysis of B. pertussis grown under biofilm or planktonic conditions 
As our initial results implied that biofilms contain protective antigens, we compared the 
proteome of cytosolic and membrane protein fractions of the mid-log, stationary, and biofilm 
cultures by mass spectrometry, as described in Supplemental Text S1. This approach 
identified a total of 749, 729, and 825 proteins in the extracts from mid-log, stationary, and 
biofilm cultures, respectively, with an overlap of 645 proteins (88%). This analysis covered 
21-24% of the predicted total of 3449 protein-coding ORFs in the B. pertussis genome (35). 
IDEAL-Q (36) was then used to identify proteins which were differentially regulated in biofilms 
(Supplemental Text S1). This method normalizes and quantifies comparable peptides between 
parallel runs of different samples (36). Proteins that were ≥3-fold more or less abundant under 
biofilm (either cytoplasmic or membrane fraction) conditions compared to either mid-log or 
stationary conditions, were defined as biofilm-upregulated and biofilm- downregulated proteins, 
respectively. This strategy yielded 60 biofilm-upregulated proteins. Aggregation based on 
function and predicted subcellular localization showed that these proteins were significantly 
enriched for (ribosomal) proteins involved in protein synthesis (N=17, 27.4%, p=7.7×10-4; Figure 
2, Supplemental Table S1). Additionally, 48 proteins were identified which were downregulated 
in biofilms. Whilst this set of proteins was not significantly enriched for any specific functional 
classes, 17 of these proteins have previously been identified as Bvg-activated genes in strain 
B1917 (10), including the virulence factors Vag8, FimX, and eight type III secretion system 
(T3SS) proteins (Supplemental Table S1). 
Vaccine candidate antigen selection
We focused on the 11 proteins that were upregulated in biofilms compared to both mid-log and 
stationary planktonic conditions, as these potentially represent protein antigens specifically 
expressed in biofilms. These proteins were ranked based on protein abundance (37, 38), as 
well as predicted surface accessibility (i.e. outer membrane or extracellular) (39) (Table 1). 
Protein abundance was estimated for each fraction and growth condition by emPAI score 
(37, 38), a method which provides an approximate protein ranking based on the number of 
observed peptides per protein relative to the number of observable peptides (Supplemental 
Table S2). Based on these criteria, Bordetella intermediate protein A (BipA) was identified as 
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the most abundant surface-associated biofilm protein. 
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Figure 2. Functional clustering of proteins identified with proteomics. 645 proteins were identified 
under all three growth conditions (biofilm, planktonic mid-log and planktonic stationary), of which 60 
and 48 proteins were found to be upregulated or downregulated, respectively, in biofilms relative to 
planktonic conditions. The identified proteins were grouped by functional categories (A) and PSORTb-
predicated subcellular localization (B). The relative frequencies of biofilm-up- or –down-regulated 
proteins, compared to the total number of annotated proteins identified under all conditions for each 
functional class, are listed on the right-hand side. Asterisks indicate statistically significant enrichment of 
biofilm-regulated proteins in a certain class as determined by Fisher’s exact test. **P<0.005.
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Table 1: Biofilm-associated proteins and vaccine candidate selection criteria
General information Fold change a Protein abundance (emPAI values) b Predicted
Locali-
zation cCytosol Membrane Cytosol Membrane
ORF Gene Protein name BF/ML
BF/
ST
BF/
ML
BF/
ST BF ML ST BF ML ST
BP1112 bipA
Bordetella 
intermediate 
protein A
5.41 4.63 4.71 7.43 1.19 0.21 0.36 3.36 0.61 0.38 Om
BP0878 phospholipase - - 3.76 3.74 - - - 0.32 - - Om
BP0038 gloA lactoylglutathione lyase 12.48 9.00 9.00* 3.13* - - - - - - C
BP0782 exported protein - - 3.90 13.56 - - - - - - Un
BP0901 oxidoreductase 5.73 7.33 - - 0.07 - - - - - C
BP1315 universal stress family protein 3.81 7.89 3.03* 2.27* 1.67 1.25 0.81 1.71 1.11 1.64 C
BP1519 fba
fructose-
bisphosphate 
aldolase
3.83 11.15 -1.33 -1.32 4.96 2.16 1.12 1.61 1.47 1.95 C
BP2039 amidase 3.62 9.89 - - - - - - - - C
BP2782 lipoprotein - - 10.64 15.84 - - - 1.18 0.80 0.93 Un
BP2873 tctC
tripartite 
tricarboxylate 
transporter family 
receptor
2.52 3.80 3.12 -1.79 0.37 0.33 0.27 0.32 0.11 - P
BP2896 hydrolase - - 4.19 6.81 - - - - - - C
Abbreviations: BF, biofilm; C, cytoplasmic; ML, mid-log; Om, outer membrane; ORF, open reading frame; P, 
periplasmic; ST, stationary; U, unknown; * not significant (p>0.05).
a) Fold change specifies the protein abundance ratio of the indicated conditions as determined using IDEAL-Q 
(Supplemental Table S1). ‘-‘: protein not quantifiable.
b) emPAI values (37) were calculated based on the protein false discovery rate validation method of Weatherly (38) 
(Supplemental Table S2). ‘-‘: protein was not detectable.
c) Localization prediction based on PSORTb v3.0 (39).
BipA expression during infection
To determine whether BipA is expressed during natural infection, naïve adult BALB/c mice were 
infected intranasally with B. pertussis strain B1917. Seven days after infection, bacteria were 
isolated from the lungs and gene expression of bipA was analyzed by qPCR and compared to 
Bvg+, Bvgi, and Bvg- in vitro conditions. As a negative control, the kpsT gene encoding a Bvg- 
protein involved in capsule biosynthesis was included (40). Transcriptional analysis showed 
that bipA is expressed in the lungs of mice, at a level also observed under virulent in vitro 
Bvg+ and Bvgi conditions (Figure 3A). Thus, these data indicate that BipA is expressed during 
respiratory infection in mice.  
To investigate whether BipA was also expressed during infection of humans, a panel of 
convalescent sera from individuals who were recently infected with B. pertussis was used to 
measure rBipA-specific antibody responses. We used serum from individuals with anti-Ptx 
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titers above 400 EU/ml, as this level is strongly indicative of recent infection (41). Sera from 
humans with undetectable titers of anti-Ptx antibodies were chosen as negative control. 
Analysis of these serum samples indicated that infection of humans also results in antibodies 
to rBipA (Figure 3B), suggesting that BipA is expressed and immunogenic during infection.
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Figure 3. BipA expression during infection. A) Naïve adult female BALB/c mice were infected 
intranasally with B. pertussis strain B1917. After 7 days, bacteria were collected through bronchoalveolar 
lavage (BAL) and used for in vivo transcriptional analysis using bipA-specific primers as described in 
the text. Expression levels were compared to in vitro Bvg+, Bvgi, and Bvg- conditions. The transcription 
data are expressed as 40-ΔCt value, which is a measure of expression relative to the recA gene (ΔCt 
= Ct target – Ct recA). *P<0.05, **P<0.005, ***P<0.0005 relative to the Bvg- condition; Student’s t-test 
with Welch’s correction. B) Human serum, from 10 confirmed B. pertussis infected individuals (Bp+) and 
4 non-infected individuals (Bp-) was diluted and incubated on ELISA plates coated with recombinant 
BipA or Ptx and the titers were determined. Horizontal lines represent the geometrical mean. **P<0.005, 
***P<0.0005 relative to Bp- sera; 1-tailed Mann-Whitney U test.
BipA is a protective B. pertussis antigen
To determine the protective effects of BipA, we constructed a recombinant His-tagged fusion 
protein of BipA (rBipA). After purification and refolding, the purity of the produced protein was 
confirmed by Coomassie staining and immunoblotting (Supplemental Figure S1). rBipA was 
then adjuvanted with Alhydrogel and used as stand-alone antigen (5 µg) to vaccinate female 
adult BALB/c mice. Mice were immunized 2× in two-week intervals, after which they were 
challenged by intranasal infection with B1917. Vaccination with rBipA resulted in a small but 
significant reduction of bacterial load in the lungs as compared to the PBS-vaccinated mice 
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(Figures 4A and 4B, 5.4 and 3.4-fold at day 3 and 7, respectively) which was not observed 
in the nasopharynx (Figures 4C and 4D). Thus, these data show that rBipA is able to reduce 
bacterial load. 
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Figure 4. Immunization with rBipA protects against B. pertussis infection. Naïve adult female 
BALB/c mice were subcutaneously immunized with recombinant BipA (rBipA) or controls as described in 
Figure 1 and infected intranasally with 2×107 CFU of B. pertussis strain B1917. The bacterial load in the 
lungs and nose was quantified three (A and C) and seven (B and D) days after challenge. Each symbol 
represents one mouse. Horizontal lines represent the mean. Dashed lines indicate the lower limit of 
detection. **P<0.005 difference between rBipA and aP and between vaccinated and PBS control mice; 
2-tailed Mann-Whitney U test.
BipA-specific antibody responses
To determine the role of antibody-mediated protection by rBipA, an ELISA was performed 
using sera from vaccinated mice. Figure 5A shows that vaccination with rBipA induced high 
levels of rBipA-specific IgG. Similarly, rBipA-specific antibodies were also detected in serum 
from biofilm-vaccinated mice, while these were below the detection limit in serum derived 
from mice vaccinated with planktonic culture-derived membrane proteins (Figure 5A). Next, 
the ability of serum and nasal lavage (NL)-derived rBipA-specific antibodies to bind its native 
epitopes on the surface of Bvg+ and Bvg- B. pertussis was assessed by flow cytometry. We 
found significant IgG-mediated opsonization of Bvg+ B. pertussis using serum, but not NL, 
from rBipA-vaccinated mice (Figure 5B). For aP-vaccinated mice, strong opsonization of Bvg+ 
B. pertussis was observed with serum IgG and NL IgG and IgA (Figures 5B, 5C, and 5D). 
Both aP- and rBipA-induced antibodies were unable to bind Bvg- bacteria, which confirms 
the lack of expression of these antigens by Bvg--phase bacteria. These data show that rBipA 
vaccination-induced antibodies recognize the native BipA epitope. Since IgG binding alone 
does not necessarily reflect the quality of the subsequent antibody response (42), the subtype 
distribution of the opsonizing IgG molecules was also determined using a whole-cell ELISA 
(31). Analysis of the IgG1, IgG2a, and IgG2b response showed that rBipA and aP antigen-
specific antibodies were predominantly of the phagocytosis-mediating IgG1 subtype  IgG1 
antibodies (43, 44) (Figure 5E).
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Figure 5. Bacterial opsonization by BipA-specific antibodies. A) Post-immune mouse sera (day 28) 
were used to determine the amount of total IgG specific for recombinant BipA (rBipA) using an ELISA. 
Each symbol represents one mouse and the geometrical mean is represented by a horizontal line. 
Dashed lines indicate the lower limit of detection (93 ng/ml). *p<0.05; 1-tailed Wilcoxon Signed Rank 
Test. The binding of serum IgG (B) and nasal lavage IgG (C) and IgA (D) antibodies from vaccinated 
mice to Bvg+ or Bvg- grown B. pertussis B1917 was determined by flow cytometry. Bars represent the 
geometric mean ± 95% confidence interval (CI) of 6 individual mice. **P<0.005, ***P<0.0005 relative 
to PBS group; Kruskal-Wallis test followed by a Dunns post-hoc test (α= 5%). E) To determine the 
distribution of IgG subtypes, the amount of pertussis-specific IgG1, IgG2a, and IgG2b binding to Bvg+ 
grown whole B1917 cells was assessed. Each symbol represents one mouse and the geometrical 
mean is represented by a line. Dashed lines indicate the lower limit of detection (23, 4, and 27 ng/ml for 
IgG1, IgG2a, and IgG2b, respectively). For IgG1, a 1-tailed Wilcoxon Signed Rank Test was performed 
because IgG1 levels of the PBS mice were below the detection limit. IgG2a and IgG2b levels were 
statistically compared to the PBS mice using a 2-tailed Mann-Whitney U-test. *P<0.05, **P<0.005.
Discussion
The recent resurgence of B. pertussis infections is of significant concern. The observation that 
Prn negative strains are now increasingly being isolated from patients with whooping cough 
(12-14) highlights the importance of identifying novel pertussis antigens. All current B. pertussis 
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antigens used in aP vaccines have been derived from planktonic grown bacteria. In this study, 
we focused on a novel class of proteins which are upregulated in biofilms. Vaccination with 
planktonic and biofilm-derived proteins may target different steps in infection and broaden 
immunity. Whilst biofilm formation has been suggested to be important for successful B. 
pertussis infection (15, 16), the ability of biofilm-antigens to protect against infection has not 
been evaluated. 
We showed that mice immunized with membrane proteins derived from biofilm bacteria 
are protected against respiratory B. pertussis infection and that the degree of protection was 
not significantly different from mice immunized with planktonic culture-derived membrane 
proteins (Figure 1). This observation suggests that pertussis biofilms are a potential target for 
vaccination, similar to other respiratory pathogens such as Pseudomonas aeruginosa (45). To 
characterize the antigenic composition of a biofilm, we compared the biofilm and planktonic 
proteomes of a representative strain of the P3 lineage (B1917) which has recently spread 
worldwide (11). 
We found 48 proteins which were downregulated in biofilms. Whilst these proteins did not 
include any of the antigens present in current aPs, a relatively high proportion of these proteins 
represent Bvg+-phase, virulence-associated proteins (10). This suggests that heterogeneous 
populations are involved in infections (46), even with respect to virulence-associated proteins. 
Therefore, inclusion of highly expressed biofilm proteins in new vaccine formulations may 
enhance the efficacy of pertussis vaccines by broadening the immune response to different 
phases of infection. Sixty proteins were identified as more abundantly present in biofilms, the 
majority of which represented ribosomal proteins involved in protein synthesis. However, the 
majority of these ribosomal proteins were biofilm-upregulated only when compared to stationary 
growth, and were expressed at similar levels under mid-log conditions (Supplemental Table S1). 
This suggests that biofilm formation requires high levels of de novo synthesis of proteins, similar 
to mid-log bacteria (20, 47). Of these 60 proteins, only 11 were upregulated when compared 
to both mid-log and stationary planktonic growth conditions. Moreover, only two of these were 
predicted to be surface-accessible, i.e. a phospholipase (BP0878) and BipA. Although BP0878 
may also have vaccine potential (48), we only assessed the vaccine potential of BipA because 
it was more abundantly expressed under biofilm conditions. Further, BipA was also found up-
regulated in Tohama I biofilms relative to planktonic cultures suggesting that expression of 
BipA is a common signature of Bordetella biofilms  (18). BipA shows a large degree of amino 
acid sequence identity with the biofilm-associated proteins (Bap) of Staphylococcus aureus 
(49) and Acinetobacter baumannii (50), which mediate cell-to-cell interactions within biofilms 
(51) (36% and 33% identity, respectively). Importantly, vaccination with Bap derived from A. 
baumannii has been shown to protect against infection (52). BipA may play a similar role in B. 
pertussis biofilm formation during infection. Some clues towards a role for BipA during infection 
were established in this work. For instance, we showed that during natural infection, BipA 
was expressed at high levels in the lungs of mice and that infection resulted in BipA-specific 
serum antibodies in humans (Figure 3). Challenge experiments showed that vaccination with 
rBipA induced significant protection to lower respiratory tract infection (Figure 4), which was 
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associated with the presence of high amounts of opsonizing, protection-associated IgG1 
antibodies (43, 44) (Figure 5). Significant amounts of rBipA antibodies were also detected 
in serum from mice vaccinated with biofilm membrane proteins, but not in mice vaccinated 
with proteins derived from planktonic bacteria, suggesting that BipA is highly expressed in B. 
pertussis biofilms and immunogenic. An important question is how efficacious BipA will be in 
natural B. pertussis populations which consist of different strains. The strain used to assess 
the vaccine efficacy of rBipA, is a representative of the P3 lineage, the members of which 
have spread worldwide in the last 10-15 years replacing the resident P1 strains (11, 53). In 
many countries, P3 strains are found in frequencies of 60-100%. Further, immune escape 
from BipA antibodies seems unlikely, as in a worldwide collection of 343 B. pertussis strains, 
only one protein variant was found (designated BipA2) (53), which differed in only one amino 
acid from the BipA variant used in this study. Further research is needed to establish the exact 
mechanisms by which antibodies to biofilms and BipA in particular interfere with infection, and 
whether protection by BipA can be enhanced through the use of alternative vaccine adjuvants 
or vaccination routes. 
Membrane proteins extracted from biofilm or planktonic grown cells conferred protection 
in the mouse lung, while only the biofilm extract induced rBipA antibodies, albeit at lower 
levels compared to vaccination with rBipA. Clearly, these planktonic fractions harbor other 
protective antigens. Proteomic analyses of these fractions revealed high expression of many 
virulence associated factors, including those who have been shown to confer protection in 
humans (i.e. Ptx, Fim3, Prn and FHA), integral outer membrane proteins and autotransporters 
(Supplemental Table S1 and S2). Further fractionation of these samples may elucidate the 
distinct role of these antigens and reveal additional vaccine candidates.
Taken together, this work provides evidence that vaccination against B. pertussis biofilms 
induces protection to infection. Whilst further research is still needed to optimize immunity, a 
strategy by which multiple steps in infection are targeted, including biofilm formation, represents 
an attractive approach to improve pertussis vaccines. The inclusion of BipA in novel vaccines 
may thus provide an additional level of protection to current aPs and thereby enhance the 
efficacy of pertussis vaccination. 
Materials and Methods
Ethics statement
Animal experiments were approved by the Radboudumc Committee for Animal Ethics and 
conducted in accordance with the relevant Dutch legislation. Bacterial strains were collected 
by regional Medical Microbiology Laboratories from patients suspected of whooping cough and 
sent to the National Institute for Public Health and the Environment (RIVM) in the context of 
routine surveillance (as required by law). The strains were sent to the RIVM for confirmation of 
clinical diagnosis, species determination and subtyping. Strictly anonymized patient information 
was included, which was limited to age, sex and postal code. For this type of surveillance 
ethical evaluation or patient consent are not required. The strains have been used in previous 
studies (10).
Biofilm vaccination against pertussis | 127
4
Bacterial strains and growth conditions
For flow cytometry and qPCR analysis, B. pertussis strains were grown under Bvg+, Bvgi, and 
Bvg- conditions as described previously (10). For modulation of the BvgASR regulatory system, 
magnesium sulfate was added to cultures at a final concentration of 5 and 50 mM to induce Bvgi 
and Bvg- conditions respectively. In the absence of additional sulfate, the concentration of free 
sulfate is 0.02 mM, thereby inducing Bvg+ conditions. For proteomics, B. pertussis was grown 
under planktonic and biofilm conditions in chemically defined THIJS medium (26) essentially 
as described previously (20). Briefly, planktonic cultures were grown overnight in chemically 
defined THIJS medium supplemented with 0.2 mg/ml Heptakis-cyclodextrin (Sigma) and then 
re-inoculated into pre-warmed medium at an optical density at 620 nm (OD620) of 0.075. 
Planktonic cultures were harvested by centrifugation (15°C, 8000g, 20 min) at mid-exponential 
(17h) and stationary (40h) growth phases, washed with phosphate-buffered saline (PBS) and 
snap-frozen in liquid nitrogen. Biofilm cultures were carried out by using glass column reactors 
(diameter = 6 cm, h = 45 cm, IVA SA, Argentina) packed with flat polypropylene beads (300 g; 
diameter = 4.2 mm, h = 1.5 mm, with an average density of 0.901 g cm-3, Petroken, Argentina), 
which served as growth support. The bioreactors were inoculated with 200 ml of a planktonic 
culture of B. pertussis B1917 (OD620 of 1.0) grown in THIJS medium and incubated for 5 h at 
37°C to allow bacterial attachment to the beads. Then, the suspension was drained to remove 
unattached cells and 200 ml of fresh THIJS medium was added to each column. Bioreactors 
were incubated aerobically (0.1 liters min-1) at 37°C and the THIJS medium was refreshed 
at 24h intervals. For proteomic analysis, biofilm cells were harvested after 72h, when the 
biofilm achieved its mature structure. Beads were washed three times with sterile PBS buffer to 
remove unattached cells. Sessile cells were gently detached from beads by slight agitation in 
PBS buffer, pelleted by centrifugation (15°C, 8000g, 20 min ), washed twice and snap-frozen in 
liquid nitrogen. Sessile cell pellets were stored at -80°C and freeze-dried for protein isolation. 
Escherichia coli OverExpress™ C41(DE3) (Lucigen, USA), used for rBipA expression, 
was grown in Luria Bertani medium (LB) containing appropriate antibiotics (ampicillin, 
kanamycin and/or chloramphenicol at a concentration of 50 µg/ml) at 37°C. 
Proteomics analysis
Bacterial pellets from 10 ml of planktonic (mid-exponential or stationary) or biofilm cultures 
were lysed by sonication and used for the isolation of cytosolic and membrane protein fractions 
using the ReadyPrep Protein Extraction Kit Membrane I (Bio-Rad Laboratories, Hercules, CA, 
USA). The obtained soluble and insoluble fractions, respectively containing the cytosolic and 
membrane (-associated) proteins were purified using the ReadyPrep 2-D clean-up Kit (Bio-
Rad Laboratories). Finally, protein pellets were dissolved in 8M urea in 10 mM Tris-HCl pH 8.0 
and subjected to in-solution digestion and C18 reversed phase nano flow LC-MS/MS analysis 
as described in Supplemental Text S1. For vaccination experiments, membrane proteins were 
diluted in PBS as described below. 
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Recombinant BipA production
The entire DNA sequence of the bipA (BP1112) gene lacking the N-terminal signal sequence 
(amino acids 1-20) and membrane spanning domain (amino acids 21-66) was codon optimized 
for expression in E. coli, synthesized by GenScript (USA), and cloned into the pET28-TEVsite 
vector (modified from pET28a vector, Novagen, Denmark) to generate an N-terminally His6-
tagged BipA protein. rBipA expression from the pET28-TEVsite vector was induced in E. coli 
OverExpress™ C41(DE3) (Lucigen, USA) cultured to OD620 = 0.6-0.7 at 37 
oC by addition 
of 1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) for 3 hours. Induced cultures were 
harvested by centrifugation (4,000g for 15 minutes at 4°C) and enzymatically lysed by 
resuspending the pellet in Bacterial Protein Extraction Reagent (B-PER, Thermo Scientific, 
USA) containing 25 U/ml benzonase nuclease (Novagen, Denmark), 100 µg/ml lysozyme, and 
protease inhibitors (Roche, Germany), and incubating for 30 minutes at room temperature. The 
cells were disrupted further by sonicating the bacterial solutions (30 s pulse for 5 minutes at 
an intensity of 70%). Cell lysates were centrifuged (4,000 g for 30 minutes at 4°C) and pellets 
containing inclusion bodies dissolved in a buffer containing 20 mM sodium phosphate, 500 mM 
NaCl, 4 M urea and 20 mM imidazole and used for protein purification. His6-tagged rBipA was 
purified on a AKTA FPLC system using affinity chromatography on a HisTrap™ FF crude 1 ml 
column prepacked with Ni Sepharose™ 6 Fast Flow (GE Healthcare, Sweden). Bound rBipA 
was eluted in a single step elution with a buffer containing 20 mM sodium phosphate, 500 mM 
NaCl, 4 M urea and 500 mM imidazole. Fractions containing rBipA were pooled and protein 
concentrations were determined using the 2-D Quant Kit according the manufactures protocol 
(GE Healthcare, USA). rBipA was refolded by rapid 50-fold dilution in 10 mM Benzamidine, 1 
mM EDTA, 100 mM NaCL, and 50 mM Tris-HCL (pH8.8) as described (27). 
Protein samples obtained after IPTG induction, cell lysis, and purification were analyzed 
on 10% Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) gradient 
gels using Colloidal Coomassie staining and immune blotting. Colloidal Coomassie staining 
was performed as previously described (28). Briefly, SDS-PAGE gels were incubated for 3 
hours in staining solution consisting of 5% aluminum sulfate 14–18 hydrate, 10% ethanol, 
0.02% of Coomassie Brilliant Blue (CBB) G-250, and 8% phosphoric acid. Then, gels were 
destained by incubation for 30 min in 2% phosphoric acid and 10% ethanol and overnight 
incubation in water. For immune blotting, proteins were transferred to polyvinylidene difluoride 
(PVDF) membranes, blocked with PBS with 0.1% Tween-20, 2% skim milk powder, and 1% 
bovine serum albumin (BSA) (1 hour at room temperature) and incubated overnight with a 
1:2000 diluted Penta-His Antibody (Qiagen, Germany) at 4°C. After washing three times for 
5 minutes in PBS with 0.1% Tween-20, the membrane was incubated for 1 hour at room 
temperature with a goat-anti-mouse light chain Horseradish Peroxidase (HRP) antibody and 
washed again in a similar manner. Finally, immunoblots were developed using an enhanced 
chemiluminescence (ECL) substrate system (GE Healthcare, USA).
Vaccination
Individual groups of naïve, female 6-8 week old BALB/c mice (Charles River) were immunized 
Biofilm vaccination against pertussis | 129
4
subcutaneously on day 0 and 14 with 5 μg rBipA or 1 µg purified membrane proteins derived 
from planktonic or biofilm bacteria, mixed 1:1 in 1.3% alum adjuvant (Alhydrogel; Sigma). As 
a negative control, mice were immunized with a similar ratio of PBS and Alhydrogel, or with 
PBS alone. In order to compare efficacy to current aPs, one group of mice was immunized 
with 1/50th of the human dose (equals 1.16 µg of B. pertussis protein) of the commercial 
hexavalent acellular pertussis vaccine InfanrixTM (GSK, Belgium, 25 µg Ptx, 25 µg filamentous 
hemagglutinin, 8 µg pertactin). On day 35, mice were challenged by intranasal (i.n.) infection 
with B. pertussis strain B1917 (2×107 colony forming units (CFU) in a total volume of 40 µL). 
On day 38 and 42, the bacterial load in the nasopharynx (upper respiratory tract, URT) and 
the lungs (lower respiratory tract, LRT) was determined as described previously (29). Serial 
dilutions of the nasal lavages (NL) and lung homogenates were plated onto Bordet Gengou 
(BG) agar plates and incubated at 37°C for 3-4 days, after which the bacterial load was 
determined. Serum samples were collected on days 0, 28, 38, and 42. 
In vivo transcriptional analysis 
Groups of 4 female BALB/c mice (6-8 weeks old) were infected i.n. with B. pertussis strain B1917 
as described above. Mice were sacrificed after 7 days, after which bacteria were collected from 
the lungs through a bronchoalveolar lavage (BAL) with PBS and stabilized with 2 volumes 
of RNA Protect Bacteria Reagent (Qiagen). Total RNA was extracted using the RNeasy Mini 
kit (Qiagen) and contaminating genomic DNA was removed by DNase treatment (DNAfree, 
Ambion). Bacterial RNA was enriched and amplified using the MICROBEnrich (Ambion) and 
SensationPlus™ FFPE Amplification (Affymetrix) kits, respectively. Enriched RNA was reverse 
transcribed using the SuperScript® One-Cycle cDNA Kit (Invitrogen) and used for quantitative 
real-time PCR analysis. To determine relative expression levels, ΔCt values were calculated 
by subtracting the Ct value of the recA (BP2546) household gene from the Ct value of the 
target gene (30). The transcription data are expressed as 40-ΔCt value, with 40 representing 
the number of PCR cycles as detection limit. A 40-ΔCt value of 0 indicates that the gene is 
expressed at equal levels as recA, while lower values correspond to lower expression. 
Antibody analysis
Protein ELISA
IgG titers against rBipA in mouse and human sera were determined by enzyme-linked 
immunosorbent assay (ELISA) analysis. Microtiter plates (F96, MaxiSorpTM, Nunc-Immuno 
Module) were coated with 2 μg/ml rBipA in 50 μl PBS per well overnight at 4°C. Control ELISAs 
were performed with plates coated with 2 µg/ml Ptx in PBS (Kaketsuken, Kumamoto, Japan). 
Plates were washed with PBS with 0.05% Tween 20 (PBST) and then incubated for 1 h with 
PBS containing 1% BSA. Serial dilutions of mouse or human sera were added to the plates 
and incubated for 1 h at 37°C. After washing, alkaline phosphatase-conjugated secondary 
goat antibody directed to mouse IgG-Fc (Sigma-Aldrich) or human IgG (Southern Biotech) was 
added for 1 h at 37°C using a 1:2,500 and 1:1,000 dilution, respectively. After washing, 50 μl 
per well of p-nitrophenyl phosphate (pNPP, 1 mg/ml) in substrate buffer (10 mM diethanolamine 
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and 0.5 mM magnesium chloride, pH 9.5) was added and the absorbance was read at 405 nm. 
IgG concentrations in mouse serum were determined using absorbance data of a standard 
curve of 1-64 ng mouse IgG1 (Sigma) on wells coated with 2 µg/ml Rat anti-mouse Ig, kappa 
light chain (BD Pharmingen). Human serum titers were calculated by multiplying the highest 
dilution with an optical density >0.2 with the corresponding dilution factor, as a value >0.2 falls 
within the linear range of the ELISA curve.
Whole-cell ELISA
Binding of IgG1, IgG2a, and IgG2b to whole bacteria was measured using a whole-cell ELISA 
method adapted from Abdillahi and Poolman (31). Briefly, ELISA plates were coated with Bvg+ 
mid-log culture of strain B1917 suspended in PBS, washed (PBS containing 0.05% Tween 
20), blocked with 1% BSA/PBS, and incubated with serial dilutions of mouse serum. After 
washing, ELISA plates were incubated with horseradish peroxidase (HRP)-conjugated rat-
anti-mouse IgG1 (BD Pharmingen, 1:50,000 dilution), HRP-conjugated rat-anti-mouse IgG2a 
(BD Pharmingen, 1:10,000 dilution), or alkaline-phosphatase-conjugated rat-anti-mouse IgG2b 
(Southern Biotech, 1:2,000 dilution) for 1 h at 37°C. 3,3’,5,5’-Tetramethylbenzidine (TMB) 
substrate was added to each well for the HRP-conjugated antibodies, whilst pNPP substrate 
was used for AP-conjugated rat-anti-mouse IgG2b. Optical density was then measured on 
an ELISA plate reader (Tecan Infinite F50) at 450 and 405 nm for TMB and pNPP substrate, 
respectively. Antibody subtype concentrations were determined by comparison to standard 
curves with known concentrations of each IgG subtype. 
Opsonization
1% BSA/PBS was used for all dilutions. 106 CFU of Bvg+ and Bvg- B1917 were incubated with 
serum or nasal lavage (NL) samples from vaccinated mice for 30 min at 4°C. Bacteria were fixed 
in 2% paraformaldehyde and surface-bound IgG or IgA was detected using anti-mouse IgG-Fc 
or IgA α-chain-FITC-conjugated antibodies (Sigma-Aldrich) on a BD LSRII flow cytometer (BD 
Biosciences). The amount of surface-bound antibodies was expressed in arbitrary units as a 
fluorescence index (FI), calculated by multiplying the geometric mean fluorescence intensity 
by the percentage of FITC-positive bacteria (32). Data were analyzed using FlowJo version 
7.6.5. 
Statistical analyses
A 2-tailed Mann-Whitney U test was used for comparison of bacterial load in NL and lung ho-
mogenate samples between PBS-vaccinated mice and rBipA or membrane protein-vaccinated 
mice. A Kruskal-Wallis test followed by a Dunns post-hoc test (α= 5%) was used for compar-
ison of antibody-mediated opsonization by serum and NL sample between PBS-vaccinated 
mice and rBipA-vaccinated mice. A 1-tailed Wilcoxon Signed Rank Test was used to determine 
whether ELISA measured IgG levels were significantly above the detection limit. A student’s 
t-test with Welch’s correction was used to compare transcription levels. All statistical analyses 
were performed using the GraphPad Prism software program, version 5.0, where p<0.05 was 
considered significant. 
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Text S1- Supplemental Methods
In-solution digestion
Cytosolic and membrane protein extracts (15 µg) present in 8M urea in 10 mM Tris-HCl 
pH 8.0 were subjected to disulfide reduction by adding 1 µL 10 mM dithiothreitol (DTT) and 
incubating for 30 min at RT prior to alkylation by adding 1 µL of 50 mM of iodoacetamide 
(IAA) in 50 mM Ammonium bicarbonate (ABC) and incubating for 20 min at RT. After digestion 
with Endoproteinase LysC (1:50 w/w) (Wako Chemicals, USA) for 3 hours at RT, the solution 
was diluted to 2M urea with ABC and incubated overnight in the presence of sequencing 
grade modified trypsin (1:50 w/w) (Promega, Madison, WI) at 37 oC for complete digestion. 
Subsequently, the peptide mixture was concentrated and desalted using stop and go elution 
(STAGE) tips as described by Rappsilber and coworkers (1). Briefly, the acidified peptides were 
bound on activated C18 reversed phase material fixed in a standard pipettor tip, washed with 
0.5% acetic acid and eluted with 80% acetonitrile 0.5% acetic acid. Finally, the acetonitrile buffer 
was removed using a SpeedVac (Savant DNA 110 SpeedVac; Global Medical Instruments) 
after which the peptides were dissolved in 0.5% acetic acid for nLC-MS/MS analysis. 
C18 Reversed phase LC-MS/MS analysis
The C18 reversed phase nanoflow LC-MS/MS analyses were performed using a Proxeon 
nanoflow liquid chromatograph (Easy-nLC, Thermo Fisher, Bremen, Germany) coupled 
on-line to a 7T linear quadrupole ion trap Fourier transform ion cyclotron resonance mass 
spectrometer (LTQ-FT Ultra, Thermo Fisher Scientific, Bremen, Germany) as described 
(2). Briefly, chromatographic separations were performed using a 15-cm fused silica emitter 
Biofilm vaccination against pertussis | 135
4
(PicoTip emitter; tip, 8 ± 1 μm; internal diameter, 100 μm; FS360-100-8-N-5-C15; New Objective) 
packed in-house with reverse phase ReproSil-Pur C18AQ 3 μm resin (Dr. Maisch GmbH). 
Peptides were eluted from the column using a linear gradient of 8-16% acetonitrile in 75 min 
and 16-32% acetonitrile in 55 minutes at a flow rate of 300 nL/min. The LTQ-FT ultra mass 
spectrometer was programmed to acquire a survey MS scan in the ICR cell (350-1600 m/z, 
R=100.000 FWHM @ 400 m/z, 1E6 ions) with parallel MS/MS spectra acquisition of the top 
4 most abundant ions in the linear ion trap (30% normalized collision energy, 30ms activation 
time, activation Q=0.250, 3000 ions). Dynamic exclusion was enabled to prevent re-analyses 
of peptides during the analysis (exclusion duration: 180 seconds, early expiration enabled: 10 
scans with S/N=2). Only peptide ions with charge states z=2+ and 3+ were considered for MS/
MS spectra acquisition.
Database searching and result validation
Database searches and validation of results was performed as described (2). Briefly, the raw 
data files acquired by the nLC-MS/MS instrument were converted to mascot generic files using 
DTA supercharge (3). Peptides and proteins were identified using Mascot software (Mascot 
2.2; Matrix Science) to search a local copy of an in-house created pan-genomic B. pertussis 
protein database (based on the sequence data as described (4)) supplemented with known 
contaminant protein sequences (e.g. Trypsin, LysC and human skin proteins). The following 
parameters were used: 15 ppm precursor mass tolerance and a 0.5 Da fragment ion mass 
tolerance. Furthermore, one missed trypsin cleavage was tolerated and carbamidomethylation 
of cysteines was set as a fixed modification. Variable modifications included oxidation of 
methionine residues and N-terminal protein acetylation. The Mascot search results were 
subjected to heuristic iterative protein false discovery rate validation method of Weatherly to 
achieve a 1% false discovery rate or better (5). A protein was considered identified when it was 
detected in at least 3 out of 4 biological replicates for the planktonic condition and 2 out of 3 
biological replicates for the biofilm condition. Exponentially modified PAI (emPAI) scores were 
calculated as described (6).
Label-Free Quantitative analysis 
The IDEAL-Q (ID-based Elution time Alignment by Linear regression Quantification) software 
program was used for the label-free quantitative analysis of the nLC-MS/MS data (7). The 
cytosolic and membrane protein fractions were processed independently. Semi-quantitative 
information was extracted from the LC-MS data and the Mascot search results by extracted 
ion currents. Details of the IDEAL-Q method are described by Tsou and coworkers (7). Briefly, 
IDEAL-Q attempts to extract ion current information for every identified peptide (identified in 
any analysis) even in the absence of Mascot identification data for a peptide in some of the 
analyses. The following peptide ion information is used by IDEAL-Q to pinpoint ions across 
files where no identification information is available: mass to charge ratio (m/z), charge state 
(z), normalized retention time, and isotopic pattern. The combination of all of the above 
mentioned peptide ion characteristics allow IDEAL-Q to identify ions when no Mascot data is 
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available for a specific analysis. Settings used by IDEAL-Q include 30 ppm mass tolerance, 
nondegenerate unique peptides only, and Dixon’s outlier test to eliminate peptide ratio outliers 
for each proteins at 95% significance level. Protein ratios were calculated as the weighted 
average of all respective peptide ratios. 
Processing semi-quantitative proteomics data
Protein abundance ratios were generated by IDEAL-Q for each biological replicate relative to 
mid-exponential sample one and normalized using the median ratio of all proteins quantified. 
The normalized ratios were Log2 transformed and used for a One-Way ANOVA with the 
maximum number of permutations (=34650) to identify proteins that were significantly different 
(p-value ≤0.05) between the three groups. Proteins that were found to be significantly different 
based on less than 3 out of 4 biological replicates (or 2 out of 3 biological replicates for the 
biofilm condition) in one of the groups, were excluded. The p-values of all the remaining 
proteins (both significant and non-significant) were corrected for multiple testing using the 
FDR method of Storey and Tibshirani to obtain q-values (8). Proteins with a q-value ≤ 0.05 and 
a fold change of ≥3 or ≤-3 were considered biofilm-regulated. Biofilm-regulated proteins were 
aggregated based on function (main role according to the TIGR B. pertussis genome and B. 
bronchiseptica database) and subcellular localization (predicted using PSORTb v3.0 (9)) and 
significant enrichment in a certain class was determined by Fisher’s exact test.
Validation proteomic datasets
Proteomics allowed us to identify a total of 749, 729, and 825 proteins in the mid-log, stationary, 
and biofilm cultures, respectively, representing 21-24% of the predicted total of 3449 protein-
coding ORFs in the B. pertussis genome. Of the 887 detected proteins, 645 (73%) were identified 
under all growth conditions (Supplementary Table S2). Of the 749 proteins identified in the 
mid-log planktonic samples, 238 (32%) proteins were found only in the cytosolic fraction, 102 
(14%) only in the membrane fraction, and 409 proteins (55%) were identified in both fractions. 
In the stationary planktonic samples, 355 of the 729 proteins (49%) were identified in both 
fractions whereas 220 (30%) and 154 (21%) proteins were found uniquely in the cytosolic and 
membrane protein fraction respectively. Of the 825 proteins identified in the biofilm samples, 
222 (27%) proteins were found only in the cytosolic fraction, 129 (16%) only in the membrane 
fraction, and 474 proteins (57%) were identified in both fractions.
Correct fractionation of the cytosolic and membrane proteins was confirmed using the 
protein abundance emPAI values of proteins with a strongly predicted cytosolic and outer 
membrane localization (determined using PSORTb 3.0). This revealed clear enrichment (high 
emPAI scores) for cytosolic predicted proteins in the cytosol fractions and membrane-predicted 
proteins in the membrane fractions of all samples in both (data not shown). Furthermore, 
western blot analysis revealed that the outer membrane protein BP0840 was exclusively 
present in the membrane protein fraction of all samples (data not shown). This data indicates 
correct protein fractionation of all samples. 
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Abstract 
Pertussis (or whooping cough) has re-emerged in vaccinated populations and adaptation of 
the etiologic agent, Bordetella pertussis may be one of the causes for this phenomenon. Both 
transcriptomic and proteomic studies have been used to study B. pertussis adaptations. How-
ever, most of these studies have focused on in vitro grown bacteria. Here we present the first 
comprehensive transcriptomic analyses of B. pertussis isolated from the upper and lower re-
spiratory tract of mice. We focused on genes affected by the Bordetella virulence gene locus 
(bvgASR), as it plays a central role in the regulation of virulence-associated genes. By varying 
in vitro growth conditions, different Bvg-controlled phases can be induced in B. pertussis char-
acterized by different expression profiles: Bvg+, Bvgi, and Bvg-. It has been assumed that the 
Bvg+ and Bvgi phase are important for infection, while the Bvg- phase may be a remnant from 
the time when B. pertussis had an environmental stage. Bvg- phase antigens are expressed 
in vivo, however, and we show that membrane fraction derived from Bvg+ and Bvg- phase 
bacteria are able to confer protection in the mouse lung. We further explore the role of the 
three Bvg phases by transcriptomic analyses of B. pertussis isolated from the upper and lower 
mouse respiratory tract. Gene expression analysis revealed major differences compared to 
in vitro growth, with 13% and 17% of all genes being significantly up- or downregulated by at 
least 4-fold, respectively. In addition, distinct gene signatures were found between the upper 
and lower respiratory tract, with multiple virulence factors being more highly expressed in the 
nose. These data provide the first comprehensive analysis of how B. pertussis adapts to local 
conditions during the course of infection and may help in designing more effective vaccines to 
target B. pertussis.
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Introduction
Infection with the Gram-negative bacterial pathogen Bordetella pertussis can cause whooping 
cough (or pertussis) in susceptible humans. Pertussis in humans is primarily an infection of 
the upper respiratory tract, while progression to the lungs mainly occurs in severe cases. 
In order to reduce severe morbidity and mortality in infants, the first generation of pertussis 
vaccines was developed and implemented in national childhood immunization schemes in the 
1940s-1960s. These whole-cell vaccines (wPs), consisting of heat- and formalin-inactivated 
bacteria, were used in industrialized countries until the 1990s. Although wPs were effective, 
concerns regarding their reactogenicity led to the development of second generation pertussis 
vaccines with a better safety profile. These acellular pertussis vaccines (aPs) consist of highly 
purified and chemically inactivated protein antigens and have nearly ubiquitously replaced 
wPs in industrialized countries in the last 10-20 years. Although currently licensed aPs are less 
reactogenic than wPs it is now clear that immunity induced by aPs is less effective compared to 
wPs with respect to protection against colonization and the duration of immunity (1-3). These 
short comings of aPs are aggravated by the emergence of B. pertussis strains which are less 
affected by host immunity (reviewed in (4)).
The resurgence of pertussis has stimulated research into the function, regulation and role 
in protection of B. pertussis antigens. The expression of most virulence factors is controlled 
by the sensory transduction bvgASR system. This system transduces environmental signals, 
such as temperature, and concentrations of small molecules such as nicotinic acid and sulfate, 
to gene regulation (reviewed in (5)). E.g. in vitro growth of B. pertussis in the presence of low 
(< 0.2 mM), medium (5 mM) or high sulfate (50 mM), induced the expression of different sets of 
genes, defined as Bvg+, Bvgi, and Bvg-repressed genes, respectively (5, 6). While B. pertussis 
bacteria in the Bvg+ and Bvgi phase are able to colonize mice, bacteria locked in the Bvg- 
phase are defective in colonization (7, 8). Based on these studies, it has long been assumed 
that the Bvg+ phase is essential for infection, while Bvg-repressed genes are a remnant from 
the time when B. pertussis had an environmental niche. Consequently, vaccine developers 
produced wPs based on liquid cultures of Bvg+ phase bacteria genes and aPs containing 1 
to 5 Bvg+ antigens. However, during infection, B. pertussis has to adapt to local conditions on 
the host respiratory mucosa, and changes in nutritional status, quorum sensing, temperature, 
pH, immune factors etc. are likely to have an impact on the expression profile of B. pertussis. 
Here, we demonstrate that not only vaccination with antigens expressed in the Bvg+ 
phase, but also membrane proteins from the Bvg- phase can protect against infection, raising 
the possibility that Bvg-repressed antigens may induce protective immunity and hence may be 
expressed during infection. Although expression and regulation of B. pertussis genes has been 
extensively studied with in vitro grown bacteria, little data are available from bacteria grown in 
vivo. Here, we examined the in vivo bacterial transcriptional response during infection of mice. 
We show that almost a third of all genes in the B. pertussis genome is differentially expressed 
during infection as compared to growth under laboratory conditions. Furthermore, we found 
that several Bvg-repressed genes were highly expressed in vivo, providing further evidence 
that the Bvg- phase may play a role during infection. Finally, this approach identified several 
142 | Chapter 5
genes that were exclusively expressed during infection, which may represent attractive novel 
vaccine candidates. Taken together, this study provides the first comprehensive analysis of 
how B. pertussis adapts to local conditions during the course of infection, which may help 
facilitate in designing more effective vaccines to target B. pertussis.
Results
Protective antigens are expressed under both Bvg+ and Bvg- conditions
Although the role of Bvg+ phase antigens in protective immunity has been well-studied, less 
is known about the ability of Bvg- phase antigens to confer protection. Here we compared the 
ability of membrane fractions derived from Bvg+ and Bvg- phase bacteria to confer protection. 
B. pertussis strain B1917, belonging to the globally dominant P3 lineage (9, 10) was cultured 
under Bvg+ (low sulfate) and Bvg- (high sulfate) conditions (6). Bacteria were harvested and 
cytosolic and membrane or membrane-associated proteins were extracted (11). The membrane 
fractions were adjuvanted with aluminum hydroxide and the equivalent of 1 µg of protein was 
used to vaccinate naïve female BALB/c mice twice by subcutaneous injection with two-week 
intervals. For comparison, mice were vaccinated with a 3-component aP (Infanrix) or adjuvant 
only. Immune mice were then challenged intranasally with strain B1917, after which the lung 
and nose bacterial load was determined three and seven days later. 
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Figure 1. Immunization with membrane proteins derived from Bvg+ and Bvg- cultures protects 
against infection. Naïve adult female BALB/c mice were immunized by subcutaneous injection with 1 
µg of membrane proteins purified from Bvg+ and Bvg- cultures. In parallel, mice were vaccinated with 
adjuvant alone (Alum), or with an acellular pertussis vaccine (aP) containing 0.5 µg Ptx, 0.5 µg FHA and 
0.16 µg Prn. Immunized mice were infected intranasally with 2×107 CFU of B. pertussis strain B1917 
and the bacterial load was assessed in the lungs and nose three (A and C) and seven (B and D) days 
after challenge. Each symbol represents one mouse. Horizontal lines represent the mean. Dashed lines 
indicate the lower limit of detection. *P<0.05, **P<0.005 relative to Alum mice; 2-tailed Mann-Whitney 
U test.
Mice vaccinated with aP showed a strong reduction (>220-fold (P = 0.001)) in lung CFUs 
at both time-points, as compared to mice treated with adjuvant only (Figure 1). After three 
days, mice vaccinated with either Bvg+ or Bvg- membrane proteins showed a significant and 
comparable ~10-fold (p = 0.001) reduction in lung CFUs compared to the alum control (Figure 
1A). At seven days after infection, a more pronounced 107- (p = 0.005) and 16-fold (p = 0.001) 
reduction in bacterial load in the lungs was observed for Bvg+ and Bvg- membrane proteins, 
respectively (Figure 1B). Although lower CFU’s were recovered from the Bvg+-vaccinated 
group compared to the Bvg--vaccinated group at day seven, the difference was not significant 
(p = 0.067). Furthermore, none of the vaccinated mice showed reduced bacterial load in the 
upper respiratory tract (Figure 1C & D). Taken together, these data suggests that antigens 
that are expressed in the Bvg- phase, which include Bvg-repressed antigens, may also confer 
protection in the lungs. The striking differences in protection observed between the upper and 
the lower respiratory tract may point to a different mechanism of immunity required for each 
site.
Transcriptional profiling of B. pertussis during respiratory infection
In order to understand how B. pertussis adapts to local conditions during infection and how this 
affects the differential expression of antigens, we investigated the global in vivo transcriptional 
response of B. pertussis in mice. Naïve adult BALB/c mice were infected intranasally with B. 
pertussis strain B1917 and B1920, two clinical isolates derived from the P3 and P1 lineages 
which dominated globally after and before the 1990s, respectively (6, 9, 12). Three and seven 
days later, bacteria were flushed from the upper respiratory tract (nasal lavage; NL) and the 
lower respiratory tract (broncho-alveolar lavage; BAL) and used for transcriptional analysis. 
These time points were chosen to reflect early and late stages of infection (13). At least three 
independent biological replicates were obtained for each strain and anatomical location, except 
for B1920 from the nasal cavity at day three (two replicates) and B1917 from the nasal cavity at 
day seven (0 replicates), due to low RNA yield. We have previously analyzed the transcriptome 
of these strains under different in vitro Bvg-conditions, using sulfate concentrations to modulate 
the Bvg-phase (6). Here, we used these data to identify differences in gene expression between 
in vivo and in vitro conditions. 
To explore global gene expression patterns, a principal component analysis (PCA) 
was performed using the expression values of all genes that we have previously identified 
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as being regulated by Bvg in vitro by at least 2-fold (Bvg+ and Bvgi vs. Bvg-). Although we 
have previously found differences in Bvg-regulation between the strains B1917 and B1920 
(6), the in vivo gene signatures from these strains clustered strongly together. Consequently, 
we were unable to identify strain-specific gene signatures during infection. In order to increase 
the statistical power of our expression analysis, we therefore pooled the expression data of 
the two strains. The PCA resulted in a very distinct dimensional segregation of in vivo and in 
vitro growth conditions (Figure 2), indicating that the global gene expression pattern of in vivo 
bacteria is highly distinct from in vitro bacteria. As expected, for in vitro grown strains, Bvg+ 
and Bvgi conditions clustered distinctly from the Bvg- condition (Figure 2), confirming that the 
Bvg- phase has a very distinct expression profile.
Figure 2. Clustering of in vivo and in vitro samples based on Principal Component Analysis. The 
in vivo (nasal lavage, NL; and broncho-alveolar lavage, BAL) and in vitro samples (Bvg-, Bvgi, Bvg+) 
of B. pertussis strains B1917 and B1920 are plotted based on the bvg-regulated expression values of 
their transcriptome, with each square representing one sample. The plotted location is based upon the 
correlation of each sample relative to the others. 
To identify pathways that were differentially regulated during infection, we initially grouped all in 
vitro conditions (Bvg+, Bvgi and Bvg-) and compared this to the combined in vivo conditions (NL 
and BAL), combining the two strains and time-points. Using a 4-fold cut-off, we found that 465 
genes were upregulated and 605 genes down-regulated during infection compared to in vitro 
growth. Functional category enrichment of these differentially expressed genes suggested 
that infection was associated with a clear down-regulation of several central metabolic 
pathways, protein production and LPS biosynthesis (Figure 3). Conversely, pathways involved 
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in chemotaxis and flagellar assembly, ABC transport systems, and amino acid and fatty acid 
metabolic pathways appeared to be upregulated (Figure 3). Furthermore, 68 and 22 putative 
pseudogenes were, respectively, specifically up- and down-regulated under in vivo conditions 
(data not shown).
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Figure 3. Functional categorization of genes differentially expressed between in vitro and in vivo 
conditions. The genes differentially expressed (>4-fold) between in vivo and in vitro conditions were 
enriched for functional categories based on KEGG pathways using bpe (B. pertussis) KEGG identifiers. 
Asterisks indicate statistically significant enrichment of genes in a certain class. * P<0.05.
 
To further understand how B. pertussis modulates its gene expression during infection, 
we individually compared all five conditions (Bvg+, Bvgi, Bvg-, NL, and BAL). This approach 
yielded a total of 1622 differentially expressed genes (4-fold cutoff). In order to visualize 
transcriptional similarity between biological samples, hierarchical clustering (HCL) analysis 
was performed using this gen set. HCL showed very strong transcriptional segregation 
between in vivo samples on the one hand and in vitro samples on the other hand (Figure 4), 
which in line with the PCA described above. By partitioning the 1622 genes based on mean 
expression values using K-means clustering into 15 expression profiles we were able to study 
the characteristics of gene clusters. For instance, cluster 6, representing 53 genes, was very 
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strongly induced under the in vitro Bvg+ and Bvgi conditions, but only weakly expressed (Log2 
signal intensity (SI) < 9) during infection. Interestingly, this cluster contained several virulence 
(-associated) factors, including 23 genes of the type III secretion system (T3SS), fimbrial 
genes (fimBC), Bordetella intermediate protein A (bipA), autotransporter subtilisin-like protease 
(sphB1), virulence regulatory genes (bvgR and bvgS) and toxins such as adenylate cyclase 
(cyaA locus), a complement resistance protein (brkA), dermonecrotic toxin (dnt) and several 
pertussis toxin transport genes (Figure 4). A second gene cluster, which was also induced 
under Bvg+ and Bvgi conditions (cluster 13, representing 20 genes) was more highly expressed 
in vivo (Log2SI > 9) and contained virulence factors such as the adhesins pertactin (prn) and 
filamentous hemagglutinin (fhaB), tracheal colonization factor (tcfA), the autotransporter Vag8, 
the T3SS toxin BteA and pertussis toxin subunits (Figure 4 & Table 1). Significantly, this cluster 
contained three aP antigens: Prn, FHA and Ptx.
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Figure 4. Clustering analysis of differentially expressed genes. Heat map showing hierarchical 
clustering of in vitro (Bvg-, Bvgi, and Bvg+) and in vivo (nasal lavage (NL) and bronchoalveolar lavage 
(BAL)) samples based on the 1622 genes that were ≥4-fold differentially expressed between all five 
conditions. Hierarchical clustering of the samples and the genes was performed using Pearson (X-axis) 
and K-means correlations (Y-axis), respectively. Gene expression levels are color-coded from low 
expression in blue to high expression in yellow based on centered Log2(signal intensity) values, with -4, 
0, and 4 representing Log2SI values of 5, 9, and 13, respectively. 
Besides the expression of virulence-activated Bvg+- and Bvgi-phase genes, we also found 
a cluster of Bvg-repressed genes (cluster 5, representing 20 genes) with in vivo expression 
levels that were almost similar to the in vitro Bvg- condition, including nine genes involved 
in capsule production (Figure 4). In line with the observation that Bvg-repressed genes may 
provide protection in the lungs (Figure 1), this data provides further evidence that expression 
of Bvg-repressed genes may in fact not be redundant during infection.    
Table 1: Virulence-associated genes highly expressed under in vivo conditions (cluster 13, 
Figure 4)
General gene information
Predicted 
localization
Gene expression relative to Bvg- 
ORF Gene Product Bvg- Bvgi Bvg+ BAL NL 
BP0500 bteA t3ss toxin E 1.0 12.4 5.4 9.8 6.8
BP0856 bfrD TonB-dependent receptor for iron transport Om 1.0 41.6 28.2 15.5 11.0
BP1054 prn pertactin E 1.0 36.2 41.4 6.9 7.3
BP1201 tcfA tracheal colonization factor E 1.0 143.6 84.2 5.0 5.5
BP1879 fhaB filamentous hemagglutinin E 1.0 93.5 99.1 3.7 3.1
BP1880 fimA fimbrial protein (pseudogene) E 1.0 99.8 92.0 21.1 24.1
BP1883 fimD fimbrial adhesin E 1.0 36.0 25.6 3.6 7.3
BP2247 bscK conserved hypothetical protein Cm 1.0 19.7 15.1 5.9 6.9
BP2315 vag8 autotransporter E 1.0 65.3 32.5 6.7 15.5
BP2924 exported protein P 1.0 172.4 137.1 6.6 9.0
BP2925 conserved hypothetical protein C 1.0 66.6 27.6 8.7 9.3
BP3785 ptxD pertussis toxin subunit 4 E 1.0 82.8 37.6 10.2 12.1
BP3786 ptxE pertussis toxin subunit 5 E 1.0 74.0 46.5 5.3 14.2
BP3787 ptxC pertussis toxin subunit 3 E 1.0 88.3 50.2 3.0 7.3
BP3788 ptlA pertussis toxin transport protein Cm 1.0 48.2 36.4 12.7 19.8
BP3790 ptlC pertussis toxin secretion protein Cm 1.0 63.8 55.8 6.0 6.3
BP3791 ptlD pertussis toxin secretion protein Cm 1.0 47.9 44.1 8.5 14.4
BP3792 ptlE pertussis toxin secretion protein Un 1.0 92.0 83.9 1.6 2.2
BP3794 ptlG pertussis toxin secretion protein Un 1.0 63.5 57.6 17.7 21.0
Abbreviations; BAL, broncho-alveolar lavage; C, cytoplasmic; Cm, cytoplasmic membrane; E, 
extracellular; NL, nasal lavage; Om, outer membrane ORF, open reading frame; Un, unknown. Gene 
expression is expressed as the fold change compared to the average Bvg- expression values (set to 
1.0). 
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Distinct gene signatures in the upper and lower respiratory tract
Although PCA using the expression values of all bvg-regulated genes (2-fold cutoff) was not 
able to discriminate between NL and BAL samples (Figure 2), hierarchical clustering of the 
samples using Pearson based on all 1602 differentially expressed genes (4-fold cutoff) did 
result in separate clusters (Figure 4). This led us to compare gene expression between NL 
and BAL at three and seven days after infection, using a four-way comparison in which the two 
strains were grouped for each condition. This strategy allowed us to identify both temporal and 
spatial differences in gene transcription. 
Temporal differences in NL gene expression were minimal, with only one hypothetical 
gene (BP3372) being differentially expressed between day 3 and 7. In contrast, a distinct 
separation was observed in the BAL (Figure 4), with 28 and 53 genes being more highly 
expressed at day 3 and 7, respectively. Functional classification indicated that ribosomal genes 
were significantly upregulated in the BAL at day 7 (N = 12, 24.5%, p < 0.001), suggesting 
increased metabolic activity at later stages of infection. Of note, the complement evasion 
protein Vag8 was also more highly expressed on day 7. 
Table 2: Virulence-associated genes differentially expressed between the NL and BALtract
General gene information
Predicted 
localization
Gene expression relative to BAL day 
(d) 3
ORF Gene Product BAL d3 BAL d7 NL d3 NL d7
BP1878 bvgA virulence factors transcription regulator C 1.0 2.4 3.2* 2.9
BP1880 fimA fimbrial protein (pseudogene) E 1.0 3.0* 2.4* 1.3
BP1883 fimD fimbrial adhesin E 1.0 1.8 3.2* 2.1
BP2231 t3ss exported protein Un 1.0 1.0 2.2* 1.9**
BP2233 type III secretion chaperone Un 1.0 5.8* 7.5* 5.4
BP2234 brpL RNA polymerase sigma factor C 1.0 1.9 2.3* 1.1
BP2237 bscU type III secretion protein Cm 1.0 1.4 2.2* 1.4
BP2238 bscT type III secretion protein Cm 1.0 1.4 3.5* 3.2**
BP2239 bscS type III secretion protein Cm 1.0 1.3 2.6* 2.0
BP2240 bscR type III secretion protein Cm 1.0 1.6 4.1* 3.5**
BP2245 bscN ATP synthase in type III secretion system C 1.0 3.0 4.1* 2.4
BP2246 bscL type III secretion protein C 1.0 1.7 2.2* 1.6
BP2256 bsp22 type III secretion secretion tip protein E 1.0 1.6 3.9* 3.4
BP2315 vag8 autotransporter E 1.0 3.2* 4.0* 3.9
BP3439 dnt dermonecrotic toxin C 1.0 0.9 2.0* 1.5**
BP3554 risA response regulator protein C 1.0 0.8 2.7* 1.3
BP3786 ptxE pertussis toxin subunit 5 E 1.0 1.8 4.0* 2.8
BP3787 ptxC pertussis toxin subunit 3 E 1.0 1.3 3.5* 1.9
BP3788 ptlA pertussis toxin transport protein Cm 1.0 2.4* 2.4* 2.2
BP3791 ptlD pertussis toxin secretion protein Cm 1.0 1.6 2.0* 2.2
Abbreviations; BAL, broncho-alveolar lavage; C, cytoplasmic; Cm, cytoplasmic membrane; E, 
extracellular; NL, nasal lavage, ORF, open reading frame; Un, unknown. Gene expression is expressed 
as the fold change compared to the average BAL d3 expression values (set to 1.0). Asterisks indicate 
a statistically significant difference compared to BAL d3. Two asterisks indicate a statistically significant 
difference compared to BAL d7.
In vivo gene expression in Bordetella pertussis | 149
5
Analysis of spatial gene signatures identified 147 and 199 genes with increased 
expression at day 3 in the BAL and NL, respectively. The 147 genes upregulated in the BAL 
were significantly enriched in metabolic pathways (N = 47, p < 0,001), while the 199 genes 
upregulated in the NL were characterized by a higher expression of ribosomal (N = 33, p < 
0,001), oxidative phosphorylation (N = 14, p < 0,001), bacterial secretion system (N = 11, 
p < 0,001), and protein export (N = 5, p = 0,037) genes. In addition, virulence-associated 
genes, such as virulence regulatory genes (bvgA and risA), vag8, fimD, dnt, T3SS genes 
including the cytotoxic effector bsp22, and pertussis toxin subunit (ptxC and E) and transport 
(ptlA and D) genes (Table 2) were also upregulated in the NL. On day 7, there were 229 
and 186 genes identified with a 2-fold increased expression in the BAL and NL, respectively. 
Genes upregulated in the BAL were significantly enriched in microbial metabolism in diverse 
environments (N = 23, p = 0,038). Among the 186 genes with increased expression in the NL, 
no pathways were significantly upregulated.
Discussion 
To understand the resurgence of B. pertussis, most studies to date have focused on pathogen 
adaptation (reviewed in (4)) and the switch from wPs to aPs. It was shown that wPs and aPs 
induce different types of immune responses and that protective immunity induced by aPs is of 
shorter duration compared to wPs vaccines (1, 2, 14-18). Further, a number of studies have 
compared in vitro grown strains by proteomics and transcriptomics (6, 19, 20). In contrast, 
there are relatively few studies that have focused on how B. pertussis adapts to the host during 
infection and escapes or delays clearance by the immune system (21-24). Here we show that B. 
pertussis changes its expression profile during infection of mice. A comprehensive comparison 
to in vitro gene expression of the different Bvg phases identified dramatic differences during 
infection. In this regard, it is important to indicate that gene expression was measured on 
bacteria derived from nasal and broncho-alveolar lavages, which mainly consist of loosely 
attached bacteria. However, complex bacterial communities such as biofilms (25-27) or 
intracellular bacteria ((28, 29)) may also be present during infection, and alternative sampling 
methods may be required to include these subpopulations in the analysis. Nonetheless, this 
study provides a first insight into the B. pertussis gene repertoire and pathways that are required 
during respiratory infection in mice. 
For decades, the Bvg+ phase has been the leading focus to study the virulence of B. 
pertussis, as almost all (known) virulence factors are maximally expressed under this condition 
(5, 30). Principal component and hierarchical clustering analysis showed that the in vivo 
conditions most closely resembled the in vitro Bvg+ and Bvgi condition, as compared to the 
Bvg- condition (Figure 2 and 4). Several of the most well-studied virulence genes were variably 
expressed during infection (Figure 4). For instance, current aP antigens (fhaB, prn, and ptx), 
tcfA, vag8, and bteA were expressed at a higher level, while bvgR/S, several T3SS genes, 
fimBC, sphB1, bipA, cyaA, brkA, and dnt were expressed at a lower level during infection. 
Similar to our data, high expression of fhaB, and bteA has also been observed during B. 
bronchiseptica infection in rats (21). Conversely, cyaA is highly expressed by B. bronchiseptica 
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in rats (21) and by B. pertussis in humans and baboons (22), indicating that expression levels 
can vary based on the type of Bordetella strain or animal model used. Nonetheless, variable 
virulence gene expression during infection appears to be a common theme for B. pertussis, 
as it was also observed in a previous study using a recombinase-based in vivo technology 
(RIVET) approach (24). Moreover, the ability to variably express virulence genes was shown 
to be important for successful intranasal infection in mice (31), suggesting that the ability to 
change the level of expression of virulence factors is essential for infection.  
Although our findings suggest that bacteria are predominantly in the Bvg+/Bvgi phase 
during infection, two findings presented in this study also point towards a role for the Bvg- phase 
during infection. First, vaccination with membrane proteins isolated from Bvg- phase bacteria 
induced protection against intranasal challenge (Figure 1). This suggest that protective antigens 
are expressed during the Bvg- phase, a hypothesis further supported by the observation that 
vaccination with outer membrane vesicles derived from Bvg- phase B. pertussis confers 
protection (32). Further evidence for a role of the Bvg- phase in pertussis pathogenesis is that 
several Bvg-repressed genes were found to be expressed during infection, which is in line 
with a recent study that showed that Bvg-repressed polysaccharide capsule transport proteins 
have an important role during infection (33). However, the complexity of gene expression 
during infection goes beyond Bvg-regulated differences alone, as >30% of the 3500 analyzed 
genes were differentially expressed between bacteria harvested during infection and those 
cultured under laboratory conditions. For instance, functional categorization of the differentially 
expressed genes suggest a role in B. pertussis adaptation to the host environment by in vivo 
specifically expressing genes required for chemotaxis, flagellar assembly, nutrient acquisition, 
and amino acid and fatty acid metabolism, while suppressing the expression of several central 
metabolic pathways, protein production and LPS biosynthesis (Figure 3). This suggests that 
in vivo bacterial populations are metabolically less active than bacteria growing exponentially 
under laboratory conditions, at least at the 3 and 7 days post challenge time-points analyzed 
here. This reduced metabolic activity together with the observed expression of genes in 
the flagella operon points towards a biofilm mode of growth (20), as has been shown for B. 
bronchiseptica, the evolutionary ancestor of B. pertussis (34). 
Our observation that the aP vaccine used was unable to prevent colonization of the 
upper respiratory tract may reflect the absence of an effective local mucosal immune response. 
Another explanation may be that the high number of bacteria used to experimentally infect 
mice is able to overcome vaccine-induced immunity in the URT. However, as suggested by 
this work, differential bacterial gene expression in the upper and lower respiratory tract may 
also play a role. We hypothesize that B. pertussis has distinct transcriptional profiles, and 
thus antigenic profiles, during upper and lower respiratory tract infection due to differences 
in the mucosal epithelial cell layer, the local immune response, microbiome composition, 
temperature, and nutrient availability (35, 36). The observation that up to 415 genes were 
differentially expressed between the upper and lower respiratory tract suggests that these two 
sites represent distinct niches for B. pertussis. Interestingly, in the early stage of infection, B. 
pertussis in the upper respiratory tract appears to express several important virulence factors 
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at a higher level than lung-derived bacteria, including Vag8 and the toxins Dnt, Ptx, and Bsp22. 
Since these factors are known to interfere with various aspects of the host immune system 
(for review see (30)), it is tempting to speculate that this may, in part, contribute to the lack of 
clearance in the upper respiratory tract of vaccinated mice.
Transcriptional profiles did not change significantly over time in the nasopharynx. 
In contrast, bacteria in the lower respiratory tract increased in metabolic activity over time. 
Although further studies are required to understand the exact mechanisms underlying these 
differences, it is possible that bacteria respond to the increased inflammatory response in the 
lungs and the influx of immune cells, which may lead to an increased release of nutrients (37).
The present study provides important new insights into the adaptation of B. pertussis 
during infection and shows that current in vitro growth conditions may not truly match the 
antigenic profile of B. pertussis in the host. This has important implications for the design 
of next-generation vaccines. For instance, by rationally designing laboratory growth medium 
and conditions, it may be possible to culture bacteria in vitro and allow production of antigens 
typically exclusively expressed during infection. Such an approach would require confirmation 
of the in vivo expression profile at the protein level, which, with current advancements in 
technology (38, 39), may be possible in the very near future. 
Materials & Methods
Ethics statement
Animal experiments were approved by the Radboudumc Committee for Animal Ethics and 
conducted in accordance with the relevant Dutch legislation. Bacterial strains have previously 
been collected by regional Medical Microbiology Laboratories from patients suspected of 
whooping cough and sent to the National Institute for Public Health and the Environment 
(RIVM) in the context of routine surveillance (as required by law). The strains are sent to 
the RIVM for confirmation of clinical diagnosis, species determination and subtyping. Strictly 
anonymized patient information is included, which is limited to age, sex and postal code. For 
this type of surveillance ethical evaluation or patient consent are not required. The strains have 
been used in previous studies (6, 10).
Bacterial strains and in vitro growth conditions
B. pertussis strains B1917 and B1920 were grown under Bvg+, Bvgi, and Bvg- conditions in 
chemically defined THIJS medium (40) as described previously (6). For modulation of the 
BvgAS regulatory system, magnesium sulfate was added to cultures at a final concentration 
of 5 and 50 mM to induce Bvgi and Bvg- conditions respectively. In the absence of additional 
sulfate, the concentration of free sulfate is 0.02 mM, thereby inducing Bvg+ conditions. Bacteria 
were harvested at mid-log (OD620 of 0.5-0.6) for RNA and protein isolation. 
Protein isolation
Bacterial pellets from 5 mL of Bvg+ and Bvg- mid-log culture were used for the isolation of 
membrane proteins using the ReadyPrep Protein Extraction Kit Membrane I (Bio-Rad 
152 | Chapter 5
Laboratories, Hercules, CA, USA). The obtained soluble and insoluble fractions, respectively 
containing the cytosolic and membrane or membrane-associated proteins were purified using 
the ReadyPrep 2-D clean-up Kit (Bio-Rad Laboratories). Finally, the proteins were dissolved 
in 8M urea in 10 mM Tris-HCl pH 8.0, clarified by centrifugation at 10,000g for 5 minutes, and 
diluted with PBS for vaccination of mice as described below. 
Vaccination
Individual groups of naïve, female 6-8 week old BALB/c mice (Charles River) were immunized 
subcutaneously on day 0 and 14 with 1 µg purified membrane proteins derived from Bvg+ or 
Bvg- bacteria, mixed 1:1 in 1.3% alum adjuvant (Alhydrogel; Sigma). As a negative control, 
mice were immunized with a similar ratio of PBS and Alhydrogel. In order to compare efficacy 
to current aPs, one group of mice was immunized with 1/50th of the human dose (equals 1.16 
µg of B. pertussis protein) of the commercially available hexavalent acellular pertussis vaccine 
InfanrixTM (GSK, Belgium, 25 µg Ptx, 25 µg filamentous hemagglutinin, 8 µg pertactin). On day 
35, mice were challenged by intranasal (i.n.) infection with B. pertussis strain B1917 (2×107 
colony forming units (CFU) in a total volume of 40 µL). On day 38 and 42, the bacterial load 
in the nasopharynx (upper respiratory tract, URT) and the lungs (lower respiratory tract, LRT) 
was determined as described previously (41). Serial dilutions of the nasal lavages (NL) and 
lung homogenates were plated onto Bordet Gengou (BG) agar plates and incubated at 37°C 
for 3-4 days, after which the bacterial load was determined.
In vivo transcriptional analysis 
Groups of four naïve 6-8 week old female BALB/c mice mice were infected with B. pertussis 
strain B1917 or B1920 (2 × 107 CFU total) as described above. Mice were sacrificed on day 3 
and 7 and bacteria were flushed from the nasopharynx (nasal lavage; NL) and lungs (broncho-
alveolar lavage; BAL) by lavage with PBS. These samples were first used to determine the 
bacterial load as described above after which they were immediately mixed with two volumes 
of RNA Protect Bacteria Reagent (Qiagen) to stabilize the RNA. To control for potential 
false-positive signals due to cross-hybridization of mouse-derived cDNA to the microarray 
(predominately due the influx of immune cells into the lungs), two mice were instilled i.n. with 
10 µg lipopolysaccharide (LPS) from Escherichia coli. LPS was selected as a pro-inflammatory 
compound to recruit immune cells to the broncho-alveolar space, which peaks at day 2 (42). At 
this time-point, mice were sacrificed and NL and BAL samples collected and mixed with RNA 
Protect as described above.
Total RNA was extracted using the RNeasy Mini kit (Qiagen) and contaminating genomic 
DNA was subsequently removed by DNase treatment (DNAfree, Ambion). Bacterial RNA 
was enriched and amplified using the MICROBEnrich (Ambion) and SensationPlus™ FFPE 
Amplification (Affymetrix) kits, respectively, according to manufacturers protocols. The resulting 
RNA was reverse transcribed using the SuperScript® One-Cycle cDNA Kit (Invitrogen) and 
5 µg of the obtained cDNA was labeled and hybridized to custom-designed microarrays as 
described previously (6). 
In vivo gene expression in Bordetella pertussis | 153
5
Statistical analysis
Microarray data from this study was combined with data from a previous study in which we 
analyzed the transcriptome of these strains under different Bvg-conditions by modulating the 
sulfate concentration in the culture medium (6). Normalized expression data was analyzed 
by ArrayStar (DNASTAR, Madison, WI, USA) using the Robust Multiarray Analysis (RMA) 
algorithm for background correction and quantile normalization (43). Based on the microarray 
data of the LPS-treated mice, 34 genes were excluded from further analysis as they exhibited 
cross hybridization with host cDNA. Gene expression values were log2-transformed and 
differentially expressed genes were identified based on log2 fold changes. P-values were 
calculated with LIMMA (44), followed by multiple testing correction of the p-values according 
to the method of Benjamini and Hochberg (45). Genes were considered differently expressed 
between in vivo and in vitro growth when gene expression in the NL and/or BAL was different 
from all tested Bvg-conditions with a log fold change (FC) >2 and corrected p <0.05 in a 5-way 
comparison, combining strains and timepoints. Gene expression between NL and BAL samples 
where compared for both timepoints in a 4-way comparison in which gene expression values 
for the strains were combined for each in vivo condition. Genes were considered differently 
expressed if they exhibited a log FC gene expression >1 and associated corrected p <0.05. 
Enrichment for specific KEGG pathways were assessed using STRING (46). Clustering and 
Principal Component Analysis of samples was performed on differentially expressed genes 
using Pearson correlations on log transformed gene expression values while clustering of 
genes was performed using K-means, both in GENESIS (47).
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Summarizing discussion
The introduction of pertussis vaccines in the 1950s significantly reduced pertussis morbidity 
and mortality. However, due to the global increase in pertussis infections observed during 
the last two decades, even in highly vaccinated populations, pertussis has again become 
a significant health burden (1). Over the past years, it has become evident that the rise in 
pertussis cases is the result of the increased use of suboptimal vaccines with rapidly waning 
immunity, improved diagnostics, and pathogen adaptation (2-4). More specifically, pathogen 
adaptation has resulted in antigenic divergence between vaccine strains and circulating strains 
and the emergence of more virulent ptxP3 strains (5-7) in which gene loss of the acellular 
pertussis vaccine (aP)-antigen pertactin (Prn) is observed (8-12). Of importance, recent studies 
showed that strains lacking Prn (Prn-deficient strains) are more likely to cause infections in aP-
vaccinated hosts compared to Prn-producing strains (12, 13). Clearly, these observations are 
worrisome, and it is of critical importance that the impact of genetic variations in B. pertussis 
on the ability of pertussis vaccines to effectively prevent pertussis colonization and disease 
is further characterized. For instance, it is currently unknown how recently emerged ptxP3 
strains adapt to pathogenically relevant conditions, such as in vitro Bvg-modulation and biofilm 
formation, or in vivo during infection. Insight into these mechanisms is important, and may allow 
the design of new and improved strategies which not only prevent disease, something already 
controlled by current aPs, but also infection, which is typically prevented only after natural 
infection (14). The current aP antigens Prn, pertussis toxin (Ptx), filamentous hemagglutinin 
(FHA), and fimbriae serotype 2 and 3 (Fim2/3) were selected more or less randomly without 
any proper analysis, and the observation that vaccine antigen-deficient strains are emerging 
highlights the importance of characterizing novel pertussis antigens for inclusion into future 
vaccines. As such, novel vaccine candidates have to be selected, which requires insight into 
the expression profile of B. pertussis during different stages of infection. 
In this context, the comparative transcriptomic and proteomic analysis of different B. 
pertussis lineages under pathogenically relevant conditions presented in this thesis resulted in 
some important findings:
•	 Transcriptomics revealed that under virulent in vitro conditions, ptxP3 strains expressed 
significantly more virulence factors, including Ptx, compared to ptxP1 strains. Further-
more, pronounced differences between these lineages in sulfate and cysteine metabo-
lism were found, suggesting a role for sulfate in host-pathogen interactions (Chapter 2). 
•	 Analysis of the Bvg-regulated (virulence) proteome identified various surface-exposed 
proteins which may be effective vaccine components. Indeed, two of the identified pro-
teins, the autotransporters SphB1 and Vag8, induced significant protection against per-
tussis in mice (Chapter 3).
•	 B. pertussis biofilm proteins induced significant protection in a mouse model. In addition, 
proteomics identified BipA as the most-abundant, surface-exposed biofilm-associated 
protein, which also induced protection as stand-alone antigen (Chapter 4).
•	 Transcriptional analysis of B. pertussis during respiratory infection in mice revealed sig-
nificant differences compared to in vitro growth conditions, as well as differences be-
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tween upper and lower respiratory tract infection (Chapter 5).
In this final chapter, the implications of these findings are discussed in more detail, 
followed by a future perspective on pertussis vaccine development. 
Phenotypic characterization of the emerging ptxP3 lineage
In many countries with high vaccination coverage, the increase in pertussis cases coincided 
with the emergence of strains carrying the ptxP3 allele for the pertussis toxin promoter. As yet, 
the earliest clinical isolate carrying the ptxP3 allele was isolated in the United States in 1984 
and has since then, globally and, in some countries, nearly completely, replaced the previously 
dominant ptxP1 strains (7, 15-19). The worldwide selective sweep of strains carrying the ptxP3 
allele indicates increased strain fitness, and thus far, studies comparing ptxP3 and ptxP1 
strains have associated ptxP3 strains with higher Ptx production and enhanced respiratory 
colonization (6, 7). However, despite the fact that the genomes of various ptxP3 and ptxP1 
strains have been (completely) sequenced (20, 21), it currently remains unknown how these 
genetic differences translate to these observed phenotypic differences. In this thesis, we 
studied how these two lineages behaved under in vitro conditions that reflect specific aspects 
of infection, as well as actual  in vivo conditions using a mouse model of infection.
The Bvg system controls the expression of the majority of B. pertussis virulence factors 
required to infect the host, persist, and cause disease (22, 23). Several external factors are 
able to modulate the activity of this system, which results in a spectrum of different Bvg-phases 
that affect bacterial virulence. For instance, low temperature, and increasing concentrations 
of nicotinic acid or sulfate suppress virulence gene expression, which facilitates the transition 
from virulent (Bvg+) through intermediate (Bvgi) to nonvirulent (Bvg-) bacteria (24, 25). As this 
system is pivotal to the ability of B. pertussis to survive in the host population, we investigated 
how the different lineages adapt to in vitro sulfate-induced modulation of the Bvg system (24). 
Comprehensive analysis of changes in gene expression profiles between the two lineages 
(Chapter 2) confirmed the higher expression of Ptx by ptxP3 strains, albeit exclusively under 
Bvgi growth conditions (5). Additionally, under the same conditions, ptxP3 strains expressed 
higher levels of the vaccine antigen pertactin (Prn), type III secretion system (T3SS) proteins, 
the complement resistance protein Vag8, and LpxE involved in lipid A modification. As these 
proteins all affect host defenses (26-34), ptxP3 strains may benefit from their increased 
expression.  
Our data provide a potential clue towards the mechanism underlying the enhanced 
expression of virulence factors by ptxP3 strains under Bvgi conditions, since ptxP3 strains 
showed enhanced expression of genes involved in sulfate metabolism, which potentially 
reduces their susceptibility to sulfate-induced suppression of virulence gene expression. 
However, whether ptxP3 strains actually benefit from an enhanced sulfate metabolism during 
infection is unknown. Although the concentration of free sulfate in the respiratory tract is almost 
10-times lower (0.6 mM; (35)) than the intermediate sulfate concentration used in this study (5 
mM), desulfation of sulfated host proteins during B. pertussis infection may increase the sulfate 
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concentration locally (36). Indeed, B. pertussis has several genes which encode proteins with 
a predicted sulfatase domain (BP1635, BP1654, BP2327, and BP3136). In addition, Bvg-
dependent virulence gene expression is not solely suppressed by sulfate, but also by increasing 
concentrations of nicotinic acid or decreasing temperature (24, 25). Future research should 
determine whether ptxP3 strains are also less responsive to these environmental modulators. 
In Chapter 3 we analyzed the Bvg-regulated proteome of a ptxP3 and ptxP1 strain with 
an emphasis on identifying potential vaccine candidates (discussed further below). In essence, 
it would also be valuable to use this proteomics data to identify additional phenotypes of the 
ptxP3 lineage which contribute to strain fitness. Unfortunately, the inter-experimental variation 
in measurements of the proteomes of the ptxP3 and ptxP1 strains made it impossible to identify 
significant Bvg-dependent differences in protein expression between the two strains. For this 
purpose, multiple non-related ptxP1 and ptxP3 strains should be analyzed in one proteomic 
experiment using either the label-free method applied in our study, or an isotope-labeled 
method such as Isobaric Tags for Relative and Absolute Quantification (iTRAQ) (37). Although 
in vitro transcriptional analysis revealed differences between a ptxP3 and ptxP1 strain, we were 
unable to measure differences in gene expression in vivo, using B. pertussis isolated from the 
respiratory tract of mice (Chapter 5). As with the proteomics data (Chapter 3), this study was 
hampered by the fact that for each strain only 3-4 in vivo replicate samples were collected with 
relatively high variation in gene expression. Therefore, a more extensive expression profiling 
experiment with multiple non-related ptxP1 and ptxP3 strains and transcriptional analysis 
of bacteria collected at several time-points after infection, might lead to the identification of 
additional beneficial phenotypes of the ptxP3 lineage during infection. 
Some studies suggest that there is an association between the emergence of ptxP3 
strains and recent pertussis epidemics (7, 18). However, thus far, merit for a direct causal link 
between ptxP3 strains and increased disease severity has come from a Dutch study (7) and 
a retrospective clinical study in Sweden (38), which found that children infected with strains of 
the pulsed-field gel electrophoresis (PFGE) profile BpSR11, which later were found to carry the 
ptxP3 allele (7), stayed significantly longer in the hospital compared to children infected with 
non-BpSR11 strains (38). In order to gain more insight into this causal relationship, the recently 
developed baboon model might be valuable, as the full course of a natural B. pertussis infection 
and human-like clinical illness (paroxysmal cough and leukocytosis with lymphocytosis) can 
be monitored in these animals in a controlled manner (39). For instance, it would be very 
interesting to compare the clinical picture of naïve (or partially immune) baboons infected with 
either a ptxP1 or ptxP3 strain. Additionally, transmission experiments can also be performed 
in baboons (40), which may reveal additional beneficial virulence traits of the ptxP3 lineage. 
Vaccine candidate discovery - a proteomic approach 
The global emergence of strains lacking expression of the current acellular pertussis vaccine 
(aP)-antigen pertactin (Prn-deficient strains) is alarming, with Prn-deficient strain frequencies 
reaching over 85% some regions (8-12). Although clinical isolates lacking Prn expression 
are not attenuated in humans (41), two recent studies showed that Prn-deficient strains may 
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have a selective advantage in vaccinated individuals. This latter is not surprising, considering 
the strong correlation between the presence of specific immunoglobulin G (IgG) antibodies 
against Prn and clinical protection (42-44). As such, there is a great demand for identification of 
alternative, conserved, protective antigens for inclusion into improved aPs. In order to identify 
novel candidates involved in specific aspects of infection, proteomics was applied on currently 
circulating strains of the ptxP1 and ptxP3 lineage grown under in vitro Bvg-modulating (Chapter 
3) and biofilm forming conditions (Chapter 4). 
Bvg-activated pertussis vaccine candidates
Bvg-activated proteins, generally associated with virulence and modulation or evasion of host 
immunity (22), represent excellent targets for vaccination, clearly indicated by the fact that all 
current aP antigens are Bvg-activated (23). To understand the differences and similarities in 
Bvg-regulation between ptxP3 and ptxP1, we studied the transcriptional response (Chapter 
2) and protein content (Chapter 3) in these strains in response to increasing concentrations of 
free sulfate. Comparison of the Bvg-proteome identified 159 and 104 Bvg-activated proteins 
in the ptxP3 and ptxP1 strain, respectively, which included almost all known virulence factors 
and all antigens used in aP vaccines. As such, this study represents the first comprehensive 
analysis of the Bvg-regulated proteome, which is highly relevant for the scientific community 
working on pertussis vaccine development.
In our study, vaccine candidates were selected on the criteria that the protein was 
Bvg-activated in both the ptxP3 and ptxP1 strain, since novel antigens should target both 
lineages predominating in the human population (20). This resulted in 51 potential candidates. 
Unfortunately, almost half of the Bvg-activated proteins not shared between the two strains 
were not identified or quantified in one of the two strains due to limitations of the proteomics 
methodology used. After further selection on Bvg-activated transcription (5), presence in the 
core genome (45) and predicted surface-exposed localization (46), OmpP, OmpA, SphB1, Vag8, 
and BP2497 were selected as promising vaccine candidates. Immunization with recombinant 
SphB1 and Vag8 conferred significant protection against pertussis in the lower respiratory 
tract of mice. Both SphB1 and Vag8 belong to the protein class of autotransporters, which also 
includes the protective antigens Prn and TcfA (47, 48). This suggests that autotransporters in 
general represent an attractive class of protective antigens. Indeed, autotransporters identified 
in other gram-negative bacteria are almost all associated with virulence-related phenotypes 
such as adhesion, auto-aggregation, invasion, biofilm formation and cytotoxicity (49), and 
are increasingly being recognized as targets for vaccination (50). Since SphB1 and Vag8 are 
surface-exposed and both have established roles in virulence, mediating the maturation of the 
adhesion and immune-modulating factor filamentous haemagglutinin (FHA) and complement 
resistance (30, 51), respectively, it is not surprising that targeting these proteins through 
vaccination provides protection against lower respiratory tract infection in mice.
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Biofilm-associated vaccine candidates
For many mucosal pathogens, biofilm formation facilitates successful colonization and 
persistence in the host by providing resistance to antimicrobial agents and immune defenses 
(52). Several studies have shown that B. pertussis is able to produce biofilms in the respiratory 
tract of mice, and that this process is important for successful infection (53-58). Furthermore, 
biofilm-associated proteins or polysaccharides are recognized as potential vaccine targets 
(59-61). Therefore, in Chapter 4 we explored the vaccine potential of B. pertussis biofilms and 
aimed to identify biofilm-antigens as potential targets for vaccination by proteomics. 
The observation that mice subcutaneously immunized with total membrane-protein 
fractions from planktonic (mid-log and stationary phase) and biofilm cultures showed a 
significant reduction in bacterial load in the lungs after respiratory challenge with B. pertussis, 
provided proof of principle that pertussis biofilms contain protective antigens (Chapter 4). For 
the identification of highly expressed biofilm-specific proteins, we applied the same proteomics 
methodology described in chapter 3 on the planktonic and biofilm material. This strategy 
allowed us to identify 60 biofilm-upregulated proteins and 48 biofilm-repressed proteins. 
After filtering the 60 biofilm-upregulated proteins based on protein abundance and predicted 
surface-exposed cellular localization, BipA was identified as the most promising biofilm vaccine 
candidate. Indeed, recombinant production and subsequent vaccination with BipA induced 
significant protection against nasal challenge with B. pertussis. 
Our study was not the first to describe that BipA is expressed at high levels in B. pertussis 
biofilms, as this protein was also identified by Serra and coworkers who applied proteomics 
on the Tohama I strain (62). Besides BipA and the universal stress protein BP1315, we found 
no overlap between the recent clinical isolate used in our study and the Tohama I strain used 
by Serra et al. with respect to biofilm-activated or -repressed proteins (62). This discrepancy 
might be strain-related, as Tohama I has been cultured in vitro for over 60 years, while the 
B1917 strain used in our study was isolated from a Dutch pertussis patient in 2000 (7). Other 
studies have also shown different phenotypes between recent clinical isolates and Tohama I. 
For instance, Tohama I responds differently to modulation of the Bvg-system (63) and lacks the 
expression of a functional T3SS (64, 65). These differences highlight the importance of using 
minimally passaged clinical isolates for studying B. pertussis pathogenesis in general.
Interestingly, 35% of the biofilm-repressed proteins of strain B1917 were also identified 
as Bvg-activated, virulence-associated proteins by transcriptional profiling in Chapter 2 (5), 
including Vag8 (30), FimX, and various T3SS proteins and effectors. In contrast, in Tohama 
I, the DNA-binding transcriptional regulator BvgA of the two-component BvgAS system was 
the only Bvg-activated protein (63) found to be repressed under biofilm conditions (62). The 
observation that some, but not all, Bvg+-phase proteins are repressed in a biofilm while the 
classical Bvgi-phase protein BipA (66) is expressed at high levels, suggests that B. pertussis 
bacteria are not in a single Bvg-phase when growing under biofilm conditions. The variation in 
Bvg-phases might be due to the heterogeneous composition of a biofilm, which is the result of 
bacteria adapting their metabolic activity to the concentration gradients of nutrients, signaling 
compounds, and bacterial waste that are present within the biofilm (67). It is important to note 
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that proteomic analysis requires a large amount of bacteria for sufficient protein isolation, 
which is typically harvested and processed as one batch that may contain cells in the biofilm 
and planktonic phase. Hence, proteomic analysis results in an average characterization of 
cells in different physiological states, rather than a characterization of biofilm bacteria per se. 
Recent advances in proteomic and microscopic technology may shed new light on the Bvg-
phases that are relevant for B. pertussis biofilm formation. For instance, by applying single-cell 
proteomic techniques on B. pertussis grown under biofilm conditions (68). Alternatively, a B. 
pertussis strain in which a fluorescent label (e.g. GFP) is expressed under control of the BvgAS 
promoter can be studied under biofilm conditions using automated time-lapse microscopy, as 
has been described for other bacteria (69, 70).
Based on our data, we propose that a strategy by which multiple steps in infection are 
targeted, including biofilm formation, may represent an attractive approach to improve pertussis 
vaccines. The inclusion of BipA in novel vaccines, in combination with current antigens that 
target other essential stages in B. pertussis pathogenesis, may provide an additional level of 
protection and thereby enhance the efficacy of pertussis vaccination. 
Limitations of the newly identified vaccine-candidates
Although SphB1, Vag8, and BipA are promising candidates for inclusion into future pertussis 
vaccines, one of the risks of adding new antigens to the current aPs is that B. pertussis will 
eliminate expression of these proteins, as was observed for Prn. For SphB1 this is rather 
unlikely, as deletion of this gene strongly attenuates the ability of B. pertussis to infect mice, 
probably due to enhanced phagocytosis (71, 72). However, a Vag8- or BipA-deficient mutant 
of B. pertussis showed no defect in mouse colonization (73, 74), so there is a risk that B. 
pertussis eliminates expression of these two proteins when used for vaccination. 
Another limitation of the current aP antigens as well as those identified in this thesis 
(Chapter 3 and 4) is that none of them is capable of providing protection against bacterial 
replication in the upper respiratory tract. As such, in current alum-formulated state these 
antigens may protect mainly against disease and not against colonization and transmission 
as has been observed for aP antigens in the baboon model (14). To tackle this problem we 
need to reconsider the vaccine formulations (e.g. delivery of antigens, adjuvant) as well as the 
route of vaccine administration. These issues are discussed further in the future perspectives 
section below.   
Adaptation of B. pertussis during respiratory infection 
To explain the drastic resurgence of pertussis in highly vaccinated populations, research of the 
past years has focused predominantly on the rapid waning of aP vaccination-induced protection 
as well differences in the quality of the immune response induced by natural infection and 
wP and aP vaccines (14, 75-80). In this regard it is important to note that wPs are prepared 
using liquid cultures of Bvg+ phase B. pertussis. In addition, currently used aPs exclusively 
consists of Bvg+ antigens. These vaccines have all been designed on the rational that the 
Bvg+ phase is essential for infection, which is supported by mouse infection experiments using 
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Bvg-phase locked mutants, as well as a plethora of in vitro studies characterizing virulence and 
antigenic properties of Bvg+ phase factors (for recent reviews see (22, 81, 82). However, the 
mechanism by which B. pertussis adapts to local conditions on the host respiratory mucosa 
during infection remain largely unknown. To address this knowledge gap, in Chapter 5 we 
examined longitudinal and tissue-specific gene expression differences in B. pertussis in mice. 
Comparison of the in vivo transcriptome to gene expression during in vitro culture identified 
very strong differences in gene expression signatures, with almost a third of all genes being 
differentially expressed. A variety of pathways involved in bacterial growth/metabolism were 
found to be downregulated during infection, indicating that B. pertussis is in a metabolically 
less active state, as has been observed in biofilms (62), during infection. The majority of genes 
upregulated in vivo were found to be involved in nutrient acquisition, chemotaxis, and amino acid 
and fatty acid metabolism. This probably reflects bacterial adaptation to nutritional immunity, 
a host defense mechanism against invading pathogens which acts through sequestration of 
essential micronutrients (83). Based on the expression pattern of bvg-regulated genes, as 
previously identified in our in vitro studies, B. pertussis is not in a single Bvg-phase. For instance, 
whilst the majority of Bvg+ phase factors were expressed during infection, we also observed 
expression of some Bvg- phase genes. This would also fit with our observation that mice that 
were vaccinated with membrane proteins extracted from Bvg- phase bacteria were almost as 
efficiently protected against respiratory challenge with B. pertussis as mice vaccinated with 
Bvg+-derived membrane proteins. Despite current assumptions (84), these data suggest that 
Bvg-repressed genes might play a role during infection. This is further supported by a recent 
study which showed that expression of the Bvg--phase specific capsule is essential for B. 
pertussis during infection (85).    
Another aim of our in vivo transcriptional analysis was to identify tissue-specific bacterial 
gene expression signatures in the nasopharynx and in the lungs. Such differences may provide 
insight into the inability of aP vaccines, and to a lesser extent wP vaccines, to induce protection 
against colonization of the upper respiratory tract (14). Furthermore, insight into tissue-specific 
differences may allow the selection of additional vaccine antigens that specifically target B. 
pertussis infection at each niche. Our data suggest that the upper and lower respiratory tract 
represent distinct niches for B. pertussis, with almost 15% of all genes being differentially 
expressed between the two anatomical locations (Chapter 5). Thus far, differential expression 
of virulence genes during infection of distinct niches of the respiratory tract has only been 
described for Streptococcus pneumoniae, which is able to colonize the human nasopharynx 
but also causes invasive diseases such as pneumonia, bacteremia, and meningitis (86). 
Interestingly, pneumococcus shows enhanced expression of several virulence factors upon 
colonization of the nasopharynx (87), which is in line with our observation that the immune 
modulating virulence factors Vag8 and the toxins Dnt, Ptx, and Bsp22 (22) were upregulated 
by B. pertussis in the upper respiratory tract compared to the lower respiratory tract during 
early infection. However, whether the increased expression of these virulence genes indeed 
contribute to the inability of aPs to protect against colonization of the nasopharynx remains 
uncertain, as, for instance, Ptx is also present in aPs. In addition, currently used aP formulations 
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predominantly induce systemic immunity, while protection in the nasopharynx requires the 
induction of local mucosal immunity (further discussed in the future perspective below). 
As a first step to measure B. pertussis gene expression during infection a non-natural 
host (mice) was used in our study. With the baboon model available, similar experiments can 
be performed to study niche-specific gene expression of B. pertussis following a more natural 
course of infection. Besides measuring the in vivo bacterial transcriptome, it would be very 
interesting to employ a combined approach in which both the host and bacterial response are 
measured (88), as this provides a more extensive view on how both the host and pathogen 
adapt during a pertussis infection. 
 
Future perspectives
Although the introduction of pertussis vaccines in the 1940s resulted in a 99% reduction in 
pertussis incidence in European countries, pertussis has re-emerged in various industrialized 
countries since the early 2000’s. With recent epidemics recorded in Australia (89), the USA 
(90), the UK (91), and the Netherlands (92), and a resurgence of disease being described 
for several other European countries, countermeasures against pertussis are required. Here, 
recommendations for pertussis control that can be implemented on the short-term as well as 
suggestions for pertussis vaccine development on the long-term are described.
Short-term control strategies
In order to control the current increase of pertussis-related deaths in infants, alternative 
vaccination strategies with the currently available vaccines have been proposed and (partly) 
introduced (93). These strategies are aimed either at providing infants, who have the highest 
risk for severe, even fatal, pertussis, indirect protection via booster vaccination of older age 
categories, or direct protection by maternal or neonatal vaccination. The principle behind 
booster vaccination is to increase herd immunity, thereby decreasing transmission to infants 
and lowering morbidity in this age category. Booster vaccination strategies can be implemented 
on a community broad level or, more focused, by vaccinating parents and others who are 
in close contact with infants (the so-called ‘cocooning’ strategy). Although community broad 
booster doses have been implemented in several countries (94), this strategy was found to be 
ineffective due to low vaccine coverage, and economically costly (76, 95). In addition, despite 
some success of the cocooning strategy in one study (96), others found that this strategy does 
not reduce pertussis illness in infants (97). The main problem with the cocooning strategy is 
low coverage due to parental refusal, low political commitment, logistical issues and cultural 
issues (98). Further, the recent observation that aPs protect mainly against disease and only 
partially against colonization and transmission (14), implies that all indirect strategies may not 
be as effective in reducing the burden of pertussis in infants. 
Therefore, providing direct protection through neonatal or vaccination during pregnancy 
might be a more appropriate short-term solution. With neonatal vaccination, infants are 
vaccinated at birth to mount an early pertussis immune response, while with vaccination during 
pregnancy, passive immunity is acquired through the in-utero transfer of maternal antibodies. 
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The latter strategy also has the potential to provide indirect protection to the infant, as it also 
protects the mother. In the baboon model, both strategies were found to be successful in 
providing newborns protection against infection (99). However, with neonatal vaccination, 
there is a delay between the birth vaccination dose and the induction of protective immunity, 
leaving infants unprotected in the period in which they are most vulnerable for severe and life-
threatening pertussis (100). In addition, the neonatal vaccination strategy is also hampered 
by concerns on immunological and clinical safety as well as public acceptance (101). On the 
other hand, vaccination during pregnancy appears to be safe for both pregnant women and 
their fetus or infant (102, 103), provides protection (104), and has been successfully adopted 
in the US (105), UK (106, 107), and several other countries, with efficacy reaching up to 
90%. Based on all these studies, WHO has recommended that countries with a high pertussis 
burden adopt maternal immunization as the most cost-effective intervention strategy to reduce 
neonatal pertussis (108). It must by noted that large-scale implementation of this strategy may 
be difficult, as it is unknown how the presence of maternal antibodies will influence the quality 
and duration of the infants own response to primary vaccination. 
Pertussis vaccine development
There are three major problems with the currently used aP vaccines. First, antigenically 
divergent and/or vaccine-antigen deficient strains expressing increased levels of virulence 
factors are emerging. Second, protection is directed mainly against disease and only in limited 
degree against transmission. Third, aPs provide only short-lived protection. Therefore, in order 
to control pertussis in the long run, the composition and administration route of the currently 
used vaccines need to be reconsidered. 
For the development of novel pertussis vaccines there are two major options:
1. New stand-alone pertussis booster vaccines. These type of vaccines consist of new or 
updated aP antigens and/or different adjuvants, B. pertussis outer membrane vesicles 
(OMVs), or potentially life-attenuated B. pertussis. These vaccines can be developed 
and registered relatively fast since they can be delivered as stand-alone vaccines.
2. New primary pertussis vaccines, containing diphtheria toxoid, tetanus toxoid, inactivated 
polio, etc. in addition to pertussis antigens. This category represents second generation 
aP (with new/updated antigens, other adjuvants etc.), whole-cell pertussis vaccine (wP; 
genetically inactivated, less reactive), but can also be an OMV or live-attenuated type of 
vaccine. Before implementation it has to be shown that these novel vaccines do not inter-
fere with other non-pertussis components of the current aPs. As such, the development 
of these type of vaccines will take at least 10 years. 
Updated current aP antigens and novel antigens 
Possible changes in the current aP have already been proposed by others, such as the 
implementation of genetically detoxified Ptx instead of the less immunogenic chemically 
detoxified Ptx currently being used (109-111). The use of genetically detoxified Ptx results 
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in higher initial Ptx antibody titers, also against other (conformational) epitopes, which may 
increase the period in which protective antibody levels are maintained. In addition, with antigenic 
divergence been observed predominantly in Prn, aPs may be improved by including protein 
variants found in current B. pertussis populations. Furthermore, aPs can also be supplemented 
with novel vaccine candidates. For instance, adenylate cyclase toxin (ACT), a multifunctional 
virulence factor which plays a crucial role during infection (112), represent a promising target for 
vaccination (113, 114). In addition, the virulence-activated autotransporters Vag8 and SphB1, 
as well as the biofilm-associated protein BipA, identified as protective antigens in this theses 
(115, 116), also represent promising candidates for future aPs. Finally, surface-exposed in vivo 
expressed proteins identified in Chapter 5 of this thesis are also promising vaccine candidates. 
The inclusion of additional antigens into aPs may address the problem of emerging vaccine-
escape mutants. However, whether this will also be sufficient to provide long-term protection 
against pertussis disease and colonization remains doubtful. 
Alternative adjuvants and administration routes
For the selection of alternative adjuvants or administration routes, a lot can be learned from 
recent experiments in the baboon model. Animals vaccinated with a whole-cell pertussis 
vaccine (wP) cleared the infection faster compared to aP-vaccinated animals, whereas 
convalescent animals were fully protected against both colonization and transmission (14). 
Although the antibody levels were similar in all treatment groups, there were differences in 
the T-cell response that was induced. Convalescent and wP-vaccinated animals showed 
strong Th1 and Th17 responses whereas aP-vaccinated animals possessed Th1 and Th2 
memory only (14). In recent years, substantial evidence has been generated which shows that 
a local Th1-Th17 response is indeed important for clearance of B. pertussis from the lungs 
(117-119), and probably also from the nose (79). These findings show ways to improve aPs. 
For instance, the classical adjuvant aluminum hydroxide, which skews the T cell response 
strongly towards Th2 (120, 121), can be replaced with CpG, an adjuvant that stimulates Th1-
mediated immunity (122), provides superior protection over alum-formulated aP (77, 123), 
and has been admitted for use in humans (124, 125). In addition, the classical intramuscular 
administration route leads to a very poor induction of mucosal immunity due to inadequate 
homing of T and B cells (126, 127), so the delivery of pertussis antigens via the mucosal 
route may offer significant advantages. However, the immunogenicity of a mucosal vaccine 
is crucially determined by its formulation. For instance, before antigens can be recognized by 
the innate immune system and induce a strong mucosal immune responses, they need to be 
transported across the epithelium. As such, the antigens should preferably be administered 
in a particulate formulation, such as biodegradable PLG (poly(lactide-co-glycide))-containing 
microparticles, liposomes or virus-like particles (VLPs), instead of a soluble formulation (128-
130). Furthermore, the efficacy of mucosal vaccines is determined by the type of adjuvant, 
which nowadays yields a plethora of possibilities (reviewed in (131)). Unfortunately, as there 
are currently no mucosal adjuvants approved for human use, the development of this type of 
vaccine will not be possible on the short-term.  
168 | Chapter 6
Novel wPs, outer membrane vesicle-based, or life-attenuated B. pertussis vaccines
Various studies have shown that wPs outperform aPs when it comes to duration of immunity 
and protection (14, 78, 132, 133). However, one the major issues of wPs is that the presence 
of lipo-oligosaccharide (LOS) causes reactogenicity. For the development of an improved, less 
reactogenic, second generation wP, the use of chemical or genetic methods to detoxify LOS 
might be an improvement (134). As an alternative to using whole-cells, recent advancement 
have been made in the development of an OMV-based vaccine for B. pertussis, which shows 
strong protection in mice (135). One of the advantages of using OMVs is that they carry a 
wide spectrum of native endogenous antigens, together with outer membrane proteins and 
lipo-oligosaccharide (LOS) that can activate innate immune responses and thereby function 
as natural adjuvants. Since both wPs and OMVs are typically derived from Bvg+ grown in vitro 
cultures, these vaccines can potentially be improved based on insights into the expression 
profile of B. pertussis during infection (Chapter 5), as these allow laboratory growth conditions 
to be rationally designed in such a way that they more accurately mimic the antigen expression 
profile during infection. As an alternative to these inactivated vaccines, enormous progress has 
been made over the last few years on the development of a live-attenuated B. pertussis vaccine 
(BPZE1) that can be applied intranasally (136). The main benefit of a life vaccine is that it has 
an antigenic profile similar to B. pertussis during natural infection and induces both local and 
systemic immunity. In addition, since the immune-modulating toxins tracheal cytotoxin (TCT) 
and pertussis toxin (Ptx) have been inactivated in BPZE1 (22), it potentially induces a more 
potent immune response. Finally, BPZE1 induces Th1- and Th17-mediated immunity, which 
is probably also important for clearance of B. pertussis from the upper respiratory tract (137, 
138). 
It is currently estimated that infection-acquired immunity against pertussis disease last 
4-20 years while protective immunity after vaccination lasts 4-12 years. Improving the duration 
of vaccine-induced immunity clearly remains important. In this regard, the newly designed 
live attenuated BPZE1 vaccine as well as the OMV-based vaccine are promising, as they 
both may induce longer-lasting immunity compared to parenteral aP-immunization by inducing 
a stronger Th1 response (139, 140). Thus far, this has only been tested in mice, and it is 
important to validate these findings in the currently available baboon model (14). Despite 
current advancements in vaccine development, new generations of pertussis vaccines should 
ideally induce life-long immunity to establish complete herd immunity and finally eradicate 
pertussis from the population. By gaining a full understanding of the mechanisms underlying 
immunological memory and differences between aP and wP vaccines in generating long-term 
protective immunity, these vaccines can hopefully be designed in the very near future. 
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De introductie van kinkhoestvaccins in de jaren 50-60 van de vorige eeuw heeft geresulteerd 
in een significante daling in kinkhoest ziekte- en sterftegevallen. De afgelopen twee decennia 
is het aantal kinkhoestinfecties wereldwijd echter sterk toegenomen, vooral in landen met een 
hoge vaccinatiegraad. Hierdoor is kinkhoest opnieuw een significant gezondheidsprobleem 
geworden. Het is de afgelopen jaren duidelijk geworden dat deze toename in kinkhoestinfecties 
het resultaat is van een toenemend gebruik van suboptimale vaccins met snel wegebbende 
immuniteit, verbeterde diagnostiek, en adaptatie van de pathogeen, Bordetella pertussis. 
Pathogeenadaptatie in het bijzonder heeft gezorgd voor antigene divergentie (mismatches) 
tussen vaccinstammen en circulerende stammen en de verschijning van meer virulente ptxP3 
stammen waarin de acellulaire vaccin (aP) component pertactine (Prn) afwezig is. Deze 
adaptaties zijn relevant omdat recente studies hebben aangetoond dat pertussis stammen 
zonder Prn (Prn-deficiënte stammen) een grotere kans hebben om succesvol aP-gevaccineerde 
individuen te infecteren dan Prn-producerende stammen. Deze observaties zijn zorgelijk en 
het is van cruciaal belang te karakteriseren wat het effect is van deze genetische variaties in 
B. pertussis op het vermogen van pertussisvaccins om effectief pertussis kolonisatie en ziekte 
te voorkomen. Zo is bijvoorbeeld niet bekend hoe recent opgekomen ptxP3 stammen zich 
aanpassen aan condities die relevant zijn voor pathogenese, zoals in vitro Bvg-modulatie en 
biofilm vorming, of in vivo tijdens infectie. Inzicht verkrijgen in deze mechanismen is belangrijk, 
en kan het mogelijk maken nieuwe en verbeterde strategieën te bedenken die niet alleen 
ziekte voorkomen, iets wat de huidige aPs voor beperkte tijd prima doen, maar ook infectie, 
wat normaliter alleen voorkomen wordt na natuurlijke infectie. De huidige aP antigenen 
Prn, pertussis toxine (Ptx), filamenteus hemagglutinine (FHA), en fimbriae serotype 2 en 3 
(Fim2/3) zijn min of meer willekeurig, zonder goede analyse, geselecteerd, en de opkomst 
van vaccinantigeendeficiënte stammen benadrukt het belang om nieuwe pertussis antigenen 
te karakteriseren die geïncludeerd kunnen worden in toekomstige vaccins. Er moeten dus 
nieuwe vaccin kandidaten worden geselecteerd, wat inzicht vereist in het expressie profiel van 
B. pertussis tijdens verschillende fasen van infectie. 
In deze context hebben de vergelijkende transcriptoom- en proteoomanalyses van 
verschillende B. pertussis stammen onder pathogenese-relevante condities beschreven in dit 
proefschrift geresulteerd in een aantal belangrijke bevindingen/inzichten. 
•	 Trancriptoomanalyse toonde aan dat ptxP3 stammen significant meer virulentie factoren, 
waaronder Ptx, produceerden onder virulente in vitro condities in vergelijking met ptxP1 
stammen. Daarnaast werden er grote verschillen in de expressie van sulfaat en cysteine 
metabolismegenen gevonden tussen deze twee stammen, wat suggereert dat sulfaat 
een rol speelt in gastheer-pathogeen interacties (hoofdstuk 2). 
•	 Analyse van het Bvg-gereguleerde (virulentie) proteoom resulteerde in de identificatie 
van verschillende geëxposeerde oppervlakte eiwitten die mogelijk effectieve vaccin 
kandidaten zijn. Uiteindelijk bleken twee geïdentificeerde eiwitten, de autotransporters 
SphB1 en Vag8, inderdaad significante bescherming te geven tegen pertussis in muizen 
(hoofdstuk 3).  
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•	 B. pertussis biofilm eiwitten bleken ook significante bescherming te geven in het muis 
model. Bovendien bleek ook BipA, het meest abundante, geëxposeerde oppervlakte 
eiwit van het biofilm proteoom, te beschermen als enkel vaccin antigeen (hoofdstuk 4). 
•	 Trancriptoom analyse van B. pertussis tijdens luchtweg infectie in muizen toonde signifi-
cante verschillen ten opzicht van in vitro groei condities aan, alsmede verschillen tussen 
infectie van de bovenste en onderste luchtwegen (hoofdstuk 5) 
In dit hoofdstuk worden de implicaties van deze bevindingen in meer detail bediscussieerd, 
gevolgd door toekomstperspectieven omtrent pertussis vaccinontwikkeling. 
Fenotype karakterisatie van de opkomende ptxP3 stammen
In veel landen met een hoge vaccinatiegraad viel de toename in kinkhoestgevallen samen met 
het opkomen van stammen die het ptxP3 allel van de pertussistoxine promoter bevatten. Tot 
noch toe is het eerst klinische isolaat met het ptxP3 allel geïsoleerd in de Verenigde Staten 
in 1984, en heeft sindsdien wereldwijd en in sommige landen, bijna volledig, de voorheen 
dominante ptxP1 stammen vervangen. Deze wereldwijde verschuiving suggereert dat ptxP3 
stammen fitter zijn dan ptxP1 stammen, en tot op heden zijn ptxP3 stammen geassocieerd 
met hogere Ptx productie en verhoogde luchtweg kolonisatie. Maar, ondanks het feit dat de 
genomen van verschillende ptxP3 en ptxP1 stammen (volledig) gesequenced zijn, blijft het tot 
noch toe onduidelijk hoe genetische verschillen zich vertalen naar de verschillende fenotypes 
die zijn geobserveerd. In dit proefschrift hebben we bestudeerd hoe deze twee stammen zich 
gedragen onder in vitro condities die specifieke aspecten van infectie weerspiegelen, alsook 
de werkelijke in vivo condities met behulp van een muizen infectie model. 
Expressie van bijna alle B. pertussis virulentiefactoren betrokken bij aanhoudende 
infectie en ziekte van de gastheer wordt gereguleerd door het Bvg systeem. De activiteit van dit 
systeem kan beïnvloed worden door verschillende externe factoren, wat kan resulteren in een 
spectrum van verschillende Bvg-fasen welke invloed hebben op de bacteriële virulentie. Zo 
remmen lage temperatuur en toenemende concentraties nicotinezuur en sulfaat de expressie 
van virulentiegenen, en faciliteren hiermee de transitie van de virulente (Bvg+) naar intermediaire 
(Bvgi) en tenslotte niet-virulente (Bvg-) fase. Omdat dit systeem cruciaal is voor het vermogen 
van B. pertussis om te overleven in de gastheer hebben we onderzocht hoe ptxP3 en ptxP1 
reageren op sulfaat geïnduceerde in vitro modulatie van het Bvg systeem. Uitgebreide analyse 
van verschillen in transcriptieprofielen tussen deze stammen (hoofdstuk 2) bevestigde dat 
ptxP3 stammen een hogere Ptx expressie hebben, zij het uitsluitend onder Bvgi groeicondities. 
Ook vonden we onder dezelfde condities dat ptxP3 stammen hogere expressie hadden van 
het vaccinantigeen Prn, eiwitten van het type III secretie systeem (T3SS), het complement 
resistentie eiwit Vag8, en LpxE, een eiwit betrokken bij modificatie van lipide A. Omdat al deze 
eiwitten invloed hebben op beschermingsmechanismen van de gastheer is het goed mogelijk 
dat ptxP3 stammen voordeel hebben bij een hogere expressie van deze factoren. 
Onze data gaf ook een mogelijke aanwijzing naar het mechanisme achter de verhoogde 
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expressie van virulentiefactoren door ptxP3 stammen onder Bvgi condities. Deze stammen 
hadden namelijk ook een verhoogde expressie van genen betrokken bij sulfaatmetabolisme, 
waardoor ze mogelijk minder gevoelig zijn voor sulfaatgeïnduceerde remming van virulentie 
genexpressie. Het blijft echter wel de vraag of ptxP3 stammen echt voordeel hebben van een 
verhoogd sulfaatmetabolisme tijdens infectie omdat de vrije sulfaat concentratie in de luchtwegen 
ongeveer 10 keer lager (0.6 mM) is dan de intermediaire sulfaatconcentratie (5 mM) gebruikt in 
onze studie. Mogelijk kan desulfatering van veel voorkomende gesulfateerde gastheereiwitten 
tijdens B. pertussis infectie wel resulteren in lokaal verhoogde sulfaatconcentraties. In deze 
context is het interessant om te noemen dat B. pertussis meerdere genen heeft die coderen 
voor eiwitten met een voorspeld sulfatasedomein (BP1635, BP1654, BP2327 en BP3136). Bvg-
afhankelijke virulentie genexpressie wordt echter niet alleen geremd door sulfaat, maar ook 
door toenemende nicotinezuur concentraties of afnemende temperatuur. Toekomstige studies 
moeten uitwijzen of ptxP3 stammen ook minder gevoelig zijn voor deze omgevingsmodulatoren. 
In hoofdstuk 3 hebben we het Bvg-gereguleerde proteoom van een ptxP3 en ptxP1 
stam bestudeert met als doel het identificeren van potentiële vaccinkandidaten (wordt 
verderop in dit hoofdstuk bediscussieerd). In principe zou deze proteomics data ook waardevol 
kunnen zijn voor het identificeren van additionele fenotypische kenmerken die de verhoogde 
fitness van ptxP3 stammen verklaren. Helaas maakte de inter-experimentele variatie in de 
proteoom data van de ptxP3 en ptxP1 stam het onmogelijk om significante verschillen in Bvg-
afhankelijke eiwitexpressie te meten tussen de twee stammen. Voor deze toepassing zouden 
er meerdere niet-gerelateerde ptxP3 en ptxP1 stammen geanalyseerd moeten worden in één 
proteomics experiment met de labelingsvrije methode gebruikt in onze studie, of een isotoop 
labelingsmethode zoals Isobaric Tags for Relative and Absolute Quantification (iTRAQ). 
Ondanks dat in vitro transcriptie analyse verschillen liet zien tussen ptxP3 en ptxP1 
stammen konden we geen verschillen meten in in vivo genexpressie van B. pertussis geïsoleerd 
uit de luchtwegen van muizen (hoofdstuk 5). Net als bij de proteomics data (hoofdstuk 3) 
werd deze vergelijking bemoeilijkt door het feit dat er slechts 3-4 in vivo replica samples 
waren verzameld met relatief grote variatie in genexpressie. Een uitgebreidere studie waarin 
transcriptieprofielen van meerdere niet-gerelateerde ptxP3 en ptxP1 stammen verzameld op 
verschillende tijdspunten van infectie worden vergeleken, zou kunnen leiden tot de identificatie 
van additionele voordelige fenotypes van de ptxP3 stammen tijdens infectie. 
Enkele studies suggereren dat er een verband is tussen de opkomst van ptxP3 stammen 
en recente kinkhoestepidemieën. Onderbouwende data voor dit causale verband tussen 
ptxP3 stammen en een toegenomen ernst van ziekte is tot nu toe echter alleen gekomen uit 
een Nederlandse studie en een retrospectieve klinische studie in Zweden, waaruit bleek dat 
kinderen die besmet waren met stammen van het pulsed-field gel electrophoresis (PFGE) 
profiel BpSR11, die later bleken het ptxP3 allel te dragen, langer in het ziekenhuis bleven 
dan kinderen die besmet waren met een niet BpSR11 stam. Om meer inzicht te krijgen in dit 
causale verband zou het recent ontwikkelde bavianenmodel waardevol kunnen zijn omdat het 
volledige verloop van een natuurlijke B. pertussis infectie met humane ziekteverschijnselen 
(krampachtig hoesten en leukocytose met lymfocytose) onder gecontroleerde omstandigheden 
Nederlandse samenvatting, dankwoord, CV and List of publications | 181
7
gevolgd kunnen worden in deze dieren. Het zou bijvoorbeeld erg interessant zijn om het 
klinische beeld van naïeve (of gedeeltelijk geïmmuniseerde) bavianen geïnfecteerd met een 
ptxP1 of ptxP3 stam te vergelijken. Bavianen kunnen ook gebruikt worden voor transmissie 
experimenten, waardoor er mogelijk nog meer voordelige virulentie eigenschappen van de 
ptxP3 stam gevonden kunnen worden. 
Ontdekking vaccin kandidaten - een proteomics benadering
De wereldwijde opkomst van Prn-deficiënte stammen, met Prn-deficiënte stam frequenties die 
oplopen tot 85% in sommige gebieden, is alarmerend. Ondanks dat Prn-deficiënte stammen 
niet geattenueerd lijken te zijn in mensen hebben twee recente studies aangetoond dat deze 
stammen mogelijk een selectief voordeel hebben bij gevaccineerde individuen. Dit laatste 
is niet verrassend aangezien er een correlatie is tussen de aanwezigheid van specifieke 
immunoglobuline G (IgG) antilichamen tegen Prn en klinische bescherming. Door de opkomst 
van Prn-deficiënte stammen is er een grote behoefte aan de identificatie van alternatieve, 
geconserveerde, beschermende antigenen die geïncludeerd kunnen worden in verbeterde aPs. 
Om nieuwe vaccinkandidaten betrokken bij specifieke aspecten van infectie te identificeren 
werd proteomics toegepast op momenteel circulerende ptxP1 en ptxP3 stammen gegroeid 
onder in vitro bvg-modulerende (hoofdstuk 3) en biofilm vormende condities (hoofdstuk 4).
Bvg-geactiveerde pertussis vaccin kandidaten
Omdat bvg-geactiveerde eiwitten over het algemeen geassocieerd zijn met virulentie en 
modulatie of evasie aan gastheerimmuniteit vertegenwoordigen zij uitstekende targets voor 
vaccinatie. Dit komt duidelijk naar voren door het feit dat alle huidige aP antigenen Bvg 
geactiveerd zijn. Om de verschillen en overeenkomsten in Bvg-regulatie tussen ptxP3 en 
ptxP1 te begrijpen hebben we de transcriptionele respons (hoofdstuk 2) en eiwit compositie 
(hoofdstuk 3) in deze stammen bestudeerd in reactie op toenemende concentraties vrij 
sulfaat. Vergelijking van het bvg-proteoom resulteerde in de identificatie van 159 en 104 Bvg-
geactiveerd eiwitten in de ptxP3 en ptxP1 stam, respectievelijk, en omvatte bijna alle bekende 
virulentiefactoren en aP antigenen. Als zodanig bevat deze studie de eerste uitgebreide 
analyse van het bvg-gereguleerde proteoom, wat zeer relevant is voor de wetenschappelijke 
gemeenschap die werkt aan de ontwikkeling van kinkhoestvaccins.
In onze studie werden vaccinkandidaten geselecteerd op basis van het criterium dat 
het eiwit bvg-geactiveerd was in zowel de ptxP3 als ptxP1 stam, omdat nieuwe antigenen 
zich moeten richten op beide type stammen omdat ze beide overheersen in de humane 
populatie. Dit resulteerde in 51 potentiële kandidaten. Na verdere selectie op bvg-geactiveerde 
transcriptie, aanwezigheid in het ‘core’ genoom en voorspelde geëxposeerde oppervlakte 
lokalisatie werden OmpP, OmpA, SphB1, Vag8 en BP2497 geselecteerd voor verder 
onderzoek. Immunisatie met recombinant SphB1 en Vag8 leidde tot significante bescherming 
tegen kinkhoest in de onderste luchtwegen van muizen. SphB1 en Vag8 behoren beide tot de 
eiwitklasse van autotransporters, die ook de beschermende antigenen Prn en TcfA bevat. Dit 
suggereert dat autotransporters in het algemeen een aantrekkelijke klasse van beschermende 
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antigenen is. Inderdaad, autotransporters geïdentificeerd in andere Gram-negatieve bacteriën 
zijn bijna allemaal geassocieerd met virulentiegerelateerde eigenschappen, zoals adhesie, 
autoaggregatie, invasie, biofilm vorming en cytotoxiciteit, en worden steeds meer erkend als 
doelwitten voor vaccinatie. Aangezien SphB1 en Vag8 beide oppervlakte geëxposeerd zijn en 
een reeds vastgestelde virulente functie hebben bij respectievelijk de maturatie van de adhesie 
en immuun-modulerende factor FHA en complement resistentie, is het niet verwonderlijk 
vaccinatie met deze eiwitten beschermt tegen infectie van de onderste luchtwegen bij muizen.
Biofilm-geassocieerde vaccin kandidaten
Voor veel mucosale pathogenen vergemakkelijkt biofilmvorming succesvolle kolonisatie en 
persistentie in de gastheer door resistentie te bieden tegen antimicrobiële agentia en immuun 
afweermechanismen. Verschillende studies hebben aangetoond dat B. pertussis biofilms kan 
produceren in de luchtwegen van muizen en dat dit proces belangrijk is voor succesvolle 
infectie. Bovendien worden biofilm-geassocieerde eiwitten of polysacchariden erkend als 
mogelijke vaccintargets. Daarom hebben we in hoofdstuk 4 het vaccin potentieel van B. 
pertussis biofilms onderzocht en met proteomics getracht biofilm-antigenen te identificeren als 
potentiële targets voor vaccinatie.
De observatie dat muizen, subcutaan geïmmuniseerd met totale membraaneiwit 
fracties van planktonische (mid-log en stationaire fase) en biofilm culturen, een significante 
vermindering van bacteriën in de longen hadden na respiratoire challenge met B. pertussis, 
bevestigde het idee dat pertussis biofilms beschermende antigenen bevatten (hoofdstuk 
4). Voor de identificatie van hoog tot expressie komende, biofilm-specifieke eiwitten hebben 
we de proteomics methodologie beschreven in hoofdstuk 3 toegepast op planktonische en 
biofilm materiaal. Deze strategie stelde ons in staat om 60 biofilm op- en 48 biofilm down-
gereguleerde eiwitten te identificeren. Na verder filtreren van de 60 biofilm-opgereguleerde 
eiwitten op eiwit abundantie en (voorspelde) geëxposeerde oppervlakte lokalisatie werd BipA 
geïdentificeerd als meest veelbelovende biofilm vaccinkandidaat. Na recombinante productie 
en vaccinatie bleek BipA inderdaad in staat significante bescherming te induceren tegen 
intranasale challenge met B. pertussis.
Onze studie was niet de eerste die beschreef dat BipA hoog tot expressie komt in B. 
pertussis biofilms, aangezien dit eiwit ook werd geïdentificeerd door Serra en collega’s die 
proteomics hebben toegepast op biofilms van de Tohama I stam. Naast BipA en het universele 
stresseiwit BP1315 vonden we verder geen overlap met betrekking tot biofilm geactiveerde 
of gerepresseerde eiwitten tussen de recente klinische stam gebruikt in onze studie en de 
Tohama I stam gebruikt door Serra et al. Dit verschil zou stam gerelateerd kunnen zijn omdat 
Tohama I al meer dan 60 jaar in vitro gekweekt is terwijl de B1917 stam uit onze studie in 2000 
is geïsoleerd uit een Nederlandse kinkhoestpatiënt. Andere studies hebben ook verschillende 
fenotypes aangetoond tussen recente klinische isolaten en Tohama I. Zo reageert Tohama I 
bijvoorbeeld anders op modulatie van de bvg-systeem en brengt het geen functioneel T3SS 
tot expressie. Deze verschillen benadrukken dat het belangrijk is om minimaal gepasseerde, 
recente geïsoleerde klinische stammen te gebruiken voor het bestuderen van B. pertussis 
Nederlandse samenvatting, dankwoord, CV and List of publications | 183
7
pathogenese in het algemeen.
Interessant is dat 35% van de biofilm gerepresseerde eiwitten van stam B1917 ook 
geïdentificeerd zijn als bvg-geactiveerde, virulentiegeassocieerde eiwitten in de transcriptionele 
expressie studie in hoofdstuk 2, waaronder Vag8, FimX en verscheidene T3SS (effector) 
eiwitten. In Tohama I daarentegen is de transcriptionele regulator BvgA, onderdeel van 
het tweecomponenten BvgAS systeem, het enige bvg-geactiveerde eiwit dat onder biofilm 
condities gerepresseerd wordt. De observatie dat sommige, maar niet alle, Bvg+ fase eiwitten 
worden onderdrukt in een biofilm, terwijl het klassieke Bvgi fase eiwit BipA hoog tot expressie 
komt, suggereert dat B. pertussis bacteriën zich niet in één specifieke Bvg fase bevinden onder 
biofilm condities. Deze variatie in Bvg fasen kan te wijten zijn aan de heterogene samenstelling 
van een biofilm, die het resultaat is van bacteriën die hun metabolische activiteit aanpassen 
aan concentratiegradiënten van voedingsstoffen, signaleringsmoleculen en bacteriële 
afvalproducten die aanwezig zijn in een biofilm. 
Het is belangrijk op te merken dat proteoom analyse een grote hoeveelheid bacteriën 
vereist voor de isolatie van voldoende eiwitten, welke geoogst en verwerkt worden als één 
batch die zowel cellen in de biofilm en planktonische fase kunnen bevatten. Derhalve resulteert 
proteoomanalyse in een gemiddelde karakterisering van cellen in verschillende fysiologische 
toestanden, in plaats van een exclusieve karakterisering van biofilm bacteriën. Recente 
ontwikkelingen in proteomics en microscopische technieken zouden gebruikt kunnen worden 
om op te helderen welke Bvg fasen relevant zijn voor B. pertussis biofilm vorming. Bijvoorbeeld 
door single-cell proteomics technieken toe te passen op B. pertussis gekweekt onder biofilm 
condities. Ook zou een B. pertussis stam waarbij een fluorescent label (bijvoorbeeld GFP) tot 
expressie wordt gebracht onder regulatie van de bvgAS promoter bestudeerd kunnen worden 
onder biofilm condities met behulp van geautomatiseerde time-lapse microscopie, zoals is 
beschreven voor andere bacteriën. 
Op basis van onze gegevens stellen wij voor dat een strategie die gericht is op meerdere 
fasen van infectie, waaronder biofilm vorming, een aantrekkelijke benadering zou kunnen 
zijn om pertussis vaccins te verbeteren. Opname van BipA in nieuwe vaccins, in combinatie 
met de huidige antigenen gericht op andere essentiële stappen in de pathogenese van B. 
pertussis, zou mogelijk extra bescherming kunnen bieden en daarbij de werkzaamheid van 
kinkhoestvaccins kunnen verbeteren. 
Beperkingen van de nieuw geïdentificeerde vaccinkandidaten
Hoewel SphB1, Vag8 en BipA veelbelovende kandidaten zijn voor opname in toekomstige 
pertussis vaccins, is één van de risico’s van het toevoegen van nieuwe antigenen aan 
het huidige aP dat B. pertussis de expressie van deze eiwitten elimineert, zoals ook werd 
waargenomen voor Prn. Voor SphB1 is dit niet erg waarschijnlijk, omdat deletie van dit gen 
het vermogen van B. pertussis om muizen te infecteren sterk verzwakt, waarschijnlijk door 
verhoogde fagocytose. Echter, een Vag8 of BipA deficiënte mutant van B. pertussis toont geen 
defect in muizen kolonisatie waardoor het gevaar bestaat dat B. pertussis de expressie van 
deze twee eiwitten elimineert wanneer die worden gebruikt voor vaccinatie.
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Een andere beperking van zowel de huidige aP antigenen als diegene geïdentificeerd in 
dit proefschrift (hoofdstuk 3 en 4) is dat geen van hen in staat is bescherming te bieden tegen 
bacteriële replicatie in de bovenste luchtwegen. In de huidige met alum geformuleerde toestand 
zullen deze antigenen dus mogelijk alleen beschermen tegen ziekte maar niet tegen kolonisatie 
en transmissie, zoals ook werd waargenomen voor aP antigenen in het baviaanmodel. Om dit 
probleem op te lossen zullen de vaccinformuleringen (bijvoorbeeld de afgifte van antigenen, 
adjuvans) en de route van toediening heroverwogen moeten worden. Deze kwesties worden 
verder in de sectie toekomstperspectieven hieronder besproken.
Adaptatie van B. pertussis tijdens luchtweginfectie
Om de drastische toename van kinkhoest in sterk gevaccineerde populaties te kunnen 
verklaren heeft het onderzoek van de laatste jaren zich vooral gericht op de snel wegebbende 
immuniteit na aP vaccinatie en verschillen in de kwaliteit van de immuunrespons geïnduceerd 
door natuurlijke infectie en wP en aP vaccins. In dit verband is het belangrijk op te merken dat 
wPs worden bereid met vloeibare kweken van Bvg+ fase B. pertussis. Bovendien, bevatten 
huidige aPs uitsluitend Bvg+ fase antigenen. 
Deze vaccins zijn allemaal ontworpen op basis van de aanname dat de Bvg+ fase 
essentieel is voor infectie, wat wordt ondersteund door muis infectie experimenten met Bvg 
phase-locked mutanten en een overvloed aan in vitro studies die de virulentie en antigene 
eigenschappen van Bvg+ fase factoren hebben gekarakteriseerd. Echter, het mechanisme 
waarmee B. pertussis zich aanpast aan lokale omstandigheden op de respiratoire mucosa 
van de gastheer tijdens infectie is grotendeels onbekend. Om inzicht te krijgen in deze 
mechanismen hebben we in hoofdstuk 5 tijd- en weefselspecifieke verschillen in B. pertussis 
genexpressie onderzocht in muizen.
Vergelijking van het in vivo transcriptoom met genexpressie tijdens in vitro kweekcondities 
toonde sterke verschillen in genexpressie profielen, met differentiële expressie van bijna een 
derde van alle genen. Verschillende routes betrokken bij bacteriegroei en metabolisme bleken 
lager tot expressie te komen tijdens infectie, wat aangeeft dat B. pertussis tijdens infectie 
metabolisch minder actief is, zoals ook waargenomen is in biofilms. De meeste genen die 
in vivo opgereguleerd waren bleken betrokken te zijn bij nutriëntopname, chemotaxis en 
aminozuur- en vetzuurmetabolisme. Dit weerspiegelt waarschijnlijk bacteriële adaptatie 
aan ‘nutritional immunity’, een afweermechanisme van de gastheer tegen binnendringende 
ziekteverwekkers die gericht is op het vasthouden van essentiële voedingsstoffen. Gebaseerd 
op het expressiepatroon van bvg-gereguleerde genen, zoals eerder beschreven in onze 
in vitro studies, bleek B. pertussis zich in vivo niet in één enkele Bvg fase te bevinden. Zo 
bleek bijvoorbeeld dat terwijl de meerderheid van Bvg+ fase factoren tijdens infectie tot 
expressie kwamen er ook expressie was van een aantal Bvg- fase genen. Dit past ook bij 
onze waarneming dat muizen die gevaccineerd waren met membraaneiwitten geëxtraheerd 
uit Bvg- fase bacteriën bijna net zo goed beschermd waren tegen respiratoire challenge met B. 
pertussis als muizen gevaccineerd met membraaneiwitten van Bvg+ fase bacteriën. Ondanks 
de huidige veronderstellingen suggereert deze data dat Bvg-gerepresseerde genen een 
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rol zouden kunnen spelen tijdens infectie. Dit wordt verder ondersteund door een recente 
studie waaruit bleek dat de expressie van het Bvg- fase specifieke kapsel essentieel is voor B. 
pertussis tijdens infectie.
Een ander doel van onze in vivo transcriptionele analyse was het identificeren van 
weefselspecifieke genexpressie profielen van bacteriën in de nasopharynx en de longen. 
Dergelijke verschillen kunnen inzicht verschaffen in het onvermogen van aP vaccins, 
en in mindere mate wP vaccins, om bescherming te bieden tegen kolonisatie van de 
bovenste luchtwegen. Bovendien laat inzicht in weefselspecifieke verschillen de selectie 
van aanvullende vaccinantigenen toe die B. pertussis specifiek in elk weefsel tot expressie 
brengt. Onze gegevens suggereren dat de bovenste en onderste luchtwegen verschillende 
niches van B. pertussis vertegenwoordigen omdat bijna 15% van alle genen differentieel 
tot expressie komen tussen deze twee anatomische locaties (hoofdstuk 5). Tot nu toe is 
differentiële expressie van virulentiegenen tijdens infectie van verschillende niches van de 
luchtwegen alleen beschreven voor pneumokokken, die in staat is de menselijke nasopharynx 
te koloniseren maar ook invasieve ziekten zoals pneumonie, bacteriemie en meningitis te 
veroorzaken. Interessant genoeg hebben pneumokokken verhoogde expressie van een 
aantal virulentiefactoren tijdens kolonisatie van de nasopharynx, wat overeenkomt met 
onze observatie dat de immuunmodulerende virulentiefactor Vag8 en de toxines Dnt, Ptx en 
Bsp22 tijdens vroege infectie zijn opgereguleerd door B. pertussis in de bovenste luchtwegen 
in vergelijking met bacteriën in de onderste luchtwegen. Of deze verhoogde expressie van 
virulentiegenen daadwerkelijk bijdraagt aan het onvermogen van aPs om te beschermen tegen 
kolonisatie van de nasopharynx blijft onzeker omdat Ptx ook aanwezig is in aPs. Bovendien 
induceren momenteel gebruikte aPs voornamelijk systemische immuniteit terwijl bescherming 
in de nasopharynx een inductie van lokale mucosale immuniteit vereist (verder besproken in 
de toekomstperspectieven hieronder).
Als eerste stap om B. pertussis genexpressie tijdens infectie te meten werd in deze 
studie gebruik gemaakt van een niet-natuurlijke gastheer (muizen). Nu het baviaanmodel 
beschikbaar is zouden soortgelijke experimenten uitgevoerd kunnen worden om niche-
specifieke genexpressie van B. pertussis tijdens een natuurlijke infectie te bestuderen. Naast 
het meten van het in vivo bacteriële transcriptoom zou het zeer interessant zijn om een 
gecombineerde benadering toe te passen waarbij zowel de gastheer en bacteriële respons 
gemeten wordt, daar dit een uitgebreider beeld geeft van hoe zowel de gastheer als pathogeen 
zich aanpassen tijdens een kinkhoestinfectie.
Toekomstperspectieven
Hoewel na de introductie van kinkhoest vaccins in de jaren ‘40 de kinkhoestincidentie in Europese 
landen met 99% is verminderd neemt het aantal infecties in diverse geïndustrialiseerde landen 
weer toe sinds het begin van 2000. Met recente epidemieën in Australië, de Verenigde Staten, 
het Verenigd Koninkrijk en Nederland, en een toename van infecties in een aantal andere 
Europese landen zijn er tegenmaatregelen tegen kinkhoest nodig. Hier zullen aanbevelingen 
om kinkhoest op de korte termijn onder controle te krijgen en suggesties voor lange termijn 
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pertussis vaccinontwikkeling worden beschreven.
Korte termijn controle strategieën
Om de toename in pertussis-gerelateerde sterfte onder zuigelingen onder controle te krijgen 
zijn alternatieve vaccinatiestrategieën met momenteel beschikbare vaccins voorgesteld en 
(deels) al ingevoerd. Deze strategieën kunnen gericht zijn op het verstrekken van indirecte 
bescherming aan baby’s (die het hoogste risico op een ernstige, zelfs fatale, kinkhoest) via 
boostervaccinatie van oudere leeftijdscategorieën, of directe bescherming door maternale 
of neonatale vaccinatie. Het principe achter boostervaccinatie is het verhogen van kudde 
immuniteit waardoor transmissie naar zuigelingen afneemt en de morbiditeit in deze 
leeftijdscategorie verlaagd wordt. Boostervaccinatie strategieën kunnen geïmplementeerd 
worden op een gemeenschapsbreed niveau of meer gericht zijn op de vaccinatie van ouders 
en anderen die in nauw contact komen met baby’s (de zogenaamde ‘cocooning’ strategie). 
Hoewel gemeenschapsbrede boosterdoses geïmplementeerd zijn in verschillende landen lijkt 
deze strategie ineffectief te zijn vanwege de lage vaccinatiegraad en kostbaarheid. Daarom lijkt 
het erop dat de cocooning strategie ook niet zorgt voor een vermindering van kinkhoest ziekte 
bij zuigelingen, ondanks dat er minimaal succes is beschreven in één studie. Het grootste 
probleem met de cocooning strategie is de lage vaccinatiegraad, welke onder andere te wijten 
is aan vaccin weigering door ouders en logistieke problemen. Daar komt bij dat aPs vooral 
beschermen tegen pertussis ziekte en slechts gedeeltelijk tegen kolonisatie en transmissie, 
wat kan betekenen dat alle indirecte strategieën niet doeltreffend zijn in het terugdringen van 
kinkhoest bij zuigelingen.
Daarom zou het bieden van directe bescherming door middel van neonatale vaccinatie 
of vaccinatie tijdens de zwangerschap een betere korte termijn oplossing kunnen zijn. Bij 
neonatale vaccinatie worden zuigelingen bij de geboorte gevaccineerd om zo een vroege 
immuunrespons tegen kinkhoest op te wekken, terwijl er bij vaccinatie tijdens de zwangerschap 
passieve immuniteit verworven wordt door de in-utero overdracht van maternale antistoffen. 
De laatstgenoemde strategie heeft ook de potentie om indirecte bescherming te bieden 
aan de zuigeling omdat het ook de moeder beschermt. In het baviaanmodel bleken beide 
strategieën in staat pasgeborenen te beschermen tegen infectie. Echter is er bij neonatale 
vaccinatie een vertraging tussen de vaccinatie dosis gegeven bij de geboorte en de inductie 
van beschermende immuniteit, waardoor zuigelingen onbeschermd zijn in de periode waarin 
zij het meest kwetsbaar zijn voor ernstige en levensbedreigende kinkhoest. Daarnaast wordt 
de neonatale vaccinatiestrategie ook belemmerd door bezorgdheid over immunologische 
en klinische veiligheid alsook de publieke acceptatie. Anderzijds blijkt dat vaccinatie tijdens 
de zwangerschap veilig is voor zowel zwangere vrouwen als hun foetus of zuigeling, 
bescherming biedt, en met succes in de VS, UK en een aantal andere landen is ingevoerd 
met een vaccineffectiviteit die oploopt tot 90%. Op basis van al deze studies heeft de WHO 
aanbevolen dat voor landen met een groot kinkhoest probleem maternale vaccinatie de meest 
kosteneffectieve interventie strategie is om neonatale pertussis te verminderen. Het moet wel 
opgemerkt worden dat grootschalige implementatie van deze strategie moeilijk kan zijn omdat 
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het nog niet goed bekend is welke invloed de aanwezigheid van maternale antistoffen heeft op 
de kwaliteit en duur van de baby’s eigen reactie op de primaire vaccinatie. 
Pertussis vaccinontwikkeling 
Er zijn drie belangrijke problemen met de momenteel gebruikte aP vaccins. Ten eerste zijn 
vaccin antigeen divergente en/of deficiënte stammen met een verhoogde virulentiefactor 
expressie in opkomst. Ten tweede is de geïnduceerde bescherming vooral gericht tegen ziekte 
en slechts in beperkte mate tegen transmissie. Ten derde bieden aPs slechts bescherming van 
korte duur. Met het oog op kinkhoest controle op de lange termijn is het daarom van belang 
de samenstelling en toedieningwijze van de momenteel gebruikte vaccins te heroverwegen.
Voor de ontwikkeling van nieuwe kinkhoestvaccins zijn er twee belangrijke opties:
1. Nieuwe stand-alone kinkhoest boostervaccins. Dit soort vaccins bestaan uit nieuwe of 
geactualiseerde aP antigenen en/of andere adjuvans, B. pertussis buitenmembraan ves-
icles (OMV), of mogelijk levend-geattenueerd B. pertussis. Deze vaccins kunnen relat-
ief snel worden ontwikkeld en geregistreerd omdat zij als stand-alone vaccins kunnen 
worden toegediend.
2. Nieuwe primaire kinkhoestvaccins met daarin difterie-toxoïde, tetanus toxoïde, geïnac-
tiveerd polio, etc. naast pertussis antigenen. Deze categorie vertegenwoordigt de tweede 
generatie aPs (met nieuwe / geactualiseerde antigenen, andere adjuvans etc.), whole-
cell kinkhoestvaccin (wP; genetisch geïnactiveerd, minder reactief), maar kan ook een 
OMV of levend-geattenueerd type vaccin zijn. Voor implementatie moet worden aange-
toond dat deze nieuwe vaccins niet interfereren met andere niet-pertussis componenten 
van de huidige aPs. Als zodanig kan de ontwikkeling van dit soort vaccins tenminste 10 
jaar duren.
Geactualiseerde huidige aP antigenen en nieuwe antigenen 
Eventuele veranderingen in het huidige aP zijn reeds door anderen voorgesteld, zoals het 
implementeren van genetisch gedetoxificeerd Ptx in plaats van het minder immunogene 
chemisch gedetoxificeerde Ptx wat momenteel wordt gebruikt. Het gebruik van genetisch 
gedetoxificeerd Ptx resulteert in hogere initiële Ptx antilichaam titers, ook tegen andere 
(conformationele) epitopen, waardoor er mogelijk voor langere tijd beschermende 
antilichaamniveaus aanwezig zijn. Omdat antigene divergentie vooral voorkomt in Prn kunnen 
aPs ook verbeterd worden door eiwit varianten van B. pertussis stammen uit de huidige 
populatie te includeren. Bovendien kunnen aPs ook aangevuld worden met nieuwe vaccin 
kandidaten. Bijvoorbeeld adenylaatcyclase-toxine (ACT), een multifunctionele virulentiefactor 
die een cruciale rol speelt tijdens infectie, is een veelbelovend doelwit voor vaccinatie. 
Bovendien zijn de virulentiegeactiveerde autotransporters Vag8 en SphB1 alsmede het biofilm-
geassocieerde eiwit BipA, allen geïdentificeerd als beschermende antigenen in dit proefschrift, 
ook veelbelovende kandidaten voor toekomstige aPs. Tot slot zijn oppervlaktegeëxposeerde 
eiwitten die in vivo tot expressie komen, geïdentificeerd in hoofdstuk 5 van dit proefschrift, 
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ook veelbelovend vaccinkandidaten. Het opnemen van additionele antigenen in aPs kan 
het probleem van de opkomende vaccindeficiënte mutanten aanpakken. Of dit echter ook 
voldoende zal zijn om langdurige bescherming te bieden tegen zowel kinkhoest ziekte als 
kolonisatie blijft twijfelachtig.
 
Alternatieve adjuvans en toedieningroutes
Voor de selectie van alternatieve adjuvans of toedieningroutes kan veel worden geleerd van 
de recente experimenten in het baviaanmodel. Dieren gevaccineerd met een wP klaarden de 
infectie sneller dan aP-gevaccineerde dieren, terwijl convalescente dieren volledig beschermd 
waren tegen zowel kolonisatie en transmissie. Hoewel de antilichaamniveaus tegen aP antigenen 
vergelijkbaar waren in alle behandelingsgroepen was er wel een verschil in de T-cel respons 
die werd geïnduceerd. Convalescente en wP-gevaccineerde dieren vertoonden een sterke 
Th1 en Th17 respons terwijl aP-gevaccineerde dieren alleen een Th1 en Th2 respons hadden. 
De laatste jaren is er substantieel bewijs gegenereerd dat aantoont dat een lokale Th1-Th17 
respons inderdaad belangrijk is voor de klaring van B. pertussis uit de longen en waarschijnlijk 
ook uit de neus. Op basis van deze bevindingen kunnen aPs verbeterd worden. Bijvoorbeeld, 
het klassieke adjuvans aluminiumhydroxide, die een sterkte Th2 respons induceert, kan 
worden vervangen door CpG, een adjuvans dat Th1-gemedieerde immuniteit stimuleert, 
superieure bescherming biedt ten opzichte van alum-geformuleerd aP en is toegelaten voor 
gebruik bij mensen. Bovendien leidt de klassieke intramusculaire toedieningroute tot een 
zeer slechte inductie van mucosale immuniteit door inadequate homing van T- en B-cellen. 
Het toedienen van pertussis antigenen via de mucosale route kan dus mogelijk belangrijke 
voordelen bieden. De immunogeniciteit van een mucosaal vaccin wordt echter wel voor een 
belangrijk deel bepaald door de formulering. Voordat antigenen herkent worden door het 
aangeboren immuunsysteem en een sterke mucosale immuunrespons induceren moeten ze 
namelijk eerst over het epitheel worden getransporteerd. Als zodanig moeten de antigenen bij 
voorkeur worden toegediend in een deeltjesvormige formulering, zoals biologisch afbreekbare 
PLG (poly (lactide-co-glycide))-bevattende microdeeltjes, liposomen of virusachtige deeltjes 
(VLP’s), in plaats van een oplosbare formulering. Deeltjes worden namelijk beter herkend 
en opgenomen door mucosale immuuncellen. Verder wordt de werkzaamheid van mucosale 
vaccins sterk bepaald door het soort adjuvans, wat vandaag de dag een overvloed aan 
mogelijkheden biedt. Ondanks de vele mogelijkheden is er op dit moment nog geen mucosaal 
adjuvans goedgekeurd voor menselijk gebruik, waardoor de ontwikkeling van dit type vaccin 
op korte termijn helaas niet mogelijk is. 
Nieuwe wPs, buitenmembraan vesicle-gebaseerde of levend-geattenueerde B. pertus-
sis vaccins
Diverse studies hebben aangetoond dat wPs beter zijn dan aPs als het gaat om de duur van 
de immuniteit en bescherming. Eén van de grootste problemen met wPs is de aanwezigheid 
van lipo-oligosaccharide (LOS) welke reactogeniciteit veroorzaakt. Voor de ontwikkeling van 
een verbeterd, minder reactogeen tweede generatie wP kan het gebruik van een chemische of 
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genetische LOS ontgiftingsmethode een verbetering zijn. Als alternatief voor het gebruik van 
whole-cells is er recent vooruitgang geboekt bij de ontwikkeling van een B. pertussis OMV-
vaccin die sterke bescherming biedt in een muizenmodel. Eén van de voordelen van OMV’s 
is dat ze een breed spectrum aan natieve endogene antigenen, alsmede buitenmembraan 
eiwitten en LOS bevatten die aangeboren immuunresponsen kunnen activeren en daardoor 
fungeren als natuurlijk adjuvans. Aangezien zowel wPs en OMV’s standaard zijn afgeleid van 
Bvg+ gegroeide in vitro kweken kunnen deze vaccins mogelijk worden verbeterd op basis 
van inzichten in het B. pertussis expressieprofiel tijdens infectie (hoofdstuk 5). Bijvoorbeeld 
door het ontwerpen van laboratorium kweekomstandigheden die het antigeen expressieprofiel 
tijdens infectie nauwkeuriger nabootsen. Als alternatief voor deze geïnactiveerde vaccins is er 
de afgelopen jaren grote vooruitgang geboekt bij de ontwikkeling van een levend-geattenueerd 
B. pertussis vaccine (BPZE1) dat intranasaal kan worden toegediend. De belangrijkste 
voordelen van een levend vaccin is dat het antigeen expressieprofiel vergelijkbaar is met 
die van B. pertussis tijdens natuurlijke infectie en zowel lokale als systemische immuniteit 
induceert. Bovendien induceert BPZE1 mogelijk een krachtigere immuunrespons omdat de 
immuunmodulerende toxines tracheaal cytotoxine (TCT) en Ptx zijn geïnactiveerd. Tenslotte 
induceert BPZE1 zowel Th1 als Th17 immuniteit, wat waarschijnlijk belangrijk is voor klaring 
van B. pertussis uit de bovenste luchtwegen.
De schatting op dit moment is dat verworven immuniteit tegen kinkhoest ziekte na infectie 
4-20 jaar duurt terwijl beschermende immuniteit na vaccinatie maar 4-12 jaar duurt. Het blijft 
dus belangrijp om de duur van vaccingeïnduceerde immuniteit te verbeteren. In deze context 
zijn de BPZE1 en OMV-gebaseerde vaccins veelbelovend, omdat zij beide voor langdurigere 
immuniteit zorgen dan parenterale aP-immunisatie, waarschijnlijk door het induceren van een 
sterkere Th1 respons. Omdat dit tot nu toe alleen is aangetoond in muizen is het belangrijk om 
deze bevindingen te valideren, bijvoorbeeld in het baviaanmodel. 
Nieuwe generaties kinkhoestvaccins induceren idealiter levenslange immuniteit waardoor 
kudde immuniteit ontstaat en kinkhoest uiteindelijk uitgeroeid wordt. Door het verkrijgen van 
een volledig begrip van de mechanismen onderliggend aan immunologisch geheugen en 
verschillen tussen aP en wP vaccins in het genereren van langdurige beschermende immuniteit, 
kunnen deze vaccins hopelijk in de zeer nabije toekomst ontwikkeld worden.
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ontdekken kunnen ontwikkelen. Ik wens je alle succes met je carrière in het bedrijfsleven en 
veel geluk voor de toekomst samen met Ria en de kinderen.
Beste prof. dr. Mooi, beste Frits, allereerst wil ik ook jou bedanken voor je vertrouwen 
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‘spelen’. Met jouw enorme kennis over kinkhoest en je wereldwijde connecties was je echt 
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van opbouwende feedback was jouw standaard en daar was ik heel blij mee. Inmiddels ben je 
met pensioen en ik wil je vrouw en jou het allerbeste toewensen voor de toekomst. 
Beste dr. Diavatopoulos, beste Dimitri, wat was ik blij met jou komst! Toen ik met mijn 
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veel geleerd van je wetenschappelijke inzicht en voortreffelijke schrijfcapaciteiten. Thanks for 
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binnen het LKI wordt voortgezet en ik weet zeker dat het door jouw betrokkenheid een groot 
succes gaat worden. Uiteraard wil ik ook jou en je gezin veel geluk toewensen voor de toekomst, 
cheers!
Beste dr. de Jonge, beste Marien, de nieuwe ‘big boss’ van het LKI, die positie staat 
je goed, daar mag je trots op zijn! Bedankt voor je gepassioneerde en enthousiasmerende 
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Nederlandse samenvatting, dankwoord, CV and List of publications | 191
7
Bij deze wil ik ook de leden van de manuscriptcommissie, prof. dr. Sauerwein, prof. dr. 
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omtrent het gedegen uitvoeren van proteomics analyses waren van cruciaal belang voor mijn 
onderzoek. Bedankt dat je me wegwijs hebt gemaakt in de magische wereld van proteomics en 
voor je significante bijdrage aan twee van mijn manuscripten. Prof. dr. Yantorno and dr. Serra, 
dear Osvaldo and Diego, thanks for your willingness to collaborate on the biofilm proteomics 
project. Osvaldo, I highly appreciate that you include me as co-author on our latest biofilm 
paper, I hope it will soon be accepted for publication! Catherine Pratt, thanks for your help on 
the autotransporters paper and the fun we had in Dublin. Beste Kees Heuvelman, bedankt 
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waren de enorme lange dagen die we soms maakten peanuts. Man, man wat hebben wij een 
lol gehad. Bedankt voor alles! Jammer dat je niet bij mijn promotie kan zijn maar ik wens jou en 
Jacqueline een hele fijne vakantie toe. Marc, onwijs bedankt voor al je hulp met ICT-gerelateerde 
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wilt staan als paranimf, proost alvast! Mijn student Alinda, bedankt voor je enorme inzet bij het 
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de koffiekamer binnen kwamen zal ik niet snel vergeten. Ada, onze duizendpoot, bedankt voor 
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Beste dr. de Vries, maestro, beste Stefan, allereerst wil ik je bedanken dat je een goed 
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ligt het nu dan eindelijk onder jullie neus. Ziet er goed uit niet? Ondanks dat ik PhD inhoudelijk 
niet veel aan jullie heb gehad wil ik jullie wel bedanken voor iets wat nog veel belangrijker is, 
jullie onvoorwaardelijke steun en liefde. Jullie hebben het eindeloze studeren van mij mogelijk 
gemaakt, dank daarvoor! Joost en Denise, we zien elkaar niet zo vaak maar als we elkaar zien 
is het gezellig. Dat er nog maar vele familievakanties in jullie aanwezigheid mogen komen! 
Lieve schoonouders, Susanne, Remco en Roeltje, ik bof maar met zo’n leuke schoonfamilie, 
jullie zijn top! Allerliefste Marleen, met jou kan ik de wereld aan, lach en geniet ik het meest! 
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alleen niet meer samen maar met zijn drieën, ik kan niet wachten! Love you!! 
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